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PREFACE 
This thesis describes the candidate’s 2.5 year full-time (2011-2013) and 2.5 years part-time 
(2013-2015) work on age-related macular degeneration (AMD) incidence and progression, 
based on the Blue Mountains Eye Study (BMES) cohort data.  
 
The BMES is a population based cohort study of vision and eye disease in an older Australian 
population residing in the Blue Mountains region, west of Sydney, Australia. The baseline 
examination was conducted from 1992 to 1994 (BMES I). The 5-, 10- and 15-year follow-up 
examinations were conducted during 1997-1999 (BMES II), 2002-2004 (BMES III) and 
2007-2010 (BMES IV), respectively. Professor Jie Jin Wang (candidate’s supervisor) was an 
associate investigator for BMES II and joint chief investigator for BMES III and IV. 
Professor Paul Mitchell (candidate’s co-supervisor) was the principal investigator for BMES 
I, II, III and IV.  
 
The findings presented in this thesis are primarily drawn from the Blue Mountains Eye Study 
(BMES) cohort. One comparative study included data from the BMES and Singapore 
Epidemiology of Eye Diseases (SEED) Study. A pooled data analysis included three 
population-based cohorts: the BMES, the Beaver Dam Eye Study (BDES) and the Rotterdam 
Study (RS), as a project in the Three Continent AMD Consortium (3CC).  
 
This thesis examines the long-term incidence, progression and associated risk factors of age-
related macular degeneration (AMD) and its component lesions including geographic 
atrophy, reticular drusen and medium drusen over 15 years in the BMES cohort, in Chapter 3. 
Comparison of two AMD classification scales, the Age-Related Eye Diseases Study 
Simplified Severity Scale and the newly developed Basic Clinical Classification Scale using 
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BMES data is shown in Chapter 4. The frequency and patterns of early AMD lesion 
distribution in Singaporean Asians compared to white Australians are documented in Chapter 
5, and the progression from unilateral to bilateral AMD is examined in three Caucasian 
populations in Chapter 6.   
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ABSTRACT 
Purpose 
To assess the long-term (>10-year) incidence and progression of age-related macular 
degeneration (AMD) and associated risk factors in an older Australian population cohort, and 
conduct pooled data analysis of three Caucasian populations to assess progression from 
unilateral to bilateral AMD. In addition, to compare the pattern of early AMD lesion 
distribution between Singaporean Asian and Australian Caucasian samples.  
 
Methods 
The Blue Mountains Eye Study (BMES) is a population-based cohort study of persons aged 
49 years and older, residing in the Blue Mountains region, west of Sydney, Australia. 
Baseline examinations were conducted from 1992 to 1994 and recruited 3654 participants 
(82.4% of those eligible). Surviving participants were invited to attend each follow-up 
examination thereafter. Of the surviving baseline participants, 2334 (75.8% of survivors), 
1952 (76.7% of survivors) and 1149 (56.1% of survivors) participants attended the 5-year 
(1997-1999), 10-year (2002-2004) and 15-year (2007-2009) follow-up examinations 
respectively.  
 
The SEED Study includes three population-based cohorts of Malays, Indians and Chinese 
aged 40-80 years old residing in Singapore. The baseline examinations were conducted 
consecutively between 2004 and 2011 starting with the Malay population, and recruited 3280 
Malays (78.7 of those eligible), 3400 Indians (75.6% of those eligible) and 3353 Chinese 
(72.8% of those eligible).  
 
7 
 
The BDES recruited 4926 participants (83.2% of those eligible) aged 43-86 years old at the 
baseline examinations between 1988 and 1990. Of these, 3684, 2764, 2119 and 1913 
participants attended the 5-year, 10-year, 15-year and 20-year examinations respectively. The 
RS recruited 7983 participants (77.7% participation rate) aged 55 years and older at the 
baseline examination (1990-1993), of which 6419 had retinal photography performed. Of 
these participants, 3637 were re-examined from 1997-1999 (6-year follow-up) and 2674 were 
re-examined from 2002-2004 (11-year follow-up). ). The BMES, BDES and RS have been 
collaborating in the two decades, leading to the establishment of the 3CC in recent decade. 
 
The presence of AMD lesions and the size and location of individual AMD lesions were 
assessed from colour retinal fundus photographs at each examination, in each study. The 
Wisconsin Age-Related Maculopathy Grading System was the primary grading protocol used 
in assessing AMD and AMD lesions. Side-by-side grading of baseline and follow-up retinal 
photographs was performed to confirm incident AMD and AMD lesions.  
 
Results 
Long-term incidence of AMD and AMD lesions in the BMES 
The 15-year incidence before and after adjusting for competing risks were 22.7% and 15.1% 
for early AMD and 6.8% and 4.1% for late AMD, respectively. Age and risk alleles of 
complement factor H (CFH-rs1061170) or age-related maculopathy susceptibility 2 (ARMS2-
rs10490924) were independently associated with early AMD incidence. Current smoking and 
≥1 risk allele of CFH-rs1061170 or ARMS2-rs10490924 were associated with late AMD 
incidence. At least one serving of fish per week was associated with 50% reduced incidence 
of late AMD. Severity of early AMD lesion characteristics was a strong predictor of 
progression to late AMD.  
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After excluding participants with GA or neovascular AMD at baseline, the 15-year incidence 
of GA was 3.6%. Current smoking and genetic risk from of CFH-rs1061170 or ARMS2-
rs10490924 were independently associated with 15-year incident GA. Baseline early AMD 
lesion characteristics (drusen type, location closer to the fovea, larger drusen area and 
presence of retinal pigment epithelium (RPE) abnormalities) were strong predictors of 15-
year incident GA. Fast progression of GA, defined as GA lesion growth of  ≥2mm2/year, was 
more frequently observed among baseline current smokers, persons with the CFH or ARMS2 
risk genotypes and in pseudophakic eyes.  
 
The 15-year cumulative incidence of reticular drusen was 4.0% after controlling for the 
competing risk of death. Increasing age, female sex, current smoking and risk alleles of CFH-
rs1061170 or ARMS2-rs10490924 were independently associated with incident reticular 
drusen. A substantial proportion (33.9%) of eyes with reticular drusen progressed to late 
AMD in 5 years, and it was 4-fold progression to late AMD of the rate from eyes with other 
early AMD lesions but without reticular drusen. A significantly low risk of progression from 
reticular drusen to late AMD was found among those with increased dietary intake of lutein-
zeaxanthin. There was no significant association between other AMD risk factors and 
progression from reticular drusen to late AMD.   
 
The 15-year cumulative incidence of medium drusen (defined as drusen with a diameter 
≥63µm and <125µm) was 13.9% after controlling for the competing risk of death. Increasing 
age and the presence of ≥3 risk alleles of the combined CFH-rs1061170 and ARMS2-
rs10490924 genes were associated with an increased incidence. There was no association 
between past or current smoking and the development of medium drusen. The proportion of 
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eyes that progressed from medium drusen to late AMD was 5.0% over 15years, however, 
when medium drusen was co-present with RPE abnormalities, the progression rate to late 
AMD increased to 23.0%. Greater total area involved by, and central location of, medium 
drusen were associated with a greater likelihood of progression to worse stages of AMD. 
 
Comparison of Two Classification Scales for AMD  
The Age-Related Eye Disease Study (AREDS) Simplified Severity Scale calculates a risk 
score based on the number of early AMD risk factors (large drusen and pigment 
abnormalities) in both eyes, while the Basic Clinical Classification Scale that defines large 
drusen and pigment abnormalities as ‘intermediate AMD’ regardless of bilaterality and is 
based on the worse eye. The AREDS Scale classified similar proportions of participants who 
developed incident late AMD in 5 year across all AMD risk levels between population-based 
BMES and clinic-based AREDS cohorts. In comparison, the Basic Clinical Classification 
Scale consistently classified 50% to 75% lower late AMD incident rates across all risk levels 
in the BMES compared to the AREDS cohorts.  
 
Comparison of Frequencies of Early AMD Lesions between Caucasians and Asians 
After age-standardization to the BMES population, the prevalence of distinct soft drusen was 
significantly higher in Singaporean Asians compared to Australians (23.9%, 95% CI 22.9-
25.0 versus 6.2%, 95% CI 5.3-7.0); adjusted OR 4.6 (95% CI 3.4-6.0). In contrast, the 
prevalence of indistinct soft or reticular drusen was non-significantly lower in Singaporeans 
compared to Australians (6.5%, 95% CI 5.9-7.1 versus 8.3%, 95% CI 7.4-9.3); adjusted OR 
1.2, (95% CI 0.8-1.7). Soft drusen of any type were frequently present at the inner and outer 
macula (within a zone ≥500µm to <3000µm radius from the foveal centre) among 
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Singaporeans, while among Australians soft drusen were more frequently present at the 
central macula (<500µm radius). 
 
Progression from Unilateral to Bilateral AMD in Three Caucasian Populations 
In pooled data analysis of the BMES, BDES and RS cohorts, the 5-year progression rates 
from unilateral to  bilateral any (early or late) AMD and bilateral late AMD ranged from 19% 
to 28% and 27% to 68%, respectively. Increasing age, the presence of 1 or  ≥2 risk alleles  
from the CFH and ARMS2 genes, past and current smoking status were significantly 
associated with increased risk of progression from unilateral to bilateral any AMD, after 
multivariable adjustment. The presence of  ≥2 risk alleles from the CFH and ARMS2 genes 
combined was significantly associated with increased progression from unilateral to bilateral 
late AMD. 
  
Conclusions 
Age and genetic risk from the CFH and ARMS2 were associated with increased long-term 
incidence of early and late AMD, GA, reticular drusen, medium drusen, and also associated 
with an increased risk of progression from unilateral any AMD to bilateral within 5 years. 
Large macular area involved by, central location and co-presence of early AMD lesions are 
indicators of high risk of progression to late AMD. Of the modifiable risk factors, smoking is 
an important risk factor associated with the progression from early to late AMD, while 
weekly fish consumption and high dietary intake of lutein-zeaxanthin are associated with a 
reduced risk of late AMD. The knowledge of these modifiable factors should be advocated by 
physicians to patients with early AMD or with high risk of AMD. With Australia's ageing 
population, it is important to prevent adverse consequences of AMD by promoting healthy 
lifestyle behaviours to minimize the economic burden of AMD. Understanding mechanisms 
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explaining the differences in AMD presentation severities between Asians and Caucasians 
may help to reduce the burden of AMD among Caucasians. 
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Chapter 1 
 
Incidence, Progression and Associated 
Risk Factors of Age-related Macular 
Degeneration: A Brief Literature Review 
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Age related macular degeneration (AMD) is the leading cause of irreversible severe visual 
impairment and blindness in the Western world, despite advances in treatment in recent 
decades1-11. A 2002 estimate by the World Health Organization revealed that 8.7% of the 
world’s blindness was due to AMD, with 14 million people suffering blindness or severe 
visual impairment as a result of the disease2. 
 
1.1 Age-related macular degeneration disease classification and 
pathogenesis 
Age-related macular degeneration is a complex, progressive degenerative disorder of the 
retina and commonly affects persons aged 50 years and older1,3,7,12-14.  
 
The sensory retina consists of nine cellular layers that are separated from the underlying 
choroidal vessels by a layer of retinal pigment epithelium (RPE) and a thin collagenous 
structure, the Bruch’s membrane. Histopathologic findings indicate that AMD originates as 
deposits of extracellular material within or internal to the Bruch’s membrane caused by the 
failure of the RPE cells to process photoreceptor cell debris15-17. These depositions are known 
as basal linear or basal laminar deposits5,18-20. Larger deposits termed drusen lying between 
the RPE and Bruch’s membrane5,19 are early clinical signs of AMD20-25. Other signs of AMD 
include RPE abnormalities (increased pigmentation in the sensory retina and/or decreased 
pigmentation of the RPE), geographic atrophy (GA) and varying manifestations of 
neovascular AMD that are visible on ophthalmoscopic examination and can be documented 
with retinal fundus photography. These degenerative changes of the retina in the macula and 
particularly the fovea (central macula) have a severe consequence of destroying central 
vision.  
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Clinical classification of AMD  
In the past four decades, a number of classification systems have been developed for 
determining the presence and severity of AMD based on colour fundus photographs13,26-32.  
 
The Wisconsin Age-Related Maculopathy Grading System (WARMGS) was developed in 
the early 1990’s by Klein and associates26, which provided comprehensive definitions and a 
grading protocol that included assessment of lesion size and location within the macular area. 
The International Classification and Grading System for Age-Related Maculopathy (ARM) 
and AMD was later developed based on the WARMGS,  a collaborative efforts by the 
leading ophthalmologists in this field around the world, in order to standardize definitions 
and terminologies for AMD and AMD lesions13. The aim was to reduce inconsistencies in 
definitions used by various studies and thus permit comparisons between studies.  
 
Several AMD classification systems were proposed thereafter, by different researchers, to 
classify AMD into a scale with steps reflecting severity stages of the disease and inherent risk 
of progression to Late AMD at each specific step27,28,30-32.  Examples include the Age-Related 
Eye Disease Study (AREDS) severity scales27,28, the Beaver Dam Eye Study (BDES) scale33, 
the Rotterdam Study (RS) scale30, the harmonized Three-Continent AMD Consortium (3CC) 
scale32 and the Basic Clinical Classification Scale (Beckman classification)31. Of these, the 
AREDS scale has been used and validated in different population-based cohort studies34,35. In 
the AREDS scale, AMD severity steps were determined by the presence of AMD lesions in 
one or both eyes, whereas the RS, BDES, 3CC and the Basic Clinical Classification scales 
stratify AMD severity stages based on lesions in the worse eye (Table 1.1-1).  
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Generally speaking, AMD has two broad disease stages; Early and Late AMD stages. The 
early stage was previously termed ARM while the late stage was termed AMD. However, the 
current convention defines both stages as AMD with differentiation imparted using the terms 
‘Early’ and ‘Late’. The Basic Clinical Classification Scale, the most recent AMD 
classification scale, also includes an ‘intermediate’ AMD stage in addition to early and  late 
stages31. In this review and the thesis, only two stages, Early and Late AMD, are used.  Early 
and Late AMD are denoted using initial capitals in this review chapter to facilitate reading.  
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Table 1.1-1: Summary of Classification Scales for AMD. 
 
 
Classification 
Scale 
Step or 
Level Definition 
Age-Related 
Eye Diseases 
Study 
(AREDS) 
simplified 
severity 
scale28* 
0 No retinal pigment changes with none or small hard drusen in 1 or both eyes 
or intermediate (but not large) drusen in 1 eye only 
1 Pigment changes in 1 eye with small hard drusen in 1 or both eyes or 
intermediate drusen in 1 eye only; No pigment changes in either eye but 
intermediate drusen in both eyes or large drusen in one eye 
2 Pigment changes in both eyes with small hard drusen in 1 or both eyes or 
intermediate drusen in 1 eye only; Pigment changes in 1 eye with intermediate 
drusen in both eyes or large drusen in 1 eye; No pigment changes in either eye 
but large drusen in both eyes.
3 Pigment changes in both eyes with intermediate drusen in both eyes or large 
drusen in 1 eye; Pigment changes in 1 eye with large drusen in both eyes.
4 Pigment changes in both eyes with large drusen in both eyes 
      
Beaver Dam 
Eye Study 
(BDES) six-
level severity 
scale33† 
10 Hard drusen or small soft drusen (<125µm in diameter) only, regardless of 
area of involvement, and no pigmentary abnormality present. 
20 Hard drusen or small soft drusen (<125µm in diameter), regardless of area of 
involvement, with increased retinal pigment present but no RPE 
depigmentation present; Soft drusen (≥125µm in diameter) with drusen area 
<196,350µm2 (equivalent to a circle with a diameter of 500µm) and no 
pigmentary abnormalities present. 
30 Soft drusen (≥125µm in diameter) with drusen area <196,350µm2 and RPE 
depigmentation present; Soft drusen (≥125µm in diameter) with drusen area 
≥196,350µm2 with or without increased retinal pigment but no RPE 
depigmentation present.
40 Soft drusen (≥125 in diameter) with drusen area ≥196,350µm2 involvement 
and RPE depigmentation present with or without increased retinal pigment.
50 Pure geographic atrophy in absence of exudative macular degeneration.
60 Exudative macular degeneration with or without geographic atrophy present.
      
Rotterdam 
Study (RS) 
stages of 
severity 
scale30† 
No ARM No ARM features or only drusen ≤63µm 
1a Soft distinct drusen
1b Pigmentary irregularities 
2a Soft indistinct or reticular drusen
2b Soft distinct drusen with pigmentary irregularities  
3 Soft indistinct or reticular drusen with pigmentary irregularities 
4 Atrophic or neovascular macular degeneration (AMD) 
      
Three 
Continent 
AMD 
Consortium 
harmonized 
severity 
scale32† 
10 No AMD: No, questionable, small, or intermediate sized drusen (<125µm in 
diameter) only, regardless of area of involvement, and no pigmentary 
abnormalities (defined as increased retinal pigment or RPE depigmentation 
present); No definite drusen with any pigmentary abnormality. 
20 Mild Early AMD: Small to intermediate sized drusen (<125µm in diameter), 
regardless of area of involvement, with any pigmentary abnormality; Large 
drusen (≥125µm in diameter) with drusen area <331,820µm2 (equivalent to O-
2 circle, defined as a circle with diameter of 650µm) and no pigmentary 
abnormalities.
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30 Moderate Early AMD: Large drusen (≥125µm in diameter) with drusen area 
≥331,820µm2 and any pigmentary abnormality; Large drusen (≥125µm in 
diameter) with drusen area ≥331,820µm2, with or without increased retinal 
pigment but no RPE depigmentation.
40 Severe Early AMD: Large drusen (≥125µm in diameter) with drusen area 
≥331,820µm2 and RPE depigmentation present, with or without increased 
retinal pigment.
50 Late AMD: Pure geographic atrophy in the absence of exudative macular 
degeneration; Exudative macular degeneration with or without geographic 
atrophy present.
      
Basic Clinical 
Classification 
Scale31† 
No apparent aging changes: No drusen and no AMD pigmentary abnormalities
Normal aging changes: Only drupelets (small drusen ≤63µm) and no AMD pigmentary 
abnormalities 
Early AMD: Medium drusen >63µm and ≤125µm and no AMD pigmentary abnormalities.
Intermediate AMD: Large drusen >125µm and/or any AMD pigmentary abnormalities. 
Late AMD: Neovascular AMD and/or any geographic atrophy
*Scale refers to lesion changes in both eyes (person-specific) 
†Scale refers to lesion changes one eye (eye-specific) 
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Early AMD 
Early AMD is characterized by the presence of drusen and/or RPE abnormalities within the 
anatomic macular area. The features described forthwith refer to observations from retinal 
colour fundus photography and not other modes of retinal imaging such as optical coherence 
tomography. Drusen are identified as discrete white-yellow spots and vary in size and 
appearance, including small distinct and indistinct hard drusen, intermediate drusen, large 
distinct and indistinct soft drusen and reticular drusen (Figure 1.1-1A). The appearance of 
drusen edge: sharp or fuzzy, are descriptors for distinct or indistinct type, respectively; while 
size of drusen, denoted by the longest diameter of a single druse, is the separator for different 
types of drusen; hard drusen are <63µm, intermediate ≥63µm but <125µm, and soft drusen 
≥125µm in diameter13,26. Reticular drusen are confluent and appear as ill-defined networks of 
interlacing ribbons13. Hard drusen are considered aging changes and not early AMD lesions.  
 
Retinal pigment epithelium abnormalities include hyperpigmentation and RPE 
depigmentation (hypopigmentation). Hyperpigmentation refers to the presence of clumps of 
gray or black pigment granules within the sensory retina. RPE depigmentation refers to a 
sharply delineated area with apparent absence of the RPE but without visible choroidal 
vessels, in contrast to the appearance of GA where choroidal vessels are visible13,26 (Figure 
1.1-1B).      
 
There are varying definitions of Early AMD used among different studies. In majority of 
population-based studies12,14,36,37 including the BDES and BMES, Early AMD is defined as 
the presence of either (1) large (>125µm diameter) indistinct soft or reticular drusen or (2) the 
co-presence of distinct soft drusen and RPE abnormalities within the macula in the absence of 
Late AMD. This definition (termed BDES Early AMD definition in this chapter) does not 
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include the presence of intermediate drusen alone, distinct soft drusen alone or retinal 
pigmentary abnormalities alone into the Early AMD stage category. Other studies have 
defined Early AMD as two or more steps in a severity scale30,38-40, or have included any 
drusen ≥63µm in diameter with or without the presence of retinal pigmentary abnormalities41-
43, which lead to variations in estimates of Early AMD prevalence and incidence.  
 
Late AMD   
The two late AMD lesions are geographic atrophy (dry form) and neovascular or exudative 
AMD (wet form)13,26. Geographic atrophy refers to a sharply defined area of RPE and 
sensory retinal disappearance with a diameter ≥175µm, exposing the choroidal vessels 
(Figure 1.1-1C). Neovascular AMD refers to various manifestations of exudative AMD 
including serous or hemorrhagic RPE/ neurosensory retinal detachment, retinal or subretinal 
haemhorrages, subretinal fibrosis (disciform scars) (Figure 1.1 -1D). Hard exudates may be 
present due to leakage of new vessels. The presence of photocoagulation scars, indicative of 
previous laser treatment of neovascularization, is also included in the definition of 
neovascular AMD (wet AMD)35,36,44,45. 
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Figure 1.1-1 Early and Late AMD lesions visible on retinal fundus photographs. (A) 
Example of various drusen types including: reticular drusen present in the upper arcade (thin 
arrows) and predominant large indistinct soft drusen (thick white arrows), with scattered 
intermediate drusen (black arrows) in the central macular. (B) Example of hyperpigmentation 
(thick arrows) and retinal pigment epithelium (RPE) depigmentation (thin arrows). (C) Large 
area of geographic atrophy involving the entire macular area (wide arrows surrounding GA 
perimeter). (D) Presence of haemorrhages (thin arrows), sensory retinal detachment and 
subretinal fibrosis (thick arrows), a scaring stage of neovascular AMD. 
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1.2 Incidence and progression of age-related macular degeneration 
Over the past four decades the prevalence, incidence and progression of AMD have been 
documented in a number of population-based studies around the world. While reports on 
AMD prevalence and short-term incidence were common, fewer reports were on the long-
term (≥10-year) incidence and progression of AMD.  
 
Relatively prominent population-based studies undertaken in the past 30 years and 
comprising AMD incident data from older populations are summarized in this chapter.  
 
1.2.1 Methods and Definitions 
 The assessment of AMD incidence from  retinal photographs is straightforward, however, 
estimation of incidence rates using various statistical methods, such as the Kaplan-Meier life 
table method, with or without consideration of competing risk of death, resulted in variations 
in estimates of incident rates.   
 
Incidence of Early AMD is defined as the presence of Early AMD at follow-up where no 
Early and Late AMD was present at baseline or a previous visit. The incidence of individual 
AMD lesions is defined similarly. Incidence of Late AMD is defined as the presence of Late 
AMD at follow-up where no Late AMD was present at baseline or a previous visit but Early 
AMD might be present. Person-specific incidence refers to the incidence of AMD in the 
worse or the first eye, that were used in many studies included in this review 29,33-35,38,39,44,46-
50, unless otherwise specified. Second eye (the fellow eye of persons with AMD in the first 
eye) incidence, or the incidence of bilateral AMD, was also investigated in some studies29,33-
35,38,39,45,47.  
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Various definitions of progression have been used across different studies. The two main 
approaches to assess progression included: (1) proportions of eyes that had an increased area 
involved by AMD lesions, such as an increase in the number of subfields involved by the 
same types of lesions, designated by the WARMGS grid that consists of 3 concentric circles 
divided into 9 subfields, and demarcates the anatomic macular area29,33,34,44 (refer to Figure 
1.2.1-1) and (2) the progression to Late AMD stage from different stages of Early AMD, 
according to early AMD lesion characteristics (type of drusen, total areas involved by, and 
location of drusen and retinal pigmentary abnormalities)33,35. Progression to Late AMD based 
on steps of AREDS AMD severity scale27,28 and BDES severity scale33,51 have also been 
reported33,35. Regression and disappearance of AMD lesions were assessed in some 
studies29,34,48, however, this phenomenon is likely due to the development of more advanced 
stage lesions on the severity scale of AMD which should not be considered as true 
regression4,52,53, and is not described in this review.   
 
 
Figure 1.2.1-1 Wisconsin Age-Related Maculopathy Grading System (WARMGS) grid and 
measurement circles. (A) Placement of the WARMGS grid over a macula photograph with 
central subfield directly over the fovea; (B) Measurement circles used for estimating drusen 
size and AMD lesion area. 
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1.2.2 Australian studies 
The Blue Mountains Eye Study (BMES) is a landmark study of vision and common eye 
disease in a representative sample of older Australians residing in the Blue Mountains region, 
west of Sydney36. Of 4433 eligible residents aged 49+ years, identified using a door-to-door 
census, 3654 (82.4% of those eligible) attended the baseline examinations between 1992 and 
199436. Of these participants, 2335 (75.1% of survivors) returned for the 5-year follow-up 
examinations (1997-1999)44, 1952 (76.5% survivors) attended the 10-year follow-up 
examinations (2002-2004)35 and 1149 (56.1% of survivors) attended the15-year follow-up 
examinations (2007-2009)54. Incidence of Early and Late AMD were calculated using 
Kaplan-Meier product limit survival estimates. 
 
Late AMD was defined as described in the International ARM Classification13. The overall 
person-specific incidence of Late AMD was 1.1% and 3.7% at 5 and 10 years, 
respectively35,44. The incidence of neovascular AMD was 1.0% and 2.2%, and the incidence 
of GA 0.8% and 1.7% at 5 and 10 years, respectively. Of participants with unilateral AMD, 
55.6% became bilateral at 5 years, and 100% bilateral at 10 years35.  
 
Early AMD was defined following the BDES Early AMD definitions35,36,44. The 
corresponding overall person-specific incidence of Early AMD was 8.7% and 14.1% at 5 and 
10 years, respectively35,44. The 5-year incidence of individual early AMD lesions including 
distinct soft, indistinct soft, and combined indistinct soft and  reticular drusen were 2.4%, 
4.2% and 4.9%, respectively; and the 5-year incidence of  retinal pigmentary abnormality, 
hyperpigmentation and RPE depigmentation were 7.0%, 7.0% and 3.8%, respectively44. The 
10-year incidence of individual early AMD lesions were not reported, however, the incidence 
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of indistinct soft and reticular drusen combined was 11.7% and the incidence of retinal 
pigmentary abnormalities was 23.3%35.    
 
The progression of AMD was investigated (by eye) in the BMES. Progression of Late AMD 
was defined as an extension of GA and neovascular AMD lesions into the fovea, an increase 
in area involved by neovascular AMD lesions by 2 or more subfields on the WARMGS grid, 
or the appearance of more advanced stage lesions of neovascular AMD44. The 5-year 
progression of GA and neovascular AMD occurred in 42.9% and 71.4% of eyes, 
respectively44.   
 
The 10-year risk of progression to Late AMD was higher in eyes with larger individual 
drusen, greater total area involved by drusen and drusen location close to the fovea35. 
Progression rate to Late AMD over 10-years was also higher for persons with more advanced 
steps of AMD on the AREDS simplified severity scale35.  
 
The Melbourne Visual Impairment Project (MVIP) is a population-based survey of eye 
disease in Melbourne residents aged 40+ years in the Melbourne metropolitan region. The 
baseline study was conducted in 1992 to 1994 and examined 3271 participants (83% of 
eligible residents)43. Of these, 2594 participants (85% of survivors) returned at the 5-year 
follow-up visit during 1997-199946.  
 
The overall 5-year incidence of Late AMD was 0.49%. The incidence of GA and neovascular 
AMD were not reported separately46.  
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Early AMD was defined as the presence of distinct soft, indistinct soft or reticular drusen or 
the presence of retinal pigmentary abnormalities in the absence of Late AMD. Early AMD 
was also defined following the BDES Early AMD definitions. Using the latter definition, the 
overall 5-year incidence of Early AMD in the first eye was 5.4%46. The 5-year incidence of 
distinct soft drusen, indistinct soft drusen, hyperpigmentation and RPE depigmentation were 
6.1%, 4.3%, 10.9% and 13.0%, respectively. The differences in the incident rates of Early 
AMD and early AMD lesions between the MVIP and the BMES may be due to age 
differences of the two populations: in the MVIP sample only 2% were aged 80+ years 
whereas in the BMES sample it was 4.8%. Differences in lesion classifications by different 
graders of these two studies, and different graders between the baseline and follow-up visits 
of the MVIP, may also have contributed to the differences43,46.  
 
Progression of AMD was assessed by 5 stages of AMD which ranged from 'no AMD' to 
either dry or wet form of Late AMD, where progression of Early AMD was defined as an 
increase in 1 or more stages, based on the worse eye46.  Progression over 5 years occurred in 
16.8% of participants with Early AMD at baseline. The 5-year risk of Late AMD for eyes 
present with indistinct soft or reticular drusen together and retinal pigmentary abnormalities 
(4th stage) was 9-fold the risk for eyes present with soft drusen alone or retinal pigmentary 
abnormalities alone (2nd stage)46.   
 
1.2.3 International studies   
Caucasian Eye Studies 
The Beaver Dam Eye Study (BDES) is a landmark population-based eye study of older 
Caucasian residents in the township of Beaver Dam, Wisconsin, USA. The study was one of 
the first comprehensive studies that collected demographic and lifestyle data and documented 
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the presence and development of retinal eye disease in a large sample of white population. It 
is also the only eye study of the general population with a follow-up period of 20 years. 
Baseline examinations were conducted in 1988-1990 and examined 4926 participants aged 
43+ years (83.2% of those eligible)14. Of these participants, 3684 attended the 5-year follow-
up examinations in 1993-199529, 2764 attended the 10-year follow-up in 1998-200034, 2119 
attended the 15-year follow-up in 2003-200533 and 1913 attended the 20-year follow-up 
examinations in 2008-20106,40. Incidence rates of Early and Late AMD, prior to the 15-year 
report, were assessed using Kaplan-Meier methods, and the 15-year incidence rates were 
reported after accounting for the competing risk of death33. The 20-year incidence of Late 
AMD, calculated directly using proportions, was reported in an article that addresses the 
long-term risk of AMD associated with smoking40. In a different report, the 20-year incidence 
of Early AMD was estimated after adjusting for competing risk of death55.  
 
Incidence of Late AMD in the first eye were 0.9%, 2.1%, 3.1% and 4.5% at 5, 10, 15 and 20 
years, respectively29,33,34,40. The incidence of GA was 0.3% to 0.8% and 1.3%and the 
incidence of neovascular AMD was 0.6% to 1.4% and 2.0% at 5, 10 and 15 years, 
respectively. The progression from unilateral to bilateral Late AMD occurred in 22.2% of 
participants over 5 years29 and 38.5% of participants over 10 years34. The 15-year cumulative 
incidence of bilateral Late AMD was 38.7%33 among participants with unilateral AMD at 
baseline. There is no 20-year incidence of GA, neovascular AMD or second eye incidence of 
Late AMD reported from the BDES to date.  
 
Early AMD was defined using the BDES Early AMD definitions: large (>125µm diameter) 
indistinct soft or reticular drusen or the co-presence of distinct soft drusen and retinal 
pigmentary abnormalities within the macula in the absence of Late AMD29,33,34,40. The 
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person-specific incidence rates of Early AMD were 8.2%, 12.1%, 14.3% and 24.4% at 5, 10, 
15 and 20 years, respectively29,33,34,40.  The 20-year cumulative incidence of Early AMD after 
adjusting for the competing risk of death was 23.0%55. The incidence rates of individual early 
AMD lesions in 5, 10 and 15 years were: 6.5%, 10.2% and 13.4%, respectively, for distinct 
soft drusen; 7.0%, 10.3% and 13.4% respectively for indistinct soft drusen; 4.9%, 8.5% and 
9.8%, respectively, for hyperpigmentation; and 3.1%, 6.3% and 7.5%, respectively, for RPE 
depigmentation29,33,34.   
 
Progression of AMD lesions (in right eyes only) were defined as presence of the lesions in at 
least 1 subfield at baseline that  had increased by 2 or more subfields at follow-up compared 
to baseline, in the absence of developing more severe lesions29,34. Progression of GA 
occurred in 50.0% and 55.6%, and neovascular AMD in 36.4% and 33.3% of eyes at 5 and 10 
years, respectively29,34. The frequency of progression to GA and neovascular AMD at 5- and 
10-year visits was highest in eyes with greater macular area involved by more advanced stage 
drusen (indistinct soft) or larger drusen (≥125µm diameter) compared to  that involved by 
less advanced, smaller drusen (<63µm)29,34. The progression of AMD over 15 years was 
assessed along the BDES AMD severity scale as an increase by ≥2 steps from level 2 or 3, or 
by 1 step from level 4, and in the AREDS AMD severity scale as a ≥2-step increase in 
severity (Table 1.1-1). The 15-year cumulative progression along the BDES scale, in the 
worse eye, was 12.2% and along the AREDS scale was 25.0%33.   
 
The Rotterdam Study (RS) is a population-based prospective cohort study conducted in 
Rotterdam, the Netherlands. Baseline examinations were conducted in 1990-1993, and 7983 
participants aged 55 to 98 years (78% of those eligible) were recruited in the initial phase of 
the study. A subsample of 7983 participants (n=6872) underwent eye examinations, and of 
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the 6872, 6418 had gradable fundus photographs30. Of the 6418 participants, 4974, 3636 and 
2674 were re-examined at the second (1993-1995)30, third (1997-1999)38 and fourth (2002-
2004)56,57 visits, respectively.  
 
The 2-year cumulative incidence of Late AMD was 0.24%30. The overall 6-year incidence of 
Late AMD was 1.8 per 1000 person-years, with the incidence of GA and neovascular AMD 
0.7 and 1.1 per 1000 person-years, respectively38. The cumulative incidence of Late AMD at 
11 years was 2.1% 58. The 2-year and 6-year cumulative incidence of bilateral Late AMD was 
28.9% and 38.7%, respectively30,38.  
 
Early AMD was defined by mutually exclusive severity stages, developed by the RS 
investigators30 (Table 1.2-1). Stages 2 and 3 correspond to Early AMD. The 6-year incidence 
of Early AMD (defined using the BDES Early AMD definitions) was 16.4 per 1000 person-
years38. The cumulative incidence of Early AMD at 11 years was 12.2%44990].  
 
Among participants with Early AMD, the 2-year cumulative progression to a more severe 
stage was 21.5%30. The 5-year risk of Late AMD was 0.0%, 0.9%, 7.8%, 28.0% for persons 
with stages 0, 1, 2 and 3 of the RS severity scale at baseline, respectively38.  
 
The Los Angeles Latino Eye Study (LALES) is a population-based cohort study of eye 
disease in self-identified Latinos aged 40+ years residing in the city of La Puente, Los 
Angeles County, California59. Latinos are a heterogeneous group of people that include 
Hispanics, Hispanic Americans and Latino Americans descended from a Spanish-speaking 
community, with a majority from Mexican ancestry (66%). Baseline examinations were 
performed on 6357 participants (82% of eligible participants) during 2000-200341. Of these, 
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4658 participants (76.4% of survivors) were examined at the 4-year follow-up 
examinations39.  
 
The overall 4-year incidence of Late AMD was 0.2%, with the same incidence rate reported 
for pure GA (0.1%) and neovascular AMD (0.1%)39. No incidence of Late AMD in the 
second eye was reported.  
 
The LALES defined Early AMD as any indistinct soft or reticular drusen; or retinal 
pigmentary abnormalities together with any type of drusen, in the absence of Late AMD, in 
the first eye. The 4-year incidence of Early AMD was 7.5%, and incident rates of distinct soft 
drusen, indistinct soft drusen, hyperpigmentation and RPE depigmentation were 10.5%, 
2.7%, 3.1% and 1.9%, respectively39. The incidence of Early AMD in the second eye was 
11.2% among persons with Early AMD in the first eye at baseline39. 
 
The progression of AMD was defined as a ≥2 step increase in the concatenated 11-step 
AREDS severity scale scores27 at the follow-up visit. The overall 4-year progression of any 
(Early and Late) AMD by the AREDS scale was 9.2%39. GA progression, defined as an 
increase in size by ≥2 disc areas or an extension of GA to the macular centre, occurred in 
33.3% of eyes with GA at baseline 39. The progression of neovascular AMD was not 
reported. 
 
The Copenhagen City Eye Study was one of the earliest population-based eye studies that 
examined 946 residents (96.9% of eligible participants) aged 60 to 80 years in the city of 
Copenhagen, between 1986 and 198860. Follow-up examinations were conducted 14 years 
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later from 2000-2002, and examined 359 persons (97.3% of survivors, and 37.9% of the 
original 946 participants)47.  
 
The overall 14-year incidence of Late AMD was 16.9%, while pure GA and neovascular 
AMD incidence rates were 4.9% and 12.0%, in the first eye47. Of 46 participants with 
unilateral Late AMD at baseline, only 2 were re-examined at follow-up, and Late AMD 
developed in the second eye of both participants (100%) in 14 years47.  
 
Early AMD was defined using the same definitions as that used in the LALES. The 14-year 
incidence of Early AMD in the first eye was 37.8%. The incidence of distinct soft drusen, 
indistinct soft drusen, pigmentary abnormalities, hyperpigmentation and RPE depigmentation 
were 30.6%, 34.7%, 32.6%, 30.0% and 23.8%, respectively47.  
 
 The risk of progression to Late AMD increased with larger drusen present at baseline47. 
Greater total macular area involved by drusen at baseline did not significantly affect the 
progression to Late AMD after adjustment for drusen type47. 
 
 The Reykjavic Eye Study was conducted in Reykjavic, Iceland in 1996 and included 1045 
participants aged 50 years and older (75.8% response rate)61. Of these, 846 participants 
(88.2% of survivors) attended the 5-year follow-up examination in 200145. Incidence rates 
were calculated directly by proportions. 
 
The 5-year incidence of Late AMD was 0.0%, 0.4%, 4.4% and 5.9% in the 50-59, 60-69, 70-
79 and 80+ age groups, respectively45. The cumulative incidence of GA at 5 years was 4.6% 
and the incidence of neovascular AMD was 0%45. Bilateral development of GA occurred in 3 
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of 3 participants (100%) with unilateral GA at baseline. There were no participants who 
developed bilateral neovascular AMD in 5 years45.  
 
Early AMD included the presence of any soft drusen or reticular drusen, and/or retinal 
pigmentary abnormalities, within the macula. The 5-year incidence of Early AMD was 
14.8%, 17.6%, 43.9% and 50.0% in those aged 50-59, 60-69, 70-79 and 80+ years, 
respectively45.  
 
Progression was not reported in the Reykjavic Eye Study.  
 
Asian Eye Studies 
The Beijing Eye Study was carried out in urban and rural communities in the north of central 
Beijing and south of Beijing, respectively. Baseline examinations were conducted in 2001 
and recruited 4439 participants (83.4% response rate) aged 40-82 years37. Of these 3251 
participants (73.2% of survivors) were re-examined in 200648.    
 
The overall 5-year incidence of Late AMD was 0.1%48. The eye-specific 5-year incidence of 
GA and neovascular AMD were 0.02% and 0.1%, respectively48. Second eye incidence of 
Late AMD was not reported.  
 
Early AMD was defined following the BDES Early AMD definitions14. The person-specific 
5-year incidence of Early AMD was 4.2%48. The eye-specific 5-year incidence rates for 
distinct soft drusen, indistinct soft drusen, hyperpigmentaion and RPE depigmentation was 
1.9%, 1.7%, 3.3% and 2.7%, respectively48. 
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Progression of AMD was defined if the AMD lesion extended into the fovea, involved ≥2 
more subfields of the WARMGS grid compared to baseline26, or developed more advanced 
stage lesions of neovascular AMD (e.g. advancing from serous or hemorrhagic retinal 
detachment to subretinal scaring), by the time the 5-year follow-up visit was conducted. GA 
progression occurred in 16.7% and neovascular AMD progression in 20.0% of eyes with the 
corresponding lesions at baseline48.   
 
The Hisayama Study is a prospective population study conducted in Hisayama, southern 
Japan42. The baseline examination took place in 1998, and 1775 participants aged 50+ years 
(58.1% of those eligible) were recruited42. Of these, 961 (% of survivors not reported) 
participants attended the 5-year follow-up examinations in 200349, and 1401 (% of survivors 
not reported) attended the 9-year follow-up examination in 200750. The 9-year incidence of 
Late AMD, Early AMD and its component lesions were reported after age-standardization to 
the 1998 World Health Organization standard population 
 
The 5-year incidence of Late AMD was 0.8%, and incidence rates for GA and neovascular 
AMD were 0.3% and 0.5%, respectively49. The age-standardized 9-year incidence of Late 
AMD was 1.4% and incidence of GA and neovascular AMD were 0.04% and 1.4%, 
respectively50.  
 
Early AMD was defined as the presence of soft drusen (distinct and indistinct) or pigmentary 
abnormalities, in the first eye. The 5-year incidence of Early AMD was 8.5%, and incidence 
of soft drusen (combined distinct and indistinct types), and pigmentary abnormalities was 
6.8% and 1.6%, respectively49. The 9-year incidence of Early AMD was 10.0% and incidence 
of soft drusen and pigmentary abnormality was 8.0% and 2.0%, respectively50.    
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Progression of AMD was not reported from the 5-year follow-up visit49, however, 
progression to Late AMD from Early AMD or specific early AMD lesions at baseline was 
reported from the 9-year follow-up visit50. The age-standardized 9-year progression to Late 
AMD from eyes with Early AMD was 4.4%, compared to only a 0.7% of eyes with no Early 
AMD at baseline50. The 9-year progression rates to Late AMD from soft drusen and 
pigmentary abnormality was 5.2% and 2.2%, respectively50. 
 
The incident rates of Early, Late AMD, and individual AMD lesions reported by population-
based studies described above are summarized in Tables 1.2-1, 1.2-2 and 1.2-3.  
 
In summary, the overall 5-year incidence of Late AMD was under 2% in all populations, and 
it increased with increasing length of follow-up period. The overall 5-year incidence of Early 
AMD varied from 5% to 15%, and it also increased with increasing length of follow-up 
period in a majority of the population-based studies included in this review. Some studies  
also reported incidence rates by age groups and sex29,33-35,44.  
 
An age-related increased incidence of AMD is evident in every study. In addition to age, 
many other systemic and lifestyle risk factors are also found to be associated with the 
incidence and progression of AMD.   
 
 
 
 
 
Table 1.2-1: Summary of the incidence of early and late age-related macular degeneration among prominent Australian and International 
population-based cohort studies.   
 
Name/Location 
of Study 
Year of 
Baseline 
Examination  
Sample 
Size at 
Baseline 
Age at 
Baseline 
(years) 
Years of 
Follow-up 
Early AMD Incidence % (by years 
of follow-up period)
Late AMD Incidence % (by years of 
follow-up period)
≤5 >5 to ≤10 >10 to ≤15 ≤5 >5 to ≤10 >10 to ≤15 
Australian   
BMES35,44 1992-1994 3654 49-97 10 8.7 14.1  -  1.1 3.7  -  
MVIP46 1992-1994 3271 40+ 5 5.4  -   -  0.5  -   -  
International   
Caucasian   
BDES29,33,34  1988-1990 4926 43-84 20 8.2 12.1 14.3 0.9 2.1 3.1 
Rotterdam38* 1990-1993 6418 55-98 11 16.4  -   -  1.8  -   -  
LALES39 2000-2003 6357 40+ 4 7.5  -   -  0.2  -   -  
Copenhagen47 1986-1988 946 60-80 14  -   -  37.8  -   -  16.9 
Reykjavik45† 1996 1045 50+ 5 14.8-50.0  -   -    0.0-5.9  -   -  
Asian   
Beijing48  2001 4439 40-82 5 4.2  -   -  0.1  -    - 
Hisayama49,50 1998 1482 50+ 9 8.5 10.0‡  -  0.8 1.4‡  -  
AMD=age-related macular degeneration, BMES=Blue Mountains Eye Study, MVIP=Melbourne Visual Impairment Project, BDES=Beaver Dam Eye Study, 
LALES=Los Angeles Latino Eye Study 
*Incidence expressed as: incidence per 1000 person-years 
†Overall incidence not reported; first value in range indicates incidence from 50-59 year age group and last value indicates incidence from 80+ year age group.  
‡Incidence age-standardized to the 1998 World Health Organization standard population  
 
 
 
 
 
Table 1.2-2: Summary of the incidence of individual early age-related macular degeneration lesions among prominent Australian and 
International population-based cohort studies.    
 
Name/Location 
of Study 
Drusen Incidence (% by years of follow-up period) Pigmentary Abnormalities Incidence (% by years of follow-up period) 
Soft distinct Soft indistinct Any  Hyperpigmentation RPE depigmentation 
≤5 >5 to 
≤10 
>10 to 
≤15 ≤5 
>5 to 
≤10
>10 to 
≤15 ≤5 
>5 to 
≤10
>10 to 
≤15 ≤5 
>5 to 
≤10
>10 to 
≤15 ≤5 
>5 to 
≤10
>10 to 
≤15 
Australian   
BMES35,44 2.4  -   -  4.9† 11.7†  -  7.0 23.3  -  7.0  -   -  3.8  -   -  
MVIP46 6.1  -   -  4.3  -   -   -   -   -  10.9  -   -  13.0  -   -  
International   
Caucasian   
BDES29,33,34   6.5 10.2 13.4 7.0 10.3 13.4  -   -  9.8 4.9 8.5 9.8 3.1 6.3 7.5 
Rotterdam38  -   -   -   -   -   -   -   -   -   -   -   -   -   -   -  
LALES39 10.5  -   -  2.7  -   -   -   -   -  3.1  -  - 1.9  -  -  
Copenhagen47  -   -  30.6  -  -  34.7  -   -  32.6  -  - 30.0  -  - 23.8 
Reykjavik45* 1.1-6.7  -   -  
1.1-
28.6  -   -   -   -   -  
10.7-
23.5  -  - 
1.9-
17.7  -  -  
Asian                         
Beijing48 1.9  -   -  1.7  -   -   -   -   -  3.3  -  - 2.7  -  -  
Hisayama49,50  -   -   -  6.8‡ 8.0‡§  -  1.6 2.0§  -   -  -  -  -  -  -  
RPE=retinal pigment epithelium, BMES=Blue Mountains Eye Study, MVIP=Melbourne Visual Impairment Project, BDES=Beaver Dam Eye Sudy, LALES=Los Angeles 
Latino Eye Study 
*Overall incidence not reported; first value in range indicates incidence from 50-59 year age group and last value indicates incidence from 80+ year age group.  
†Soft indistinct and reticular drusen combined 
‡Combined soft distinct and indistinct drusen 
§Incidence age-standardized to the 1998 World Health Organization standard population  
  
 
 
Table 1.2-3: Summary of the incidence of individual late age-related macular degeneration lesions among prominent Australian and 
International population-based cohort studies. 
 
 
Name/Location of 
Study 
Late AMD  Incidence (% by years of follow-up period)
Geographic Atrophy Neovascular AMD  
≤5 >5 to ≤10 >10 to ≤15 ≤5 >5 to ≤10 >10 to ≤15 
Australian             
BMES35,44 0.8 1.7  -  1.0 2.2  -  
MVIP46  -   -   -   -   -   -  
International             
Caucasian             
BDES29,33,34    0.3 0.8 1.3 0.6 1.4 2.0 
Rotterdam38 0.7  -   -  1.1  -   -  
LALES39 0.1  -   -  0.1  -   -  
Copenhagen47  -   -  4.9  -   -  7.6 
Reykjavik45 4.6  -   -   -   -   -  
Asian             
Beijing48 0.0  -   -  0.1  -   -  
Hisayama49,50 0.3 0.04*  -  0.5 1.4*  -  
AMD=age-related macular degeneration, BMES=Blue Mountains Eye Study, MVIP=Melbourne Visual 
Impairment Project, BDES=Beaver Dam Eye Sudy, LALES=Los Angeles Latino Eye Study
*Incidence age-standardized to the 1998 World Health Organization standard population  
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1.3 Risk factors associated with the incidence and progression of age-
related macular degeneration 
1.3.1 Systemic risk factors  
Age 
The association between increasing age and the incidence and progression of AMD are 
consistent across all populations29,34,35,39,44,47, including clinic-based patient cohorts such as 
the AREDS62. In the BMES, the 5-year incidence of Late AMD increased with age from 
0.0%  in persons aged <60 years to 5.4% in those aged 80+ years and older. The 
corresponding incidence of Early AMD increased from 3.2% in persons aged <60 years to 
18.3% in those aged 70-79 years, and 14.8% in those aged 80+ years44. Increased incidence 
of Early and Late AMD with increasing age was also found at the 10-year follow-up visit of 
the BMES35, the 5- and 10-year follow-up visits in the BDES29,34, the14 year visit in the 
Copenhagen Eye Study47 and a number of other studies that assessed incidence of Early and 
Late AMD between intervals of 5 to 10 years48-50,63. Slightly decreased incident rates of both 
Early and Late AMD in the oldest old age group were also observed in the BDES 15-year 
follow-up visit, regardless of considering the competing risk of death33. 
 
Sex   
While incident Early and Late AMD is consistently associated with age, the association with 
sex varies among different studies29,34,35,38,44,47,48. In the BMES, the 5- and 10-year incidence 
of AMD (Early and Late) was slightly higher in women than in men, and the incidence of 
neovascular AMD in women doubled that in men35,44, although the differences were not 
statistically significant. Similar to the BMES, the BDES also reported a higher overall 5- and 
10-year incidence of Early and Late AMD in women (9.0% and 1.3%, respectively at 5-year 
visit; 13.0 and 2.4% at 10-year visit) compared to men (7.1% and 0.5%, respectively at 5-year 
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visit; 10.9% and 1.7%, respectively at 10-year visit). These gender differences could not be 
explained by selective mortality, according to the authors’ opinion29,34. The Rotterdam study 
did not find a significant gender difference in 5-year incident Late or Early AMD38. Likewise 
the incidence of any (Early and Late) AMD was also not significantly different between the 
two genders in the Copenhagen Study47 and the Beijing Eye Study48.  
 
Similarly, in some Asian studies no significant difference in the incidence of AMD was 
documented between men and women64,65, while in others, incident Late AMD was found to 
be greater in men compared to women66-68, likely due to a substantially higher proportion of 
smokers among Asian men compared to Asian women. In the Hisayama Study population, 
74.8% of men were current smokers compared to only 7.1% of women who were, and the 5-
year incidence of Late AMD in this study population was 1.9% in men compared to 0.2% in 
women49. Similar findings were also reported from the 9-year follow-up of this cohort50. 
 
Overall there has been no strong and consistent evidence to support that women have a higher 
risk of AMD than men.  
 
Genetic Risk of AMD  
Genetic influences on AMD were initially documented in family and twin studies69-73. 
Studies using genome wide association scanning (GWAS) have revealed many gene loci 
related to AMD74-78. One with the largest sample size, the International AMD Gene 
Consortium (IAMDGC)79, reported 19 gene loci associated with Late AMD. Of these loci, 
the complement factor H (CFH) and age-related maculopathy susceptibility (ARMS2) are the 
two showing the strongest risk magnitude. The association of the CFH with AMD has been 
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consistently documented in European studies and the association of ARMS2 with AMD was 
relatively more prominent in Asian populations57,79-86. 
 
The CFH is a regulator gene in Chromosome 1 for the alternative pathway of the complement 
activation: the CFH protein binds to C-reactive protein induced by damaged tissues87-89, a 
regulatory action to eliminate ongoing activation of complement system. 
 
The CFH-rs1061170 (Y402H) polymorphism is relatively common in Caucasian populations, 
with this minor allele frequency ranging from 28% to 35%90-95. Each risk alleles of CFH 
increased the risk of incident Early or Late AMD in the order of 1.6 to 2.9 after age- and sex-
adjustment, compared to persons with no risk allele of CFH 82,96,97. Risk of progression from 
less to more advanced stage of Early AMD and from Early to Late AMD also increased with 
increased number of risk alleles of the CFH, after adjustment81,97.  
 
The ARMS2 gene in Chromosome 10 is more common in Asians compared to Caucasians, 
and has been shown to be associated with an increased risk of AMD84-86,98,99, independent of 
the CFH gene100,101. There have been several single nucleotide polymorphisms (SNPs; 
rs10490924, rs10490923, rs3750847,) identified; the first-reported SNP, rs10490924, is also 
known as the LOC387715. Many findings on the association between ARMS2 and AMD have 
originated from case-control studies and limited data exist on the association between ARMS2 
and the incidence and progression of AMD99,102.  
 
The risk magnitudes for incident Late AMD were in the range of 2.7 to 4.1 with the presence 
of one or two risk alleles of ARMS2, compared to those with no risk allele of ARMS282,103. 
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The risk magnitude for incident Early AMD was 2.0 with both risk alleles of ARMS2 
compared to none, reported from a clinic-based study82.  
 
Prediction of AMD risk using risk scores generated based on the presence of risk alleles of 
AMD-related genes and known AMD risk factors (environmental exposures such as smoking, 
and the presence early AMD lesions) has been examined104,105. The risk of developing Late 
AMD was increased substantially in those with high risk score compared to low risk score in 
a model accounting for age, sex, 26 SNPs of known AMD-related genes, smoking, body mass 
index (BMI) and baseline early AMD phenotypes, reported from the 3CC105. In another 
study, the incidence of Late and Early AMD were increased in those with a higher genetic 
risk score compared to those with a lower genetic risk score, after adjusting for age104. Using 
area under the Receiver Operating Characteristic (ROC) curve to assess performance of the 
prediction models, findings consistently showed incremental gains after including known 
AMD environmental risk exposures such smoking, hypertension, history of physical activity, 
BMI, education, antioxidant and multivitamin use in age-adjusted prediction models 
containing genetic scores only91,104-108. Gene and environment risk models provided better 
performance in AMD risk prediction than models containing genes alone or environmental 
factors alone. Incorporating genetic factors into prediction models containing early AMD 
phenotypes provided a small improvement to the risk prediction performance104,107.   
 
Knowledge gained from GWAS studies of AMD genetic risk supports current understanding 
of complex disease that genetic influence contributes only a small proportion of the disease 
risk.  Influence from environmental exposures, given that most of the exposures are 
modifiable, should be a main focus of research attention and public health interventions. 
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1.3.2 Lifestyle risk factors  
Smoking   
Cigarette smoke is known to increase oxidative stress levels, increase the number of 
inflammatory mediators and reduce antioxidant levels, all relevant to the proposed 
inflammation pathway, one of the proposed AMD pathogenesis theories109-113. Smoking is 
consistently identified to be associated with an increased risk of AMD in many studies50,63,114-
117. Age-adjusted risk ratios for smokers compared to non-smokers in terms risk of Late and 
Early AMD are presented in Table 1.3.2-1.  
 
The BMES and the Hisayama Study reported a significant association between current 
smoking and incident Late AMD, with overall risk ratios for current smokers compared to 
non-smokers ranging from 2.5 to 6.3, after adjusting for age 50,114,115. One study found an 
increased risk of incident Early AMD among current smokers116. Other studies including 
BDES 5- and 10-year reports, the LALES and the Copenhagen Eye Study did not find a 
significant association between smoking and incident AMD51,63,118,119.  
 
Among past smokers, the Rotterdam Study reported a 3-fold risk of incident Late AMD 
compared to non-smokers, after adjusting for age117. In other studies, the risk ratios for Early 
and Late AMD among past smokers were comparable to that of non-smokers114,115. Any 
smoking (past or current) was significantly associated with incident Late AMD in the 
Hisayama Study50.  
 
Selective survival and small numbers of participants with incident Late AMD cases could 
have limited the power to detect an association between smoking and incident Late 
AMD51,118,119. Cessation of smoking after AMD development in some older participants, an 
56 
 
indication bias, could have also biased the association towards the null in cross-sectional 
studies66,120-124, but not in longitudinal studies where smoking status is defined prior to AMD 
development.   
 
Current smoking was also significantly associated with progression of AMD, defined by an 
increase by  ≥2 steps in the BDES severity scale (Table 1.1-1) over 4 years in the LALES, 
after adjusting for age, sex, pulse pressure and history of diabetes63. Progression rate of AMD 
in the BDES, defined as an increase by ≥1 step in the BDES severity scale (Table 1.1-1), was 
also higher among current smokers compared to non-smokers, after adjusting for age, sex and 
baseline AMD severity level116.  
 
 
 
Table 1.3.2-1: Age-adjusted risk ratios for incident Late and Early age-related macular degeneration (AMD) among current and past smokers 
compared to non-smokers, summarized from Australian and International population-based cohort studies.  
 
 
Name/Location 
of Study 
Year 
(Incidence) 
Age-adjusted Relative Risk/Odds Ratio (95% Confidence Intervals) 
Current Smoker Past Smoker 
Late AMD Early AMD Late AMD Early AMD 
BMES 5 2.5 (1.0-6.2) 1.2 (0.8-1.9) 0.8 (0.4-1.8) 0.9 (0.7-1.2) 
10* 4.9 (2.5-9.7) 1.2 (0.8-1.9) 1.4 (0.8-2.5) 1.0 (0.8-1.4) 
BDES  5 [men] 0.0 1.69 (0.96-2.98) 1.72 (0.23-13.05) 1.04 (0.64-1.68) 
5 [women] 0.44 (0.07-2.68) 0.80 (0.48-1.33) 0.85 (0.32-2.26) 1.11 (0.79-1.57) 
10 0.51 (0.18-1.46) 1.37 (0.98-1.94) 0.61 (0.33-1.13) 1.12 (0.85-1.47) 
15† 0.69 (0.27-1.76)‡ 1.47 (1.08-1.99) 1.12 (0.62-2.01)‡ 1.16 (0.91-1.48) 
0.18 (0.02-1.40)§ 0.88 (0.41-1.88)§ 
Rotterdam 5 6.32 (2.10-19.1)  -  3.29 (1.17-9.22)  -  
LALES 4ǁ  -  non-significant  -  non-significant 
Copenhagen 14 1.6 (0.6-3.9) 1.2 (0.6-2.6) 1.3 (0.6-3.1) 1.1 (0.5-2.2) 
Hisayama 5 2.22 (1.14-4.33)¶ 
  9 Late AMD: 4.59 (1.86-11.3)# / Early AMD: 1.07 (0.73-1.55)#  
BMES=Blue Mountains Eye Study, BDES=Beaver Dam Eye Study, LALES=Los Angeles Latino Eye Study 
*Adjusted for age and sex 
†Adjusted for age, sex and baseline AMD severity level 
‡Neovascular AMD 
§Geographic Atrophy 
ǁOR not provided as association is non-significant for incidence of early or any AMD 
¶OR for incidence of any (either Late or Early) AMD among past or current smokers combined 
#OR for incidence of Late and Early AMD separately among past or current smokers combined  
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Fish Consumption 
Omega-3 (ω-3), and omega-6 (ω-6) fatty acids, are found in high concentrations in the 
retina125 and are important structural components of photoreceptor outer segments and the 
retinal vasculature126,127.  
 
Fish intake, and specifically intake of ω-3 fatty acids (including docosahexaenoic acid (DHA) 
and eicosapentaenoic acid (EPA)), have been found associated with a reduced risk of AMD 
in population-based cohorts128-133.  In the BMES, fish consumption of ≥3 servings per week 
was associated with reduced 5-year incident rate of Late AMD 130. The joint effect of low fish 
consumption (<1 serving per month) and current smoking status significantly increased the 
risk of 10-year Late AMD incidence in the BMES115.  The Nurses’ Health Study (NHS) and 
Health Professionals Follow-up Study (HPFS), and the Progression of Age-Related Macular 
Degeneration Study found inverse associations between fish consumption and incidence and 
progression of Late AMD128,129.  
 
In the BMES, the incidence of Early AMD at the 5- and 10-year follow-up visits was reduced 
by 30% to 40% among participants who consumed fish at least once per week130,131.  The risk 
of incident Early AMD was reduced further among those who had a low dietary intake of 
linoleic acid (a type of ω-6 fatty acid) if they also consumed fish at least once per week, 
compared to those who consumed fish less than once a week, in the BMES and the 
Progression of Age-Related Macular Degeneration Study129,131. In contrast, the Reykjavic 
Eye Study and the Melbourne Collaborative Cohort Study found no significant association of 
fish consumption with the incidence of Early AMD or early AMD lesions134,135. Fish 
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consumption of 1-2 servings per week was not associated with a reduced risk of progression 
from bilateral drusen to Late AMD in the AREDS132.  
 
Associations between dietary intake of ω-3, ω-6 and incident AMD was also examined130-
133,135,136. In the BMES, there was no significant association between high ω-3 or ω-6 intake 
and incident Late AMD in 5 or 10 years130,131. Similarly, no association of these fatty acids 
with incident Late AMD was observed in the Melbourne Collaborative Cohort Study135. In 
comparison, incident Early AMD was significantly reduced among participants with higher 
intake of ω-3 in the BMES and Melbourne Collaborative Cohort Study130,131,135. Further, 
higher intake of ω-3 long chain fatty acids (EPA + DHA) were shown associated with a  
reduced risk of  developing visually impaired consequence (defined as best-corrected visual 
acuity 20/30 or worse) that was attributed to AMD in the Women’s Health Study136. Higher 
intake of EPA + DHA was also associated with a reduced risk of progression to late AMD in 
the AREDS clinical trial132,133.  
 
Though a beneficial role of ω-3 fatty acids (EPA + DHA) in reducing AMD risk is likely, 
inconsistencies in findings in this regard suggest that more prospective studies and 
randomized controlled trials are needed to provide further evidence, in order to guide clinical 
recommendation137,138.  
 
Antioxidants  
Antioxidants are known to have anti-inflammatory properties and have been investigated for 
their association with AMD137,139-147. Lutein and zeaxanthin (LZ) are of particular interest as 
they are found high in concentrations in the macula. The associations between LZ intake or 
other antioxidant intake and incident Late or Early AMD are summarized in Table 1.3.2-2. 
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There was a reduced likelihood of 10-year incidence of neovascular AMD associated with 
high baseline dietary intake of LZ in the BMES139, whereas no association was found in the 
RS at 11 years140, or in the Prospective Cohorts of the NHS and the HPFS populations, at 18 
years141. However, by the time of 24-26 year follow-up visits of the same two prospective 
cohorts, a 40% reduced risk of incident Late AMD was observed among participants with 
higher plasma LZ levels at baseline142.  
 
An increased risk of incident neovascular AMD was found associated with high β-carotene 
intake from diet and supplements in the BMES, but not associated with dietary intake of β-
carotene alone139. In comparison, a reduced risk or no association was found between 
combined diet and supplement intake of β-carotene and incident Late AMD in the NHS and 
HPFS, and the RS 140-142. The AREDS investigators reported a decreased likelihood of 
incident Late AMD in participants with increased supplement intake of β-carotene143, and a 
reduced risk of Late AMD in those who received antioxidants or antioxidants plus zinc 
supplements (which contained β-carotene) from the original AREDS formula144. However, in 
the AREDS2, a new trial focusing on LZ supplements in the AREDS population, found that 
elimination of β-carotene showed no effect on progression to Late AMD. The AREDS 2 also 
found that addition of either LZ, DHA + EPA or both to the original AREDS formula did not 
further reduce the risk of progression to Late AMD in the whole study sample137, a generally 
well-nourished population. However, in a subgroup analysis, among participants in the lowest 
quintile of dietary LZ intake, those receiving LZ supplements had a significantly reduced risk 
of progression to late AMD compared to those who received the placebo137,145. Therefore, 
supplementary LZ was recommended as an appropriate substitute for β-carotene, as β-
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carotene supplements may also potentially increase the incidence of lung cancer among 
former smokers137,145.  
 
High dietary intake of LZ was reported to be associated with a reduced risk of developing 
indistinct soft or reticular drusen at the 10-year visit of the BMES139. No significant 
associations were found between dietary LZ intake and incident Early AMD or early AMD 
lesions in the BMES and BDES, at 5 years146,147. Among other antioxidants, α-carotene was 
found associated with a reduced risk of incident Early AMD in the BDES 5-year follow-up 
visit147.  
 
Although only a limited number of studies have reported the risk of AMD in relation to 
dietary intake of antioxidants, many clinic-based studies and clinic trials including the 
AREDS have reported a protective effect of LZ supplements on AMD137,145. The AREDS2 
investigators recommends the use of LZ supplements for patients with advanced stage of 
Early AMD who are at high risk of Late AMD145.   
 
 
 
 
Table 1.3.2-2: Summary of population-based cohort studies reporting risk of Late and Early age-related macular degeneration (AMD) associated 
with intake of lutein-zeaxanthin and other antioxidants. 
 
Name/Location of 
Study Type of Study 
Method of 
analyses Adjustment  Lutein-Zeaxanthin (dietary intake) 
Other antioxidants (diet and/or 
supplement intake) 
BMES139,146 Population-based 
cohort  
Highest 
compared to 
lowest tertile 
Age, sex, 
smoking and 
other factors 
Late AMD: RR 0.35 (95% CI 0.13-0.92) 
for 10-year incident neovascular AMD.  
Late AMD: RR 2.68 (95% CI 1.03-
6.96) for 10-year incident neovascular 
AMD from baseline β-carotene intake 
(diet and supplements).  
    Early AMD: No significant association 
for 5-year incident early AMD. RR 0.66 
(95% CI 0.48-0.92) for 10-year incident 
indistinct soft or reticular drusen 
Early AMD: No significant 
associations.  
BDES147  Population-based 
cohort  
Highest 
compared to 
lowest quintile 
Age, sex, 
smoking and 
other factors 
Early AMD: No significant association 
for 5-year incident early AMD, or early 
AMD lesions including large drusen and 
pigmentary abnormalitites. 
Early AMD: OR 0.52 (95% CI 0.3-1.0) 
for 5 year incident large drusen from 
previous intake of α-carotene (diet 
only).  
Rotterdam140 Population-based 
cohort  
Per 1-SD 
increase 
Age, sex, 
smoking and 
other factors 
Any AMD: No significant association at 
11 years.  
Any AMD: No significant association at 
11 years.  
NHS and 
HPFS141,142* 
Prospective 
cohort  
Highest 
compared to 
lowest quintile 
Age, smoking 
and other factors 
Late AMD: No significant association 
between noeovascular AMD and LZ 
intake at 18 years. RR 0.59 (95% CI 
0.48-0.73) for incident late AMD at 26 
years. 
Late AMD (26-year follow-up): β-
cryptoxanthin RR 0.73 (95% CI 0.60-
0.89); α-carotene RR 0.69 (95% CI 
0.56-0.84); β-carotene RR 0.82 (95% CI 
0.67-1.01) (diet and supplements).
       Early AMD: No significant association 
at 18 years. 
Early AMD: No significant associations 
found at 26 years for any early AMD 
lesions. 
BMES=Blue Mountains Eye Study, BDES=Beaver Dam eye Study, NHS=Nurses Health Study, HPFS=Health Professionals Follow-Up Study, SD=standard deviation, 
RR=relative risk, OR=odds ratio, CI=confidence interval
*Self-reported AMD with diagnosis confirmed by participants eye care professional
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Vitamins and Zinc   
The relationship between dietary intake of vitamins, vitamin supplement use, dietary or 
supplementary zinc and the incidence of AMD have also been investigated, with inconsistent 
findings 57,139,140,146,147. The associations between vitamin or zinc intake and incident AMD in 
three population-based studies are summarized in Table 1.3.2-3. 
 
After adjusting for age, sex, smoking and other factors, vitamin E intake from diet and 
supplements was associated with an increased risk of Late AMD at the 10-year follow-up 
visit of the BMES139; whereas, there was a reduced likelihood of incident any AMD 
associated with higher intake of vitamin E in the RS140. Increased vitamin E intake from diet 
alone was also associated with a reduced 5-year incidence of large drusen in the BDES147 
(Table 1.3.2-3). 
 
After adjusting for age, sex, smoking and family history of AMD, vitamin C intake from diet 
and supplements was associated with a 2-fold risk of Early AMD in 5 years, reported by the 
BMES team146 (Table 1.3.2-3). No other significant associations between vitamin C and 
incident AMD were reported from other studies.    
 
After adjusting for age, sex, smoking and other factors, dietary zinc intake was associated 
with reduced incidence of any (Early or Late) AMD in both the BMES and RS139,140. Higher 
dietary zinc intake was found associated with reduced risk of Early AMD and early AMD 
lesions in the BMES57,139 (Table 1.3.2-3). 
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Dietary intake of combined vitamins (vitamin C, E and zinc) and antioxidant (β-carotene) 
was found associated with a 35% reduced risk of any (Early or Late) AMD at11 years in the 
RS, after adjusting for age, sex, smoking status and other factors140.  
 
The AREDS found zinc supplements to be beneficial to reduced progression to Late AMD 
among patients with advanced stage of Early AMD (AREDS categories 2 and 3) 144. Thus 
zinc is an essential component of supplement formula recommended to patients with Early 
AMD145.   
 
 
 
 
Table 1.3.2-3: Summary of findings from population-based studies regarding the risk of Late AMD in relation to dietary and supplementary 
intake of vitamins and zinc. 
 
Name/Location 
of Study Type of Study 
Method of 
analyses Adjustment  Vitamins (diet and/or supplements) Zinc (dietary intake) 
BMES139,146 Population-
based cohort  
Highest 
compared to 
lowest tertile 
Age, sex, 
smoking and 
other factors 
Late AMD: vitamin E intake (diet and 
supplements): RR 2.55 (95% CI 1.14-
5.70) for 10-year incident late AMD.  
Any AMD: RR 0.56 (95% CI 0.32-0.97) 
for incident any AMD (top decile 
compared to rest of population) 
    Early AMD: vitamin C intake (diet and 
supplements): OR 2.2 (95% CI 1.3-3.9) 
for 5-year incident early AMD. 
Early AMD: RR 0.54 (95% CI 0.30-0.97) 
for incident early AMD (NB. For top 
decile compared to rest of population) 
BDES147  Population-
based cohort  
Highest 
compared to 
lowest quintile 
Age, sex, 
smoking and 
other factors 
Early AMD: vitamin E intake (diet only): 
OR 0.4 (95% CI 0.2-0.9) for 5-year 
incident large drusen.  
Early AMD: No significant association 
for 5-year incident early AMD or early 
AMD lesions. 
Rotterdam140 Population-
based cohort  
Per 1-SD 
increase 
Age, sex, 
smoking and 
other factors 
Any AMD: vitamin E intake (diet and 
supplements): HR 0.92 (95% CI 0.84-
1.00) for 11-year incident any AMD. 
Any AMD: HR 0.91 (0.83-0.98) for 11-
year incident any AMD.  
BMES=Blue Mountains Eye study, BDES=Beaver Dam Eye Study, AMD=age-related macular degeneration, SD=standard deviation, RR= relative risk, 
OR=odds ratio, HR=hazard ratio, CI=confidence interval
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1.3.3 Other Risk Factors  
Systemic risk factors found to be inconsistently associated incident AMD include blood 
pressure (BP), white blood cell count (WBCC), and serum lipids, in particular total 
cholesterol and high-density lipoprotein (HDL) cholesterol. A number of population-
based cohort studies have reported the associations between these possible risk factors 
and prevalent AMD148-153, however limited data exist on the associations with incidence 
or progression of AMD. Among dietary risk factors, alcohol consumption has also been 
investigated for its role in the incidence of AMD.  
 
Blood Pressure 
The relationship between increased BP or the presence of hypertension and incident 
AMD were assessed in majority of the studies mentioned in section 1.2. Overall, there 
were no significant associations between baseline BP and incident Early or Late AMD, 
after  adjustment for age and sex in most cohorts50,63,117,119,154,155, except for the 10-year 
follow-up report of the BDES where increase in systolic BP was found independently 
associated with the 10-year incidence of neovascular AMD156. Similarly, higher 
baseline pulse pressure was associated with the 10-year incidence of Early and Late 
AMD in the BDES156 and the 4-year incidence of any AMD in the LALES63, but not in 
any other population-based cohort.     
 
White Blood Cell Count 
The association between WBCC and incident AMD is inconsistent across different 
studies.  Initial reports of this association were derived from observations of pathology 
specimens where leukocytes were present in neovascular membranes of eyes with 
neovascular AMD157-159. These findings suggested a link between inflammation and late 
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AMD, prompting the investigation of WBCC as a risk factor for AMD. C-reactive 
protein (CRP) is another inflammatory marker, found in drusen that may be considered 
as a risk factor for AMD.  
 
There was no significant association between WBCC and incident Late AMD in most 
cohorts 117, except in the Hisayama study where higher circulating WBCC was 
associated with 9-year incident Late AMD after multivariable adjustment50. In the 
BMES, when stratified by sex and smoking status, there was an increased risk of 10-
year incident Late AMD in men and in former smokers who had the highest compared 
to lowest tertile of baseline WBCC levels160. In the RS, increased high sensitivity CRP 
levels were associated with an increased risk of incident Late AMD at 11 years161.   
 
Of the two cohort studies that reported associations between WBCC and incident Early 
AMD, no significant associations were found in the BDES over 10 and 20 years55,162, 
however,  elevated baseline WBCC was associated with 10-year incidence of Early 
AMD in the BMES160. In an analysis of combined effects there was a >2-fold increased 
risk of 10-year incident Early AMD among those who had both WBCC in the highest 
tertile and ≥1 risk allele of CFH, compared to persons who had neither, in the BMES96. 
Combined effects for the presence of ≥1 risk allele of ARMS2 together with a number of 
inflammatory markers on the incidence of Early AMD were demonstrated at 10-year 
follow-up of the BMES102.  
 
Lipids 
The relationship between lipids, particularly total serum cholesterol and HDL 
cholesterol, and incident AMD have been widely examined, partly because cholesterol 
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was an important constituent of drusen163-165. Associations between cholesterol and 
incident AMD have been reported in a number of population-based cohorts117,154-156.  
 
Total cholesterol was associated with an increased risk of incident GA in a pooled data 
analyses of the BMES, BDES and RS117, but was not associated with 5-year incidence 
of Late AMD in the Reykjavic Study155.  
 
High HDL cholesterol was associated with increased incidence of GA in the BDES156, 
and also associated with increased incidence of GA and Late AMD in the Reykjavic 
Study155. In comparison, there was a reduced risk of GA and Late AMD over 5 and 10 
years associated with increased baseline HDL cholesterol levels in the BMES117,154. 
 
Increased HDL cholesterol is known to be protective for cardiovascular disease risk166-
168, however, evidence to date about the associations between lipids and the long-term 
incidence and progression of AMD is largely inconsistent169.  
 
Alcohol  
Alcohol is a modifiable dietary risk factor shown to increase oxidative stress, which can 
cause tissue damage in various organs including the retina170,171. Previous cross-
sectional studies have shown that moderate alcohol consumption may provide a 
protective effect against AMD prevalence, with a J-shaped association172,173. Risk of 
developing AMD associated with low, moderate and high level consumption of alcohol 
also followed a similar pattern in magnitude of odds ratios in cohort studies, although 
the association was non-significant122,174-176.   
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Heavy drinking or increased alcohol intake ≥4 drinks per day, compared to abstainers, 
was significantly associated with a 5-fold risk of developing Late AMD and a 9-fold 
risk of developing GA in the BDES, after adjusting for age, sex and other factors118,177. 
The effect was based on limited number of heavy drinkers, however, and therefore this 
observation could have been a chance finding118,177.  
 
Increased alcohol intake was significantly associated with increased incidence of Early 
AMD, observed in a number of studies 119,134,151, and marginally associated with 5-year 
incidence of Early AMD in men only after adjusting for age and sex in the BDES178. 
 
There were no significant associations between increased alcohol intake and incident 
Early or Late AMD in the Hisayama Study, Rotterdam Study, Physicians’ Health Study 
and the NHS and HPFS over the follow-up periods of 8-13 years50,174-176. Lack of a 
uniform definition for heavy and moderate drinking across most population-based 
studies makes it difficult to compare findings about the associations between pattern of 
alcohol consumption and incident AMD.  
 
1.3.4 Combined Risk Factors 
Combinations of two or more risk factors have also been assessed for associations with 
AMD in a number of studies and in pooled cohort data of two or more study 
populations56,57,115. In the BMES, the 10-year incidence of Late AMD was increased 
among participants with joint exposure to smoking and low fish consumption compared 
to those with no exposure to either factor115. In the 3CC, pooled data analyses showed 
that the risk of Early AMD or any (Early and Late) AMD was significantly reduced 
among persons with high genetic risk (≥2 risk alleles of CFH and/or ARMS2) if they 
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consumed foods rich in LZ , compared to those with the same genetic risk but low 
dietary intake of LZ57. In the RS a similarly reduced risk of Early AMD was 
documented among persons with high genetic risk if they had high intake of zinc or zinc 
plus ω-3 fatty acids from diet or supplements, compared to those with low intake of the 
same nutrients56.  
 
Each risk factor may contribute a small proportion of risk for AMD development and 
progression. When two factors co-present, the risk difference between the exposed 
group (to both factors) and the non-exposed group (to either factor) would be stronger 
and easily detected.   
 
In summary, age and genetic risk from the CFH and ARMS2 genes are the most 
consistent risk factors for Early and Late AMD development29,33-35,39,44,47-
50,62,63,81,82,82,96,97,103,105. A modifiable factor, smoking, is also consistently found to 
contribute an increased risk of Late AMD50,63,114-117. Of the other modifiable factors, 
diet rich in ω-3 fatty acids or regular fish consumption, intake of zinc and consumption 
of food rich in LZ, are relatively consistent protective factors associated with reduced 
incidence and progression of AMD, according to a majority of population-based and 
clinic-based studies57,128-133,139,139,140,142,144. Differentiated effect of these nutrients 
depending on the genetic susceptibility to AMD of individuals has been 
suggested56,57,96,102, however, confirmation of these observations in different samples is 
needed.     
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Justification of the projects in the thesis 
Many population-based cohort studies have described the incidence and progression of 
Early and Late AMD among older people of different ethnicities over the short- and 
mid-terms (<10 years in follow-up duration), and reported risk factors associated with 
the incidence and progression 29,30,38,39,44-46,48-50,50,63,96,114,117,122,130,134,140,146,147,155,175,178. 
However, there is limited knowledge on the long-term (15+ years) incidence and 
progression of AMD and individual AMD lesions. There is also limited assessment of 
risk factors associated with the long-term incidence and progression of AMD. Projects 
included in this PhD thesis will fill in the gap of knowledge in this regard.     
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Chapter 2 
 
Methods 
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2.1 Population-based cohorts 
The findings presented in this thesis have been primarily drawn from the Blue 
Mountains Eye Study (BMES). In addition, comparisons between the BMES and the 
Singapore Epidemiology of Eye Diseases (SEED) study were made in one manuscript, 
and data from other cohorts within the Three Continent AMD Consortium (3CC) are 
also used in two manuscripts.  
 
2.1.1 The Blue Mountains Eye Study (BMES) 
Study Population 
The BMES is a population-based study of vision and eye disease in older persons 
residing in the Blue Mountains region, west of Sydney Australia. The population was 
chosen from two postcode areas within the Blue Mountains region covering the suburbs 
of Katoomba, Leura and Medlow Bath (postcode 2780) and Wentworth Falls (postcode 
2782).  
 
Briefly, the two postcode areas were considered suitable for the study, with the 
population relatively stable and homogenous, largely European descents36. The 
population had an older age distribution compared with that of NSW and a slightly 
higher socioeconomic status compared to that of the Australian population179,180.  
 
At baseline, the BMES recruited 3654 participants (82.4% of those eligible) aged 49 
years and older in 1992-1994 (BMES I). Surviving participants were invited to attend 
the next examination. Of the surviving baseline participants, 2334 (75.8% of survivors; 
575 deceased) attended the 5-year follow up examinations in 1997-1999 (BMES II). 
The 10-year examinations were attended by 1952 participants (76.7% of survivors; a 
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further 535 deceased) in 2002-2004 (BMES III), and the final 15-year follow up 
examinations were attended by 1149 participants (56.1% of survivors; a further 496 
deceased) in 2007-2009 (BMES IV). A flow chart of participation in the BMES is 
presented in Figure 2.1.1-1.  
 
The mean (median, minimum and maximum) follow-up period for the 2334 BMES II 
participants was 5.1 years (4.9, 3.4 and 7.8 years); for the 1952 BMES III participants it 
was 10.5 years (10.4, 8.9 and 12.9 years) and for the 1149 BMES IV participants it was 
15.6 years (15.5, 13.6 and 17.7 years). All 4 examinations were approved by Human 
Research Ethics Committees of the University of Sydney and Western Sydney Area 
Health Service, and adhered to the tenets of the Declaration of Helsinki. Written 
informed consent was obtained from all participants at each visit.  
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Figure 2.1.1-1 Flow chart of 15-year participation in the Blue Mountains Eye Study 
cohort, indicating eligible participants, refusals and examined participants at each time 
point.  
 
 
  
4433 Eligible persons
3079 Eligible persons
2544 Eligible persons
2048 Eligible persons
575 Died
535 Died
496 Died
3654 Examined (82.4%)
2334 Examined (75.8%) 
1952 Examined (76.7%) 
1149 Examined (56.1%) 
745 Refused/moved
592 Refused/moved
454 Refused
81 Too frail
364 Moved
BMES I, 1992-1994 
Baseline 
BMES II, 1997-1999 
5-year follow-up 
BMES III, 2002-2004 
10-year follow-up 
779 Refused/died 
before examination
BMES IV, 2007-2010 
15-year follow-up 
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Procedures  
A comprehensive questionnaire was administered and eye examinations were performed 
at each visit, as described previously35,36,44.  
 
Trained interviewers completed a face-to-face interview with each participant using  
questionnaires that composed of comprehensive demographic and medical history 
information, including a detailed list of past and current medications, family histories of 
some systemic and ocular conditions, past medical diagnoses and surgeries, self-rated 
health and vision, smoking status and alcohol consumption (Appendix A). These 
questionnaires were completed prior to eye examinations.  
 
Eye examinations included measurement of vision and subjective refraction using the 
BDES modification of the Early Treatment Diabetic Retinopathy Study (ETDRS) 
protocol with logMAR chart181, slit lamp examination of the lens and retinal fundus 
photography after pupil dilation using 1.0% tropicamide and 10% phenylephrine. 
Stereoscopic 30° retinal fundus photographs of the optic disc (ETDRS standard field 1) 
and macula (ETDRS standard field 2)182 were obtained from both eyes. Non-
stereoscopic photographs of the upper and lower arcades, fields temporal and nasal to 
the optic disc and temporal to the fovea were also taken (in total seven fields from each 
eye following the ETDRS protocol 182,183. A Zeiss FF3 fundus camera (Carl Zeiss, 
Oberkochon, Germany) and Kodachrome 25 slide film (Kodak) were used for 
photography at the BMES I, II and III examinations. At the BMES IV examination, 
because of the unavailability of Kodachrome, 40° degree digital retinal images were 
obtained using a Canon CF-60 DSi fundus camera with DS Mark II body (Canon Inc., 
Tokyo, Japan).  
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Photographs were obtained from both eyes in 98%, 98%, 85% and 92% of the study 
populations at baseline, the 5-, 10- and 15-year examinations, and from at least 1 eye in 
99%, 99%, 87% and 92% of the populations at baseline, the 5-, 10- and 15-year 
examinations, respectively.  
 
Diet was assessed using a self-administered 145-item semi-quantitative food frequency 
questionnaire (FFQ) (Appendix B), which participants completed at home after 
attending their examination at baseline and each follow-up visit. Fasting blood samples 
were collected from participants who attended the BMES I, II and III examinations, for 
hematologic analysis and clinical biochemistry assessment. DNA extraction and 
genotyping were also performed in over 80% of BMES II and III participants. 
 
2.1.2 The Singapore Epidemiology of Eye diseases Study (SEED) 
Study Population 
The SEED study includes three population-based study populations, namely the 
Singapore Malay Eye Study (SiMES), the Singapore Indian Eye Study (SINDI) and the 
Singapore Chinese Eye Study (SCES), representing the Malay, Indian and Chinese 
populations in Singapore. Baseline examinations of the SEED were conducted between 
2004 and 2009.  
 
Briefly, age-stratified random sampling was used to select 5600 Malay, 6350 Indian and 
6752 Chinese names from the Ministry of Home Affairs184-186. Only residents aged 40-
80 years were selected. After excluding participants who had moved from the 
residential address, had not lived at the address in the past 6 months, or were deceased 
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or terminally ill, the number of eligible participants included 4168 Malays, 4497 Indians 
and 4606 Chinese. Of these, a total of 3280 Malays (78.7% of those eligible) 
participated in the SiMES baseline examination between 2004-2006187, 3400 Indians 
(75.6% of those eligible) participated in the SINDI baseline examination between 2007-
2009, and 3353 Chinese (72.8% of those eligible) participated in the baseline 
examinations between 2009-2011187. All three studies were approved by the SingHealth 
Institutional Review Board and all examinations conducted at the Singapore Eye 
Research Institute in accordance with the Declaration of Helsinki. Written informed 
consent was obtained from all participants prior to examinations. 
 
Procedures 
Each participant in the SEED studies underwent detailed interviewer-administered 
questionnaires and comprehensive  eye examinations. The questionnaires contained 
sociodemographic, lifestyle data and medical histories, adapted from the BMES 
protocol and modified accordingly. The ocular examinations included assessment of 
visual acuity and subjective refraction, slit-lamp biomicroscopy, gonioscopy, intraocular 
pressure measurement using Goldmann applanation tonometry and ophthalmoscopy 
performed by ophthalmologists or ophthalmologist trainees.  Pupils were dilated with 
1% tropicamide and 2.5% phenylephrine hydrochloride, and 45° digital retinal 
photographs of the optic disc and macular fields were obtained using a Canon CR-DGi 
digital fundus camera, with10D SLR digital camera back (Canon, Tokyo, Japan). 
Retinal photographs of at least 1 eye were taken in 96.3% Malay, 97.9% Indian and 
98.8% Chinese participants187.  
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Non-fasting blood samples were collected for laboratory investigations including 
hematologic biochemistry tests and DNA extraction. Urine samples were also collected 
for biochemistry tests188.  
 
2.1.3 Cohorts of the Three Continent AMD Consortium (3CC)  
The 3CC consists of four population-based cohort studies, including the BMES, BDES, 
RS and LALES. Only BDES and RS cohorts are briefly described in this sub-section. 
 
The Beaver Dam Eye Study 
Study Population 
The BDES was conducted in the town of Beaver Dam, Wisconsin following a private 
census of the population from 1987-1988. Of 5924 eligible participants, 4926 (83.2%) 
aged between 43 and 86 years attended the baseline examination between 1988 and 
1990. Of these participants, 3684 (81.1% of survivors) attended the 5-year follow-up 
examination from 1993-1995, 2764 (82.9% of survivors) attended the 10-year follow-up 
examination from 1998-2000, 2119 (85.4% of survivors) attended the 15-year follow-up 
examination from 2003-2005 and 1913 (over 80% of survivors) attended the 20-year 
follow-up examination from 2008-2010. Data were collected at each visit with 
institutional review board approval from the University of Wisconsin-Madison in 
conformity with all federal and state laws; the work was compliant with the Health 
Insurance Portability and Accountability Act and adhered to the tenets of the 
Declaration of Helsinki. Written informed consent was obtained from all participants at 
each visit. 
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Procedures 
At each visit, participants underwent a standardized face-to-face interview with 
questionnaires and examinations. Ocular examinations pertaining to AMD assessment 
included pharmacologic mydriasis, 30° stereoscopic color photographs of the optic disc 
and macula fields, and non-stereoscopic photographs of the other five retinal fields 
following the ETDRS protocol182 were taken from both eyes, using a Zeiss FF4 fundus 
camera (Carl Zeiss, Oberkochon, Germany). Of the 2119 participants seen at the 
baseline, 5-, 10- and 15-year follow-up examinations, 96.4% had gradable retinal 
photographs in at least one eye at each visit. Casual blood specimens were also obtained 
at the time of each examination. 
 
The Rotterdam Study 
Study Population 
The RS is a cohort study of persons aged 55+ years residing in Ommoord, a district of 
Rotterdam, the Netherlands. Names and addresses of residents were drawn from a 
municipal register. In random clusters all potential participants were invited to the study 
by letter and telephone call189. An interview was conducted at each participant’s home 
that included questions of demographic characteristics, medical and ophthalmological 
histories, level of education obtained, ability in daily activities and a variety of other 
variables190. Physical examinations were later conducted at a screening centre. 
Residents living in nursing homes within the target area were also included, and 
examined in their homes190.  
 
At baseline (1990-1993), 7983 participants (77.7% participation rate) were examined in 
the RS, of whom 6419 had ophthalmic examinations and retinal photography 
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performed. Of these participants, 4977 (estimated 82.1% of survivors), 3637 (estimated 
71.2% of survivors), and 2674 (number of survivors for this visit could not be 
estimated) were re-examined at the second (1993-1995), third (1997-1999) and fourth 
(2002-2004) visits, respectively. To correspond with the BMES and BDES 5-year 
follow-up interval, data from the second (2-year) follow-up visit (1993-1995) were 
excluded in analyses except for incident AMD cases that were included as the outcome 
event in the third (6-year) follow-up visit. All examinations were approved by the 
Medical Ethics Committee of the Erasmus Medical Centre and by the Ministry of 
Health, Welfare and Sport of the Netherlands, implementing the Wet 
Bevolkingsonderzoek: ERGO (Population Studies Act: Rotterdam Study). All 
examinations adhered to the tenets of the Declaration of Helsinki. Written informed 
consent was obtained from all participants at each visit. 
 
Procedures 
Prior to physical examinations, a 170-item validated semi-quantitative FFQ was 
administered during a face-to-face interview with a trained dietician, at the study site. 
Ocular examinations pertinent to AMD assessment included pharmacologic mydriasis 
and 35° stereoscopic colour retinal photographs of the macular field obtained using the 
Topcon TRV-50VT fundus camera (Topcon Optical Co., Tokyo, Japan) in the first 3 
visits. At the fourth visit, 35° digital photographs were obtained using a Topcon TRC 
50EX fundus camera with Sony DXC-950P digital camera (Topcon Optical Co.).  
 
Casual blood samples were collected at baseline and fasting blood samples obtained at 
each of the follow-up examinations for clinical biochemical analyses and DNA 
extraction.     
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2.2 Assessing AMD 
2.2.1 Photographic Grading  
Photographic grading conducted for the BMES and SEED cohorts followed the 
Wisconsin Age-related Maculopathy Grading System (WARMGS) protocol26, after 
simple modification by the BMES principal investigator (Paul Mitchell).  
 
For each eye, the presence of AMD lesions, maximum individual drusen size, location 
and total macular areas involved by these lesions were assessed. The WARMGS grid 
was overlaid on the macular field of positive slides and a series of measurement circles 
were used to estimate drusen sizes and total areas involved by the lesions (Figure 1.2.1-
1). All retinal photographs taken from the same eye were placed into a clear plastic 
sheet to form the best stereo view of paired images for macular and optic fields. The 
sheet is then placed on a fluorescent viewing box (light box) with a Kelvin rating 6200°, 
and examined by graders using a Donaldson stereo-viewer with 5x magnification. For 
grading of digital images, a software program containing the digitized WARMGS grid 
and measurement circles (DH Client (Digital Healthcare: Image Management Systems, 
www.digital-healthcare.com, Cambridge, UK)) was used and applied in the same 
manner, overlying the macular photograph. Magnification was calculated and matched 
between the retinal images and WARMGS grid and measurement circles.   
 
The WARMGS grid consists of 9 subfields demarcated by 3 concentric circles which 
are intersected by 4 radial lines (Figure 1.2.1-1). The radius of the inner circle 
corresponds to 500µm, the middle circle corresponds to 1500µm and the outer circle 
corresponds to 3000µm26. The subfields are designated as the following: the central 
subfield, the ‘inner’ superior, inferior, temporal and nasal subfields, and the ‘outer’ 
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superior, inferior, temporal and nasal subfields. An example of the WARMGS grid 
placement over the macular field, and the grading circles are shown in Figure 1.2.1-1.  
 
The three sets of smaller measurement circles, C0, C1 and C2, have diameters of 63µm, 
125µm and 250µm, primarily used to estimated maximum drusen size26,29. The 
intermediate sized and large sized circles, I1, I2, O1 and O2, have diameters of 175µm, 
350µm, 325µm and 650µm, respectively.  These circles and additional two circles 
equivalent to a half a disc area (0.5 DA) and 1 disc area (1 DA) are primarily used to 
measure the collective area involved by various lesions including drusen, retinal 
pigment epithelium (RPE) abnormalities and sensory retinal or RPE detachment29,36. 
 
Retinal photographs taken at all visits of the BMES, and digital images of the SEED 
studies were graded in a masked manner by the same senior photographic graders in the 
BMES team. In the BDES and RS, retinal photographs were assessed by trained graders 
of each study team separately.  
 
In the BMES, the presence, size and area of AMD lesions were recorded on a grading 
form (Appendix C). Inter- and intra-grader reliability showed good agreement for AMD 
grading, with quadratic weighted kappa values ranging from 0.64-0.93 and 0.54-0.94, 
respectively36.  
 
In the BMES and BDES, side-by-side grading was performed. For example, 
photographs of BMES I and II, and BMES I and III were graded side-by-side for 
participants with AMD lesions identified at any of the baseline and follow-up 
examinations36,44. Similar manner was also applied in the BDES.  
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2.2.2 Definitions of AMD and AMD Lesions 
Late AMD Lesions 
Neovascular AMD 
Presence of either sub-retinal new vessels, serous or haemorrhagic detachment of the 
RPE or sensory retina, or sub-retinal fibrous scar in the macular area without other 
pathologic aetiology can be identified. 
 
Geographic Atrophy (GA) 
Sharply defined area of RPE and the sensory retinal loss with a diameter ≥175µm, 
exposing choroidal vessels. 
 
Early AMD Lesions 
RPE depigmentation  
Sharply demarcated area with absence of the RPE but without visible choroidal vessels.  
 
Hyperpigmentation  
Granules or clumps of gray or black pigment in or beneath the retina. 
 
Drusen  
Discrete whitish-yellow material deposited between RPE cells and its basement 
membrane, the Bruch’s membrane, which may be confluent, with sharp or fuzzy edges. 
 
 
 
85 
 
Types of Drusen 
 Hard distinct drusen  - drusen less than 63µm in diameter, with sharp edges but 
without a solid, thick, nodular appearance. This is not considered an AMD 
lesion. 
 Intermediate soft drusen – maximum diameter of the drusen larger than 63µm 
but smaller than 125µm  
 Soft distinct drusen  - drusen greater than 125µm in diameter with uniform 
density, sharp edges and a solid thick appearance 
 Soft indistinct drusen - drusen greater than 125µm in diameter with decreasing 
density from centre to periphery and fuzzy edges 
 Reticular drusen – drusen that form ill-defined networks of broad interlacing 
ribbons.  
 
Examples of neovascular AMD, GA, RPE depigmentation, hyperpigmentation and 
drusen were presented in Figure 1.1-1 (Chapter 1).  
 
AMD Stage 
Late AMD 
Late AMD was defined as the presence of any neovascular AMD lesions (RPE or 
sensory retinal detachment, disciform scars), photocoagulation scars with history of 
neovascular AMD, or GA13.  
 
Early AMD  
Early AMD was defined as the presence of large (≥125µm in diameter) indistinct soft 
drusen, reticular drusen or the co-presence of large distinct soft drusen and retinal 
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pigmentary abnormalities (hyperpigmentation or RPE depigmentation) within the 
macula, in the absence of any late AMD lesions.  
 
2.2.3 Definitions for AMD and AMD Lesion Incidence, Progression and 
Bilaterality 
Incident AMD and incidence of individual AMD lesions; unilateral and bilateral AMD; 
and progression of AMD will be presented in chapters or sub-chapters that address these 
outcomes specifically. 
 
Confirmation of AMD Incidence 
All late AMD prevalent and incident cases in the BMES, BDES and RS were 
crosschecked by lead investigators of the 3CC study teams, and consensus was achieved 
on all late AMD cases that were used in research projects conducted by individual study 
teams or by the 3CC32.      
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2.3 Risk Factor Assessment 
Risk factors were assessed in relation to the incidence and progression of AMD and 
specific AMD lesions in the BMES. Common AMD risk factors assessed include age, 
sex and presence of genetic polymorphisms, as well as modifiable risk factors such as 
smoking and fish consumption. 
 
Age, sex and smoking status were obtained from interviewer-administered examination 
questionnaires.  
 
The Australian tables of food composition191,192 and the United States Department of 
Agriculture carotenoid food composition database193 were used to calculate the intake of 
nutrients from food and drink consumption specified in the FFQs.  
 
Genetic polymorphisms were ascertained from genotyping. In the BMES, the 
complement factor H (CFH) single nucleotide polymorphism (SNP) rs1061170 was 
genotyped using TaqMan assays (Applied Biosystems, Foster City, California)96 and the 
age-related maculopathy susceptibility 2 (ARMS2) SNP rs10490924 genotyped using 
restriction fragment length polymorphism analysis102. Additional genotyping was also 
performed with an Illumina Human 670-Quad custom array, version 1 (Illumina Inc., 
San Diego, CA) with stringent quality control testing using PLINK (Purcell S. PLINK 
version 1.07. Available at: http://pngu.mgh.harvard.edu/purcell/plink/ accessed July 12, 
2013). After quality checking, genome-wide association scan (GWAS) data were 
imputed with the 1000 Genomes panel (Version 1 initially and Version 3 subsequently), 
using IMPUTE 2.0 (Department of Statistics, University of Oxford, Oxford, UK)194. 
The imputation r2 was 0.968 for CFH-rs1061170 and 0.996 for ARMS2-rs104900924.  
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2.4 Data Handling and Common Statistical Analyses 
In the BMES, data recorded from the interviewer-administered questionnaires, the FFQ, 
blood test results and AMD grading sheets were entered into Microsoft Access 
databases by two independent data entry staff. Data entry errors were checked and any 
discrepancy between the two entries were verified and corrected.  
 
The Statistical Analysis System, SAS195, version 9.3 (SAS Institute Inc., Cary NC) was 
used for all statistical analyses. 
 
Incident rates of AMD and AMD lesions were calculated using the Kaplan-Meier 
product-limit survival estimate and alternatively after adjusting for the competing risk 
of death. The BMES population was also directly age-standardized to the BDES 
population for comparison33. 
 
Frequency tables and the χ2 statistic or Mantel-Haenszel procedure were used for 
comparing proportions. Logistic regression models were used to analyse associations 
between risk factors and the incidence or progression of AMD after adjusting for age, 
sex and smoking, and additional potential confounding variables. Generalized 
estimating equation (GEE) models using the GENMOD procedure in SAS196 were 
applied to eye-specific data when assessing early AMD lesions characteristics in 
relation to AMD progression.    
 
All means are presented with standard deviations (SD) and medians presented with 
maximum and minimum values. All association estimates are presented as odds ratios 
(ORs) with 95% confidence intervals (CIs).  
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Chapter 3 
 
Long-Term Incidence of Age-related 
Macular Degeneration (AMD) and 
AMD Lesions in the Blue Mountains 
Eye Study      
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3.1 The 15-year incidence, progression and risk factors associated with 
age-related macular degeneration 
 
Publication relating to this section of Chapter 3: 
Joachim N, Mitchell P, Burlutsky G, Kifley A, Wang JJ. The Incidence and Progression 
of Age-Related Macular Degeneration over 15 Years: The Blue Mountains Eye Study. 
Ophthalmology 2015; 122 (12): 2482-2489 
  
91 
 
ABSTRACT 
Purpose: To assess the 15-year incidence and progression of age-related macular 
degeneration (AMD) in an older Australian population. 
 
Methods: Blue Mountains Eye Study (BMES) participants (n=3654), aged 49+ years 
were examined during 1992-1994. Of these 2334 participants (75.8% of survivors) were 
re-examined after 5 years (1997-1999), 1952 (76.7% of survivors) after 10 years (2002-
2004) and 1149 (56.1% of survivors) after 15 years (2007-2010). Color retinal 
photographs were taken and comprehensive questionnaires administered at each visit. 
Blood samples were collected and DNA genotyped. Retinal photographic grading was 
performed by the same graders at each examination following the Wisconsin AMD 
grading protocol. Side-by-side comparisons were used to confirm newly-developed 
AMD lesions. Incidence was estimated using Kaplan-Meier estimates. Associations of 
AMD incidence with age, sex, smoking status, presence of the complement factor H 
(CFH)-rs1061170 and age-related maculopathy susceptibility 2 (ARMS2)-rs10490924 
polymorphisms and fish consumption were analyzed using discrete logistic regression 
models. Generalized estimation equation models were used to assess the risk of incident 
late AMD associated with baseline AMD lesion characteristics. 
 
Results: The 15-year incidence was 22.7% for early AMD and 6.8% for late AMD. 
After adjusting for competing risks, early and late AMD incidence was 15.1% and 
4.1%, respectively. Age was strongly associated with early and late AMD incidence 
(both p<0.0001). After age-standardization to the Beaver Dam Eye Study (BDES) 
population, early and late AMD incidence in the BMES was 13.1% and 3.3%, 
respectively. Female sex and the presence of both risk alleles of CFH-rs1061170 or 
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ARMS2-rs10490924 were independently associated with early AMD incidence, whereas 
current smoking and presence of ≥1 risk allele of CFH-rs1061170 or ARMS2-
rs10490924 were associated with late AMD incidence. Fish consumption was inversely 
associated with late but not early AMD incidence. Severity of early AMD lesion 
characteristics was a strong predictor of progression to late AMD. 
 
Conclusion: We documented the 15-year incidence of early and late AMD in an older 
Australian population that were comparable to BDES observations. Risk of progression 
to late was strongly associated with severity of early AMD lesions.  
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BACKGROUND 
Age-related macular degeneration continues to be one of the leading causes of blindness 
and visual impairment in older populations despite recent advances in 
treatments6,45,54,197. The incidence and progression of early and late-stage AMD over 5 
and 10 years has been reported in a number of large population-based studies in the 
United States, Europe, Asia and Australia over the past two decades29,34,35,38,44,45,48. 
Greater severity of early AMD lesions including increased drusen area, presence of 
pigmentary abnormalities and location of lesions close to the fovea, was shown to be 
associated with greater risk of progression to late AMD33-35,38. The relationship between 
demographic and lifestyle risk factors including older age, sex and smoking status with 
the incidence and progression of AMD was also shown in some of these populations117.  
 
However, data on the incidence of AMD over the long-term (>10 years) are limited. 
The Copenhagen City Eye Study and the Beaver Dam Eye Study (BDES) are the only 
population-based studies thus far, to report 14- and 15-year AMD incidence, 
respectively33,47. In this report, we aimed to build on the previous 5- and 10-year AMD 
incidence findings to describe the 15-year incidence of early and late AMD and its 
component lesions in an older Australian population (the Blue Mountains Eye Study 
(BMES)); and to assess risk factors and baseline early AMD lesions characteristics 
associated with the risk of progression to late AMD over the longer term. 
 
METHODS: 
Study Population, Procedures and Photographic Grading 
Details of the BMES population and the general procedures conducted at each 
examination have been described in Methods (Chapter 2). Retinal fundus photographs 
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were obtained and comprehensive demographic and lifestyle questionnaires 
administered at the baseline, 5-year, 10-year and 15-year examinations. Photographs 
were obtained for both eyes in 98%, 98%, 85% and 92% at the baseline, 5-, 10- and 15-
year examinations, and for at least 1 eye in 99%, 99%, 87% and 92% at the baseline, 5-, 
10- and 15-year examinations, respectively. Diet was assessed from a self-administered 
food frequency questionnaire completed by participants at each examination.  
 
Retinal photographic grading was performed by 2 senior graders and closely followed 
the Wisconsin Age-Related Maculopathy Grading System (WARMGS) protocol26. 
Adjudication was provided by a senior retinal specialist (Paul Mitchell) if needed. 
Consensus on BMES incident late AMD cases was provided by lead investigators of the 
Three Continent AMD Consortium32. 
 
Late AMD was defined as the presence of neovascular AMD, indicated by retinal 
pigment epithelial or neurosensory subretinal detachment, retinal or subretinal 
hemorrhage, subretinal fibrosis or old atrophic disciform scars, or photocoagulation 
scars with history of neovascular AMD; or the presence of pure geographic atrophy 
(GA) within the macula, as described in the International Age-Related Maculopathy 
Classification13. Early AMD was defined as the presence of large (≥125µm in diameter) 
indistinct soft drusen, reticular drusen or the co-presence of large distinct soft drusen 
and retinal pigmentary abnormalities (hyperpigmentation or depigmentation of retinal 
pigment epithelial (RPE) cells), within the macula, in the absence of any late AMD 
lesions. The maximal diameter of individual drusen and collective macular areas 
involved by drusen and pigmentary abnormalities within the eye was estimated using 
the WARMGS measurement circles 26. 
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Definition of AMD Incidence  
Incident late AMD in the first eye was defined as the appearance of neovascular AMD 
or GA in either eye at any follow-up examination when the lesion was not present in 
either eye at baseline. For participants at risk of incident neovascular AMD, cases with 
this lesion at baseline were excluded but cases with GA at baseline were not excluded. 
Participants with GA or neovascular AMD at baseline and with neovascular AMD at 
follow-up were excluded from those at risk of incident GA. If GA was secondary to 
neovascular AMD or laser treatment of neovascular AMD it was not considered as 
incident GA. The BMES participants who developed late AMD during the follow-up 
period were all seen by the principal investigator of the BMES (Paul Mitchell) for 
confirmation, and were treated and followed at the Eye Clinic, Westmead Hospital. 
These participants also were labelled using BMES identification numbers in their 
patient records and were included as incident late AMD cases. 
 
Incident early AMD in the first eye was defined as the appearance of either indistinct 
soft or reticular drusen, or the co-presence of distinct soft drusen and retinal pigmentary 
abnormalities in either eye, at any follow-up examination in whom no late or early 
AMD was present in either eye at baseline. Participants with either distinct soft drusen 
or retinal pigmentary abnormalities alone at baseline who later developed 
complementary lesions that comprised a diagnosis of early AMD were included as 
incident early AMD cases. Incidence of indistinct soft or reticular drusen was defined as 
the appearance of these lesions in either eye at follow-up visits, where none were 
present at baseline, and excluding late AMD, regardless of the presence of retinal 
pigmentary abnormalities. Incidence of retinal pigmentary abnormalities was defined as 
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the appearance of these abnormalities in either eye at follow-up visits in participants 
with no pigment abnormalities at baseline, and no late AMD at any follow-up visits. 
 
The incidence of early and late AMD in the second eye of participants with unilateral 
early or late AMD at baseline, and the progression from early AMD to late AMD in at 
least one eye over 15 years, were assessed among persons with AMD in one or both 
eyes at baseline. 
 
Risk Factors for Incident AMD 
Lifestyle, genetic and dietary data were obtained at each examination as described in 
Methods (Chapter 2). Briefly, for smoking history, participants were classified as non-
smokers if they answered ‘no’ to the question whether they smoke regularly. Past 
smoking was defined if participants had smoked regularly but quit smoking more than 1 
year prior to the examination. Current smoking was defined if participants were current 
smokers or had stopped smoking <1 year before the examination. Regular fish 
consumption was defined as consuming ≥1 serving of fish per week. 
 
Statistical Analyses   
The 15-year person-specific incidence of early and late AMD and their component 
lesions were estimated using Kaplan-Meier product limit survival estimates, and 
alternatively, using competing risk analyses to control for the risk of death. The BMES 
population was also directly age-standardized to the BDES population33, to compare 15-
year AMD incident rates between the two populations. Further, the probabilities of late 
AMD development from different severity levels of AMD over 15 years were reported 
according to steps on the AREDS simplified severity scale28.  
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The associations between known AMD risk factors (age, sex, smoking, fish 
consumption, the complement factor H (CFH)-rs1061170 and age-related maculopathy 
susceptibility 2 (ARMS2)-rs10490924 risk alleles) and the 15-year incidence of early 
and late AMD were assessed using age-sex-adjusted, and multivariable-adjusted 
discrete logistic regression models. Generalized estimating equation models were 
applied to eye-specific data to assess the associations between incidence of late AMD 
and early AMD lesion characteristics (area and location of drusen and retinal 
pigmentary abnormality). For comparison, the association between 15-year incident late 
AMD and steps on the AREDS simplified severity scale28 were also assessed using 
person-specific data, with time intervals included in the model. Association estimates 
are presented as age-sex-smoking-adjusted or multivariable-adjusted (age, sex, 
smoking, fish consumption, the CFH-rs1061170 and ARMS2-rs10490924 risk alleles) 
odds ratios (ORs) and 95% confidence intervals (CIs).  
 
RESULTS 
We included participants who were censored up to either the 5-, 10- or 15-year follow-
up examination to estimate incidence. Of 3654 baseline participants, 854 (23.4%) died 
with no follow-up information available and 326 (8.9%) were lost to follow-up and had 
no retinal photographs available at all 3 time points, leaving 2474 (67.7%) with 
gradable retinal photographs who were examined at either the 5-, 10- or 15-year 
examinations, or 2 or all 3 examinations. Of these 2474 participants, 574 (23.2%), 75 
(3.0%) and 7 (0.3%) were seen only at 5-, 10- or 15-year examination, respectively, 789 
(31.9%) were seen at two of the examinations (5- and 10-year, 5- and 15-year or 10- 
and 15-year examinations) and 1029 (41.6%) were seen at all three examinations. 
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Table 3.1-1 compares the baseline characteristics between participants examined at 
either or all of the 5-, 10- or 15-year examination (n=2474) and those who were alive 
but not examined at any follow-up examination (n=326) or those who died (n=854) 
without re-examination in the BMES cohort. Compared to those who were followed, 
those who were lost to follow-up were more likely to have been younger at baseline 
(mean age: 60.6 versus 64.3 years), to have a lower socioeconomic status (defined by 
homeownership and trade or higher qualification), to be current smokers (22.5% versus 
13.1%) but less likely to have a history of heart disease (7.7% versus 14.4%). Histories 
of stroke, cancer, diabetes, hypertension and self-ranked health were not significantly 
different among those examined versus those not examined. Participants who died 
without attending any follow-up were on average 10 years older, more likely to be 
living alone, to have walking disabilities and systemic diseases and to use community 
services at baseline (Table 3.1-1).  
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Table 3.1-1: Comparison of baseline characteristics between participants examined and 
not examined at 15 years in the Blue Mountains Eye Study Cohort. 
 
Baseline Characteristics Examined (n=2474) 
Not examined or no 
photographs 
(n=326)
P Value* Died (n=854) 
Mean age (years) (95% 
CI) 64.3 (64.0-64.7) 60.6 (59.8-61.5) <0.0001 
73.7 (73.1-
74.4)
Age group:  %  %     %  
<60 31.6 50.3 <0.0001 8.7
60-69 40.7 35.0 0.05 22.1
70-79 22.9 13.5 0.0001 41.0
≥80 4.8 1.2 0.003 28.2
Women  57.6 63.5 0.04 51.5
Currently married  66.1 62.0 0.1 53.0
Home owner 91.1 82.4 <0.0001 83.8
Low job prestige 36.3 37.4 0.7 42.5
Trade or higher 
qualification 60.6 55.3 0.08 51.2 
Living alone 25.5 24.2 0.6 34.6
Walking disability 3.3 3.4 1.0 20.4
Regular use community 
services 3.7 4.6 0.4 15.8 
Self-ranked health:   
Excellent 21.8 20.9 0.7 13.8
Good 57.1 56.7 0.9 47.4
Fair 18.9 18.4 0.8 29.8
Poor 2.2 4.1 0.04 9.0
History of Stroke 3.3 3.1 0.8 12.1
History of heart disease 14.4 7.7 0.0009 24.3
History of cancer 7.4 6.1 0.4 12.5
History of diabetes 6.3 8.6 0.1 11.6
Presence of hypertension 70.0 66.6 0.2 78.2
Smoking status:      
Never 85.6 75.9 <0.0001 80.6
Past 1.3 1.6 0.6 1.3
Current 13.1 22.5 <0.0001 18.1
Fish Consumption (≥1 
serving/wk) 59.4 62.0 0.4 60.2 
CFH-rs1061170     
TT 39.3 25.0
0.5† 
20.0
CT 46.7 75.0 60.0
CC 14.0 0.0 20.0
ARMS2-rs10490924     
GG 61.8 25.0
0.2† 
50.0
GT 34.0 75.0 50.0
TT 4.3 0.0 0.0
n=sample size; CI=confidence interval; CFH=complement factor H (C risk allele); ARMS2=age-related 
maculopathy susceptibility gene 2 (T risk allele)
*P-value for difference between participants examined and not examined (or had no photographs), 
excluding those who had died.  
†Unadjusted tests for heterogeneity used to calculate P values 
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The 15-year incidence of early and late stage AMD lesions by age and sex is presented 
in Table 3.1-2. There was an increased 15-year incidence of late AMD associated with 
older age. Although a similar increase was observed for early AMD including up to 80 
years of age, the 15-year incidence of early AMD, particularly incidence of indistinct or 
reticular drusen, decreased in those aged ≥80 years old at baseline. The 15-year 
incidence of both early AMD and neovascular AMD was higher in women compared to 
men. After adjusting for gender, age was strongly associated with incidence of early and 
late AMD lesions (both P<0.0001).  
 
 
 
 
Table 3.1-2: Fifteen-year incidence of late and early AMD lesions by age and sex. 
 
Incident AMD 
Lesions  
Age at Baseline (years) 
Women Men 
<60 60-69 70-79 ≥80 All Ages 
No. at 
Risk 
Incidence 
(%) 
No. at 
Risk
Incidence 
(%)
No. at 
Risk
Incidence 
(%)
No. at 
Risk 
Incidence 
(%)
No. at 
Risk
Incidence 
(%)
Incidence 
(%)
Incidence 
(%)
Geographic 
atrophy 774 0.4 960 2.1 519 9.5 102 19.3 2355 2.6 2.5 2.8 
Neovascular 
AMD 778 0.7 988 4.8 547 12.9 108 13.8 2421 4.4 5.2 3.3 
Any late AMD 778 1.1 988 6.8 547 20.2 108 27.3 2421 6.8 7.5 6.0 
Early AMD  737 8.7 855 26.9 388 51.4 56 29.3 2036 22.7 25.7 18.4 
Indistinct/ 
reticular drusen 755 7.1 918 21.0 440 40.3 72 19.2 2185 18.1 21.5 13.5 
Pigmentary 
abnormality 729 21.4 871 32.4 440 48.7 83 42.6 2124 31.1 32.1 29.6 
*Using Kaplan-Meier estimates incorporating persons censored up to the 5-, 10- and 15-year examinations. 
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The 15-year incidence of early and late AMD in the BMES population, after adjusting 
for the competing risk of death, was 15.1% and 4.1%, respectively. Using the 
competing risk method, the BMES early and late AMD incidence was age-standardized 
to that of the BDES population. We found similar age-standardized incident rates of 
early AMD (13.1%, 95% CI 11.7% -14.6%, versus 14.3%, estimated 95% CI 13.1% -
15.5%) and late AMD (3.3%, 95% CI 2.6%-4.0%, versus 3.1%, estimated 95% CI 
2.6%-3.6%) over 15 years in the BMES when compared to the corresponding incidence 
rates in the BDES population33.  
 
The AREDS simplified severity scale was applied to the BMES baseline AMD status, 
and the probabilities of developing late AMD over 15 years from various levels in the 
scale are shown in Table 3.1-3. The 15-year incidence of late AMD among persons at 
Step 0 at baseline ranged from 1.1% to 4.5%; at Step 1, 2 and 3, the 15-year incidence 
of late AMD ranged from 4.5% to 12.0%, 21.1% to 41.7% and from 0.0% to 33.3%, 
respectively. Corresponding incidence among persons at Step 4 (baseline) was 76.5% 
(Table 3.1-3).   
 
 
 
Table 3.1-3: Number and proportion of participants who developed late AMD over 15 years by levels of the Age-Related Eye Disease Study 
(AREDS) simplified severity scale for AMD at baseline  
 
Drusen size and 
number of eyes  
Pigment Abnormality 
None (C1) One eye (C2) Two eyes (C3) 
No. of events/ No. of 
subjects %
* No. of events/ No. of subjects %
* No. of events/ No. of subjects %
* 
None or small, only 
one or both eyes (R1) 19/1573 1.2 (0.6) 3/67 4.5 (1.5) 4/19 21.1 (21.1) 
Intermediate, one 
eye (no large) (R2) 10/224 4.5 (2.7) 3/25 12.0 (4.0) 5/12 41.7 (36.4) 
Intermediate, both 
eyes (no large) (R3) 6/55 10.9 (7.4) 3/10 30.0 (20.0) 0/4 0.0 (0.0) 
Large, one eye (R4) 7/61 11.5 (8.1) 4/14 28.6 (28.6) 5/26 19.2 (11.5) 
Large, both eyes 
(R5)  5/18 27.8 (27.8) 3/9 33.3 (33.3) 13/17 76.5 (70.6) 
*Blue Mountains Eye Study 10-year incidence rates in parentheses. 
AREDS Step 0 = R1C1 and R2C1; No retinal pigment changes with none or small hard drusen in 1 or both eyes or intermediate (but not large) drusen in 1 
eye only.  
AREDS Step 1 = R1C2, R2C2, R3C1 and R4C1;  Pigment changes in 1 eye with small hard drusen in 1 or both eyes or intermediate drusen in 1 eye only/no 
pigment changes in either eye but intermediate drusen in both eyes or large drusen in one eye.
AREDS Step 2 = R1C3, R2C3, R3C2, R4C2 and R5C1; Pigment changes in both eyes with small hard drusen in 1 or both eyes or intermediate drusen in 1 
eye only/pigment changes in 1 eye with intermediate drusen in both eyes or large drusen in 1 eye/no pigment changes in either eye but large drusen in both 
eyes. 
AREDS Step 3 = R3C3, R4C3, R5C2; Pigment changes in both eyes with intermediate drusen in both eyes or large drusen in 1 eye/ pigment changes in 1 eye 
with large drusen in both eyes. 
AREDS Step 4 = R5C3; Pigment changes in both eyes with large drusen in both eyes. 
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After controlling for the competing risk of death, the cumulative incidence of early 
AMD in the second eye of persons with early AMD in the first eye was 67.0% over the 
follow-up period. The corresponding incidence of late AMD in the second eye of 
persons with late AMD in the first eye was 35.4%, and of those with early AMD in the 
first eye, was 24.6%.  
 
Known AMD risk factors associated with 15-year incident early and late AMD are 
listed in Table 3.1-4. In the age-sex adjusted model, 2 risk alleles of CFH-rs1061170 
(OR 2.8) and either 1 or 2 risk alleles of ARMS2-rs10490924 (ORs 1.6-2.6) were 
associated with greater risk of 15-year incident early AMD. There was no significant 
association between smoking or fish consumption and 15-year early AMD incidence. 
Current smoking at baseline and the presence of at least 1 risk allele of CFH-rs1061170 
(ORs 1.9-3.8) or ARMS2-rs10490924 (ORs 1.8-4.9) were significantly associated with 
an increased risk of 15-year incident late AMD. Conversely, the incidence of late AMD 
was significantly reduced among persons who consumed ≥1serving of fish per week 
(OR 0.5) compared to those who consumed fish less than weekly. These associations 
remained significant after multivariable adjustment as shown in Table 3.1-4. 
 
 
 
 
Table 3.1-4: Common AMD risk factors associated with 15-year incidence of early and late stage AMD 
 
 
Risk Factor  
15-year Incidence of Age-related Macular Degeneration 
Early AMD Late AMD 
Age-sex adjusted 
OR (95% CI) 
Multivariable-adjusted 
OR (95% CI)* 
Age-sex adjusted 
OR (95% CI) 
Multivariable-adjusted 
OR (95% CI)* 
Age, per 10 years 1.12 (1.10-1.14) 1.11 (1.09-1.14) 1.17 (1.13-1.20) 1.20 (1.16-1.25) 
Sex (male) 0.70 (0.55-0.90) 0.66 (0.48-0.90) 0.77 (0.50-1.16) 0.80 (0.48-1.32) 
Smoking (current) 1.14 (0.74-1.73) 1.45 (0.90-2.36) 3.96 (2.31-6.80) 3.63 (1.86-7.06) 
CFH-rs1061170 
TT 1.00 1.00 1.00 1.00 
CT 1.18 (0.88-1.59) 1.08 (0.78-1.51) 1.91 (1.12-3.29) 2.25 (1.22-4.15) 
CC 2.81 (1.97-4.00) 2.56 (1.71-3.84) 3.77 (2.03-6.99) 4.45 (2.19-9.03) 
ARMS2-rs10490924 
GG 1.00 1.00 1.00 1.00 
GT 1.63 (1.24-2.14) 1.53 (1.12-2.08) 1.79 (1.14-2.80) 2.59 (1.56-4.31) 
TT 2.58 (1.38-4.81) 2.16 (1.07-4.37) 4.88 (2.06-11.55) 5.81 (2.09-16.12) 
Fish Consumption (≥1 
servings/wk) 
0.90 (0.69-1.17) 0.92 (0.68-1.24) 0.45 (0.29-0.71) 0.48 (0.29-0.79) 
OR=odds ratio; CI=confidence interval; CFH=complement factor H (C risk allele); ARMS2= age-related maculopathy 
susceptibility gene 2 (T risk allele)
*Mulivariable-adjusted logistic regression model including age, sex, smoking, CFH and ARMS2 polymorphisms and fish 
consumption. 
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Table 3.1-5 presents the eye-specific associations between baseline early AMD lesion 
characteristics and the 15-year incidence of late AMD. After adjusting for age, sex and 
smoking, the presence of large drusen (OR 7.0), indistinct soft drusen (OR 19.3), drusen 
location closer to the foveal centre (OR 7.3-21.0) and larger drusen area (OR 7.2-30.9) 
were highly predictive of the late AMD development. Likewise, the presence of retinal 
pigmentary abnormalities (OR 6.6) was associated with increased risk of late AMD as 
was each step increment in the AREDS 5-Step scale (ORs 4.8-169.4). These 
associations remained after further adjustment for fish consumption and CFH-
rs1061170 and ARMS2-rs10490924 polymorphisms. 
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Table 3.1-5: The 15-year risk of late AMD by baseline early AMD characteristics.  
 
Baseline Early AMD Lesion 
Characteristics*  
Crude Late AMD Incidence (%) Age, Sex and 
Smoking Adjusted 
OR (95% CI) 
Multivariable 
Adjusted OR (95% 
CI)† 5 Year 10 Year 15 Year 
Eye-Specific 
Maximum Drusen size  
None or <125µm 0.5 3.1 3.0 1.0 1.0 
≥125µm 13.0 39.7 14.3 7.0 (4.0-12.2) 7.4 (4.0-14.0) 
Drusen type  
None or small drusen <125µm 0.5 2.9 3.0 1.0 1.0 
Distinct soft drusen 1.3 11.5 3.7 1.3 (0.5-3.9) 1.6 (0.5-5.1) 
Indistinct soft drusen 22.6 62.5 50.0 19.3 (9.7-38.6) 21.4 (9.4-48.5) 
Drusen location 
None or <63µm with an area <250µm in 
diameter  0.3 2.0 2.5 1.0 1.0 
1500-3000µm from foveal centre 1.0 2.6 5.9 1.0 (0.3-2.8) 1.4 (0.5-4.3) 
500-1500µm from foveal centre 9.3 39.3 21.4 7.3 (3.7-14.5) 8.2 (3.7-18.2) 
within 500µm radius of foveal centre 17.8 51.2 50.0 21.0 (10.7-41.0) 18.5 (8.7-39.2) 
Drusen area  
None or <375µm in diameter 0.5 2.9 3.0 1.0 1.0 
≥375µm in diameter to <0.5 disc area 7.0 34.8 16.7 7.2 (3.2-16.3) 7.9 (3.2-19.7) 
≥0.5 disc area  30.0 79.0 66.7 30.9 (13.8-69.2) 33.0 (12.3-88.4) 
Retinal pigmentary abnormality 
Absent 0.4 3.4 2.8 1.0 1.0 
Present 10.9 34.6 13.1 6.6 (3.9-11.1) 7.2 (4.1-12.8) 
Person-Specific  
AREDS simplified AMD severity scale 
Step 0‡ 0.2 1.8 1.9 1.0 1.0 
Step 1§ 2.4 9.0 13.3 4.8 (2.5-9.3) 7.8 (3.6-17.0) 
Step 2ǁ 11.0 50.0 10.5 12.6 (6.2-25.6) 15.2 (6.8-34.0) 
Step 3¶ 12.8 9.1 22.2 10.1 (3.5-28.8) 13.1 (3.3-52.1) 
Step 4# 47.1 80.0 100.0 169.4 (55.2-519.9) 119.4 (24.6-580.5) 
OR = odds ratio, CI = confidence interval, AREDS = Age-Related Eye Disease Study  
*Assessed within the anatomical macular area (within 3000µm radius of the foveal centre) 
†Multivariable ORs adjusted for age, sex, smoking status, CFH-rs1061170, ARMS2-rs10490924 and fish consumption 
‡No retinal pigment changes with none or small hard drusen in 1 or both eyes or intermediate (but not large) drusen in 1 eye only.  
§Pigment changes in 1 eye with small hard drusen in 1 or both eyes or intermediate drusen in 1 eye only/no pigment changes in either 
eye but intermediate drusen in both eyes or large drusen in one eye. 
ǁPigment changes in both eyes with small hard drusen in 1 or both eyes or intermediate drusen in 1 eye only/pigment changes in 1 eye 
with intermediate drusen in both eyes or large drusen in 1 eye/no pigment changes in either eye but large drusen in both eyes. 
¶Pigment changes in both eyes with intermediate drusen in both eyes or large drusen in 1 eye/ pigment changes in 1 eye with large 
drusen in both eyes. 
#Pigment changes in both eyes with large drusen in both eyes. 
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DISCUSSION 
We found an overall 15-year incidence of 22.7% for early AMD and 6.8% for late 
AMD, in persons aged 49+ years in this older Australian cohort. After adjusting for the 
competing risk of death, the incidence of early and late AMD was 15.1% and 4.1%, 
respectively. The 15-year incidence of late AMD or late AMD lesions increased with 
increasing age, however, the incidence of early AMD decreased in persons aged 80+ 
years at baseline. Women had a higher 15-year incidence of any AMD compared to 
men.  
 
Our study is one of very few studies to report the long-term (>10 years) incidence of 
AMD from an older population-based cohort. The Copenhagen City Eye Study47 
reported the 14-year incidence of early and late AMD as 31.5% and 14.8%, 
respectively, considerably higher than our incidence estimates observed in the BMES. 
The older age range (60-80 years) of the Copenhagen study sample and the low 14-year 
follow-up rate of 38%47 could explain the relatively high incidence found in this study. 
In the BDES, the 15-year early AMD incidence was 14.3%, while late AMD was 
3.1%33, comparable to our 15-year incidence estimates in the BMES, after age 
standardization to the BDES population.  
 
We found that the overall 15-year incidence of both early and late AMD was 
substantially higher, compared to the 10-year incident rates in the BMES cohort. 
However, the 15-year incidence of early AMD was relatively lower among participants 
aged 80 years or older, dissimilar to previous findings of 10-year early AMD incidence 
in the same cohort35. The lower incidence in this oldest old age group may be due to 
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high mortality and the low number of subjects who were at risk of early AMD at this 
age.  
 
The AREDS simplified severity scale was previously validated using the 10-year 
incidence of late AMD data from the BMES35. We found that the probabilities of 
developing late AMD by baseline AREDS scale Steps 0 and 1 over 15 years were twice 
as high as the 10-year late AMD incidence from the same steps. Whereas the 
probabilities of developing late AMD by baseline AREDS scale Steps 2, 3 or 4 (when 
both eyes had large soft drusen and/or retinal pigmentary changes) over 15 years were 
somewhat similar to the 10-year late AMD incident rates35. This observation could 
suggest that the time needed for progression from severe early AMD to late AMD may 
likely be within 10 years or less, while the duration of 15 years is more applicable to 
those with less severe stages of early AMD at baseline.  
 
Second eye incidence of late AMD has been reported in a number of clinic-based 
studies198-201. In the BMES, we found substantially higher incidence of early or late 
AMD in the second eye of persons with either early or late AMD in the first eye at 
baseline. This is comparable to previous observations in the BDES which reported a 
39% second eye incidence of late AMD in those with unilateral late AMD at baseline33.  
 
We previously demonstrated that incidence of specific early AMD lesions and late 
AMD was greater in women compared with men35,44. Although we found a similar 
pattern in this report, the association between female sex and 15-year incident AMD 
was only significant for early but not for late AMD. We also found that current smoking 
at baseline was significantly associated with incident late but not incident early AMD 
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over 15 years. This is in keeping with previous findings from the BMES and other 
studies of white populations including the Rotterdam study115,117,123,150. Weekly fish 
consumption of at least one or more servings was associated with a reduced risk of late 
but not early AMD over the 15-year follow-up period. Similar findings were reported in 
a meta-analysis of pooled data from nine studies, in that fish intake at least twice a week 
was associated with reduced risks of early and late AMD202. Consistent with genetic 
knowledge of AMD, 2 risk alleles of CFH and either 1 or 2 risk alleles of ARMS2 were 
significantly associated with increased risk of early and late AMD over the longer term, 
with a greater risk magnitude for late AMD78.  
 
Increasing severity of baseline early AMD lesions, including larger drusen size 
(≥125µm), drusen location closer to the fovea, larger area involved by drusen and the 
presence of RPE abnormalities, have been well-recognized to predict the incidence of 
late AMD33-35,38. We also previously reported high risk of developing GA from eyes 
with indistinct soft and reticular drusen, central location and larger area involved by 
drusen over 15 years203. These associations were generally consistent across the 10- and 
15-year AMD incidence although with different risk magnitude: the risk of late AMD 
associated with baseline early AMD lesion characteristics was higher for the 10-year 
than the 15-year data, and particularly so for central location of soft drusen. This 
observation may suggest that early AMD characteristics are indicative of a more severe 
stage likely leading to late AMD within 10 years rather than 15 years.  
 
We were able to follow about 75% of survivors of this older cohort at the 5- and 10-year 
visits. However, follow-up rate reduced to only 56% by the time the 15-year 
examinations were performed. This could have introduced selection bias due to 
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selective follow-up and survival. Persons who died were older and more likely to have 
chronic systemic conditions and disabilities. Participants who were lost to follow up 
were likely to have been younger (mean age, 61, versus 64) and more likely to smoke 
(23% versus 13%) at baseline. It is thus likely that our estimates of the 15-year 
incidence of AMD could have been underestimated, although the “true incidence” 
would not be more useful than the current estimate, as only those who survived demand 
eye health and aged care services.  
 
Strengths of this study include the relatively long-term follow-up of a population-based 
cohort, the use of retinal photographs to document macular conditions and a validated 
AMD grading system to assess size and location of AMD lesions. A major limitation of 
our study is the substantial number of participants lost to follow-up at the 15-year visit, 
as mentioned above. A further limitation includes lack of high-resolution imaging (e.g. 
spectral-domain optical coherence tomography), unavailable at the time of the BMES 
examinations, that might have increased the ability to detect some AMD lesions such as 
early stage GA. 
 
SUMMARY 
This report shows the 15-year incidence of early and late AMD in an older Australian 
cohort, particularly among persons with no lesions or only early-stage lesions at 
baseline. The incidence rates for early and late AMD in this cohort were comparable to 
those reported in the BDES population over the same follow-up period.  Current 
smoking at baseline was a stronger risk factor for 15-year incidence of late AMD than 
early AMD.  
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3.2 Long-Term Incidence and Natural History of Geographic Atrophy 
Secondary to Age-related Macular Degeneration 
 
Publication relating to this section of Chapter 3: 
Joachim N, Mitchell P, Kifley A, Rochtchina E, Hong T, Wang JJ. Incidence and 
Progression of Geographic Atrophy: Observations from a Population-Based Cohort. 
Ophthalmology 2013; 120: 2042-2050 
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ABSTRACT 
Purpose: To examine early AMD lesion characteristics and risk factors associated with 
the long-term development and progression of geographic atrophy (GA). 
 
Methods: Of 3654 participants aged 49+ years in the Blue Mountains Eye Study, 
75.8%, 76.7% and 56.1% of survivors attended the 5-, 10- and 15-year follow-up 
examinations, respectively. Retinal photographs were taken at each visit. Incident GA 
was confirmed using a side-by-side grading method. Computer planimetry was used to 
measure the area involved by GA. Fast and slow/normal progression rates were defined 
as GA area enlargement by ≥2 and <2 mm2/year, respectively. Incident GA was 
estimated using the Kaplan-Meier product-limit method. Early AMD lesion 
characteristics were assessed for association with GA incidence, using eye-specific data 
and generalized estimating equation models adjusting for age, current smoking and 
presence of risk alleles of the complement factor H (CFH) or age-related maculopathy 
susceptibility 2 (ARMS2) genes, genotyped or imputed using genome-wide scan data. 
 
Results: By excluding 41 subjects with GA at baseline, of 2503 participants at risk of 
GA, incident pure GA (without co-existing neovascular AMD lesions) was confirmed in 
57 participants, a 15-year incidence of 3.6%. Baseline early AMD lesion characteristics 
associated with GA incidence included drusen type (soft indistinct: OR 59.0, 95% CI 
20.4-171.0, and reticular drusen: OR 13.9, 95% CI 4.0-47.6); drusen location within 
500µm radius of the fovea (OR 15.1, 95% CI 7.4-30.8); drusen area greater than 375µm 
in diameter (OR 10.1, 95% CI 4.0-25.6), presence of retinal pigment epithelial 
depigmentation (OR 9.0, 95% CI 4.1-19.8) or hyperpigmentation (OR 12.0, 95% CI 
6.1-23.5), referenced to subjects with no or hard drusen only. Fast progression was more 
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frequent among baseline current smokers at baseline, subjects with the CFH or ARMS2 
risk genotypes and pseudophakic eyes. 
 
Conclusions: Early AMD lesion characteristics (type, location, area involved) were 
strongly associated with higher long-term risk of developing GA, independent of age, 
smoking and AMD genetic susceptibility from the CFH or ARMS2 genes. Known AMD 
risk factors were also more frequently present among fast progressing GA cases. 
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BACKGROUND 
Geographic atrophy (GA) is 1 of 2 types of late AMD and is characterized by a sharply 
defined area of RPE degeneration in which choroidal blood vessels are visible26. It 
accounts for approximately 35% to 40% of late stage AMD cases148. There is currently 
no effective treatment for GA, and once the foveal centre is involved, affected patients 
are deprived of central vision and may develop legal blindness204-206. 
 
Although the short term (e.g., 2 to 5 years) incidence of GA is available from 
population- based studies30,45,63,207, there are limited data available on long-term 
incidence (over 10 to 15 years). Two large population-based studies with long-term 
follow-up, the Beaver Dam Eye Study (BDES) and the Blue Mountains Eye Study 
(BMES), reported that the 10-year incidence of pure GA was 0.8%34 and 1.7%35, 
respectively. The 15-year incidence of pure GA in the BDES was 1.3%33. In both 
studies, the presence of large drusen and retinal pigmentary abnormalities were found to 
be associated with increased long-term incidence of late AMD, including GA and 
neovascular AMD29,34,35,208. However, population-based data for the associations of 
early AMD lesions with long-term incidence of pure GA are limited.  
 
The natural history and progression of GA have also been assessed in both the BDES 
and BMES populations44,205 and clinic-based cohort studies209,210. Larger atrophy areas 
at baseline were found to be associated with fast progression of GA lesions204,209, and 
the shape of the atrophic area, termed ‘GA configuration’ (classic, multifocal and 
merged), also appears to have different progression rates205. In a previous BMES report, 
5-year progression of GA occurred in 43% of eyes with GA at baseline, where GA 
progression was defined as an increase in the atrophic area by ≥2 subfields of the 
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Wisconsin grading grid or by extension of atrophy into the foveal center without 
quantitative measures44. 
 
We aimed in this report to examine the 15-year incidence of pure GA, and associations 
of early AMD lesion characteristics with GA incidence in the BMES cohort. We also 
assess the 5-year GA progression rate, indicated by quantitative measures of the size of 
atrophic areas and GA involvement with respect to the fovea, and explore factors 
associated with fast versus slow progression of prevalent and incident cases of pure GA.    
 
METHODS 
Procedures and Photographic Grading 
At each BMES examination, in addition to retinal fundus photography, visual acuity 
was assessed following the Early Treatment Diabetic Retinopathy Study (ETDRS) 
protocol211. Demographic and lifestyle questionnaires were also administered and blood 
collected for genotyping, as described previously (Methods, Chapter 2).  
 
Geographic atrophy refers to a sharply defined area of RPE and the sensory retinal loss 
with a diameter ≥175µm, exposing choroidal vessels.For this report, side-by-side 
grading of retinal photographs of each subject taken at BMES I, II, III and IV was 
performed to confirm incident pure GA cases. Incident pure GA was defined as the first 
appearance of GA in either eye of subjects who had no sign of GA at the previous visit 
and no neovascular AMD (including pigment epithelial or sensory subretinal 
detachment, retinal or subretinal hemorrhage, subretinal fibrosis or old atrophic 
disciform scars, or photocoagulation scars) at all previous and current examinations. All 
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incident late AMD cases including incident GA cases were also confirmed by BDES 
and Rotterdam Eye Study principal investigators.   
 
Early AMD and early AMD lesion characteristics were defined as in Methods (Chapter 
2)  
 
Computer Planimetry 
GA progression was assessed in both prevalent (from baseline examination, BMES I) 
and incident pure GA cases (detected at follow-up visits, either BMES II or BMES III) 
that had retinal photographs available at subsequent visits. Progression was measured as 
increasing size of the atrophic areas over 5 years from one BMES examination to the 
next, and converted to progression rate in mm2 per year. The retinal photographs from 
BMES I, II and III, on 35mm film, were scanned using a CanoScan 5600F scanner at 
2400 dots per inch. The digital format of the Wisconsin Age-Related Maculopathy 
Grading System (WARMGS) grid was enlarged according to the resolution of the 
scanned photographs using Adobe Photoshop CS4 (Adobe Systems Incorporated, USA) 
so that the measurements could be performed digitally. The resolution of the grid was 
amended according to the resolution of BMES IV digital photographs when used for 
images taken at BMES IV. A random sample of retinal photographs without pathology 
from each BMES examination were used to obtain the scaling factor (microns per pixel) 
using Photoshop (Adobe Systems Incorporated, USA). This was calculated by dividing 
4500µm, taken as the constant distance between the center of the optic disc to the center 
of the fovea, by the same distance measured in pixels, to obtain the number of microns 
per pixel. This scale factor was then set into Image J (National Institutes of Health, 
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NIH)212 to allow measurements to be read in microns. Tracings were made along the 
margin of GA and area measurements obtained using ‘region of interest’ manager.    
 
Definition of GA Progression 
The average progression of GA was calculated using data from the BMES, BDES205 
and the Age Related Eye Disease Study (AREDS)213 and was found to be an area 
between 1 and2mm2 per year. We defined this as the normal progression rate. If the GA 
progression rate was greater than 2mm2/year this was defined as fast progression, and if 
less than 1mm2/year, was defined as slow progression. Figure 3.2-1 shows examples of 
cases with different progression rates.  
 
The configuration of GA has been used and described by previous studies205,214. The 
‘classic’ configuration is defined as a single round atrophic area, ‘multifocal’ as two or 
more areas of atrophy within the macula region and the ‘merged’ configuration as two 
or more initially separate areas (multifocal) which subsequently amalgamated into a 
large irregular atrophic area. We added a ‘mixed’ configuration in our report to include 
eyes with two or more configuration types described above. 
 
GA progression was assessed using two indicators: enlargement of the atrophic area and 
progression to involve the fovea associated with worsened best-corrected visual acuity 
(BCVA), in eyes that had not yet developed GA at the fovea when it was first detected.  
 
  
119 
 
 
Figure 3.2-1: Examples of the fast (A), normal (B) and slow (C) progression of 
geographic atrophy (GA) by enlargement of atrophic areas. Tracings around the GA 
perimeter show the increase in area from the first detection of GA (i), to 5 years (ii), and 
to 10 years (iii) after first detection of GA.  
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Genotyping 
The complement factor H (CFH) single nucleotide polymorphism (SNP) rs1061170 and 
the age-related maculopathy susceptibility gene 2 (ARMS2) SNP rs10490924 were 
genotyped in 1874 and 593 participants, respectively, and imputation performed in the 
remaining subjects, as described in Methods (Chapter 2). In our study sample, 1501 and 
509 participants had both typed and imputed rs1061170 and rs10490924, respectively, 
and the concordance rate between typed and imputed SNPs were 99.6% for rs1061170 
and 99.2% for rs10490924. Of 2503 participants used in our analyses, 151 participants 
had rs1061170 imputed and 1287 had rs10490924 imputed.  
 
Definition of Baseline Variables Associated with GA 
For smoking history, if participants answered ‘no’ to smoking regularly they were 
classified as non-smokers. If participants answered ‘yes’ and had given up smoking ≥1 
year prior to the baseline examination, they were classified as past smokers. Current 
smokers were defined as participants who currently smoked or stopped smoking <1 year 
before baseline examinations. Regular fish consumption was defined as 1 or more 
servings per week, compared to infrequent consumption (<1 serving per week). 
 
Statistical Methods 
Fifteen-year person-specific GA incidence was assessed using Kaplan-Meier product 
limit survival estimates, including overall and incident rates by the AREDS simplified 
severity scale (5 steps)28 according to baseline AMD levels. Estimates were then re-
calculated after adjusting for the competing risk of death.  
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Associations between 15-year incidence of GA and common AMD risk factors (age, 
current smoking status, sex, presence of risk alleles of CFH-rs1061170 or ARMS2-
rs10490924, and regular fish consumption) were assessed using age-adjusted and 
multivariable adjusted discrete logistic regression models, and expressed as ORs. CFH-
rs1061170 and ARMS2-rs10490924 were assessed categorically, in a general model, 
using homozygous wild genotype (no risk alleles) as the referent and heterozygous (one 
risk allele) and homozygous risk genotypes (two risk alleles) as separate categories. 
These SNPs were also assessed in an additive model where genotype was treated as a 
continuous variable. Eye-specific data were used to assess the association between early 
AMD risk characteristics (type, area and location of early lesions) and the 15-year 
incidence of GA. To handle the correlation between the two eyes of the same individual 
and multiple measures of the same eyes (observations from the same individual are in a 
cluster), the GENMOD procedure in SAS was used to perform generalized estimation 
equation modeling with an exchangeable working correlation matrix, using subject 
identification as a cluster indicator196. Due to the small number of cases available for 
assessment of GA progression, only descriptive data are provided.  
 
RESULTS   
Of 3654 baseline participants, 2572 had been followed-up at least once since the 
baseline examination. Of these, 68 participants developed late AMD at baseline or 
neovascular AMD at first follow-up after baseline (and were thus not at risk of 
developing GA), and 1 participant had ungradable photographs at all visits. This left 
2503 participants included in the assessment of GA incidence. Table 3.2-1 presents 
baseline characteristics of the BMES participants with incident GA and without any late 
AMD. Subjects with incident GA were significantly older and had significantly worse 
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BCVA in both their better and worse eyes, compared to those without late AMD. 
Participants with incident GA were also more likely to have two risk alleles of the CFH 
gene compared to those without any late AMD. The frequency of one or two ARMS2 
gene risk alleles was slightly higher in subjects with incident GA, but the differences 
were not statistically significant (Table 3.2-1). 
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Table 3.2-1: Comparison of baseline characteristics between participants with and 
without incident GA, examined up to 15 years in the Blue Mountains Eye Study cohort 
 
Characteristic 
% Participants*   
No Late AMD 
(n=2446) 
Incident 
GA (n=57) P-value
† 
Mean age, years (SD) 63.9 (8.5) 72.3 (6.7) <0.0001
Mean BCVA, no. of letters read (SD)
Better eye 56.2 (4.8) 52.8 (5.5) <0.0001
Worse eye 51.5 (10.9) 46.5 (10.6) 0.0006
Sex (male) 42.6 36.8 0.4
Smoking 
Current  12.9 19.6 0.1
Past 35.7 30.4 0.4
Fish consumption (≥1 serving/week) 60.4 43.5 0.02
CFH-rs1061170 
TT 40.3 24.0 0.0
CT 46.5 46.0 0.9
CC 13.3 30.0 0.0007
ARMS2-rs10490924 
GG 62.5 54.0 0.2
GT 33.6 40.0 0.3
TT 4.0 6.0 0.5
AMD = age-related macular degeneration; SD = standard deviation; BCVA = best 
corrected visual acuity; CFH = complement factor H gene (C risk allele); ARMS2 = age-
related maculopathy susceptibility gene 2 (T risk allele).
*% where appropriate. 
†Mantel-Haenszel Chi-Square.
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Incidence of pure geographic atrophy 
Incident pure GA was identified in 57 participants (82 eyes) of 2503 subjects at risk, 
with an overall 15-year incidence of 3.6% (95% confidence interval (CI) 2.7-4.7). After 
accounting for the competing risk of death, the 15-year incidence of GA reduced to 
2.2% (95% CI 1.6-2.8). After age-standardization to the Australian census 2011 
population aged 50+ years, the estimated 15-year incidence became 1.8% (95% CI 1.2-
2.4). Bilateral involvement occurred in 27 of the 57 participants (47.4%). Of the 
bilateral cases, 21 were bilateral at the same follow-up visit, 4 became bilateral at the 
subsequent follow-up visit and 2 cases that had unilateral GA at baseline developed 
incident GA in the fellow eye during the follow-up period.  
 
Table 3.2-2 presents the incidence of pure GA at the 5-, 10- and 15-year follow-up 
examinations by different stages of AMD at baseline according to the AREDS 5-step 
severity scale28. Age was significantly associated with advancing severity level (p for 
trend < 0.0001). At each of the follow-up visits, incidence of pure GA increased with 
increasing baseline AREDS severity step from 0 to 4, except for cases with AREDS 
scale step 3 (Table 3.2-2). 
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Table 3.2-2: Incidence of pure GA at the 5-, 10- and 15-year follow-up visits of the 
Blue Mountains Eye Study population by the Age-Related Eye Disease Study (AREDS) 
5-step severity scale28. 
 
AREDS 
category at 
baseline 
Number of 
participants 
(n=2503) 
Mean age in 
years ±SD) 
Mean BCVA in 
worse eye, no. of 
letters read ±SD 
Incidence GA (%) 
5 year 10 year 15 year 
Step 0* 1873 62.6±7.9 53.4±6.8 0.0 0.2 1.0 
Step 1† 207 67.4±8.4 50.0±10.8 0.5 4.7 9.6 
Step2‡ 72 71.3±9.0 50.6±7.4 6.9 23.9 38.4 
Step 3§ 36 71.1±8.5 49.5±7.8 8.3 8.3 19.8 
Step 4ǁ 13 70.5±7.0 48.1±9.7 30.8 60.4 100.0 
n = sample size; SD = standard deviation; BCVA = best-corrected visual acuity  
*no retinal pigment changes with none or small hard drusen in one or both eyes or intermediate (but not 
large) drusen in one eye only.  
†pigment changes in 1 eye with small hard drusen in 1 or both eyes or intermediate drusen in 1 eye only; no 
pigment changes in either eye but intermediate drusen in both eyes or large drusen in 1 eye. 
§pigment changes in both eyes with small hard drusen in 1 or both eyes or intermediate drusen in 1 eye only; 
pigment changes in 1 eye with intermediate drusen in both eyes or large drusen in 1 eye; no pigment changes 
in either eye but large drusen in both eyes. 
dpigment changes in both eyes with intermediate drusen in both eyes or large drusen in 1 eye; pigment 
changes in 1 eye with large drusen in both eyes. 
ǁpigment changes in both eyes with large drusen in both eyes.   
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Age-related macular degeneration risk factors assessed for association with the 15-year 
incidence of GA are presented in Table 3.2-3. Increasing age was significantly 
associated with the development of GA within 15 years (p<0.0001). In an age-adjusted 
model, current smoking (p=0.0001) and homozygous risk genotypes of CFH-rs1061170 
(p=0.002) and ARMS2-rs10490924 (p=0.04) were associated with an increased risk of 
incident GA. There was no significant sex difference found in the long-term risk of GA. 
Regular fish consumption had a significant protective effect against the development of 
GA (p=0.02). In a model simultaneously adjusting for the above mentioned risk factors, 
the significant associations of age, current smoking, and genetic risks from the CFH and 
ARMS2 with GA incidence remained, and the association of weekly fish consumption 
with incident GA became non-significant (Table 3.2-3). 
 
Table 3.2-3: Common age-related macular degeneration risk factors associated with 15-
year incidence of GA 
 
  15-year incidence of GA 
Risk factor Age-adjusted (where appropriate) Multivariate adjusted
* 
  OR 95% CI OR 95% CI 
Age, per year 1.18 1.14-1.22 1.22 1.16-1.27 
Sex (male) 0.84 0.49-1.47 0.77 0.39-1.49 
Smoking (current) 4.11 2.01-8.38 4.20 1.76-10.02
CFH-rs1061170† 1.92 1.28-2.88 1.99 1.26-3.15 
TT 1.00  -  -  
CT 1.66 0.82-3.38  -  -  
CC 3.65 1.66-8.03  -  -  
ARMS2-rs10490924† 1.66 1.02-2.70 2.38 1.41-4.02 
GG 1.00  -  -  
GT 1.54 0.85-2.79  -  -  
TT 3.32 0.96-11.53  -  -  
Fish Consumption (≥ 1 
servings/wk) 0.48 0.27-0.88 0.54 0.28-1.03 
OR = odds ratio; CI = confidence interval; CFH = complement factor H gene (C risk allele); 
ARMS2 = age-related maculopathy susceptibility gene 2 (T risk allele).
*multivariate model adjusted for age, sex, smoking, CFH and ARMS2 and regular fish 
consumption. 
†computed using additive model 
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Table 3.2-4 demonstrates the relationship between early AMD lesion characteristics 
and 15-year incidence of GA using eye-specific data. Drusen characteristics that were 
strongly associated with increased risk of developing GA over the 15-year period 
included soft indistinct (OR 28.58) and reticular drusen (OR 14.39), drusen within 
500µm radius of the foveal center (OR 9.97) and a collective drusen area greater than 
375µm in diameter (ORs 7.62-33.36). The baseline presence of RPE depigmentation 
(OR 6.99) and hyperpigmentation (OR 11.27) were significantly associated with higher 
risk of developing pure GA over the same period, as was location of pigmentary 
abnormalities within 1500µm radius of the foveal center. These associations remained 
significant after adjusting for age, sex, smoking, regular fish consumption, and presence 
of the CFH and ARMS2 risk alleles (Table 3.2-4).  
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Table 3.2-4: Relationship between baseline drusen and retinal pigmentary 
abnormalities and the 15-year incidence of geographic atrophy (GA), analyzed by eye, 
and presented as odds ratios (OR) with 95% confidence intervals (CI). 
 
  No. that 
developed 
GA  
No. at 
risk 
15-year incidence of GA 
Early AMD characteristics Age-adjusted Multivariate adjusted* 
  OR 95% CI OR 95% CI 
Drusen Type: 
None or hard drusen only 27 4094 1.00 1.00 
Intermediate 24 488 3.92 2.36-6.52 5.30 2.67-10.49 
Soft distinct 2 100 1.61 0.41-6.26 3.02 0.70-13.08 
Soft indistinct 24 100 28.58 12.66-64.53 59.02 20.38-170.95 
Reticular 15 44 14.39 5.56-37.22 13.85 4.03-47.64 
Drusen Location: 
None or ≥ 3000µm from foveal centre 27 4094 1.00 1.00 
1500-3000µm from foveal centre 1 42 1.93 0.38-9.92 3.40 0.49-23.73 
500-1500µm from foveal centre 4 188 1.83 0.61-5.50 3.65 1.21-10.99 
Within 500µm radius of foveal centre 48 451 9.97 5.88-16.90 15.08 7.38-30.82 
Drusen Area: 
None or <375µm in diameter 39 4535 1.00 1.00 
≥ 375 to <0.5 disc area 16 156 7.62 3.76-15.4 10.11 4.00-25.57 
≥ 0.5 disc area 25 87 33.36 13.65-81.56 61.12 18.37-203.34 
RPE Depigmentation: 
Present vs absent 20 144 6.99 3.87-12.32 9.02 4.10-19.80 
Location 
None or ≥1500µm from foveal centre 62 4881 1.00 1.00 
500-1500µm from foveal centre 8 72 5.24 2.31-11.90 8.04 2.84-22.80 
Within 500µm radius of foveal centre 12 67 10.35 4.74-22.67 11.20 3.61-34.75 
Area 
None to <375µm in diameter 70 4932 1.00 1.00 
>375µm to <2 disc areas 12 88 8.40 4.04-17.46 5.62 2.07-15.28 
≥ 2 disc areas  -   -   -     -  
Hyperpigmentation: 
Present vs absent 41 317 11.27 6.70-18.96 12.02 6.14-23.53 
Location 
None or ≥1500µm from foveal centre 41 4723 1.00 1.00 
500-1500µm from foveal centre 16 98 13.17 6.33-27.38 14.91 6.47-34.37 
Within 500µm radius of foveal centre 25 146 16.37 8.55-31.33 14.97 5.95-37.63 
Area 
None  or <64µm in diameter 45 4727 1.00 1.00 
≥ 64µm in diameter 37 240 12.21 7.08-21.05 11.18 5.65-22.10 
AMD = age-related macular degeneration 
*multivariate model adjusted for age, sex, smoking, regular fish consumption, the CFH and ARMS2 risk alleles. 
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Progression of pure geographic atrophy 
To investigate the progression of pure GA, both prevalent (n=7) and incident GA cases 
(n=12) with gradable follow-up retinal photographs were included. There were 41 
baseline participants with GA but only 7 were pure GA cases (10 eyes) and had follow-
up retinal photographs available for this analysis. There were 16 participants (23 eyes) 
with incident GA and follow-up retinal photographs, and 4 persons (5 eyes) were 
excluded due to subsequent development of neovascular AMD, leaving a total of 19 
participants (28 eyes) that met the criteria for analysis of progression rate. 
 
The average size of the GA lesions at first observation among eyes with baseline pure 
GA and incident pure GA was 5.0 mm2 (standard deviation (SD) 7.0) and 4.6 mm2 (SD 
4.5), respectively. Five years after the first detection of GA, average size of baseline 
pure GA lesions had increased to 13.0 mm2 (SD 8.8) and incident GA lesions increased 
to 15.9 mm2 (SD 8.1). The average GA progression rate for baseline and incident eyes 
combined (n=28) was 1.95mm2/year. Table 3.2-5 presents the three indicators of GA 
progression (enlargement of atrophic area, progression of atrophy into the fovea and 
worsening in BCVA). Of participants with baseline GA, none survived to the 15-year 
follow-up. These participants were significantly older than participants without GA at 
baseline (mean age 82.6 years versus mean age 65.9 years, respectively). The multifocal 
configuration of GA had the fastest progression rate from the first detection to the next 
examination 5 years later, while the slowest progression rate was observed in eyes 
presenting with the classic configuration. Central GA (involving the fovea) was present 
in 57% (n=16) of 28 eyes with GA at the first detection. Of the remainder, 92% of 12 
eyes with GA had progressed into the fovea within the next 5 years. The mean BCVA 
deteriorated by an average 18 letters over the same period.  
 
 
Table 3.2-5: Progression in atrophic area, foveal involvement and best-corrected visual acuity over 5 and 10 years in eyes with pure geographic 
atrophy (GA). 
 
Characteristics of progression 
GA progression 
First observation - 5 years Between 5 - 10 years First observation - 10 years 
n mean mm2 (SD) n mean mm2 (SD) n mean mm2 (SD) 
Change in mean GA area             
Prevalent (baseline) GA eyes (n=10) 9 7.7 (5.2) 3 4.5 (2.9) 4 7.5 (4.4) 
Incident GA eyes (n=18) 18 11.2 (6.0) 3 8.6 (6.3) 3 20.3 (16.2) 
All GA eyes (n=28) 27 10.1 (5.9) 6 6.6 (4.9) 7 13.0 (12.0) 
Change in mean GA area (by GA 
configuration)*       
Classic 7 5.5 (5.3) 4 4.7 (4.6) 5 9.3 (10.3) 
Merged 7 10.3 (6.0) 0  -  0  -  
Multifocal 6 13.8 (6.2) 3 13.7 (1.0) 3 31.1 (1.9) 
Mixed 7 11.2 (3.8) 1  -  1  -  
Change in foveal involvement* n % n % n % 
11 92 0 0 2 67 
Change in BCVA*  n Difference in the mean no. of letters read correctly (SD) n 
Difference in the mean no. 
of letters read correctly 
(SD) 
n 
Difference in the mean no. 
of letters read correctly 
(SD) 
(later visit minus previous visit) 27 -18.6 (17.9) 8 1.25 (6.6) 8 -9.5 (21.6) 
N=number of eyes; SD=standard deviation; BCVA=best-corrected visual acuity. 
*prevalent and incident GA eyes were combined. 
NB. For foveal involvement n: number of eyes which had GA that progressed of the number of eyes with GA that were at risk of progression into the 
fovea (eyes which had already developed GA in the fovea were not included). 
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Table 3.2-6 presents the frequencies of risk factors in fast or slow/normal progression 
groups. Fast, slow and normal progression were observed in 10, 7 and 2 participants 
respectively, according to the worse eye if the cases were bilateral (n=2). A larger 
proportion of participants with fast progressing GA were current smokers (30% versus 
0% in the slow/normal progression group), had one or both eyes pseudophakic prior to 
or at first detection of GA in the same eye (30% versus 11%), and had the homozygous 
risk genotype of either the CFH (50% versus 22%) or the ARMS2 (10% versus 0%), 
compared to subjects who had slow/normal progress. Participants that regularly 
consumed fish were more frequently represented in the slow/normal progress groups 
compared to the fast progress group (57% versus 38%). 
 
Table 3.2-6: Proportion of participants presenting with the selected risk factors by fast 
and slow progression of pure geographic atrophy (GA). 
 
Risk characteristics 
% Participants with GA progression 
Fast  
(≥2mm2/year) 
(n=10) 
Slow 
(<1mm2/year) 
(n=7) 
Slow/Normal 
(<2mm2/year) 
(n=9) 
Mean baseline age (years) 71.9 72.4 75.2 
Sex (male) 30.0 28.6 33.3 
Smoking 
Past  40.0 28.6 33.3 
Current 30.0 0.0 0.0 
Fish consumption (≥1 
serving/wk) 37.5 50.0 57.1 
Pseudophakic* 30.0 14.3 11.1 
CFH-rs1061170 
TT 10.0 71.4 55.6 
CT 40.0 14.3 22.2 
CC 50.0 14.3 22.2 
ARMS2-rs10490924 
GG 50.0 57.1 55.6 
GT 40.0 42.9 44.4 
TT 10.0 0.0 0.0 
n = sample size; CFH = complement factor H gene; ARMS2 = age-related maculopathy 
susceptibility gene 2. 
*pseudophakia detected prior to or at the same examination as GA detected. 
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DISCUSSION   
In this older Australian cohort we found an overall 3.6% incidence of pure GA over 15 
years. Common AMD risk factors including increasing age, history of smoking, genetic 
risk from the CFH and ARMS2 alleles and regular fish consumption were associated 
with long-term incidence of pure GA. In addition, early AMD lesion characteristics 
strongly predicted risk of GA independent of the known risk factors mentioned above. 
We also found that fast progression of GA was more likely to occur in affected 
individuals who were current smokers, or possessed at least one risk allele of the CFH 
gene or both risk alleles of the ARMS2 gene, and in pseudophakic eyes, while slow 
progression of GA was more likely to occur in those who consumed one or more 
servings of fish weekly. 
 
The BMES and the BDES33 are the only two studies to have reported GA incidence 
over a 15-year follow-up period in population-based older samples.  Both study 
protocols and methods used including examination procedures and retinal photographic 
grading of AMD signs were similar, while the BDES population had a slightly younger 
age limit (43+ years) than the BMES (49+ years). The BMES found an incidence of 
3.6% that was double the 1.3% rate observed in the BDES33 over the 15-year period. 
The 10-year cumulative incidence of GA was also double in the BMES (1.7%)35 than in 
the BDES (0.8%)34. After accounting for the competing risk of death and age-
standardization of the BMES population to the general Australian population, the 15-
year incidence of pure GA was 1.8%, however, the 95% CI 1.2-2.4 is consistent with 
the finding of a 1.3% 15-year incidence reported from the BDES. Apart from the 
different age ranges of the two study samples, there are likely different environmental 
exposures (smoking, sunlight exposure) that could explain the difference in GA 
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incidence between the two studies. The association between smoking and the incidence 
of late AMD was somewhat dissimilar in the BMES compared to the BDES, as 
previously reported115,117,118. There was a higher frequency of baseline current smokers 
in the BDES (men 21%; women 18%), compared to the BMES (men 15%; women 
11%). However, current smokers had a 4-fold greater risk of incident late AMD 
compared to non-smokers in the BMES115, while no similar association was found 
between past or current smoking and incident late AMD (or GA),  in the BDES116,118.  
 
A Danish study of 946 subjects aged 60+ years, which used a similar grading system to 
detect AMD from color fundus photographs, reported a 14-year incidence of GA of 
4.9%47, substantially higher than the 15-year incidence found in the BDES and BMES. 
The difference could be due to an older baseline age (60+ years) of the Danish study 
sample compared to the baseline ages of the BDES or BMES. Participants aged under 
60 years at baseline comprised 32.5% of the BMES population compared to none in the 
same age group in the Danish Study, which could have accounted for the differences in 
the incidence rates between the two studies. We do not have directly comparable data 
from the Danish study, so that direct age-standardization between the two study samples 
is not possible. Due to relatively high proportions of study participants who had died or 
were lost to follow-up (37.9%) in the Danish study47 and in the 15-year follow-up 
examinations of our study cohort, survival bias could have also affected differently the 
incidence estimates of the two studies.  
 
Previous studies have documented that eyes with early AMD lesions had a substantially 
higher risk of progression to late AMD including GA and neovascular AMD29,44,215. 
134 
 
Therefore the strong association between early AMD lesion characteristics and risk of 
developing GA, found in our study, is expected.  
 
We found that average progression of GA, measured as enlargement in GA area, was 
between 1.95mm2/year, which is similar to the average progression found in other 
population-based studies (1.2-1.8 mm2/year)205,213 but lower than the progression rate 
found in a clinic-based sample (2.6 mm2/year)209. In defining the progression rate in 
terms of enlargement in area, we have assumed a steady, similar enlargement rate in GA 
area across all stages of GA progression. Whether such an assumption holds is unclear, 
as indicated by Klein et al205. We also found a faster progression rate among cases with 
multifocal compared to classic GA configuration, consistent with the BDES finding in 
pure GA cases205. However, multifocal GA configuration usually indicates a more 
advanced stage of GA, and therefore the different progression rates observed may be 
due to differing stages of GA rather than the morphological differences of GA 
configurations per se. Nevertheless, these findings were based on a very small number 
of GA cases and should be interpreted with caution. 
 
Older age and history of smoking have been consistently identified in population-based 
studies as risk factors for late AMD63,123,216,217. The association between smoking and 
15-year incident GA, documented in this study, is in keeping with previous 
observations115,117. Past smokers in the BMES were shown to have a 3-fold higher risk 
of incident GA after adjusting for age, sex and other factors as previously reported115. 
We found that similar risk factors that were associated with high risk of developing GA 
were also associated with fast progression of GA, including genetic influence from the 
CFH and ARMS2 genes, current smoking and less frequent consumption of fish. The 
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higher proportion of participants who consumed fish at least weekly in the slow/normal 
progression group compared to the fast progression group accords with evidence 
suggesting beneficial effect of omega 3 fatty acids on the development and progression 
to either form of late AMD218-220. The higher proportion of pseudophakic participants in 
the fast than slow/normal progression groups lends support to the hypothesis that 
sunlight exposure could also be a risk factor for GA221,222.  
 
Strengths of our study include its long-term follow-up of an older predominantly 
Caucasian cohort that is comparable with the BDES cohort. The low follow-up rate at 
the 15-year examinations, however, could have led to either an over- or underestimation 
of GA incidence.  Our findings from all GA cases including both clinical and 
subclinical cases without apparent visual symptoms reflect the natural history of the 
condition. We were able to assess GA progression and risk characteristics associated 
with the progression by comparing fast to slow/normal progression groups. However, 
we cannot exclude the possibility that GA progresses differently at different stages of 
the disease and that fast progress cases may occur in a more advanced stage. Limitations 
of this study include the lack of optical coherence tomography (OCT) measures, due to 
timing (early 1990s when OCT was not available), and lack of fundus autofluorescence 
images, which may have allowed for better detection of the borders and extent of GA. 
We also could not statistically validate the association between certain risk factors and 
progression of GA lesions due to the small number of cases available to analyze 
progression. Concordance studies have shown differences in progression between 
bilateral GA cases and unilateral GA cases with early AMD in the fellow eye223, 
however, as above, we were unable to assess this due to very small number of GA cases 
in these subgroups. 
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SUMMARY 
This report shows the 15-year incidence of GA to be 3.6% in this older Australian 
cohort, and confirmed strong associations between baseline early AMD lesion 
characteristics with higher risk of developing GA over the  long-term, independent of 
age, smoking and genetic susceptibility from the two major AMD genes (CFH and 
ARMS2). Similar AMD risk factors were also found to be associated with fast 
progression of GA over 5 to 10 years.  
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3.3 The incidence and progression of reticular drusen in age-related 
macular degeneration 
 
Publication relating to this section of Chapter 3: 
Joachim N, Mitchell P, Rochtchina E, Tan AG, Wang JJ. Incidence and Progression of 
Reticular Drusen in Age-related Macular Degeneration: Findings from an Older 
Australian Cohort. Ophthalmology 2014; 121: 917-925 
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ABSTRACT 
Purpose: To assess the 15-year incidence and progression of reticular drusen and 
associations of this lesion with age-related macular degeneration (AMD) risk factors. 
 
Methods: Of 3654 Blue Mountains Eye Study (BMES) participants aged 49+ years, 
examined at baseline, 75.8%, 76.7% and 56.1% of survivors attended 5-, 10- and 15-
year follow-up examinations, respectively. Color retinal photographs were obtained and 
comprehensive questionnaires administered at each visit, and DNA samples were 
genotyped. Fundus autofluorescence images were not available. Reticular drusen 
identified from photographs were confirmed with side-by-side grading, using the 
Wisconsin AMD grading protocol. Incidence was assessed using Kaplan-Meier product 
limit survival methods, controlling for competing risk of death. Associations between 
smoking, fish consumption, serum lipids, systemic and dietary factors, the complement 
factor H (CFH-rs1061170) and age-related maculopathy susceptibility 2 (ARMS2-
rs10490924) genes and the 15-year incidence of reticular drusen were analyzed in 
discrete logistic regression models. Generalized estimating equation models were used 
to analyze eye-specific relationships between these risk factors and 5-year progression 
from reticular drusen to late AMD.  
 
Results: The 15-year cumulative incidence of reticular drusen was 4.0% (n=95). 
Increasing age (per decade increase; odds ratio, OR 3.4, 95% confidence interval, CI, 
2.6-4.4), female sex (OR 2.0, 95% CI 1.3-3.2) and presence of risk alleles of CFH-
rs1061170 (OR 1.8, 95% CI 1.3-2.4) or ARMS2-rs10490924 (OR 3.0, 95% CI 2.1-4.4) 
were associated with higher reticular drusen incidence. Current smoking at baseline 
predicted higher reticular drusen incidence (OR 2.1, 95% CI 1.0-4.5) after adjusting for 
139 
 
age, sex, CFH-rs1061170 and ARMS2-rs10490924 polymorphisms. Of 118 eyes with 
reticular drusen, 40 (33.9%) developed late AMD over 5 years. A higher proportion of 
eyes with reticular drusen located outside versus within the macular area progressed to 
late AMD (50.0% versus 37.8%). Dietary lutein-zeaxanthin intake was associated with 
decreased likelihood of progression from reticular drusen to late AMD (adjusted OR 
0.5, 95% CI 0.3-1.0). 
 
Conclusions: Known AMD risk factors were associated with greater long-term risk of 
reticular drusen. Neither total area nor central location of reticular drusen predicted 5-
year progression to late AMD. Increased consumption of lutein-zeaxanthin predicted a 
lower risk of progression. 
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BACKGROUND 
Described as soft, confluent drusen forming ill-defined networks of interlacing 
ribbons26, reticular drusen have been relatively under-researched and their incidence, 
prognosis and risk factors have not been well characterized. Reticular drusen are also 
termed ‘reticular pseudodrusen’ and ‘subretinal drusenoid deposits’, as a result of 
observations using different imaging modalities224-226. For the purpose of this report, we 
retain the term reticular drusen designated by Klein et al for reticular drusen lesions 
detected using only color fundus photographic grading26.   
 
In most previous studies, reticular drusen were grouped together with large drusen into 
the category of soft indistinct drusen, with only a few studies reporting the prevalence 
and incidence of reticular drusen as a separate lesion. The Beaver Dam Eye Study 
(BDES) reported a reticular drusen prevalence of 0.7% and an overall 15-year incidence 
of 3.0% in a population aged 43 to 86 years at the baseline examination227. We 
previously reported a 2.0% 5-year incidence of reticular drusen in the Blue Mountains 
Eye Study (BMES) population44. In a report of BMES 10-year AMD incidence, we 
included both reticular drusen and soft indistinct drusen in the incidence of 11.7% 35.  
 
Findings from clinic-based samples that used multimodal imaging methods have shown 
strong associations between reticular drusen and late AMD224,228-230. Some studies 
reported that reticular drusen were detected commonly co-existing with geographic 
atrophy (GA)225,231, whereas others suggested that reticular drusen commonly 
accompanied neovascular AMD229. Lack of longitudinal data in these studies, however, 
precludes important prognostic information that ophthalmologists need in providing 
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advice to patients found to have signs of reticular drusen, for example about the 
timeframe of progression from reticular drusen to late AMD.   
 
In this report we aimed to assess the prevalence, and 15-year incidence and progression 
of reticular drusen as a standalone lesion, in a well-characterized older Australian 
population sample. We also aimed to assess associations of common AMD risk factors 
and other early AMD lesion characteristics with the incidence of reticular drusen, as 
well as its progression to late AMD, over a 15-year period.  
 
METHODS 
Procedures 
Retinal photography was conducted at each BMES examination as described in 
Methods, Chapter 2. 
 
Reticular drusen was defined as confluent drusen forming an interlacing ribbon-like 
network, with individual lesions usually >125µm in diameter26 (Figure 3.3-1). 
 
Systolic and diastolic blood pressure (BP) measurements were recorded from the first 
and fifth Korotkoff sounds using a mercury sphygmomanometer after participants were 
seated for at least 5 minutes232. Diet was assessed from a self-administered food 
frequency questionnaire completed by participants at each examination, which included 
questions on dietary supplement use139. The Australian tables of food composition191,192 
and the United States Department of Agriculture carotenoid food composition 
database193 were used to calculate or estimate, respectively, the intake of nutrients, 
including lutein and zeaxanthin in µg.  
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Fasting blood samples were collected from 3222 participants at BMES I to assess white 
cell count (WCC) and cholesterol levels, as previously described154,160,233. Briefly, WCC 
(x109/L) was determined using Coulter Counter methods (Beckman Coulter, Inc, 
Fullerton, CA)160 or an Advir 120 autoanalyzer (Bayer, Leverkusen, Germany)102, and 
total cholesterol, high density lipoprotein (HDL) and triglyceride concentrations 
(mmol/L) were measured on a Reflotron reflectance photometric analyser (Roche 
Diagnostics, Germany)233. Blood samples collected from 2272 participants during the 
BMES II and III examinations were additionally used for genotyping. 
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Figure 3.3-1: (A) Example of reticular drusen (distinguished as soft confluent drusen 
that form broad ribbon-like networks) in the upper and lower arcades of the macula with  
the Wisconsin Age-Related Maculopathy Grading System (WARMGS) grid centered on 
the fovea; (B) Reticular drusen visible in the upper arcade of the same eye in Figure 
1(A). 
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Photographic Grading  
Retinal photographic grading was conducted by two senior graders using the Wisconsin 
Age-Related Maculopathy Grading System (WARMGS) protocol, as described 
previously36. The presence and location of reticular drusen within or outside the 
WARMGS grid was recorded.  
 
The author (Nichole Joachim) re-graded cases with confirmed or questionable reticular 
drusen in a side-by-side manner using all available retinal photographs from baseline 
and follow-up visits. Location of reticular drusen was recorded as presence in each 
subfield of the WARMGS grid. Reticular drusen area was measured for three concentric 
circles, within a 500µm, 1000µm and 3000µm radius of the foveal center. Difficult 
cases, where the presence of reticular drusen was questionable or where discrepancies 
existed between the original and subsequent side-by-side grading, were adjudicated and 
verified by a senior researcher with grading experience (Jie Jin Wang) and a retinal 
specialist (Paul Mitchell). 
 
Late and early AMD were defined in Methods, Chapter 2. Early AMD lesion type, area 
and location were defined using the WARMGS protocol26. Briefly, individual lesion 
size and collective area of drusen and pigmentary abnormalities were estimated using 
the WARMGS measurement circles. Location of lesions was defined as within 500µm, 
between 500 and 1500µm and between 1500 and 3000µm radius of the foveal center, in 
the WARMGS grid26. 
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Definition of Reticular Drusen Incidence and Progression  
Incident reticular drusen was defined as the first occurrence of reticular drusen at the 5-, 
10- or 15-year follow-up in eyes without reticular drusen or any late AMD, at previous 
visits. For cases where reticular drusen and late AMD were both present for the first 
time in a follow-up visit, we assumed that reticular drusen developed first, before the 
occurrence of late AMD during the 5-year interval between the two visits.  
 
Progression from reticular drusen to late AMD was defined as the development of any 
late AMD (GA or neovascular AMD) that followed the development of reticular drusen. 
Progression was assessed for baseline and incident reticular drusen cases where reticular 
drusen progress could be assessed for at least 5 years (with 5 or more years follow-up 
information). Location of reticular drusen was defined by subfields of the WARMGS 
grid, and the area of reticular drusen defined as small if <2DA and large if ≥2 DA, 
within the confines of the WARMGS grid26.   
 
Definition of Risk Factors 
Lifestyle, genetic and dietary data was obtained as described in Methods, Chapter 2. 
Smoking status was ascertained from an interviewer-administered questionnaire and 
participants were classified as non-smokers if they answered ‘no’ to smoking regularly. 
If participants had quit smoking more than 1 year prior to the examination they were 
classed as past smokers. Current smokers were defined as participants who currently 
smoked or had stopped smoking <1 year before the examination. Regular fish 
consumption was defined as consuming ≥1 serving of fish per week. Alcohol 
consumption (including beer, wine or spirits) was categorized as none, >0 to ≤2 
standard drinks and >2 standard drinks, per day. These categories were formulated 
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based on Australian National Health and Medical Research Council (NHMRC) 
recommendations of up to 2 standard drinks per day234.  
 
Statistical Analyses 
SAS (version 9.1, SAS Institute Inc, Cary, NC) was used. The 15-year incidence of 
reticular drusen was estimated using the Kaplan-Meier product limit survival method 
controlling for competing risk of death. Age was treated categorically (49-54, 55-64, 
65-74 and 75+ years) and the 15-year incidence of reticular drusen is presented by sex 
within each age-group. Age- and sex-adjusted discrete logistic regression models were 
used to assess associations between well known AMD risk factors (age, sex, smoking, 
presence of risk alleles for CFH-rs1061170 and ARMS2-rs10490924, BP, WCC, total 
cholesterol, HDL, triglycerides, fish consumption, alcohol consumption, vitamin 
supplementation and lutein-zeaxanthin dietary intake) and the 15-year development of 
reticular drusen using person-specific data. If risk factors were significantly associated 
with the 15-year incidence of reticular drusen in age-and sex-adjusted models, they 
were further adjusted for in a multivariable-adjusted model, and expressed as odds 
ratios (ORs). The two SNPs (CFH-rs1061170 and ARMS2-rs10490924) were assessed 
additively, where genotype (none, one or two risk alleles) was treated as a continuous 
variable.  
 
Generalized estimating equation models, using the GENMOD procedure in SAS196 was 
used to analyze eye-specific data for associations between other early AMD lesion 
characteristics and the 15-year incidence of reticular drusen. This method was also used 
to assess the relationship between the common AMD risk factors and 5-year 
progression of reticular drusen to late AMD using eye-specific data. Each risk factor 
147 
 
was defined using information collected at the time when reticular drusen was detected. 
Estimates are expressed as age- and sex-adjusted or multivariable-adjusted (age, sex, 
smoking, CFH-rs1061170 and ARMS2-rs10490924 polymorphisms) OR and 95% 
confidence intervals (CI). 
 
RESULTS 
Prevalence and Incidence of Reticular Drusen 
Reticular drusen were present in 1.95% of the baseline BMES population sample. Of 
the 65 participants with reticular drusen, in 38 (58.5%) this sign was present in both 
eyes (bilateral). The co-presence of reticular drusen with late AMD occurred in 7 of the 
total 103 eyes (6.8%) with prevalent reticular drusen. 
 
Incident reticular drusen were identified in 95 (152 eyes) of 2738 participants at risk, 
with an overall 15-year incidence of 4.0% (95% CI 3.2-4.8) after controlling for the 
competing risk of death. Of the 95 cases, 57 (60.0%) were bilateral. Baseline 
characteristics of participants with and without incident reticular drusen are presented in 
Table 3.3-1. Participants who developed reticular drusen were more likely to be female, 
older at baseline, to have at least one risk allele of CFH-rs1061170 or ARMS2-
rs10490924, and to have higher mean HDL and lower mean triglyceride levels than 
participants who did not develop reticular drusen.  
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Table 3.3-1: Comparison of baseline characteristics between participants with and 
without incident reticular drusen. 
 
Characteristic 
% Participants 
P-value No reticular 
drusen (n=2135)
Incident reticular 
drusen (n=95) 
Mean Age, years (SD) 63.4 (8.2) 69.5 (6.4) <0.0001 
Sex (female) 56.6 73.7 0.001 
Smoking 
Non-smoker 51.8 57.5 
0.6* Ex-smoker 35.3 30.9 
Current smoker 13.0 11.7 
CFH-rs1061170 
TT 40.3 22.0 
0.0008* CT 46.2 53.7 
CC 13.5 24.4 
ARMS2-rs10490924 
GG 62.9 37.0 
<0.0001* GT 33.2 51.9 
TT 3.8 11.1 
Mean Blood Pressure (mmHg; SD)
Systolic 144.6 (20.4) 147.7 (20.4) 0.1 
Diastolic 83.5 (9.9) 83.2 (8.4) 0.7 
Mean White Cell Count (x109cells/L; 
SD) 6.4 (1.7) 6.5 (1.5) 0.3 
Mean Total Cholesterol (mmol/L; SD) 6.0 (1.0) 6.2 (1.1) 0.3 
Mean High Density Lipoprotein 
(mmol/L; SD) 1.4 (0.4) 1.5 (0.4) 0.01 
Mean Triglycerides (mmol/L; SD) 1.8 (1.1) 1.6 (0.8) 0.02 
Fish Consumption (≥1 servings/week) 60.1 52.0 0.2 
Daily Alcohol Consumption 
None 20.0 18.2 
0.6* >0 to ≤2 standard drinks 59.7 64.9 
>2 standard drinks 20.2 16.9 
Any Current Vitamin Supplement 
Intake 39.6 40.3 0.9 
Mean Dietary Lutein and Zeaxanthin 
Intake (µg; SD) 829.0 (480.2) 907.5 (691.4) 0.3 
SD = standard deviation; CFH = complement factor H (C risk allele); ARMS2 = age-related 
maculopathy susceptibility gene 2 (T risk allele)
*Unadjusted tests for heterogeneity used to calculate p-values 
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The 15-year cumulative incidence of reticular drusen by age and sex is presented in 
Table 3.3-2. It was significantly associated with increasing age (P for trend <0.0001) in 
both men and women. After adjusting for age, the 15-year cumulative incidence of 
reticular drusen was twice as likely in women than in men (5.6%, 95% CI, 5.59-5.61 
versus 2.2%, 95% CI, 2.19-2.21; Table 3.3-2). 
 
Table 3.3-2: Fifteen-year cumulative incidence of reticular drusen by age and sex 
 
Age (years)  
15-year Incidence of Reticular Drusen 
Women  Men  Both 
No. of 
cases/ 
no. at 
risk 
% (95% CI)  
No. of 
cases/ 
no. at 
risk
% (95% CI)  
No. of 
cases/ 
no. at 
risk 
% (95% CI) 
49 to 54 0/205 0 1/162 0.8 (-0.8-2.4) 1/367 0.4 (-0.4-1.2) 
55 to 64 13/519 3.1 (1.4-4.8) 4/420 1.1 (0.0-2.2) 17/939 2.2 (1.2-3.2) 
65 to 74 42/530 10.3 (7.4-13.2) 12/414 3.2 (1.4-5.0) 54/944 7.0 (5.2-8.8) 
75+ 15/259 6.2 (3.3-9.1) 8/229 3.5 (1.2-5.8) 23/488 4.9 (3.0-6.8) 
P trend < . 0001 < . 0001 < . 0001 
Total 70/1513 5.6 (4.3-6.9)*  25/1225 2.2 (1.3-3.1)*  95/2738 4.0 (3.2-4.8) 
CI = confidence interval 
*Age-adjusted difference between sex, P = 0.0032 
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In an age- and sex-adjusted model (Table 3.3-3), each additional risk allele of CFH-
rs1061170 and ARMS2-rs10490924 was also associated with a greater 15-year risk of 
incident reticular drusen (p=0.0004 and p<0.0001, respectively). Increasing WCC was 
positively associated with reticular drusen incidence, but this association was 
marginally non-significant (p=0.07). Current smoking at baseline was not associated 
with the 15-year development of reticular drusen in the age- and sex-adjusted model, 
but became so after adjusting for age, sex and presence of the CFH-rs1061170 and 
ARMS2-rs10490924 polymorphisms. In the multivariable-adjusted model, increasing 
age, female sex and presence of risk alleles for CFH-rs1061170 and ARMS2-
rs10490924 remained significantly associated with an increased risk of incident 
reticular drusen, in addition to current smoking status (Table 3.3-3). 
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Table 3.3-3: Associations between well-known age-related macular degeneration risk 
factors and the 15-year incidence of reticular drusen. 
 
Risk Factor 
15-year Incidence of Reticular Drusen 
Age and Sex 
Adjusted (where 
appropriate)
Multivariable 
Adjusted* 
OR 95% CI OR 95% CI 
Age, per 10 years 3.4 2.6-4.4 4.3 3.1-5.9 
Female Sex 2.0 1.3-3.2 2.2 1.3-3.8 
Smoking 
Ex-smoker 1.0 0.6-1.7 1.3 0.7-2.1 
Current smoker 1.7 0.9-3.4 2.1 1.0-4.5 
CFH allele - rs1061170† 1.8 1.3-2.4 1.8 1.3-2.6 
ARMS2 allele - rs10490924† 3.0 2.1-4.4 3.2 2.2-4.6 
Blood Pressure, per 10mmHg 
Systolic 1.0 0.9-1.1  -   -  
Diastolic 1.0 0.8-1.3  -   -  
White Cell Count‡ 1.2 1.0-1.5  -   -  
Total Cholesterol‡ 1.0 0.8-1.3  -   -  
High Density Lipoprotein‡ 1.2 0.9-1.4  -   -  
Triglycerides‡ 0.8 0.6-1.1  -   -  
Fish Consumption (≥1 servings/wk) 0.8 0.5-1.2  -   -  
Daily Liquor Consumption 
None 0.7 0.4-1.2  -   -  
>0 to ≤2 standard drinks (referent) 1.0 
>2 standard drinks 1.0 0.5-1.9  -   -  
Vitamin Supplementation (current baseline 
intake) 1.0 0.6-1.5  -   -  
Lutein-Zeaxanthin Intake‡ 1.1 0.9-1.4  -   -  
OR = odds ratio; CI = confidence interval; CFH = complement factor H; ARMS2 = age-related 
maculopathy susceptibility gene 2
*Multivariable ORs adjusted for age, sex, past and current smoking, the CFH and ARMS2 risk 
alleles as additive variables 
†Analyzed using additive models; estimates represent risk associated with each additional single 
nucleotide polymorphism of the minor variants. 
‡Per standard deviation increase in each risk factor 
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The association between early AMD lesion characteristics and the 15-year incidence of 
reticular drusen is shown in Table 3.3-4. After adjusting for age and sex, the presence 
of soft indistinct drusen (excluding reticular drusen) (OR 4.3), location of any soft 
drusen within 500µm radius of the foveola (OR 2.6) and a collective area of any soft 
drusen ≥375µm (ORs 3.1 – 6.3) were all predictive of the development of reticular 
drusen. After further adjusting for smoking and the CFH-rs1061170 and ARMS2-
rs10490924 risk alleles, only the location of any soft drusen at close proximity to the 
fovea (OR 2.2) and an area of soft drusen ≥375µm but <0.5DA in diameter (OR 3.2) 
were significantly associated with a greater risk of reticular drusen (Table 3.3-4). 
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Table 3.3-4: Relationship between baseline early age-related macular degeneration 
(AMD) lesion characteristics and the 15-year incidence of reticular drusen, analyzed by 
eye. 
 
Early AMD Characteristics  
No. eyes that 
progressed/ no. 
eyes  at risk of 
progression to 
reticular drusen
15-year Incidence of Reticular Drusen
Age and Sex 
Adjusted 
Multivariable 
Adjusted*
OR 95% CI OR  95% CI 
Drusen Type 
None or hard distinct 99/3823 1.0 1.0 
Intermediate 21/439 1.1 0.7, 1.8 1.1 0.6, 1.8
Soft distinct 9/94 2.0 0.9, 4.3 1.8 0.7, 4.4
Soft indistinct 12/73 4.3 1.7, 10.8 2.1 0.6, 7.7
Drusen Location 
None or ≥500µm radius of foveal centre 101/4034 1.0 1.0 
<500µm radius of foveal centre 40/385 2.6 1.7, 4.1 2.2 1.3, 3.7
Drusen Area 
None or <375µm in diameter 111/4238 1.0 1.0 
≥375µm to <0.5 disc area in diameter 21/143 3.1 1.8, 5.4 3.2 1.7, 5.8
≥ 0.5 disc area in diameter 8/40 6.3 2.2, 18.1 2.3 0.4, 12.2
RPE Depigmentation 
Absent 141/4402 1.0 1.0 
Present 9/131 1.3 0.6, 2.7 1.5 0.6, 3.4
Location 
None or ≥1500µm radius of foveal centre 141/4405 1.0 1.0 
≥500µm to <1500µm radius of foveal 
centre 4/67 1.4 0.6, 3.1 1.8 0.7, 4.5 
<500µm radius of foveal centre 5/61 1.3 0.4, 4.5 1.2 0.3, 5.6
Area 
None or <375µm in diameter 146/4451 1.0 1.0 
≥375µm in diameter 4/82 1.2 0.4, 3.7 1.3 0.4, 4.7
Hyperpigmentation 
Absent 135/4260 1.0 1.0 
Present 15/274 1.2 0.6, 2.2 1.2 0.6, 2.7
Location 
None or ≥1500µm radius of foveal centre 135/4278 1.0 1.0 
≥500µm to <1500µm radius of foveal 
centre 4/86 1.1 0.5, 2.5 1.4 0.6, 3.3 
<500µm radius of foveal centre 10/124 1.4 0.5, 3.7 1.3 0.4, 4.4
Area 
None or <64µm in diameter 137/4280 1.0 1.0 
≥64µm in diameter 12/208 1.1 0.5, 2.3 1.1 0.5, 2.6
OR = odds ratio; CI = confidence interval; RPE = retinal pigment epithelial
*Multivariable ORs adjusted for age, sex, current smoking, the CFH and ARMS2 risk alleles 
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Progression of Reticular Drusen 
Of the 65 participants with prevalent reticular drusen, 37 had retinal photographs 
available from at least one follow-up visit. Of these, 18 participants (48.6%) progressed 
to late AMD within 15 years, in at least one eye. Five-year progression from reticular 
drusen to late AMD occurred in 14 of the 37 (37.8%) participants (18 of 59 eyes; 
30.5%). 
 
Of the 95 participants (152 eyes) with incident reticular drusen detected at either of the 
5-, 10- or 15-year follow-up visits, only 40 participants (59 eyes) had follow-up 
information. Overall, 18 of 40 participants (26 of 59 eyes) progressed to late AMD 
within 5 to 10 years. Of the 26 eyes with reticular drusen that progressed, 22 eyes 
progressed to late AMD in 5 years. This included eyes in which both reticular drusen 
and late AMD were detected at the same visit and in which reticular drusen was 
assumed to have developed prior to the late AMD. 
 
Of a total 118 eyes with either prevalent or incident reticular drusen that were available 
for assessment of progression, 33.9% (40 eyes; 18 with prevalent and 22 with incident 
reticular drusen) progressed to late AMD over 5 years. Of these, 23 (57.5%) progressed 
to GA, 12 (30.0%) progressed to neovascular AMD and 5 (12.5%) developed both GA 
and neovascular AMD in the same eye. By comparison, of 722 eyes with other early 
AMD lesions (excluding reticular drusen), that were available for assessment of 
progression, 62 (7.9%) eyes progressed to late AMD over 5 years, including 27 (43.6% 
of the 62 eyes) that developed GA, 30 (48.4%) that developed neovascular AMD and 5 
(8.1%) that developed both late AMD lesions. Further, of 4176 eyes with no prior early 
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AMD lesions, 6 (0.1%) progressed to late AMD over 5 years, all of which developed 
neovascular AMD.  
 
A higher proportion of eyes with reticular drusen outside the WARGMS grid 
progressed to late AMD compared to eyes with reticular drusen in the central, inner or 
outer circles (50.0% versus 23.5-37.8%). Of eyes with reticular drusen present within 
the grid, there was no difference in proportion of eyes that progressed to late AMD 
between eyes with small (28.6%) or large (37.9%) areas of reticular drusen.  
 
No significant associations were found between the 5-year progression from reticular 
drusen to late AMD and most known AMD risk factors assessed (age, female sex, 
smoking status, genetic risk from CFH-rs1061170 and ARMS2-rs10490924 
polymorphisms, BP, WCC, total cholesterol, HDL, triglycerides, fish consumption, 
alcohol consumption and vitamin supplementation; data not shown). However, a 
significantly lower risk of progression to late AMD was evident in the eyes of subjects 
with increased intake of dietary lutein-zeaxanthin (OR 0.5, 95% CI 0.3-1.0, p=0.046) 
after adjusting for age, sex, current smoking, and presence of the CFH-rs1061170 and 
ARMS2-rs10490924 polymorphisms. 
 
DISCUSSION  
We found an overall 15-year incidence of reticular drusen of 4.0% in this older 
Australian cohort, with over 50% of incident cases developing bilaterally. The incidence 
of reticular drusen rose with increasing age and was significantly higher in women than 
in men. Current smoking and presence of the CFH-rs1061170 and ARMS2-rs10490924 
risk alleles were also independently associated with higher 15-year incidence of 
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reticular drusen. A substantially higher proportion (34%) of eyes with reticular drusen 
(with or without early AMD lesions) compared to eyes without reticular drusen but with 
other early AMD lesions (8%) progressed to late stage AMD within 5 years. Increased 
dietary lutein-zeaxanthin intake was associated with a lower risk of progression from 
reticular drusen to late AMD over 5 years. 
 
The BDES and the BMES are the only two longitudinal population-based studies to 
have reported 15-year incidence of reticular drusen in older cohorts to date. Although 
the prevalence of reticular drusen in the BMES (1.95%) was more than double the 
prevalence reported in the BDES (0.7%), the 15-year incidence of reticular drusen in the 
BMES, after accounting for competing risk of death (4.0%) was similar to the incidence 
in the BDES (3.0%), given that the BMES population was slightly older than the BDES 
population at baseline (43 to 86 years for the BDES; and 49 to 97 years for the BMES). 
In addition to age, differences in environmental exposures (smoking, diet, sunlight 
exposure) could also account for the differences in prevalence and incidence of reticular 
drusen between these two studies. 
 
We confirmed that older age and female sex are associated with a greater risk of 
reticular drusen, consistent with the BDES227 and previous cross-sectional studies that 
reported a female preponderance for reticular drusen225,228. Smoking was independently 
associated with incident reticular drusen, as it was with late AMD in the BMES115. The 
risk of incident reticular drusen for current smokers was 2.1-fold the risk for non-
smokers in our cohort, similar to that found in the BDES (current smokers had 1.9 times 
the risk of reticular drusen compared to non-current smokers)227, though no similar 
association was found between smoking and incident late AMD in the BDES34,116,117. 
157 
 
 
The BDES previously reported a higher prevalence of reticular drusen in those with 
than without the CFH-rs1061170 polymorphism227, however, the increased risk of 
reticular drusen associated with the presence of either or both the CFH-rs1061170 and 
ARMS2-rs10490924 minor alleles, found in our study, has not been demonstrated 
previously 227. An inflammatory basis has been hypothesized for the development of 
reticular drusen228,235, however, we did not observe a significant relationship between 
WCC levels and 15-year incident reticular drusen.  
 
Of other early AMD lesions and early AMD lesion characteristics, we found that soft 
drusen location close to the fovea and an intermediate area of soft drusen was associated 
with 15-year incident reticular drusen. This finding is inconsistent with the BDES 
finding that presence of more severe drusen type but not drusen location or area 
predicted 15-year development of reticular drusen227. 
 
About one in three eyes with reticular drusen progressed to late AMD in 5 years in our 
study, compared to >50% of eyes that progressed to late AMD in a cohort of the 
Nutritional AMD Treatment 2 (NAT 2) study236. The NAT 2 study, however, assessed 
participants who had unilateral neovascular AMD already present, which may explain 
the higher frequency of eyes that progressed from reticular drusen to late AMD35. We 
found that progression from reticular drusen to pure GA was slightly more frequent than 
the progression to neovascular AMD, a finding that appears to conflict with other 
reports, although the previous findings were based on associations between reticular 
drusen and late AMD detected at the same visit224,229,231.  
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In the Geographic Atrophy Progression study population 237, the average growth rate of 
reticular drusen area was found to be 4.4mm2/year over a period of 18 months; although 
this observation was obtained from 16 eyes only237. We did not conduct quantitative 
measures of areas of reticular drusen, as the majority of reticular drusen were located 
outside the WARMGS grid and therefore the photographic fields taken might not 
include all of the reticular drusen in the eye.  
 
We found that the proportion of eyes with reticular drusen that progressed to late AMD 
in 5 years was 4-fold the corresponding proportion of eyes without reticular drusen but 
with other early AMD lesions. This finding is consistent with clinicians’ experience as 
well as observation from other studies. Klein et al227 demonstrated that eyes with 
reticular drusen conferred a 6-fold risk of late AMD compared to eyes with soft 
indistinct drusen but no reticular drusen. We also observed that reticular drusen 
progressed to RPE depigmentation followed by GA. Fading of reticular drusen as 
neovascular AMD developed has also been documented in previous studies236.    
   
Although we observed a decreased risk of 5-year progression from reticular drusen to 
late AMD associated with increased dietary intake of lutein-zeaxanthin, this observation 
was based on a relatively small sample of eyes of participants who had dietary intake 
information available. Nevertheless, our observation is in keeping with findings from 
the Age-Related Eye Disease Study (AREDS) that showed a protective effect of dietary 
lutein-zeaxanthin intake on the development of late AMD143 and a similar protective 
effect for treatment with lutein-zeaxanthin supplements in participants with low dietary 
intake of lutein-zeaxanthin (AREDS2)137. 
 
159 
 
Strengths of this study include long-term follow-up of participants in an older 
Australian cohort, and side-by-side grading of retinal photographs taken over the 
follow-up period of the same participants. The low follow-up rate in the 15-year visits, 
however, could have led to an over- or under-estimation of reticular drusen incidence. 
Limitations include that only color retinal fundus photographs were used to detect 
reticular drusen, resulting in substantial under-estimation of reticular drusen prevalence 
and incidence, compared to multimodal imaging methods (fundus autofluorescence, 
infrared reflectance, blue light photography and spectral domain optical coherence 
tomography), as used in other studies 225,231,238,239,  therefore caution must be exercised 
when interpreting these findings. The distinction between soft indistinct drusen and 
reticular drusen can be differentiated well with monochromatic blue light as well as red 
free images, and therefore misclassification of drusen was unlikely in our study.   
 
SUMMARY 
This report shows the 15-year incidence of reticular drusen was 4.0% in this older 
Australian cohort, and was associated with well-known AMD risk factors. Reticular 
drusen was, however, documented only from standard color photography, which could 
have substantially underestimated the prevalence and incidence compared to that found 
using multimodal imaging methods. The proportion of eyes that progressed from 
reticular drusen to late AMD over 5 years was four-fold that in eyes without reticular 
drusen, suggesting that this sign portends a higher risk. High dietary intake of lutein-
zeaxanthin was associated with a lower risk of progression from reticular drusen to late 
AMD over 5 years, though confirmation of this finding in future studies will be 
important. 
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3.4 The incidence and progression of medium drusen over 15 years 
 
Publication relating to this section of Chapter 3: 
Joachim N, Mitchell P, Kifley A, Wang JJ. Incidence, Progression and Associated Risk 
Factors of Medium Drusen in Age-related Macular Degeneration: Findings from an 
Older Australian Cohort. JAMA Ophthalmology 2015; 133(6): 698-705 
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ABSTRACT 
Purpose: To assess the 15-year incidence and progression of medium drusen and 
associated risk factors. 
 
Methods: Of 3654 participants, aged 49+ years who attended baseline examinations of 
the Blue Mountains Eye Study (1992-1994), 75.8%, 76.7% and 56.1% of survivors 
attended 5-, 10- and 15-year follow-up examinations, respectively.  Colour retinal 
fundus photographs were taken at each examination. Incidence and progression of 
medium drusen (maximum diameter ≥63µm-<125µm) were assessed using Kaplan-
Meier product limit survival methods controlling for the competing risk of death. 
Factors associated with the 15-year incidence of medium drusen were assessed using 
discrete logistic regression models after adjusting for age, sex, smoking, serum lipids, 
systemic and dietary factors, complement factor H (CFH-rs1061170) and age-related 
maculopathy susceptibility 2 (ARMS2-rs10490924) polymorphisms. Associations 
between lesion characteristics and progression to late AMD were assessed using 
generalized estimating equation models and eye-specific data. 
 
Results: Of 1317 participants at risk the 15-year cumulative incidence of medium 
drusen was 13.9% (n=281). Increasing age (per decade older, odds ratio, OR 1.4; 95% 
confidence interval (CI) 1.2-1.8) and the presence of ≥3 risk alleles of the CFH-
rs1061170 or ARMS2-rs10490924 genes (OR 2.1, 95% CI 1.1-4.1) were associated with 
a higher incidence. There was no association between past or current smoking and 
development of medium drusen (OR’s 0.8, 95% CI 0.6-1.1 and 0.6, 95% CI 0.4-1.1, 
respectively). The progression rate to late AMD in eyes that had both medium drusen 
and retinal pigmentary abnormalities was 4-fold higher than that of eyes with medium 
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drusen alone. Larger total area and central location of medium drusen were associated 
with a greater likelihood of progression to worse stages of AMD. 
Conclusion: Older age and presence of CFH and ARMS2 risk alleles are two main risk 
factors associated with medium drusen development. The co-presence of medium 
drusen and retinal pigmentary abnormalities signals a greater risk of progression to late 
AMD than the presence of medium drusen alone.  
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BACKGROUND 
Early age-related macular degeneration (AMD) is characterized by the presence of 
drusen and retinal pigmentary abnormalities13,28. Drusen vary in size (with diameters 
ranging from ≤63µm to ≥250µm) and type (hard, soft, distinct and indistinct). Pigment 
abnormalities include clusters of pigment granules within the sensory retina (increased 
pigmentation) and sharply demarcated areas of retinal pigment epithelial (RPE) 
depigmentation.  
 
The International Classification and Grading System for AMD termed medium drusen 
as 'intermediate' soft drusen, defined as drusen with maximum diameter ≥63µm but 
<125µm, larger than the maximum diameter of hard drusen (<63µm) but smaller than 
the minimum diameter of large soft drusen (≥125µm)13. A similar definition of this 
drusen type was used by Age-Related Eye Disease Study (AREDS)28 and the Basic 
Clinical Classification System31, and termed 'medium' drusen. Similarly the Wisconsin 
Age-Related Maculopathy Grading System (WARMGS) defines medium drusen by 
maximum diameter, although the term medium drusen is not used26. In this report, we 
use the term 'medium' drusen for this type of drusen. 
 
Although medium drusen have attracted some attention recently and was included in 
AMD incidence reports61,62, knowledge of the associated risk factors and  progression of 
medium drusen is limited. It has been relatively under researched compared to large, 
soft drusen and pigmentary lesions29,31,240,241. In this report, we aimed to assess the 15-
year incidence and progression of medium drusen in an older Australian cohort and 
associations between common AMD risk factors and the development and progression 
of medium drusen.  
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METHODS   
Procedures 
The study population and procedures for retinal fundus photography acquisition and 
grading of AMD are described in Methods, Chapter 2.  
 
Late and early AMD were also defined in Methods, Chapter 2. The maximal diameter 
of individual drusen and collective macular areas involved by drusen and retinal 
pigment epithelium (RPE) abnormalities within the eye were estimated using the 
WARMGS measurement circles26. 
 
Definition of Medium Drusen Incidence and Progression 
Medium drusen is defined as soft drusen with a diameter larger than 63µm but smaller 
than 125µm. Incidence of medium drusen were defined as its presence at the 5-, 10- or 
15-year follow-up in persons who had no drusen or hard drusen only in any eye at the 
baseline visits. Progression of medium drusen was defined as the progression to worse 
AMD lesions including large soft drusen, retinal pigmentary abnormalities or late AMD 
at follow-up visits, in eyes with medium drusen as the most severe lesion at baseline.  
 
Genotyping 
Genotyping was performed on 2761 participants with blood samples collected during 
the BMES II examinations as described in Methods (Chapter 2) After quality checking, 
2534 subjects with genome-wide association scan (GWAS) data were imputed.  
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The complement factor H (CFH) single nucleotide polymorphism (SNP) rs1061170 was 
also genotyped in 1874 participants and the age-related maculopathy susceptibility 2 
(ARMS2) SNP rs10490924 genotyped in 593 participants as described (Methods, 
Chapter 2). Imputed SNPs of these two genes were used for the remaining participants. 
Of the 1501 and 509 participants who had both typed and imputed rs1061170 and 
rs10490924, respectively, the concordance rates between typed and imputed SNPs were 
99.6% for rs1061170 and 99.2% for rs10490924. 
 
Other Risk Factors  
Participants were classified as non-smokers if they answered ‘no’ to the question 
whether they smoke regularly. Past smoking was defined if participants had smoked 
regularly but quit smoking more than 1 year prior to the examination. Current smoking 
was defined if participants were current smokers or had stopped smoking <1 year before 
the examination. Alcohol consumption (including beer, wine or spirits) was categorized 
as none, >0 but ≤2 standard drinks and >2 standard drinks per day. These categories 
were based on Australian National Health and Medical Research Council (NHMRC) 
recommendations of up to 2 standard drinks per day234. 
 
Systolic and diastolic blood pressure (BP) measurements were recorded from the first 
and fifth Korotkoff sounds using a mercury sphygmomanometer after participants were 
seated for at least 5 minutes232. Dietary consumption and supplement use were extracted 
from the self-administered FFQ 139. The Australian tables of food composition191,192 and 
the United States Department of Agriculture carotenoid food composition database193 
were used to estimate, respectively, the intake of nutrients, including lutein and 
166 
 
zeaxanthin in µg. Regular fish consumption was defined as consuming ≥1 serving of 
fish per week. 
 
Fasting blood samples were collected from 3222 baseline participants to assess white 
cell count (WCC) and cholesterol levels, as previously described154,160,233. Briefly, WCC 
(x109/L) was determined using Coulter Counter methods (Beckman Coulter, Inc, 
Fullerton, CA)160, and total cholesterol, high density lipoprotein (HDL) and triglyceride 
concentrations (mmol/L) were measured on a Reflotron reflectance photometric 
analyser (Roche Diagnostics, Germany)233.  
 
Statistical Analyses 
SAS software version 9.3 (SAS Institute, Inc., Cary NC) was used. The 15-year 
incidence of medium drusen was estimated using Kaplan-Meier product limit survival 
estimates and competing risk analyses that control for the competing risk of death 
among persons at risk of medium drusen, after excluding participants with any worse 
stage of early or late AMD lesions at baseline. The associations between common AMD 
risk factors (age, sex, smoking status, numbers of CFH-rs1061170 and ARMS2-
rs10490924 risk alleles, BP, WCC, total cholesterol, HDL, triglycerides, fish 
consumption, alcohol, antioxidant and zinc supplementation intake) and the 15-year 
incidence of medium drusen were assessed using age and sex-adjusted discrete logistic 
regression models. If these risk factors had a P value ≤0.09 in the age and sex-adjusted 
regression models, they were included in the multivariable-adjusted logistic regression 
model. The final multivariable-adjusted logistic regression model includes age, sex, past 
and current smoking, zinc supplementation and the combined CFH-rs1061170 and 
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ARMS2-rs10490924 risk alleles as co-variables. The combined CFH-rs1061170 and 
ARMS2-rs10490924 risk alleles were categorized as none, 1, 2 or ≥3. 
 
The frequencies of progression from medium drusen alone, and from medium drusen 
plus RPE abnormalities to worsening stages of AMD were reported. Generalized 
estimating equation models, using the GENMOD procedure in SAS196, were applied to 
eye-specific data to assess the associations between medium drusen area and location 
characteristics and progression to early or late AMD. Association estimates are 
presented as age- and sex-adjusted or multivariable-adjusted odds ratio (ORs) and 95% 
confidence intervals (CIs).  
 
RESULTS 
Prevalence of Medium Drusen 
Of 3654 baseline participants, we excluded persons with late AMD (n=75), early AMD 
(n=185) and large soft distinct drusen (n=113), and included 3281 for the assessment of 
medium drusen. Medium drusen status can be clearly defined in 2959 participants, of 
which 534 (18.0%) had medium drusen, including, 445 (83.3%) present with medium 
drusen only and 89 (16.7%) co-present with retinal pigmentary abnormalities. Medium 
drusen was bilateral in 16.6% (74/ 445).  
 
Incidence of Medium Drusen 
Among 1317 persons without any AMD lesions at baseline who had been followed up, 
the 5-, 10- and 15-year cumulative incidence of medium drusen was 10.1% (95% CI 8.6 
- 11.9), 17.7% (95% CI 15.6 - 20.1) and 30.8% (95% CI 27.7 - 34.3), respectively. After 
controlling for competing risk of death, the 5-, 10- and 15-year cumulative incidence of 
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medium drusen was 5.7% (95% CI 4.8 – 6.6), 9.2% (95% CI 9.1 – 9.3) and 13.9% (95% 
CI 12.5-15.3), respectively. The 15-year incidence of medium drusen by age and sex are 
presented in Table 3.4-1. The incidence rates across all age groups were comparable, 
except for those aged 75 years and older. Incidence of medium drusen was slightly 
lower in men compared with women. 
 
 
 
 
Table 3.4-1: Fifteen-year incidence of medium drusen by age and sex. 
 
 
Age (years)  
15-year Kaplan-Meier Incidence of Medium Drusen* 
Women Men Both 
No of cases/ No. 
at risk % (95% CI) 
No of cases/ No. 
at risk % (95% CI) 
No of cases/ No. 
at risk % (95% CI) 
49-54 32/145 28.5 (20.8-38.3) 17/110 19.9 (12.7-30.3) 49/255 24.7 (19.1-31.6) 
55-64 68/319 28.9 (23.3-35.4) 49/257 27.0 (20.8-34.6) 117/576 28.1 (23.8-32.9) 
65-74 59/219 41.1 (31.3-52.7) 43/167 43.9 (32.8-57.0) 102/386 42.7 (35.1-51.3) 
75+ Aug-51 15.7 (8.2-28.9) May-49 15.8 (5.5-40.5) 13/100 16.2 (8.6-29.4) 
Total 167/734 32.2 (28.0-36.9) 114/583 29.0 (24.5-34.3) 281/1317 30.8 (27.7-34.3) 
Age (years)  
15-year Cumulative Incidence of Medium Drusen after Controlling for Competing Risk of Death 
Women Men Both 
No. of deaths/ No. 
at risk % (95% CI) 
No. of deaths/ No. 
at risk % (95% CI) 
No. of deaths/ No. 
at risk % (95% CI) 
49-54 13/145 24.1 (17.0-31.2) 8/110 16.8 (9.7-23.9) 21/255 20.9 (15.8-25.9) 
55-64 37/319 22.2 (17.6-26.7) 48/257 17.6 (13.3-21.9) 85/576 20.0 (16.9-23.2) 
65-74 63/213 17.8 (13.9-21.8) 79/167 13.0 (9.7-16.4) 142/386 15.5 (13.0-18.1) 
75+ 40/51 2.5 (0.8-4.1) 39/49 1.8 (0.3-3.3) 79/100 2.2 (1.0-3.3) 
Total 153/734 15.8 (13.7-17.9) 174/583 11.8 (9.9-13.7) 327/1317 13.9 (12.5-15.3) 
CI = confidence interval 
*Definition of medium drusen herein excludes larger soft drusen, pigment abnormalities and late age-related macular degeneration 
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Baseline characteristics of participants with and without incident medium drusen are 
presented in Table 3.4-2. There were no significant differences in the mean age or the 
frequency of females between participants with and without incident medium drusen. 
However, participants with incident medium drusen were marginally more likely to 
have ≥1 risk allele of ARMS2-rs10490924, lower mean WCC and were less likely to be 
past or current smokers or to take zinc supplements.  
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Table 3.4-2: Comparison of baseline characteristics of participants with versus without 
incident medium drusen. 
 
Baseline Characteristic 
Participants (%) 
P value No Medium 
Drusen 
Incident 
Medium 
Drusen 
Mean age (SD), yrs 62.1 (8.1) 62.3 (7.5) 0.7 
Female sex 54.7 59.4 0.2 
Smoking Status 
non-smoker 47.8 61.8 
<.001* past smoker 37.3 28.7 
current smoker 14.8 9.5 
CFH-rs1061170 
TT 42.3 38.2 
0.4* CT 47 49 
CC 10.6 12.9 
ARMS2-rs10490924 
GG 65.6 57.9 
0.09* GT 30.4 37.8 
GT 4 4.3 
CFH and ARMS2 combined risk 
No risk alleles  28.7 21.3 
0.2* 1 risk allele 40.6 44 
2 risk alleles 25.5 27.6 
≥3 risk alleles 5.2 87.1 
Mean blood pressure (SD), mmHg 
Systolic 143.4 (19.9) 144.6 (21.1) 0.4 
Diastolic 83.2 (10.0) 83.8 (9.1) 0.4 
Mean white cell count (SD), x109 cells/l 6.4 (1.7) 6.2 (1.4) 0.06 
Mean total cholesterol (SD), mmol/l 6.0 (1.1) 6.1 (1.1) 0.6 
Mean high-density lipoprotein (SD), 
mmol/l 1.4 (0.5) 1.5 (0.4) 0.3 
Mean triglycerides (SD), mmol/l 1.8 (1.1) 1.7 (1.1) 0.2 
Fish consumption (≥1 serving/wk) 60.3 60.2 1 
Alcohol consumption 
none 29.6 31.6 
0.7* >0 to ≤2 standard drinks/day 58.6 55.5 
>2 standard drinks/day 11.8 12.9 
Any antioxidant supplement 36.1 35.2 0.8 
Any zinc supplementation 16.9 11.6 0.04 
Mean dietary lutein-zeaxanthin intake 
(SD), µg 0.8 (0.5) 0.8 (0.4) 0.6 
CFH = complement factor H, ARMS2 = age-related maculopathy susceptibility gene 2, SD = standard 
deviation 
*Unadjusted tests for heterogeneity used to calculate P values. 
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Table 3.4-3 presents associations between known AMD risk factors and the incidence 
of medium drusen. Each decade increase in age was significantly associated with 15-
year incident medium drusen after adjusting for sex. The presence of ≥3 risk alleles of 
CFH-rs1061170 and ARMS2-rs10490924 combined were significantly associated with 
an increased risk of developing medium drusen (OR 2.1, 95% CI 1.1-3.9), after age-sex 
adjustment. These associations remained similar after additional adjustment for past and 
current smoking, and zinc supplementation (Table 3.4-3). The 15-year incidence of 
medium drusen was inversely associated with higher intake of zinc, however, this 
association was marginally non-significant in both age-sex-adjusted and multivariable-
adjusted models. Risk factors including smoking, blood pressure, WCC, serum lipids, 
fish and liquor consumption, antioxidant supplementation and lutein-zeaxanthin intake 
were not significantly associated with the 15-year incidence of medium drusen in the 
age-sex adjusted models (data not shown). 
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Table 3.4-3: Associations between known age-related macular degeneration risk factors 
and the 15-year incidence of medium drusen 
 
Risk Factor 
15-year Incidence of Medium Drusen 
Age and Sex Adjusted 
(where appropriate) OR 
(95% CI) 
Multivariable Adjusted* 
OR (95%CI) 
Age, per 10 years 1.4 (1.2-1.7) 1.4 (1.2-1.8) 
Male Sex 0.2 (0.6-1.0) 0.9 (0.6-1.2) 
Smoking status 
Never Smoker 1.0 (reference) 1.0 (reference) 
Past smoker 0.7 (0.5-0.9) 0.8 (0.6-1.1) 
Current smoker 0.6 (0.4-1.0) 0.6 (0.4-1.1) 
CFH and ARMS2 combined 
risk†  
No risk alleles 1.0 (reference) 1.0 (reference) 
1 risk allele 1.4 (1.0-2.0) 1.6 (1.1-2.4) 
2 risk alleles 1.4 (0.9-2.1) 1.5 (0.9-2.2) 
≥3 risk alleles 2.1 (1.1-3.9) 2.1 (1.1-4.1) 
Zinc supplementation  0.7 (0.5-1.1) 0.7 (0.4-1.0) 
OR = odds ratio, CI = confidence interval, CFH = complement factor H, ARMS2 = age-related 
maculopathy susceptibility gene 2
*Adjusted for age, sex, past and current smoking, any zinc supplementation and the combined 
CFH and ARMS2 risk alleles. 
†Single nucleotide polymorphisms CFH-rs1061170 and ARMS2-rs10490924; reference group = 
no risk alleles 
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Progression of Medium Drusen 
The frequency of progression to large soft drusen, was similar in eyes with medium 
drusen only as in eyes with medium drusen and RPE abnormalities (41.8% and 50.0%, 
respectively, p=0.2). However, progression to late stage AMD or late AMD lesions 
(either geographic atrophy or neovascular AMD) was 4-fold greater in eyes co-present 
with medium drusen and RPE abnormalities, compared to eyes with medium drusen 
alone (23.0% versus 5.0%, respectively). An example of medium drusen progression is 
shown in Figure 3.4-1.  
 
 
Figure 3.4-1: An example of the progression of medium drusen over 15 years. (A) Left 
eye with medium drusen and retinal pigment epithelium abnormalities at baseline; (B) 
Large soft drusen at 5 years; (C) More apparent retinal pigmentary abnormalities at 10 
years; (D) Geographic atrophy at 15 years.  
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Table 3.4-4 presents the 15-year progression of medium drusen to early and late AMD 
in relation to total areas and locations of medium drusen. Eyes co-present with medium 
drusen and RPE abnormalities were excluded. After adjusting for age and sex, a large 
(≥375µm) compared to small total area (<375µm) of medium drusen, was significantly 
associated with high risk of developing early AMD (OR 2.9, 95% CI 1.5-5.4) and any 
(early or late) AMD (OR 3.0, 95% CI 1.6-5.5). However, it was not significantly 
associated with risk of late AMD (OR 2.3, 95% CI 0.8-6.8). After further adjusting for 
past and current smoking, fish consumption and the CFH and ARMS2 risk alleles, these 
associations remained (Table 3.4-4). Similarly, the association between central location 
of medium drusen and the development of early AMD and any AMD was significant 
after adjusting for these co-variables (OR 2.6, 95% CI 1.4-4.8 and OR 2.4, 95% CI 1.3-
4.5, respectively; Table 3.4-4). 
 
 
 
 
Table 3.4-4: Fifteen-year progression of medium drusen to worse age-related macular degeneration stages by medium drusen are and location at 
baseline. 
 
Meidum Drusen 
Characteristics 
15-year Progression to Worse AMD Stage 
Early AMD* Any Late AMD Any Early* or Late AMD 
No. of 
cases/ No. 
at risk  
Age-sex 
adjusted 
OR (95% 
CI)
Multivariable 
adjusted OR 
(95% CI)† 
No. of 
cases/ No. 
at risk  
Age-sex 
adjusted OR 
(95% CI) 
Multivariable 
adjusted OR 
(95% CI)† 
No. of 
cases/ No. 
at risk  
Age-sex 
adjusted 
OR (95% 
CI)
Multivariable 
adjusted OR 
(95% CI)† 
Area                   
<375µm in diameter 73/308 1.0 1.0 13/327 1.0 1.0 76/311 1.0 1.0 
≥375µm in diameter 41/68 2.9 (1.5-5.4) 3.2 (1.4-7.2)   9/71 2.3 (0.8-6.8) 1.6 (0.4-6.6) 44/71 3.0 (1.6-5.5) 3.3 (1.5-7.4) 
P value‡ <0.0001  -   -  0.03  -   -  <0.0001  -   -  
Location   
≥500µm radius of the 
foveal centre 30/150 1.0 1.0 5/160 1.0 1.0 32/152 1.0 1.0 
<500µm radius of the 
foveal centre 82/222 2.6 (1.5-4.3) 2.6 (1.4-4.8) 17/235 3.1 (0.8-11.4) 3.5 (0.6-20.4) 86/226 2.5 (1.5-4.2) 2.4 (1.3-4.5) 
P value‡ 0.0002  -   -  0.06  -   -  0.0002  -   -  
AMD = age-related macular degeneration, OR = odds ratio; CI = confidence interval 
*Early AMD as defined in the BMES: large indistinct soft or reticular drusen or large distinct soft drusen with retinal pigmentary abnormalities. 
†Odds ratios adjusted for age, sex, past and current smoking, fish consumption and increasing numbers of complement factor H and age-related maculopathy susceptibility 
gene risk alleles (0, 1 or 2).  
‡P values for differences in number of cases between small versus large areas or between further versus closer locations of intermediate drusen by AMD stage. 
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DISCUSSION 
We found an overall 13.9% of persons aged 49+ years developed medium drusen over 
15 years. The incidence of medium drusen did not appear to be different across the three 
age groups from 49 to 74 years, but was slightly higher in women compared to men. 
The lower incidence of medium drusen observed in participants aged 75+ years at 
baseline is likely due to the fact that most persons in this age group had either died or 
passed this very early stage of AMD, and very few numbers of participants in this age 
group were considered at risk of medium drusen.  
 
Per decade increase in age, and the presence of ≥3 risk alleles of the CFH-rs1061170 
and ARMS2-rs10490924 combined were independently associated with increased risk of 
developing medium drusen. No other known AMD risk factors were found to be 
associated with the incidence.  
 
There were limited numbers of population-based reports on the incidence of medium 
drusen available in the literature. The 5-, 10- and 15-year incidence rates of medium 
drusen in the BMES were 5.7%, 9.2%, and 13.9%, respectively. In the Reykjavik Eye 
Study, a population-based study of residents in Iceland, the 5-year incidence rate of 
medium drusen increased with increasing age, ranged from 5.0% in 50-59 year olds to 
22.7% in those aged 70-79 years45. In comparison, the overall 5-year incidence of 
medium drusen was 10.1% in the BMES (Kaplan–Meier method), or 5.7% after 
accounting for competing risk of death. The Copenhagen Eye Study reported the 14-
year incidence of medium drusen to be 27.4%, among persons aged 60-80 years at 
baseline47. The Beaver Dam Eye Study (BDES) found the 10- and 15-year cumulative 
incidence of medium drusen to be 14.0% and 23.9%, respectively, after adjusting for the 
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competing risk of death33,34, higher than the 9.2% and 13.9% of incidence in 10amd 15 
years in our cohort study. Sources of disparity between findings of our and the above-
mentioned two studies likely include variations in defining medium drusen and different 
methods used to calculate incidence estimates, e.g., the competing risk approach was 
not used in both the Reykjavik and Copenhagen Eye Studies. While the BDES had a 
lower age limit (43 years at baseline) in the study sample, variations in other 
environmental exposures in addition to grading variations in defining medium drusen, 
could also explain the difference in incidence between the two studies.  
 
The age-related increase in medium drusen incidence before adjusting for competing 
risk of death, found in our study, is consistent with other AMD stages and 
lesions35,44,242. Interestingly, past or current smoking was not associated with the 15-
year incidence of medium drusen, a finding in keeping with previous BMES 
observations although current smoking was strongly associated with prevalence and 
incidence of late AMD, the association between smoking and early AMD was much 
weaker than that with late AMD115,117. Smoking may likely be a promoter playing a 
greater role in the progression from early to late AMD than in the initiation of early 
AMD.  
 
We demonstrated that the risk of progression of medium drusen to late AMD was 
substantially higher if medium drusen was co-present with RPE abnormalities. This 
parallels previous findings that demonstrated the faster progression from early to late 
AMD in eyes with large drusen and RPE abnormalities compared to eyes with large 
drusen alone30,35,243. This observation supports severity scales that incorporate multiple 
lesion types to better classify risk of progression to late AMD 28,31,32.  
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We also found that eyes with medium drusen located closer to the fovea or eyes with 
large total macular areas involved by medium drusen were more likely to progress to 
early AMD. The non-significant association of these characteristics with the progression 
to late AMD was likely due to the relatively small numbers of incident late AMD cases 
in this cohort. These findings are consistent with the BDES that the 15-year incidence of 
both early and late AMD were higher in eyes with a large compared to small total area 
of medium drusen at baseline33.  
 
The strengths of this study include its long-term follow-up of an older Australian 
cohort, the use of retinal photographs and a validated AMD grading system to assess 
size and location of AMD lesions. Limitations include the relatively low follow-up rate 
at the 15-year examination that could have led to an over- or under-estimation of the 
incidence. As only colour fundus photographs, rather than high resolution imaging (e.g. 
spectral-domain optical coherence tomography) was available during the baseline and 
follow-up examinations, this may have led to an underestimation of the prevalence and 
incidence. However, we used colour photographs only throughout the BMES cohort to 
make sure that the comparisons are valid. Although the medium drusen category was 
included in the retinal photographic grading since the 5-year follow-up examinations, 
side-by-side grading of baseline and follow-up retinal images provided precise 
classification of this drusen type.  
 
SUMMARY 
In this report, we document the 15-year incidence of medium drusen as 13.9% in this 
older Australian cohort. The proportion of eyes that progressed to late AMD was 
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significantly higher when medium drusen co-presented with RPE abnormalities, 
compared to eyes with medium drusen alone. Large total area and close to foveal 
location of medium drusen were associated with a high likelihood of progression to 
more advanced AMD lesions. These findings are informative for the monitoring and 
management of patients at risk of early and late AMD.  
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Chapter 4 
 
Comparison of Two Classification 
Scales for Age-related Macular 
Degeneration      
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Comparing the predictive ability of two severity scales for 
classification of age-related macular degeneration in population and 
clinic based samples 
 
Publication relating to this Chapter: 
Liew G, Joachim N, Mitchell P, Burlutsky G, Wang JJ. Validating the AREDS 
Simplified Severity Scale of Age-related Macular Degeneration with 5- and 10-Year 
Incident Data in a Population-Based Sample. (Article in Press, Ophthalmology: May 
2016) 
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ABSTRACT 
Purpose: A number of classification systems for age-related macular degeneration 
(AMD) have been developed from observations of patients in clinical trials. We aimed 
to validate two AMD classification systems using 5-year incident late AMD data from 
the population-based Blue Mountains Eye Study (BMES) cohort, and compare the 
published 5-year late AMD incident estimates from the Age-Related Eye Diseases 
Study (AREDS) clinical trial.    
 
Methods: This comparative study included BMES participants aged 49-97 years at 
baseline (n=2134) and AREDS participants aged 55-80 years (n=3640). AMD lesions in 
the BMES were graded according to the Wisconsin AMD grading protocol from 
stereoscopic color photographs and classified according to: 1) the AREDS Simplified 
Severity Scale, and the 2) Basic Clinical Classification Scale. The AREDS Simplified 
Severity Scale calculates a risk score based on the number of early AMD risk factors 
(large drusen and pigment abnormalities) in both eyes. The Basic Clinical Classification 
Scale categorizes large drusen and pigment abnormalities as intermediate AMD 
regardless of bilaterality and is based on the worse eye. The main outcome measure was 
the 5-year incidence of late AMD. 
 
Results: Over 5 years there were 32 participants who developed late AMD in either eye 
in the BMES, and 316 participants in the AREDS.  The AREDS Simplified Severity 
Scale classified similar proportions of participants who developed incident late AMD in 
both the BMES and AREDS. The Basic Clinical Classification Scale consistently 
categorized 2-3 fold lower late AMD incidence rates across all risk levels in BMES 
compared to AREDS.  
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Conclusions: The AREDS Simplified Severity Scale classified late AMD risk levels 
similarly when applied to population-based and clinic-based samples, whereas the Basic 
Clinical Classification resulted in lower incidence rates in population-based samples. 
The choice of classification system may need to take into account the study population 
as actual observed incidence rates may differ from predicted rates.  
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BACKGROUND 
There are several classification systems for age-related macular degeneration 
(AMD)13,27,28,31,32,48,244. Most are derived from observations of patients in clinical trials. 
Recently two widely used AMD severity scales have been updated and simplified for 
use in clinical practice. The Age-Related Eye Diseases Study (AREDS) Simplified 
Severity Scale was published in 200528, and is based on data from 3212 participants of 
the AREDS clinical trial population27. The scale uses a scoring system that assigns 1 
risk factor for the presence of 1 or more large (≥125 μm) drusen and 1 risk factor for the 
presence of any retinal pigment abnormalities in an eye.(Table 1) Risk factors are 
summed across both eyes, forming a 5-step scale (steps 0 to step 4) for which the 5-year 
risk of developing advanced AMD in at least  one eye increases as follows: 0 factors, 
0.5%; 1 factor, 3%; 2 factors, 12%; 3 factors, 25%; and 4 factors, 50%28. 
 
The Basic Clinical Classification Scale was published in 201331 and is also based on 
data from the AREDS. This was an update on the International Classification System 
first published in 199513. It is based on the same lesions as the AREDS Simplified 
Severity Scale but differs in that both large drusen and retinal pigment abnormalities are 
categorized into the same risk category, with both lesions assigned to the same risk 
regardless of  lesion type and their bilaterality, while medium (or intermediate) drusen 
are given their own risk category (refer to Table 1.1-1). Five categories are defined 
based on the lesions in the worst eye, and the 5-year risk of developing late AMD for 
persons with none/normal ageing changes, early AMD, and intermediate AMD is 0.5%, 
0.9% and 20.5 %, respectively, based on published data13,31. In both severity scales, 
advanced or late AMD is identical and defined as the presence of geographic atrophy or 
choroidal neovascularization.    
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Severity scales are useful to stratify risk categories and likely prognosis within a defined 
period, and facilitate communication and comparison across different samples. They are 
also useful endpoints for interventional therapeutic trials, where sample size and study 
power calculation are often based on risk estimates of incident late AMD. However, 
patients in clinical trials may not be representative of the general population and 
therefore risk estimates that were developed based on patient samples may differ when 
applied to general populations. This has implications for study design and power 
calculations and for projections of future burden of disease in populations.  
 
We therefore aimed to examine the ability of two AMD classification systems to predict 
5-year incident late AMD in a population-based cohort and compared the results with 
published estimates from a clinical trial.  
 
METHODS 
We used data from the population-based Blue Mountains Eye Study 
(BMES)(n=2134)36,44, and compared this to incident data from the AREDS clinical trial 
(n=3640)27,245. 
 
Population-based cohort 
Details of the BMES population, examination procedures and photographic grading 
were described in Methods, Chapter 2.  
 
In this report, incident late AMD was defined as the appearance at 5-year follow up of 
either two characteristic late AMD lesions, geographic atrophy (GA) and neovascular 
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AMD, in either eye of persons in whom no late AMD lesion was present in both eyes at 
baseline. 
 
Clinic-based cohort 
The AREDS is a multicenter prospective cohort study of the clinical course, prognosis, 
and risk factors for AMD and cataract conducted between 1992 and 1998, when 11 
retina clinics in the United States enrolled 4757 people aged 55 to 80 years245. The 
study included a randomized, placebo-controlled clinical trial of treatment with high-
dose antioxidant vitamins and/or zinc on the incidence of late AMD and vision loss. 
Participants were examined at baseline, at the 2-year visit, and annually thereafter.  This 
report uses published data from the baseline and 5-year visit.  
 
Methods for taking and grading stereoscopic colour fundus photographs in AREDS 
have been described elsewhere245,246. In short, stereoscopic colour fundus photograph 
pairs of fields 1 (optic disc) and 2 (macula) and a single photograph of field 3 (temporal 
to the macula) were taken with 30° retinal fundus cameras.   
 
In the AREDS, AMD and early AMD lesion characteristics such as drusen number, size 
and location was graded in a similar masked manner as in the BMES. Incident late 
AMD was also defined as that used in the BMES. 
 
Statistical Analyses 
 We tabulated the 5-year incidence of late AMD in the BMES according to baseline 
severity levels of both classification systems, the AREDS Simplified Severity Scale28, 
and the Basic Clinical Classification Scale31. These estimates were compared to the 
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published estimates from the AREDS. The 5-year incident late AMD rates from the 
AREDS  for the AREDS Simplified Severity Scale were published in 200528 while the 
rates for the Basic Clinical Classification Scale are derived from Table 2 in the 2013 
publication31. Patients with late AMD in either eye at baseline were excluded.  
 
RESULTS 
The baseline characteristics of participants differed between the BMES and AREDS 
populations, as the BMES is a population-based study and the AREDS, a clinical trial of 
patients with AMD. In the BMES, participants were slightly younger, (median age 65 
years versus 69 years) and had a higher proportion of current smokers at baseline (13% 
versus 8%), compared to the AREDS44,245. In both studies, a similar proportion of 
participants were female (58% versus 56%)44,245. 
 
Table 1.1-1 (Chapter 1) summarizes the two classification systems and definitions of 
AMD lesions used in this report.  
 
Figures 4-1 and 4-2 show the 5-year observed incidence of late AMD lesions in the 
BMES cohort compared to the predicted incidence by the two severity scales. There 
were 32 patients with incident late AMD in either eye in BMES, and 316 in AREDS. 
The AREDS Simplified Severity Scale resulted in similar proportions of patients 
developing incident late AMD when applied to both the BMES and AREDS samples 
(Figure 4-1). Categories 1, 2 and 4 had similar incidence rates (0.2 vs 0.5%, 2.4 vs 
3.0%, 11.0 vs 12.0% and 47.1 vs 50.0% respectively), but in category 3 the incidence of 
late AMD in the BMES was half that in AREDS (12.8% vs 25.0%). The Basic Clinical 
Classification Scale showed major differences in the incidence of late AMD, with 
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consistently 2-3 fold lower rates at all categories in the BMES compared to AREDS, 
i.e., for patients with No or Normal ageing changes, Early AMD and Intermediate 
AMD, the rates were 0.1 vs 0.4%, 0.4 vs 0.9% and 7.0 vs 19.6%  respectively (Figure 
4-2).  
 
 
Figure 4-1 Observed 5-year incident late age-related macular degeneration (AMD) by 
categories on the AREDS Simplified Severity Scale. AREDS refers to the Age-Related 
Eye Diseases Study clinical trial. BMES refers to the population-based Blue Mountains 
Eye Study.   
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Figure 4-2 Observed 5-year incident late age-related macular degeneration (AMD) by 
categories on the Basic Clinical Classification. AREDS refers to the Age-Related Eye 
Diseases Study clinical trial. BMES refers to the population-based Blue Mountains Eye 
Study.   
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DISCUSSION 
There is increasing interest in evaluating interventions that may slow progression from 
early AMD to vision-threatening late AMD. Severity scales are useful for documenting 
progression and comparing the effects of interventions and several have been 
proposed13,27,28,31,32,48,244. Most are based on data from clinical trials, in particular the 
AREDS trial, but have not been validated in general populations. We therefore sought 
to compare the predicted rates of 5-year incident late AMD to observed rates in the 
population based BMES. We report that the AREDS Simplified Severity Scale 
performed similarly when applied to population-based as well as clinic-based samples. 
The Basic Clinical Classification consistently resulted in lower rates in population-
based compared to clinic-based samples. These results suggest that the AREDS 
Simplified Severity Scale may be more robust when applied to different populations.   
 
It is worthwhile to bear in mind when interpreting the findings, that the AREDS 
Simplified Severity Scale calculates a risk score based on the number of risk factors 
(namely large drusen and pigment abnormalities) in both eyes, whereas, the Basic 
Clinical Classification Scale assigns patients with these lesions the same risk regardless 
of the  lesion type and their bilaterality, and is driven by the lesions in the worse eye. 
The divergent results may be related to differences in the way the two scales are 
constructed, as mentioned above. The AREDS scale places greater emphasis on the 
presence of large drusen and pigment abnormalities, and acccounts for the presence of 
these lesions in both eyes28. Data from both eyes and from the more advanced and 
fellow eye are used in calculating risk categories. It has incorporated limited 
quantitative information (number of eyes involved) in the scale.  Whereas the Basic 
Clinical Classification Scale categorizes large drusen and pigment abnormalities as the 
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same category, termed Intermediate AMD, and assigns patients with these lesions in the 
worse eye to the same risk level regardless of the type of lesion and their bilaterality31. 
It is therefore determined primarily by the type of lesions in the worse eye, but not the 
numbers of eyes with these lesions. The closer concordance between observed 5-year 
late AMD risk in clinic-based and population-based samples for the AREDS Simplified 
Severity Scale suggests that the number of large drusen, retinal pigment abnormalities, 
and bilaterality are important variables in predicting late AMD, and that concatenating 
these variables into a single risk category as in the Basic Clinical Classification Scale 
may lose important prognostic information.  
 
A second likely reason for the difference in performance of the two scales is the 
difference in baseline prevalence of no AMD lesions and early AMD lesions (such as 
medium drusen or retinal pigmentary abnormalities). The BMES had only 7.2% of 
baseline participants with early AMD lesions and a large majority of participants 
without any drusen or other AMD signs36. In contrast, the large majority of the AREDS 
clinical trial population had early AMD at baseline245. There were thus far fewer 
patients in the early and intermediate AMD categories of the Basic Clinical 
Classification in the BMES than in the AREDS study, which may partially account for 
the lower incidence of late AMD in these categories observed in the BMES.  
 
Our results suggest the choice of using AMD classification scale may have a major 
impact on late AMD risk estimates depending on the study samples. This has 
implications for power calculations for intervention trials of early AMD. If the study 
population to be recruited is similar in composition to the AREDS clinical trial 
population, our results suggest both the Simplified Severity Scale and Basic Clinical 
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Classification Scale will result in similar late AMD incidence estimates. However, if the 
study population is more similar to a general population, then the Basic Clinical 
Classification may overestimate the predicted incidence by 2-3 folds.    
 
Limitations of the report are, firstly, the small number of incident late AMD cases in the 
BMES. Longer follow-up will result in a higher number of incident cases247 but these 
data have not yet been published for the AREDS and we therefore cannot compare 
longer term incidence rates. Secondly, comparing data across different studies is 
difficult due to differences in methodology. In this context it is reassuring that similar 
incidence estimates were obtained from the BMES and AREDS using the Simplified 
Severity Scale, as it suggests there is a reasonable degree of similarity in defining AMD 
lesions and levels between the two studies. Finally, these risk estimates are derived from 
predominantly white populations. It remains unclear how the severity scales will 
perform when applied to other populations such as Asian or black populations where the 
incidence of AMD may be lower48.    
 
SUMMARY 
In this report, we validated and compared the performance of two AMD classification 
systems in predicting incident late AMD. We found that the AREDS Simplified 
Severity Scale classified late AMD risk levels similarly when applied to population-
based and clinic-based samples, whereas the Basic Clinical Classification resulted in 2-
3 fold lower incidence rates in a population-based sample. The choice of classification 
system may need to take into account the study population as actual observed incidence 
rates may differ considerably from predicted rates.      
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Chapter 5 
 
Comparison of Frequencies of Early 
AMD Lesions between Caucasians and 
Asians      
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Ethnic variation in early age-related macular degeneration lesions 
between White Australians and Singaporean Asians 
 
Publication relating to this Chapter: 
Joachim N, Mitchell P, Younan C, Burlutsky G, Cheng CY, Cheung CMG, Zheng Y, 
Moffitt M, Wong TY, Wang JJ. Ethnic Variation in Early Age-related Macular 
Degeneration Lesions between White Australians and Singaporean Asians. Investigative 
Ophthalmology and Visual Science 2014; 55 (7): 4421-4429 
  
196 
 
ABSTRACT 
Purpose: To compare early age-related macular degeneration (AMD) lesion 
characteristics between white Australians and Singaporean Asians. 
 
Methods: Participants of the Blue Mountains Eye Study (BMES; whites, n=3508) and 
the Singapore Epidemiology of Eye Disease Study (SEED, Malay, n=3280, Indian, 
n=3400 and Chinese, n=3353) underwent examinations including retinal photography. 
AMD lesions were assessed following the Wisconsin AMD grading protocol by the 
same photographic grader. Prevalence and characteristics of early AMD lesions were 
compared between the BMES and the SEED. The associations between ethnicity and 
early AMD lesion types were analyzed using logistic regression models adjusting for 
age, sex, smoking status, lipids and genetic polymorphisms associated with AMD. 
 
Results: After age-standardization to the BMES population, the prevalence of distinct 
soft drusen was significantly higher in Singaporeans compared to Australians (23.9%, 
95% confidence interval (CI) 22.9-25.0 versus 6.2%, 95% CI 5.3-7.0), with an adjusted 
odds ratio (OR) 4.6 (95% CI 3.4-6.0). In contrast, the prevalence of indistinct soft or 
reticular drusen was significantly lower in Singaporeans compared to Australians 
(6.5%, 95% CI 5.9-7.1 versus 8.3%, 95% CI 7.4-9.3), with non-significant adjusted OR 
1.2, (95% CI 0.8-1.7). Soft drusen of any type were frequently present at the inner and 
outer macula (within a zone ≥500µm to <3000µm radius from the foveal centre) among 
Singaporeans, while among Australians soft drusen were more frequently present at the 
central macula (<500µm radius). 
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Conclusion: Singaporean Asians had a milder spectrum of early AMD lesions and 
lesion characteristics (predominantly distinct soft drusen and noncentral location) 
compared to white Australians.  
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BACKGROUND 
Differences in the prevalence of early and late signs of age-related macular degeneration 
(AMD) and specific AMD lesions, between whites and blacks residing in the U.S. have 
long been observed and documented; these findings have been suggested to reflect 
underlying ethnic predisposition to AMD 248-250. For example, larger drusen and retinal 
pigmentary abnormalities have been reported to be more frequently present, and the 
advanced forms of AMD more prevalent, in whites compared to blacks 248,250.  
 
Emerging data on AMD in Asians are now available251,252. Although it was suggested 
that AMD was not common in Asians251, the pooled  prevalence of early (6.8%) and late 
AMD (0.56%) in four Asian populations in a meta-analysis was comparable to the 
prevalence of early (8.8%) and late AMD (0.59%) in white populations68, challenging 
this previous assumption that AMD is less frequent in Asians than in whites253. 
However, these previous studies comparing differences in prevalence of AMD between 
white and Asian populations have only focused on the overall prevalence of any, early 
or late AMD. The prevalence of individual early AMD lesions in particular, may exhibit 
ethnic variability. Similar to white populations, the type and frequency of different early 
AMD lesions in Asians may indicate a certain risk of progression to late AMD, for 
example, eyes with indistinct soft drusen having a higher risk of developing late AMD 
compared to those with distinct soft drusen, in mainly Caucasian populations28,254. Few 
studies have assessed the differences in specific AMD lesion characteristics and 
distributions between different ethnic groups255,256. Such information may yield further 
insights into the early pathogenesis and presentation of AMD in diverse ethnic groups.  
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In this report we aim to directly compare the frequencies of different types of early 
AMD lesions, bilateral involvement and lesion location between population-based 
samples of white Australians and Asians living in Singapore 
 
METHODS 
Study Populations and Procedures 
Details of the BMES study population are described in Methods, Chapter 2.  At the time 
of the 5-year examinations an additional 1378 eligible permanent residents were 
identified following a second door-to-door census in 1999. This included residents who 
had moved into the study area or had reached 49 years of age during the intervening 
period. Of these newly eligible persons, 1174 participated in the study (85.2% of those 
eligible). Prevalence of AMD was derived from the entire BMES II survey sample 
(BMES II-a: returning participants of the BMES baseline cohort and BMES II-b: newly 
identified participants) with a total number of 3508 participants.  
 
Details of the SEED study are described in Methods, Chapter 2. Each participant in the 
BMES and the SEED study cohort underwent a comprehensive ocular examination and 
retinal fundus photography as previously described (Methods, Chapter 2). 
 
Blood samples were collected from 3222 BMES and 9670 SEED participants at 
examination. Total cholesterol and high density lipoprotein (HDL) concentrations 
(mmol/l) were measured on a Reflotron reflectance photometric analyser (Roche 
Diagnostics, Manheim, Germany) in the BMES, or were obtained from the 
biochemistry tests conducted.at the Singapore National University Hospital Reference 
Laboratory.  Blood samples collected were also used for genotyping. 
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AMD Grading and Definitions 
Retinal photographs taken from participants of both the BMES and SEED studies were 
graded by a single senior grader (Mireille Moffitt) in a masked manner at the Centre for 
Vision Research, University of Sydney, Australia, and adjudication provided by a senior 
researcher (Jie Jin Wang) or retinal specialist (Paul Mitchell). The presence and location 
of AMD lesions were graded using the WARMGS grid and measurement circles as 
described in Methods (Chapter 2).  
 
Late AMD was defined as the presence of any sign of neovascular AMD (pigment 
epithelial or neuro-sensory subretinal detachment, retinal or subretinal hemorrhage, 
subretinal fibrosis or old atrophic disciform scars, or photocoagulation scars) as 
described in the International Age-Related Maculopathy classification13 or geographic 
atrophy (GA) involving the fovea. Distinct soft drusen were distinguished as discrete 
whitish-yellow nodules >125µm in diameter with uniform density and sharp edges.  
Indistinct soft drusen were described as >125µm in diameter with decreasing density 
from centre outwards to the periphery and fuzzy edges. Confluent indistinct soft drusen 
with the appearance of broad interlacing ribbons were distinguished as reticular drusen. 
Retinal pigment epithelial (RPE) depigmentation was defined as faded but sharply 
demarcated areas of the RPE without visible choroidal vessels underneath. Clumps of 
granules of gray or black pigment beneath the retina were distinguished as 
hyperpigmentation26. Early AMD was defined as the presence of either large (>125µm 
diameter) indistinct soft or reticular drusen, or distinct soft drusen with retinal 
pigmentary abnormalities (RPE depigmentation and hyperpigmentation). In the 
following analyses we have included reticular drusen under the broader category of 
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indistinct soft drusen. Macular areas involved by early AMD lesions were categorized 
as small, intermediate and large areas for each lesion type; and location of early AMD 
lesions categorized as within the central macula, inner macula, outer macula or outside 
the macula area, as shown in Table 5-1.  
 
Bilateral involvement of early or late AMD was defined among persons with early or 
late AMD respectively. Participants with early AMD in one eye and late AMD in the 
fellow eye were considered bilateral for any AMD but unilateral for early or late AMD. 
If maculopathy data were missing in one eye, the study subject was excluded from 
analysis of bilateral involvement. 
 
Table 5-1 Definitions of the area and location of the early AMD lesions assessed. 
Area and Location Definitions
Drusen Area  
Small  None or <375µm in diameter
Intermediate ≥375µm to <0.5 disc area in diameter
Large ≥ 0.5 disc area in diameter
RPE Depigmentation Area  
Small  None or <375µm in diameter
Intermediate ≥375µm to <2 disc area in diameter
Large ≥2 disc area in diameter
Hyperpigmentation Area  
Small  None or <64µm in diameter
Intermediate ≥64µm to <660µm in diameter
Large ≥660µm in diameter
Location (All Lesions)  
Central macula <500µm radius from the foveal centre
Inner macula zone ≥500µm to <1500µm radius from the foveal centre 
Outer macula zone ≥1500µm to <3000µm radius from the foveal centre 
Outside macula ≥3000µm radius from the foveal centre 
RPE = retinal pigment epithelium
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Genotyping 
Genotyping procedures carried out in the BMES were described in Methods (Chapter 
2). In the SEED, genotyping was performed using the Illumina Human 610-Quad array. 
Similar quality control procedures were applied in the SEED as in the BMES prior to 
analysis. Imputation was then performed using HapMap II penal and IMPUTE 5.0.   
 
Definitions of Other Variables 
For smoking status, participants categorized as non-smokers were those who answered 
“no” to smoking regularly. If participants answered “yes” but had stopped smoking ≥1 
year prior to the examination they were categorized as past smokers. Participants who 
currently smoked or had stopped smoking <1 year prior to the examination were 
categorized as current smokers. In the BMES, hypertension was considered present if 
participants were taking anti-hypertensive medication at the time of examination, or 
blood pressure was ≥140mmHg or diastolic blood pressure was ≥90mmHg at 
examination. In the SEED, hypertension was considered present if systolic blood 
pressure ≥140mmHg, diastolic blood pressure ≥90mmHg or with previous physician 
diagnosis reported by the participant. Body mass index (BMI) was calculated from 
weight and height measurements taken at examination.  
 
Statistical Analyses 
SAS (version 9.1, SAS Institute Inc. Cary, NC) was used for all analyses. We included 
participants aged 50 years or older only, with 3508 from the BMES, 2453 from the 
SiMES, 2427 from the SINDI and 2633 from the SCES. The worse eye prevalence of 
late and early AMD in the BMES were compared with worse eye prevalence estimates 
of the SiMES, SINDI and SCES, respectively after direct age-standardization to the 
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BMES population. Comparisons were also performed within subgroups stratified by 
smoking status after age-standardization to the BMES population. Differences in the 
frequencies of bilateral involvement of early AMD lesions between the ethnic groups 
were assessed using Fisher’s exact test. Logistic regression models adjusted for age, 
sex, smoking, lipids, hypertension, BMI and the CFH and ARMS2 polymorphisms were 
used to estimate association magnitudes between each Asian ethnicity and the presence 
of distinct soft drusen and indistinct soft drusen, with reference to the BMES. 
 
Early AMD lesion characteristics, including the areas involved by the lesions and 
location of the lesions within the central, inner and outer zones were compared between 
the BMES and the Asian samples combined. Data of both eyes and generalized 
estimating equation (GEE) models were used in these analyses. 
 
RESULTS 
Table 5-2 shows the characteristics of participants without AMD and with early AMD 
in the BMES compared to the SiMES, SINDI, SCES or these Asian samples combined. 
Among participants with and without early AMD, both the mean age and frequency of 
women were lowere in the the three Asian populations combined, compared to the 
BMES (p<0.0001 for age and sex). There was a lower frequency of past smokers and 
higher frequency of current smokers in the combined Singaporean Asian sample 
compared to the BMES (both p<0.0001).  The mean ages of participants with early 
AMD were higher than among participants without any AMD across all the study 
samples (Table 5-2).  The frequency of participants with 1 or 2 risk alleles of CFH was 
significantly lower in the SiMES, SINDI and SCES compared to the BMES, whereas, 
there was a higher frequency of 2 risk alleles for ARMS2 across the Singaporean Asian 
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samples compared to the BMES sample (all p<0.0001). Mean cholesterol, high density 
lipoprotein and BMI were significantly lower in the Asian samples compared to the 
BMES in both subgroups with and without early AMD lesions (Table 5-2). 
 
 
 
 
 
 
Table 5-2 Characteristics in participants without AMD and with early AMD in the Blue Mountains Eye Study compared to participants of the 
Singapore Malay Eye study, the Singapore Indian Eye Study, the Singapore Chinese Eye Study and the three Asian samples combined. 
 
 
 
Characteristic 
% participants with no AMD
BMES 
(n=2867) 
SiMES 
(n=1746) P-value
* SINDI (n=1806) P-value
* SCES (n=2046) P-value
* 
Combined 
Asian 
(n=5598)
P-value† 
Mean age (years, SD) 65.1 (8.7) 61.2 (8.1) <0.0001 60.0 (7.8) <0.0001 60.9 (8.2) <0.0001 60.7 (8.0) <0.0001
Sex (female) 56.5 51.7 0.002 48.3 <0.0001 52.2 0.003 50.8 <0.0001
Smoking status 
non-smoker 49.2 62.3
<0.0001‡ 
73.1
<0.0001‡ 
74.8
<0.0001‡ 
70.4
<0.0001‡ past smoker 40.1 18.5 12.6 12.9 14.5
current smoker 10.8 19.2 14.3 12.4 15.1
Hypertension (present) 75.5 75.3 0.9 62.7 <0.0001 61.9 <0.0001 66.3 <0.0001
CFH (rs1061170-
BMES/rs1080155-SiMES, SINDI, 
SCES)          
no risk alleles 38.4 83.0
<0.0001‡ 
54.0
<0.0001‡ 
93.7
<0.0001‡ 
75.7
<0.0001‡ 1 risk allele 47.3 15.8 37.9 6.2 21.0
2 risk alleles 14.4 1.2 8.1 0.1 3.4
ARMS2 (rs10490924-
BMES/rs3750847-SiMES, SINDI, 
SCES)          
no risk alleles 62.6 37.8
<0.0001‡ 
40.8
<0.0001‡ 
31.5
<0.0001‡ 
37.1
<0.0001‡ 1 risk allele 32.7 47.4 47.7 49.3 48.0
2 risk alleles 4.8 14.8 11.5 19.2 14.9
Mean total cholesterol (mmol/L; 
SD) 5.8 (1.1) 5.7 (1.2) <0.0001 5.2 (1.1) <0.0001 5.5 (1.1) <0.0001 5.5 (1.1) <0.0001 
Mean HDL (mmol/L; SD) 1.5 (0.4) 1.4 (0.3) <0.0001 1.1 (0.3) <0.0001 1.3 (0.4) <0.0001 1.3 (0.4) <0.0001
Mean BMI (kg/m2; SD) 27.8 (4.9) 26.4 (4.9) <0.0001 26.3 (4.7) <0.0001 23.7 (3.7) <0.0001 25.4 (4.6) <0.0001 
 
 
  
% participants with early AMD
n=284 n=147  n=166   n=219  n=532  
Mean age (years, SD) 75.1 (8.4) 67.6 (7.8) <0.0001 67.0 (8.6) <0.0001 66.9 (8.1) <0.0001 67.1 (8.2) <0.0001
Sex (female) 62.7 39.5 <0.0001 44.0 0.0001 39.3 <0.0001 40.8 <0.0001
Smoking status 
non-smoker 53.0 57.9
0.01‡ 
68.7
0.0002‡ 
69.9
<0.0001‡ 
66.2
<0.0001‡ past smoker 38.8 26.9 19.9 18.7 21.3
current smoker 8.2 15.2 11.5 11.4 12.5
Hypertension (present) 82.0 85.7 0.3 78.9 0.4 78.1 0.3 80.5 0.6
CFH (rs1061170-
BMES/rs1080155-SiMES, SINDI, 
SCES)          
no risk alleles 26.6 80.5
<0.0001‡ 
52.0
<0.0001‡ 
90.3
<0.0001‡ 
74.6
<0.0001‡ 1 risk allele 50.0 19.5 35.0 9.0 20.8
2 risk alleles 23.4 0.0 13.0 0.8 4.6
ARMS2 (rs10490924-
BMES/rs3750847-SiMES, SINDI, 
SCES)          
no risk alleles 48.8 32.7
<0.0001‡ 
43.9
<0.0001‡ 
20.2
<0.0001‡ 
31.9
<0.0001‡ 1 risk allele 47.3 41.6 37.4 54.5 44.9
2 risk alleles 4.0 25.7 18.7 25.4 23.2
Mean total cholesterol (mmol/L; 
SD) 5.9 (1.0) 5.6 (1.2) 0.01 4.8 (1.1) <0.0001 5.3 (1.1) <0.0001 5.2 (1.2) <0.0001 
Mean HDL (mmol/L; SD) 1.5 (0.4) 1.4 (0.4) <0.0001 1.1 (0.3) <0.0001 1.3 (0.4) <0.0001 1.3 (0.4) <0.0001
Mean BMI (kg/m2; SD) 27.0 (4.5) 26.1 (5.5) 0.09 26.2 (4.8) 0.1 23.2 (3.7) <0.0001 24.9 (4.8) <0.0001 
AMD = age-related macular degeneration, BMES = Blue Mountains Eye Study, SiMES =  Singapore Malay eye study, SINDI = Singapore Indian eye study, 
SCES = Singapore Chinese eye study, Combined Asian = SiMES, SINDI and SCES combined, n = sample size, SD = standard deviation, CFH = complement 
factor H, ARMS2 = age-related maculopathy susceptibility gene 2, BMI = body mass index. 
*P-value for comparison between participants of the BMES and SiMES or SINDI or SCES 
†P-value for comparison between participants of the BMES and participants of the SiMES, SINDI and SCES combined 
‡Unadjusted tests for heterogeneity used to calculate p-values 
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The crude prevalence of AMD in each study population is presented in Table 5-3 and 
age-standardized prevalence presented in Table 5-4. After direct age-standardization, 
late AMD prevalence was non-significantly lower in the combined Asian sample 
compared to the BMES, whereas the prevalence of early AMD was significantly higher 
in the combined Asian samples compared to the BMES.  
 
The prevalence of distinct soft drusen was substantially higher in each of the Asian 
samples or in the combined Asian samples, compared to the BMES.  In contrast, the 
prevalence of indistinct soft drusen was significantly lower in SiMES and SCES, or in 
the combined Asian samples, compared to the BMES sample. A finding of note was 
that the prevalence of indistinct soft drusen in SINDI was similar to the BMES, after 
age-standardization to the BMES sample (Table 5-4). There was no difference in the 
prevalence of retinal pigmentary abnormalities in the combined Asian samples 
compared to the BMES sample. 
  
 
 
 
Table 5-3 Comparison of the crude prevalence of age-related macular degeneration in the Blue Mountains Eye Study to the Singapore Malay, 
Singapore Indian and Singapore Chinese Eye Study samples and the three Asian samples combined. 
 
Lesion 
BMES SiMES   SINDI   SCES   Combined Asian   
 Prevalence % 
(No. affected/ 
total  no.) 
 Prevalence % 
(No. affected/ 
total  no.) 
P-value* 
 Prevalence % 
(No. affected/ 
total  no.) 
P-value* 
 Prevalence % 
(No. affected/ 
total  no.) 
P-value* 
 Prevalence % 
(No. affected/ 
total  no.) 
P-value* 
Any late AMD  1.76 (60/3410) 0.97 (20/2060) 0.02 0.54 (13/2427) <0.0001 0.95 (25/2633) 0.008 0.81 (58/7120) <0.0001 
Pure GA   0.67 (23/3410) 0.39 (8/2060) 0.2 0.00 (0/2427) <0.0001 0.19 (5/2633) 0.006 0.18 (13/7120) <0.0001 
Neovascular AMD 1.09 (37/3409) 0.58 (12/2059) 0.06 0.54 (13/2427) 0.02 0.76 (20/2633) 0.2 0.63 (45/7119) 0.01 
Any early AMD 9.01 (284/3152) 7.76 (147/1894) 0.1 8.42 (166/1972) 0.5 9.67 (219/2265) 0.4 8.68 (532/6132) 0.6 
Any large drusen‡ 13.06 (412/3154) 20.62 (398/1930) <0.0001 21.11 (422/1999) <0.0001 26.83 (620/2311) <0.0001 23.07 (1440/6241) <0.0001 
Soft distinct drusen 6.00 (194/3235) 17.02 (326/1915) <0.0001 17.54 (348/1984) <0.0001 24.12 (556/2305) <0.0001 19.82 (1230/6205) <0.0001 
Soft indistinct or 
reticular drusen 7.65 (241/3149) 4.35 (82/1886) <0.0001 4.33 (85/1964) <0.0001 3.63 (82/2258) <0.0001 4.08 (249/6109) <0.0001 
Any pigment 
abnormality 15.08 (487/3229) 15.65 (323/2064) 0.6 14.98 (319/2129) 0.9 16.04 (385/2400) 0.3 
15.57 
(1027/6594) 0.5 
RPE depigmentation 9.34 (301/3221) 11.49 (236/2054) 0.01 7.91 (169/2136) 0.07 7.71 (185/2398) 0.03 8.95 (590/6589) 0.5 
Hyperpigmentation 14.33 (463/3230) 11.25 (231/2053) 0.001 12.71 (270/2124) 0.09 14.11 (338/2395) 0.8 12.76 (839/6573) 0.03 
BMES = Blue Mountains Eye Study, SiMES =  Singapore Malay Eye Study, SINDI = Singapore Indian Eye Study, SCES = Singapore Chinese Eye Study, Combined Asian 
= SiMES, SINDI and SCES combined, AMD = age-related macular degeneration, GA = geographic atrophy, RPE = retinal pigment epithelial
*P-value for crude prevalence comparison between participants of the BMES and the SiMES, SINDI, SCES or Combined Asian sample 
†Unadjusted tests for heterogeneity used to calculate p-values 
‡Includes soft distinct, soft indistinct and reticular drusen 
 
   
 
 
Table 5-4 Prevalence of age-related macular degeneration lesions in the Singapore Malay, Singapore Indian, Singapore Chinese and combined 
Asian eye study samples age-standardized to the Blue Mountains Eye Study population. 
 
Lesion 
Age-standardized prevalence % (95% CI) 
BMES SiMES SINDI SCES  Combined Asian 
Any late AMD 1.76 (1.32-2.20) 1.09 (0.64-1.54) 0.76 (0.42-1.11) 1.52 (1.05-1.99) 1.3 (1.04-1.56) 
Pure GA  0.68 (0.40-0.95) 0.43 (0.15-0.72) 0.00 (0.00-0.00) 0.28 (0.08-0.48) 0.26 (0.15-0.38) 
Neovascular AMD 1.09 (0.74-1.43) 0.66 (0.31-1.01) 0.76 (0.42-1.11) 1.24 (0.82-1.67) 1.03 (0.80-1.27) 
Any early AMD 9.72 (8.69-10.76) 10.98 (9.57-12.38) 13.53 (12.02-15.04) 13.01 (11.63-14.40) 12.51 (11.69-13.34) 
Any large drusen* 13.88 (12.68-15.09) 26.72 (24.75-28.69) 28.35 (26.37-30.33) 32.36 (30.45-34.26) 28.84 (27.72-29.96) 
Soft distinct drusen 6.15 (5.32-6.98) 22.73 (20.85-24.60) 21.75 (19.94-23.57) 28.76 (26.91-30.60) 23.93 (22.87-24.99) 
Soft indistinct or 
reticular drusen 8.32 (7.35-9.28) 4.92 (3.94-5.90) 8.36 (7.14-9.59) 5.20 (4.28-6.11) 6.52 (5.91-7.14) 
Any pigment 
abnormality 15.52 (14.27-16.77) 15.76 (14.19-17.34) 18.02 (16.39-19.65) 18.50 (16.95-20.06) 17.62 (16.70-18.54) 
RPE depigmentation 9.63 (8.61-10.65) 10.35 (9.03-11.66) 9.07 (7.85-10.28) 7.65 (6.59-8.72) 8.97 (8.28-9.66) 
Hyperpigmentation 14.78 (13.56-16.01) 12.03 (10.62-13.44) 15.64 (14.10-17.19) 16.74 (15.24-18.23) 15.06 (14.20-15.93) 
BMES = Blue Mountains Eye Study, SiMES =  Singapore Malay Eye Study, SINDI = Singapore Indian Eye Study, SCES = Singapore Chinese Eye 
Study, Combined Asian = SiMES, SINDI and SCES combined, AMD = age-related macular degeneration, GA = geographic atrophy, RPE = retinal 
pigment epithelial, CI = confidence interval
*Includes soft distinct, soft indistinct and reticular drusen 
Bold font indicates significant difference between the BMES and SiMES, SINDI, SCES or the Combined Asian samples. 
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Compared to the BMES, the combined Asian sample had a lower frequency of bilateral 
late AMD (17.24% versus 58.33%, p<0.0001) and bilateral early AMD (30.31% versus 
48.13%, p<0.0001). Bilateral retinal pigment abnormalities were also less frequent in 
the SiMES, SINDI and SCES compared to the BMES (all p<0.0001).  However, there 
was no difference in the frequencies of bilateral reticular drusen or other soft drusen 
between the Asian and the BMES samples (all p>0.05; data not shown).   
 
After stratifying by smoking status, the age-standardized prevalence of early AMD was 
not significantly different between the combined Asian and the BMES sample in each 
category of non-smokers and current smokers. However, there was a significantly 
higher prevalence of early AMD in past smokers in the combined Asian sample 
compared to the BMES (Table 5-5). Distinct soft drusen prevalence remained 
significantly higher in all three Asian ethnicities compared to the BMES, regardless of 
smoking status, whereas indistinct soft drusen prevalence remained significantly lower 
in the combined Asian samples compared to the BMES in the non-smoking subgroup. 
In the two subgroups of past-smokers and current smokers, the differences in the 
prevalence of indistinct soft drusen between the combined Asian samples and the 
BMES were non-significant (Table 5-5).  
 
 
 
Table 5-5 Comparison of the prevalence of early AMD by smoking status in the Blue Mountains Eye Study to the Singapore Malay, Singapore 
Indian, Singapore Chinese Eye Studies and the three Asian samples combined. 
 
AMD Lesion Age-standardized Prevalence (95% CI)BMES SiMES SINDI SCES Combined Asian
Non-smoker 
Any early AMD 10.41 (8.88-11.94) 10.49 (8.74-12.25) 13.41 (11.64-15.17) 12.77 (11.18-14.37) 12.20 (11.22-13.18)
Any large drusen 14.72 (12.94-16.49) 25.03 (22.57-27.48) 28.42 (26.10-30.74) 32.48 (30.26-34.70) 28.86 (27.51-30.20)
Soft distinct drusen 6.71 (5.48-7.95) 19.64 (17.37-21.90) 22.54 (20.39-24.70) 29.03 (26.87-31.18) 24.18 (22.90-25.45)
Soft indistinct or reticular 
drusen 8.66 (7.25-10.07) 6.40 (4.99-7.80) 7.69 (6.31-9.07) 4.98 (3.94-6.02) 6.15 (5.43-6.87) 
Any pigment abnormality 15.74 (13.94-17.54) 13.49 (11.62-15.37) 18.96 (17.02-20.91) 16.51 (14.79-18.24) 16.31 (15.25-17.38)
RPE depigmentation 9.33 (7.89-10.77) 7.87 (6.39-9.35) 8.38 (7.00-9.75) 5.94 (4.84-7.04) 7.27 (6.52-8.02)
Hyperpigmentation 14.74 (12.99-16.50) 10.77 (9.07-12.47) 16.47 (14.63-18.32) 15.36 (13.68-17.04) 14.27 (13.26-15.28)
Past Smoker 
Any early AMD 9.44 (7.81-11.07) 13.46 (9.94-16.98) 15.53 (11.14-19.93) 14.57 (10.61-18.54) 14.30 (12.04-16.55)
Any large drusen 13.77 (11.85-15.68) 26.60 (22.09-31.11) 28.42 (26.10-30.74) 33.12 (27.94-38.30) 29.92 (27.01-32.83)
Soft distinct drusen 6.27 (4.94-7.61) 21.29 (17.09-25.50) 22.54 (20.39-24.70) 29.78 (24.74-34.82) 24.93 (22.17-27.69)
Soft indistinct or reticular 
drusen 8.10 (6.58-9.62) 7.73 (4.97-10.50) 9.27 (5.74-12.80) 5.07 (2.61-7.54) 7.07 (5.42-8.73) 
Any pigment abnormality 14.44 (12.50-16.37) 22.07 (18.00-26.13) 20.50 (15.76-25.23) 22.58 (18.04-27.11) 21.74 (19.19-24.29)
RPE depigmentation 9.15 (7.56-10.74) 17.14 (13.43-20.85) 12.80 (8.89-16.72) 12.29 (8.74-15.84) 14.26 (12.10-16.42)
Hyperpigmentation 14.12 (12.20-16.03) 16.30 (12.66-19.94) 17.86 (13.37-22.36) 19.27 (14.99-23.55) 17.63 (15.27-19.99)
Current Smoker
Any early AMD 7.66 (4.78-10.55) 7.85 (5.06-10.64) 7.86 (4.69-11.04) 10.66 (7.03-14.29) 8.82 (6.98-10.66)
Any large drusen 10.68 (7.34-14.03) 22.77 (18.46-27.08) 20.85 (16.08-25.61) 30.67 (25.32-36.03) 24.82 (22.04-27.60)
Soft distinct drusen 3.60 (1.60-5.60) 17.11 (13.23-20.98) 17.44 (12.98-21.90) 27.03 (21.86-32.21) 20.32 (17.72-22.91)
Soft indistinct or reticular 
drusen 7.37 (4.54-10.20) 5.63 (3.23-8.02) 4.24 (1.87-6.61) 5.24 (2.61-7.87) 5.21 (3.77-6.66) 
Any pigment abnormality 18.99 (14.78-23.31) 19.45 (15.48-23.42) 16.37 (12.12-20.62) 21.74 (17.03-26.46) 19.42 (16.92-21.91)
RPE depigmentation 12.51 (8.96-16.07) 15.98 (12.30-19.65) 10.58 (7.06-14.10) 13.17 (9.30-17.03) 13.44 (11.29-15.59)
Hyperpigmentation 17.81 (13.70-21.92) 13.13 (9.73-16.53) 12.92 (9.07-16.77) 17.81 (13.41-22.20) 14.72 (12.48-16.96)
BMES = Blue Mountains Eye Study, SiMES =  Singapore Malay Eye Study, SINDI = Singapore Indian Eye Study, SCES = Singapore Chinese Eye Study, Combined 
Asian Sample = SiMES, SINDI and SCES combined, CI = confidence interval, AMD = age-related macular degeneration,  RPE = retinal pigment epithelial
Bold font indicates significant difference between the BMES and SiMES, SINDI, SCES or the Combined Asian samples.
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Table 5-6 presents a comparison of the areas and location of early AMD lesions in right 
eyes, between the BMES and the combined Asian samples, shown with age-adjusted p 
values. Larger areas of soft drusen were more frequent in the SiMES, SINDI and SCES 
than in the BMES (age-adjusted p<0.0001). The frequencies of larger areas involved by 
RPE depigmentation were similar in both Australian and Singaporean Asian samples, 
while small areas involved by hyperpigmentation were more frequent in theAsian 
sample compared to the  BMES (6.7% versus 9.6%; age-adjusted p=0.01). Singaporean 
Asians were more likely to have eyes with drusen located only at the inner and outer 
macula zones, but were significantly less likely to have eyes with drusen located  at the 
central macula  compared to the BMES sample (age-adjusted p<0.0001; Table 5-6, 
examples shown in Figure 5-1). A more central location for hyperpigmentation was 
also significantly less likely in the Singaporean Asian samples than in the BMES (age-
adjusted p<0.03). 
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Table 5-6 Area and location of drusen and pigmentary abnormalities in the Blue 
Mountains Eye Study compared to the combined Asian samples (Singapore Malay, 
Singapore Indian and Singapore Chinese Eye Studies combined). 
 
  % Eyes 
Age-
adjusted 
P-value† 
Odds Ratio 
(95% CI)‡ Early AMD lesion Characteristics BMES Combined Asian Samples* 
AREA         
Drusen 
None or <375µm in diameter 92.4 91.8 
<0.0001 1.0 ≥375µm in diameter 7.7 8.2 1.8 (1.6-2.1) 
RPE Depigmentation 
None or <375µm in diameter 96.3 96.7 
0.9 1.0 ≥375µm in diameter 3.7 3.3 1.0 (0.9-1.2) 
Hyperpigmentation 
None or <64µm in diameter 90.5 93.3 
0.01 1.0 ≥64µm in diameter 9.6 6.7 0.9 (0.8-1.0) 
LOCATION     
Drusen 
Central macula 87.5 59.3 
<0.0001 1.0 
Inner and outer macula zone 12.5 40.7 5.8 (2.7-12.3) 
RPE Depigmentation 
Central macula 58.4 62.4 
0.7 1.0 
Inner and outer macula zone 41.6 37.6 0.9 (0.5-1.5) 
Hyperpigmentation 
Central macula 80.8 63.6 
0.03 1.0 
Inner and outer macula zone 19.2 36.4 2.0 (1.1-4.0) 
AMD= age-related macular degeneration, BMES = Blue Mountains Eye Study, RPE = retinal 
pigment epithelial 
Location definitions: Central macula = <500µm radius from foveal centre; Inner macula zone = 
≥500µm to <1500µm radius from the foveal centre; Outer macula zone = ≥1500µm to <3000µm 
radius from the foveal centre 
* Singapore Malay, Indian and Chinese Eye Study samples combined  
†Unadjusted tests for heterogeneity used to calculate p-values 
‡Odds ratios estimated with BMES as reference group, using generalized estimating equation 
models and both eyes from each participant.
 
 
 
 
 
 
 
Figure 5-1 Examples of the different distribution of early age-related macular degeneration lesions in white Australians and Singaporean Asians: 
Central location of drusen in an Australian participant (A), compared to the more peripheral location of drusen in an Asian participant (B). 
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The associations between ethnicity and soft drusen types were further assessed after 
adjusting for age, sex, smoking status, total cholesterol, HDL, hypertension, BMI and  
the CHF SNP’s rs1061170 and rs1080155 and ARMS2 SNP’s rs10490924 and 
rs3750847 (Table 5-7). With reference to Australians, there was a significantly higher 
likelihood of having distinct soft drusen in Malays, Indians or Chinese (ORs 4.0, 4.6 
and 7.0, respectively). By comparison, there was a similar likelihood of having 
indistinct soft or reticular drusen among Malays, Indians and Chinese, compared to the 
Australian population (OR’s 1.1, 1.1 and 1.3, respectively), though these associations 
were not significant (Table 5-7).  
 
Table 5-7 The association between Asian ethnicity (Singapore Malay, Singapore 
Indian, and Singapore Chinese and combined Asian sample) and the prevalence of soft 
drusen, with reference to whites (the Blue Mountains Eye Study population), shown as 
odds ratios (OR) with 95% confidence intervals (95% CI). 
 
  Soft Drusen Type
Ethnic Group  
Distinct Soft Indistinct Soft and Reticular 
Multivariable adjusted OR* 
(95% CI) 
Multivariable adjusted OR* 
(95% CI) 
BMES (reference group) 1.0 1.0 
SiMES 4.0 (3.0, 5.4) 1.1 (0.7, 1.7) 
SINDI 4.6 (3.4, 6.3) 1.1 (0.7, 1.8) 
SCES 7.0 (5.1, 9.6) 1.3 (0.7, 2.2) 
Combined Asian Sample  4.6 (3.4, 6.0) 1.2 (0.8, 1.7) 
OR = odds ratio, CI = confidence interval, BMES = Blue Mountains Eye Study, SiMES =  
Singapore Malay eye study, SINDI = Singapore Indian eye study, SCES = Singapore Chinese 
eye study, Combined Asian = SiMES, SINDI and SCES combined
*Adjusted for age, sex, smoking, cholesterol, high density lipoprotein, hypertension, body 
mass index and the complement factor H and age-related maculopathy susceptibility gene 2 
risk alleles as categorical variables.
Bold font indicates significant differences. 
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DISCUSSION 
In this study, we found a significantly lower prevalence of distinct soft drusen in 
Australians compared to Asians (Malays, Indians and Chinese). In contrast, we found a 
significantly higher prevalence of indistinct soft drusen in Australians compared to 
Malays and Chinese; while Indians had a similar prevalence of indistinct soft drusen to 
Australians. This similarity between Indians and whites could be explained by their 
relatively close genetic make-up, compared to less similarity in the genome between 
whites and other Asian ethnicities.  
 
Similar to the previous report by Kawasaki et al. of a meta-analysis of findings from 
nine Asian population-based samples aged 40-79 years68, we found a 1.76% prevalence 
of late AMD in the BMES population to be comparable to the 1.30% prevalence in the 
combined Asian samples of Malays, Indians and Chinese, all aged 50 years or older. 
The age-standardized prevalence of early AMD was slightly lower in Australians and 
Malays compared to that of Indians or Chinese (9.72% and 10.98% versus 13.53% and 
13.01%, respectively).  
 
The early AMD prevalence of 10.98% and 13.53% found in our study contrasts with 
previously published prevalence of 3.5% and 4.5% for the same Singaporean population 
of Malays67 and Indians257, respectively. These differences are likely due to the age of 
the populations under investigation:  ≥50 years in our study versus 40 to 80 years in the 
previous study; and age-standardization to the BMES in our study versus age-
standardization to the Singapore population at the 2000 Singapore census67,257. Our 
finding also contrasts with another study of a different multiethnic cohort of 
Singaporean Malays, Indians and Chinese aged 40+ years that reported similar 
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prevalence of any AMD among the three ethnic groups (5.7%-7.7%)256, which was 
comparable to white populations around the world.  
 
Although the overall prevalence of early AMD was found to be similar between 
Australians and Singaporean Asians in our study, the frequency of various lesions 
forming early AMD was different. Malays and Chinese predominantly presented with a 
milder spectrum of lesions such as distinct soft drusen and a lower frequency of 
advanced lesions including indistinct soft drusen, compared to Australians. Of a few 
studies that have specifically investigated the prevalence of the individual lesions of late 
and early AMD, our observation is consistent with previous findings from the Multi-
Ethnic Study of Atherosclerosis (MESA) that found higher prevalence of distinct soft 
drusen among Chinese compared to black, white or Hispanic participants249.  
 
The BMES consists of participants with predominantly European ancestry and has 
found comparable early and late AMD prevalence and incidence to other population-
based epidemiological studies including the Beaver Dam Eye Study and the Rotterdam 
Eye study14,29,36,44,189. Singaporeans consist of many different Asian ethnicities, however 
the three ethnic groups captured in the SEED study were the three predominant ethnic 
groups of Asians184,188. Similar estimates of early and late AMD prevalence were found 
between Singaporean Indians and Indians living in India257.  
 
The single nucleotide polymorphisms (SNP’s) at the CFH and ARMS2 loci are 
significant risk factors for early AMD, though they present a weaker risk for early than 
for late AMD, as shown in a recent genome wide association study (GWAS) meta-
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analysis78. The differences in early AMD lesion prevalence between Australians and 
Asians could be partly explained by genetic differences78,258-261. 
 
The bilateral involvement of early, late and any AMD were shown to be comparable 
between the Malay and Australian populations in a previous report255. In the current 
analysis, we found that the frequency of bilateral late and early AMD was significantly 
lower in Malays, Indians and Chinese compared to Australians. The higher frequencies 
of bilateral involvement of late and early AMD in Australians compared to Singaporean 
Asians in our study could have been partly due to differences in age ranges of the 
samples, as age-standardization was not performed in the earlier comparison of bilateral 
involvement, due to small numbers. The lower frequency of bilateral early AMD in 
Asians may also be explained by the lower prevalence of the CFH Y402H 
polymorphism in Asian populations262,263, which has been found to be associated with 
bilateral early AMD involvement264,265.   
 
In addition to increasing age, smoking is an established risk factor for AMD in many 
white populations115,148,266. Similar associations between smoking and an increased 
AMD risk has also been documented in Asians64,120,267. Among past and current 
smokers, we found no difference in the age-standardized prevalence of indistinct soft 
and reticular drusen between Australians and Singaporean Asians. This could have been 
due to reduced numbers of subjects in these smoking subgroups.  
  
A higher risk of developing late AMD has been associated with a more central location 
of drusen and more advanced stages of early AMD lesions35,208. Our findings of a 
predominantly distinct soft drusen pattern among early AMD lesions and relatively high 
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prevalence of drusen and retinal pigmentary changes located away from the foveal 
center in Singaporean Asians compared to white Australians, reinforce the impression 
that Asians present a milder spectrum of early AMD lesions than whites, despite the 
overall lack of a substantive difference in the prevalence of early and late AMD 
between the Singaporean Asians and white Australians.  
 
The strengths of this study include the large sample size of each ethnic group and the 
direct comparison of AMD lesion and lesion characteristics among the studies. All 
studies used the same standardized grading protocol to determine AMD lesions and 
lesion characteristics, with AMD grading performed by the same principle grader 
(Mireille Moffit), adjudicated by the same senior researcher (Jie Jin Wang) and 
ophthalmologist (Christine Younan), with all late AMD cases confirmed by the same 
retinal specialist (Paul Mitchell). Limitations of the study include the small sample size 
in some groups when bilaterality and area and location of early AMD lesions were 
assessed, where it was not possible to obtain an age-standardized frequency. There is 
also a difference in the examination time between the BMES II study and the three 
Asian studies conducted in succession of each other, and this may have influenced the 
comparison between the studies if there was a temporal change in the prevalence of 
AMD.255 This does not seem likely given the relatively narrow time interval. The 
difference in types of fundus photographs taken between the BMES and the three Asian 
studies (35mm colour film versus colour digital images; 30° versus 45° photographs; 
and stereo versus non-stereo, respectively), however, could have had subtle effects on 
the quantitative measurements of lesion area and location but is unlikely to have 
affected the assessment of the prevalence of different AMD lesions. 
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SUMMARY 
In this report, we found that overall, Asians (including the three major Asian ethnic 
groups, Malays, Indians and Chinese) living in Singapore, had a predominantly milder 
spectrum of early AMD lesions compared to whites living in Australia, after age 
standardization. Further studies of environmental and genetic risk factors and their 
associations with early AMD lesions and lesion characteristics may elucidate insights 
into the similarities and dissimilarities in mechanisms that lead to AMD occurring in 
either Asians or whites. 
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Chapter 6 
 
Progression from Unilateral to Bilateral 
AMD among Three Caucasian 
Populations  
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Five-year progression from unilateral to bilateral age-related macular 
degeneration: The Three Continent AMD Consortium report 
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Continent AMD Consortium Report. Submitted to American Journal of Ophthalmology 
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ABSTRACT 
Purpose: To assess the 5-year progression from unilateral to bilateral age-related 
macular degeneration (AMD) and associated risk factors in populations. 
 
Methods: Participants of the Blue Mountains Eye Study (BMES), Beaver Dam Eye 
Study (BDES) and Rotterdam Study (RS) cohorts underwent similar examination 
procedures. Color retinal photographs were taken at each visit and comprehensive 
questionnaires administered. Blood samples were collected and DNA genotyped. 
Photographic grading was performed by trained graders following the modified 
Wisconsin AMD grading protocol. Five-year progression to bilateral any (early and late 
AMD) or late AMD was assessed in persons with unilateral any or late AMD in each 
study and in the pooled cohort. Associations of known AMD risk factors with 
progression to bilateral AMD were assessed using logistic regression models and 
expressed as odds ratios (ORs) and 95% confidence intervals (CIs).   
 
Results: In any 5-year duration over the follow-up periods, progression rates ranged 
from 19% to 28% for bilateral any AMD and 27% to 68% for bilateral late AMD in 
persons with prior unilateral involvement. In the pooled cohort, progression to bilateral 
any AMD was associated with increasing age and increased number of risk alleles of 
the CFH and ARMS2 genes (all Ptrend<0.0001). After multivariable adjustment, the 
presence of 1 or ≥2 risk alleles  from the complement factor H (CFH) and age-related 
maculopathy susceptibility 2 (ARMS2) genes was associated with increased progression 
to bilateral any AMD (OR 1.76, CI 1.17-2.64 or OR 3.34, CI 2.21-5.04), as was past 
(OR 1.64, CI 1.16-2.33) and current smoking status (OR 1.67, CI 1.10-2.55). In addition 
to age, the presence of ≥2 risk alleles form the CFH and ARMS2 genes combined was 
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significantly associated with increased progression to bilateral late AMD (OR 12.46, CI 
1.52-101.97). Increased cholesterol levels were inversely associated with progression to 
bilateral late AMD (OR 0.47, CI 0.26-0.84). 
 
Conclusions: One in five to one in four persons with unilateral any AMD progressed to 
bilateral, and nearly one in two with unilateral late AMD progressed to bilateral in 5 
years. Carrying risk alleles of CFH or ARMS2 and smoking increased this progression 
risk.       
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BACKGROUND 
Age-related macular degeneration (AMD) is a leading cause of blindness in western 
populations around the world2,211. While the presence of AMD in one eye can be 
debilitating, vision loss and eventual blindness in both eyes due to bilateral AMD will 
have severe consequences for the affected individuals 268,269.  
 
Population-based studies with follow-up data and few clinic-based studies have reported 
the development of bilateral late AMD (fellow eye involved) to be between 20% to 50% 
over 5 to 10 years29,33-35,38,44,270. However, the progression from unilateral early AMD to 
bilateral early or any AMD has been less well described271. The relationship between 
known AMD risk factors and the progression from unilateral to bilateral AMD is also 
not well-documented.  
 
We therefore aim to report the 5-year progression rates from unilateral to bilateral 
involvement by any or late AMD (termed progression to bilateral any or late AMD in 
this report). Also to investigate the progression in relation to age, genotypes of the 
complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) 
genes, smoking status and other known AMD risk factors, in the Three Continent AMD 
Consortium (3CC).  
 
METHODS 
We included three cohorts of non-Hispanic white, European-origin populations of the 
3CC conducted in Australia, USA and the Netherlands respectively: the Blue Mountains 
Eye Study (BMES), Beaver Dam Eye Study (BDES) and Rotterdam Study (RS); all had 
a follow-up period of 10 or more years32,169. Details of the three study populations are 
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described in Methods, Chapter 2. The total follow-up period in the BMES, BDES and 
RS taken into account in this study was 15 years, 20 years and 10 years, respectively, on 
average. To correspond with the BMES and BDES 5-year follow-up visit intervals, data 
from the second follow-up visit (1993-1995) of the RS were excluded. 
 
Photographic Grading and Definitions of AMD  
Retinal photographs of both eyes were initially graded by trained graders of each study 
following the Wisconsin Age-related Maculopathy Grading System26. All late AMD 
incident cases detected from each study were adjudicated and confirmed by the retinal 
specialists of the corresponding study team, followed by cross-checking among chief 
investigators of the BMES, BDES and RS57.  
 
A 5-step severity scale that was developed after phenotype harmonization of AMD by 
the Three Continent AMD Consortium32, was used to define AMD severity stage (refer 
to Table 1.1-1). The scale defines AMD by levels 10, 20, 30, 40 and 50, corresponding 
to: no AMD, mild early, moderate early, severe early and late AMD. Early AMD was 
defined as levels 20-40 and late AMD was defined as level 50 that includes geographic 
atrophy and neovascular AMD.  Unilateral any AMD was defined as the presence of 
either early or late AMD in one eye, without any AMD in the fellow eye. Unilateral late 
AMD was defined as the presence of late AMD in one eye without late AMD and with 
or without early AMD in the fellow eye. Bilateral any AMD was defined as presence of 
any AMD in both eyes, and the same held for bilateral late AMD. 
 
Total drusen area, measured as a proportion of the Wisconsin Age-Related Maculopathy 
Grading System (WARMGS), and presence of any retinal pigmentary abnormality in 
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the unilaterally affected eye at ‘baseline’ were also assessed as prognostic factors for 
bilateral involvement. As the studies differed slightly in their method of calculation of 
total drusen area, we derived quintiles of drusen area within each study to obtain 
comparable measures. Next, drusen area was categorized as small, intermediate or large, 
representing participants who had the lowest 20%, the middle 60% and the highest 20% 
of drusen area in each specific population accordingly. 
 
Genotyping 
In the BMES genotyping was performed as described in Methods (Chapter 2).After 
quality-control checking, genotypes of 2534 participants (544, 802 single nucleotide 
polymorphisms (SNPs)) were imputed. Additionally, genotype data was previously 
obtained for CFH SNP rs1061170 in 1840 participants and ARMS2 SNP rs10490924 in 
615 participants who attended the 5-year follow-up96, and these subjects had one or both 
of the SNPs typed and imputed. The concordance rates between typed and imputed 
SNPs were 99.6% for rs1061170 and 99.2% for rs10490924. The genotyped SNPs were 
used whenever available. 
 
In the BDES, CFH-rs1061170 was genotyped using TaqMan assays (Applied 
Biosystems, Foster City, CA) in 3015 participants, and a custom Illumina array in 2940 
participants with subsequent data imputation techniques performed with Markov chain 
haplotyping, version 1.0.32 (http://www.sph.umich.edu/csg/abecasis/MACH/)104. The 
concordance rate between typed and imputed data among 1476 samples was 99.8%. 
Similarly the ARMS2-rs10490924 SNP was genotyped using 2 platforms, including 
TaqMan assay and an iSelect array (Illumina, Inc.). The concordance rate between the 
588 samples genotyped with both platforms was 99.7%104. 
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In the RS, CFH-rs1061170 was successfully genotyped in 6345 participants and 
ARMS2-rs10490924 in 6411, using TaqMan assays (Applied Biosystems, Foster City, 
CA).  Additionally, for participants without genotyped data, data was imputed from a 
genome-wide association scan dataset, genotyped using the Illumina Infinium II 
HumanHap550. Imputation was performed using Markov Chain Haplotyping software 
version 1.0.15 (http://www.sph.umich.edu/csg/abecasis/MACH/, accessed June 4, 2013) 
and HapMap CEU data (NCBI build 36, release 22, The International HapMap Project). 
There were 6478 participants with typed or imputed CFH and ARMS2 SNPs. 
 
Assessment of Other Risk Factors  
In each study, smoking status was assessed using an interviewer-administered 
questionnaire. In the BMES, participants were classified as non-smokers if they 
answered ‘no’ to smoking regularly. If participants had quit smoking more than 1 year 
prior to the examination, they were classed as past smokers. Current smokers were 
defined as participants who currently smoked or had stopped smoking <1 year before 
the examination. In the BDES, participants were classified as non-smokers if they had 
smoked fewer than 100 cigarettes in their lifetime, as a past smoker if they smoked 
≥100 cigarettes but had stopped smoking before the examination, or a current smoker if 
they had not stopped smoking118. In the RS, smoking status was defined as never, past 
or current according to participants responses ‘no, never smoked’, ‘yes, stopped 
smoking’ and ‘yes, still smoking’, respectively123.    
 
In each study, the mean systolic and diastolic blood pressures were taken from the 
average of 2 readings of systolic and diastolic blood pressure. Serum total cholesterol 
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levels, high density lipoprotein (HDL) levels and white blood cell count were measured 
at baseline from non-fasting blood samples in the BDES and RS and fasting blood 
samples in the BMES117.  
 
Statistical Analyses 
All statistical analyses were performed using SAS version 9.3 (SAS Institute, Inc., Cary 
NC). Progression to bilateral AMD was assessed using discrete time survival analysis 
focusing solely on the first 5 year interval after detection of unilateral AMD. 
Participants were included in the cohort at first detection of unilateral AMD, whether at 
the baseline, 5-year, 10-year or 15-year visits, and were assessed for progression to 
bilateral involvement 5 years later.  
 
The progression was assessed by age, the number of risk alleles of the CFH and ARMS2 
genes individually or in combination (categorized as combined genetic risk scores: 0 
risk alleles, 1 risk allele and 2-4 risk alleles), and smoking status, by each study sample 
and next in pooled data of three cohorts, using Mantel-Haenzel χ2 tests for linear 
association. 
 
Associations between progression to bilateral involvement and known or potential 
AMD risk factors (age, sex, smoking status, numbers of the CFH and ARMS2 risk 
alleles, blood pressure, white blood cell count, total cholesterol and HDL-cholesterol 
levels) were assessed in age-adjusted and multivariable-adjusted logistic regression 
models, both within each cohort and in pooled three cohorts. Age was defined as a time-
dependent variable corresponding to the visit when unilateral AMD was first detected. 
All other co-variables were defined using data collected at baseline visits. Final models 
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included age, sex, smoking status and any other variables that remained statistically 
significant at p<0.05. In addition, indicators of study site were included in models using 
pooled data.  
 
Total drusen area and the presence of retinal pigmentary abnormalities in the 
unilaterally affected eye at ‘baseline’ (i.e. the beginning of each 5-year interval) were 
also included in the final models to assess whether these early AMD lesion 
characteristics contribute to an increased progression risk to bilateral any AMD. 
 
To exclude possible influence of different timing when unilateral AMD was detected on 
the associations, additional analyses were performed to include secular trends in final 
models, to accommodate potential cohort effect. This was to assess whether there were 
systematic differences between individuals who developed unilateral AMD at the 
beginning of the study period and those who developed unilateral AMD in later periods. 
Association estimates are presented as age-adjusted or multivariable-adjusted odds 
ratios (ORs) and 95% confidence intervals (CIs).  
 
To assess how useful the final model might be in predicting progression to bilateral any 
AMD in 5 years, we also produced the receiver operating characteristic (ROC) curve 
and area under the ROC curve (AUC) to gauge the prognostic value of the model. The 
AUC is a measure of discrimination and, in this case, indicates the probability that a 
person with progression will have a higher score in the model than a person without 
progression.  
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The association between the systemic risk factors and progression to bilateral late AMD 
could not be assessed in the BMES, BDES and RS separately due to small number of 
cases, and therefore was only examined in pooled three cohort data. The association 
between ocular factors (drusen area, presence of retinal pigmentary abnormalities) and 
progression to bilateral late AMD could not be assessed even in pooled data, due to the 
small number of cases. Therefore a ROC curve and AUC were not produced for this 
model. 
 
RESULTS  
Participants aged 51+ years from the BMES, aged 44+ years from the BDES and aged 
55+ years from the RS who had unilateral any or late AMD were included in this report. 
Of 1490 participants (BMES n=335, BDES n=625 and RS n=530) who had unilateral 
any AMD detected at any visit except for the last visit, 94 (28%) progressed to bilateral 
in the BMES, 119 (19%) in the BDES and 126 (24%) in the RS. Of 96 participants 
(BMES n=25, BDES n=51 and RS n=20) who had unilateral late AMD detected at any 
visits except for the last visit, 17 (68%) progressed to bilateral in the BMES, 14 (27%) 
in the BDES and 11 (55%) in the RS.  
 
Factors associated with progression to bilateral any AMD 
Table 6-1 presents comparisons of baseline characteristics between those who did and 
did not progress in the separate and pooled three populations. Compared to participants 
who remained unilateral, those who progressed to bilateral were older, and more likely 
to have at least 1 risk allele of CFH or ARMS2 or at least 2 risk alleles of combined 
CFH and ARMS2. There was no difference in smoking status among those who 
progressed compared to those who did not (Table 6-1).    
 
 
Table 6-1 Comparison of baseline characteristics of participants who did and those who did not progress from unilateral to bilateral any age-
related macular degeneration (AMD), or from unilateral to bilateral late AMD, in the Blue Mountains Eye Study (BMES), Beaver Dam Eye 
Study (BDES), Rotterdam Study (RS) individually and combined three cohorts. 
 
 
Characteristics 
5-Year Progression 
BMES  BDES RS Combined 
No 
progression Progression P-value
* No progression Progression P-value
*  No progression Progression P-value
* No progression Progression P-value
*  
    Unilateral Any AMD to Bilateral Any AMD 
Participants, n(%) 241 94 (28.1)  506 119 (19.0)  404 126 (23.8)  1151 339 (22.8)  
Mean Age (SD) 66.1 (7.5) 72.4 (7.12) <0.0001 63.6 (9.4) 69.8 (9.0) <0.0001 68.1 (7.3) 70.9 (7.8) 0.0002 65.7 (8.5) 70.9 (8.1) <0.0001 
Sex (male) % 41.5 46.8 0.4 49.2 42.9 0.2 44.1 40.5 0.5 45.8 43.1 0.4 
Smoking Status % Never 57.5 49.5 0.3 43.1 40.3 0.9 34.3 29.6 0.6 42.9 38.9 0.3 
Past 28.8 37.6 37.2 39.5 45.0 48.8 38.2 42.4 
Current 13.7 12.9 19.8 20.2 20.8 21.6 18.9 18.7 
CFH (rs1061170) 
% 
TT 44.2 32.1 0.04 40.3 21.9 0.0003 45.9 34.5 0.02 43.0 29.2 <0.0001 
CT 40.9 41.7 47.8 57.1 42.0 44.5 44.5 48.5 
CC 14.9 26.2 11.9 21.0 12.2 21.0 12.6 22.4 
ARMS2 
(rs10490924) % 
GG 66.7 46.8 0.003 62.5 47.1 0.003 65.7 53.8 0.004 64.4 49.5 <0.0001 
GT 31.8 46.8 33.0 42.9 32.2 38.7 32.5 42.3 
TT 1.5 6.3 4.6 10.1 2.1 7.6 3.1 8.2 
Combined Genetic 
Risk Score‡ % 
0 risk alleles 27.8 11.4 0.007 23.5 10.9 <0.0001 29.6 18.5 0.003 26.5 13.9 <0.001 
1 risk allele 43.3 45.6 46.3 35.3 43.1 38.7 44.6 39.1 
2-4 risk alleles 28.9 43.0 30.2 53.8 27.3 42.9 28.9 47.0 
Mean Systolic BP (SD), mmHg 142.9 (19.4) 147.6 (21.5) 0.05 130.4 (19.9) 131.9 (18.7) 0.4 140.9 (21.4) 140.5 (20.6) 0.9 136.7 (21.1) 139.4 (21.1) 0.03 
Mean Diastolic BP (SD), mmHg 84.6 (10.2) 83.2 (9.9) 0.3 78.4 (10.1) 76.3 (10.0) 0.04 75.6 (11.7) 71.3 (10.0) 0.0002 78.7 (11.1) 76.4 (11.0) 0.0006 
Mean WBCC (SD), x109 cells/L 6.6 (1.8) 6.4 (1.6) 0.4 7.2 (1.9) 7.2 (1.9) 0.8 6.4 (1.8) 6.3 (1.6) 0.5 6.8 (1.9) 6.7 (1.8) 0.2 
Mean Total Cholesterol (SD), mmol/L 6.1 (0.9) 6.3 (1.0) 0.09 6.0 (1.1) 6.1 (1.0) 0.7 6.4 (1.1) 6.2 (1.1) 0.09 6.2 (1.1) 6.2 (1.0) 0.9 
Mean HDL Cholesterol (SD), mmol/L 1.4 (0.4) 1.5 (0.5) 0.2 1.4 (0.5) 1.3 (0.4) 0.4 1.4 (0.4) 1.4 (0.4) 0.6 1.4 (0.4) 1.4 (0.4) 0.6 
 
 
  Unilateral Late AMD to Bilateral Late AMD 
Participants n (%) 8 17 (68.0)  37 14 (27.5)  9 11 (55.0)  54 42 (43.8)  
Mean Age (SD) 77.3 (6.2) 76.5 (6.2) 0.8 73.2 (8.0) 79.4 (6.8) 0.01 73.4 (6.8) 75.9 (5.3) 0.4 73.8 (7.6) 77.3 (6.2) 0.02 
Sex (male) % 25.0 23.5 0.9 46.0 35.7 0.5 66.7 63.6 0.9 46.3 38.1 0.4 
Smoking Status % Never 37.5 47.1 0.6 56.8 50.0 0.3 11.1 9.1 0.6 46.3 38.1 0.5 
Past 50.0 29.4 32.4 50.0 66.7 45.5 40.7 40.5 
Current 12.5 23.5 10.8 0.0 22.2 45.5 13.0 21.4 
CFH (rs1061170) 
% 
TT 12.5 31.3 0.6 16.2 14.3 0.9 33.3 9.1 0.3 18.5 19.5 0.6 
CT 50.0 43.8 67.6 64.3 55.6 54.6 63.0 53.7 
CC 37.5 25.0 16.2 21.4 11.1 36.4 18.5 26.8 
ARMS2 
(rs10490924) % 
GG 62.5 31.3 0.2 29.7 21.4 0.03 33.3 27.3 0.6 35.2 26.8 0.2 
GT 37.5 50.0 40.5 78.6 66.7 63.6 44.4 63.4 
TT 0.0 18.8 29.7 0.0 0.0 9.1 20.4 9.8 
Combined Genetic 
Risk Score† % 
0 risk alleles 12.5 6.3 0.8 13.5 0.0 0.3 22.2 9.1 0.4 14.8 4.9 0.3 
1 risk allele 37.5 31.3 16.2 21.4 22.2 9.1 20.4 22.0 
2-4 risk alleles 50.0 62.5 70.3 78.6 55.6 81.8 64.8 73.2 
Mean Systolic BP (SD), mmHg 146.4 (20.3) 147.5 (16.2) 0.9 136.4 (19.8) 136.6 (18.0) 0.97 137.6 (12.2) 144.3 (17.7) 0.4 138.1 (18.9) 143.0 (6.2) 0.2 
Mean Diastolic BP (SD), mmHg 82.9 (8.5) 83.5 (8.2) 0.9 75.7 (9.3) 71.7 (11.2) 0.2 71.6 (10.2) 78.4 (11.2) 0.2 76.1 (9.7) 78.2 (11.0) 0.3 
Mean WBCC (SD), x109 cells/L 6.9 (2.3) 6.8 (1.1) 0.8 7.2 (2.3) 7.1 (2.1) 0.9 6.6 (1.2) 6.9 (1.6) 0.6 7.0 (2.2) 6.9 (1.6) 0.8 
Mean Total Cholesterol (SD), mmol/L 6.6 (1.3) 6.3 (0.9) 0.4 6.1 (1.2) 5.7 (0.8) 0.3 5.9 (1.0) 5.8 (0.9) 0.7 6.1 (1.2) 5.9 (0.9) 0.4 
Mean HDL Cholesterol (SD), mmol/L 1.5 (0.3) 1.4 (0.5) 0.6 1.4 (0.5) 1.6 (0.4) 0.4 1.4 (0.3) 1.6 (0.8) 0.4 1.4 (0.4) 1.5 (0.5) 0.4 
n=sample size, SD=standard deviation, CFH=complement factor H (risk allele C), ARMS2=age-related maculopathy susceptibility gene 2 (risk allele T), BP=blood pressure, WBCC=white blood cell count, 
HDL=high density lipoprotein 
*P-value for association between baseline characteristics and progression of AMD from unilateral to bilateral (categorical factors) and P-value for difference in mean baseline level (continuous factors). 
†Total number of risk alleles from CFH and ARMS2 combined  
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Table 6-2 presents proportions of progression to bilateral any AMD by age, genotype 
and smoking status in separate and pooled populations. The progression was associated 
with increasing age and increasing numbers of risk alleles of the CFH and ARMS2 
genes. However, there was no significant crude association between smoking status and 
progression to bilateral any AMD (Table 6-2).  
 
 
 
 
Table 6-2 Five-year progression from unilateral to bilateral any and late AMD, by age, genotype and smoking status in the Blue Mountains Eye 
Study (BMES), Beaver Dam Eye Study (BDES), Rotterdam Study (RS) individually and combined three cohorts. 
  5-Year Progression from Unilateral to Bilateral AMD
Factors 
BMES BDES RS Combined
Any AMD* Late AMD† Any AMD* Late AMD† Any AMD* Late AMD† Any AMD* Late AMD† 
No. of 
cases/ 
No. at 
risk 
% 
No. of 
cases/ 
No. at 
risk 
% 
No. of 
cases/ 
No. at 
risk
% 
No. of 
cases/ 
No. at 
risk
% 
No. of 
cases/ 
No. at 
risk 
% 
No. of 
cases/ 
No. at 
risk
% 
No. of 
cases/ No. 
at risk 
% 
No. of 
cases/ 
No. at 
risk
% 
Age (years)  
40-49  -   -   -   - 3/44 6.8 0/0 0.0  -   -  -  - 3/44 6.8 0/0 0.0 
50-59 4/47 8.5 0/0 0.0 11/137 8.0 0/1 0.0 11/58 19.0 0/0 0.0 26/242 10.7 0/1 0.0 
60-69 24/136 17.7 2/3 66.7 42/241 17.4 1/11 9.1 40/233 17.2 1/3 33.3 106/610 17.4 4/17 23.5 
70-79 51/127 40.2 10/14 71.4 46/163 28.2 8/27 29.6 59/197 30.0 7/12 58.3 156/487 32.0 25/53 47.2 
80+ 15/25 60.0 5/8 62.5 17/40 42.5 5/12 41.7 16/42 38.1 3/5 60.0 48/107 44.9 13/25 52.0 
Total 94/335 28.1 17/25 68.0 119/625 19.0 14/51 27.5 126/530 23.8 11/20 55.0 339/1490 22.8 42/96 43.8 
P trend‡ <0.0001 0.8 <0.0001 0.07 0.0005 0.5 <0.0001 0.06
Smoking Status 
Never 46/180 25.6 8/11 72.7 48/266 18.1 7/28 25.0 37/174 21.3 1/2 50.0 131/620 21.1 16/41 39.0 
Past 35/102 34.3 5/9 55.6 47/235 20.0 7/19 36.8 61/241 25.3 5/11 45.5 143/578 24.7 17/39 43.6 
Current 12/44 27.3 4/5 80.0 24/124 19.4 0/4 0.0 27/110 24.6 5/7 71.4 63/278 22.7 9/16 56.3 
P trend‡ 0.1 0.4 0.6 0.8 0.4 0.3 0.4 0.2
CFH 
(rs1061170) 
TT  27/119 22.7 5/6 83.3 26/230 11.3 2/8 25.0 41/218 18.8 1/4 25.0 94/567 16.6 8/18 44.4 
CT 35/120 29.2 7/11 63.6 68/310 21.9 9/34 26.5 53/215 24.7 6/11 54.6 156/645 24.2 22/56 39.3 
CC 22/53 41.5 4/7 57.1 25/85 29.4 3/9 33.3 25/72 34.7 4/5 80.0 72/210 34.3 11/21 52.4 
P trend‡ 0.01 0.3 <0.0001 0.6 0.006 0.1 <0.0001 0.5
ARMS2 
(rs10490924) 
GG 37/169 21.9 5/10 50.0 56/372 15.1 3/14 21.4 64/317 20.2 3/6 50.0 157/858 18.3 11/30 36.7 
GT 37/100 37.0 8/11 72.7 51/218 23.4 11/26 42.3 46/124 27.1 7/13 53.9 134/488 27.5 26/50 52.0 
TT  5/8 62.5 3/3 100.0 12/35 34.3 0/11 0.0 9/17 52.9 1/1 100.0 26/60 43.3 4/15 26.7 
P trend‡ 0.0008 0.09 0.0006 0.3 0.003 0.5 <0.0001 0.8
 
 
 
 
 
 
Combined 
Genetic Risk 
Score§  
0 risk alleles 9/63 14.3 1/2 50.0 13/132 9.9 0/5 0.0 22/136 16.2 1/3 33.3 44/331 13.3 2/10 20.0 
1 risk allele 36/120 30.0 5/8 62.5 42/276 15.2 3/9 33.3 46/212 21.7 1/3 33.3 124/608 20.4 9/20 45.0 
2-4 risk alleles 34/90 37.8 10/14 71.4 64/217 29.5 11/37 29.7 51/156 32.7 9/14 64.3 149/463 32.2 30/65 46.2 
P trend‡ 0.002 0.5 <0.0001 0.3 0.0008 0.2 <0.0001 0.2
CFH=complement factor H (risk allele C), ARMS2=age-related maculopathy susceptibility 2 (risk allele T) 
*Unilateral any AMD progression to bilateral any AMD 
†Unilateral late AMD progression to bilateral late AMD 
‡P trend calculated using Mantel-Haenszel χ2 test for linear association 
§Combined risk dichotomised as 0 or 1 risk allele of CFH or ARMS2 or 2 to 4 risk alleles of CFH and/or ARMS2
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Table 6-3 presents ORs of AMD risk factors associated with progression to bilateral 
any AMD by individual cohorts. After adjusting for sex, smoking, diastolic BP, total 
drusen area, presence of retinal pigmentary abnormalities and number of risk alleles of 
the CFH and ARMS2 genes, age was associated with the risk of progression. Similarly, 
the presence of risk genotypes of the CFH or ARMS2, or the presence of ≥2 risk alleles 
from these two genes, was associated with an increased risk of progression. These 
associations were consistent across three cohorts while smoking was non-significantly 
associated with this progression. Large total drusen area (the highest quintile compared 
to the lowest) contributed significantly to the risk of progression in each cohort. 
Presence of any retinal pigmentary abnormality was associated with a significantly 
increased risk of progression in the BMES and BDES but not in the RS (Table 6-3).    
 
 
 
 
Table 6-3 Associations of age-related macular degeneration (AMD) risk factors with 5-year progression from unilateral to bilateral any AMD in 
the Blue Mountains Eye Study (BMES), Beaver Dam Eye Study (BDES) and Rotterdam Study (RS) populations. 
 
Risk Factors 
BMES BDES RS 
Age-Adjusted OR 
(95% CI) 
Multivariable-
Adjusted* OR (95% 
CI) 
Age-Adjusted OR 
(95% CI) 
Multivariable-
Adjusted* OR (95% 
CI) 
Age-Adjusted OR 
(95% CI) 
Multivariable-
Adjusted* OR (95% 
CI) 
Age per year 1.12 (1.08-1.16) 1.15 (1.09-1.21) 1.08 (1.05-1.10) 1.07 (1.04-1.10) 1.05 (1.02-1.09) 1.04 (1.00-1.07) 
Sex (male) 1.54 (0.91-2.60) 1.02 (0.49-2.12) 0.90 (0.59-1.36) 0.76 (0.47-1.24) 0.96 (0.63-1.46) 0.92 (0.54-1.56) 
Smoking Status Never 1.00 1.00 1.00 1.00 1.00 1.00 
Past 1.74 (0.98-3.08) 1.43 (0.65-3.12) 1.33 (0.83-2.12) 1.57 (0.91-2.70) 1.51 (0.93-2.45) 1.79 (0.98-3.29) 
Current 1.61 (0.70-3.67) 2.10 (0.73-5.98) 1.48 (0.83-2.63) 1.47 (0.78-2.77) 1.71 (0.93-3.13) 1.69 (0.83-3.43) 
CFH 
(rs1061170) 
TT 1.00  -  1.00  - 1.00  -  
CT 1.33 (0.70-2.51)  -  2.37 (1.43-3.93)  - 1.35 (0.84-2.15)  -  
CC 3.55 (1.64-7.67)  -  3.53 (1.85-6.74)  - 2.42 (1.32-4.41)  -  
ARMS2 
(rs10490924) 
GG 1.00  -  1.00  - 1.00  -  
GT 2.72 (1.48-4.99)  -  1.94 (1.24-3.02)  - 1.39 (0.89-2.16)  -  
TT 7.48 (1.57-35.6)  -  4.37 (1.96-9.74)  - 4.55 (1.67-12.4)  -  
Combined 
Genetic Risk 
Score† 
0 risk alleles 1.00 1.00 1.00 1.00 1.00 1.00 
1 risk allele 2.93 (1.22-7.05) 3.46 (1.33-9.02) 1.71 (0.87-3.37) 1.57 (0.77-3.20) 1.42 (0.80-2.49) 1.52 (0.83-2.79) 
2-4 risk alleles 5.36 (2.16-13.30) 5.19 (1.93-13.93) 4.75 (2.43-9.27) 4.25 (2.11-8.54) 2.49 (1.40-4.40) 2.51 (1.35-4.67) 
Blood Pressure 
(per 10mmHg) 
Systolic 1.03 (0.91-1.17)  -  0.99 (0.90-1.11)  -  0.95 (0.86-1.05)  -  
Diastolic 0.90 (0.70-1.16) 0.96 (0.68-1.34) 0.97 (0.78-1.21) 0.93 (0.73-1.18) 0.72 (0.59-0.86) 0.71 (0.57-0.88) 
WBCC (per SD increase) 0.93 (0.69-1.23)  -  1.12 (0.88-1.43)  -  0.96 (0.77-1.19)  -  
Total Cholesterol (per SD increase) 1.25 (0.92-1.69)  -  0.95 (0.76-1.19)  -  0.88 (0.71-1.08)  -  
HDL Cholesterol (per SD increase) 1.15 (0.86-1.54)  -  0.93 (0.75-1.15)  -  1.04 (0.85-1.27)  -  
Drusen Area‡ Low 1.00 1.00 1.00 1.00 1.00 1.00 
Intermediate 1.32 (0.58-2.99) 1.83 (0.75-4.49) 1.79 (0.88-3.66) 2.75 (1.26-5.99) 2.99 (1.52-5.90) 2.65 (1.32-5.31) 
High 9.62 (3.77-24.55) 15.26 (5.08-45.83) 7.93 (3.69-17.04) 12.32 (5.10-29.79) 9.11 (4.27-19.43) 9.62 (4.29-21.57) 
RPE Abnormality Presence 1.18 (0.65-2.15) 2.61 (1.21-5.66) 0.93 (0.61-1.42) 1.73 (1.03-2.90) 1.02 (0.67-1.56) 1.49 (0.91-2.43) 
OR=odds ratio, CI=confidence interval, CFH=complement factor H, ARMS2=age-related maculopathy susceptibility gene 2, WBCC=white blood cell count, HDL=high density lipoprotein, 
SD=standard deviation, RPE=retinal pigment epithelium 
*Adjusted for age, sex, smoking, combined genetic risk score, diastolic blood pressure, drusen area and RPE abnormalities.   
†Total number of risk alleles from CFH and ARMS2 combined (reference: 0 risk alleles) 
‡Total drusen area categorised as low, intermediate and high representing the lowest 20% of drusen area, the central 60%, and highest 20%, respectively. 
Bold values indicate significant odds ratios. 
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Table 6-4 presents ORs of AMD risk factors associated with progression to bilateral 
any AMD in pooled data after age-adjustment and multivariable adjustment including 
age, sex, smoking, diastolic blood pressure, total drusen area and the presence of retinal 
pigmentary abnormalities. This progression was more commonly observed in the BMES 
compared to the BDES. Older age was associated with progression while sex was not. 
Past and current smoking was significantly associated with increased risk of 
progression, compared to persons who never smoked. The presence of ≥1 risk allele of 
CFH, ARMS2, or in combination, also showed an increased risk of progression (Table 
6-4). Large total drusen area and retinal pigmentary abnormalities substantially 
increased risk of the progression. The ROC curve of this final model is shown in Figure 
6-1, and the AUC was 0.79, which indicates reasonable but not excellent discrimination 
for a clinical tool. 
 
 
 
 
 
Table 6-4 Associations of age-related macular degeneration (AMD) risk factors with 5-year progression from unilateral to bilateral any AMD 
and late AMD in pooled data of the Blue Mountains Eye Study (BMES), Beaver Dam Eye Study (BDES) and Rotterdam Study (RS). 
 
 
 
Risk Factors 
BILATERAL ANY AMD BILATERAL LATE AMD 
Age-Adjusted OR (95% 
CI) 
Multivariable-Adjusted* OR 
(95% CI) 
Age-Adjusted OR (95% 
CI) 
Multivariable-Adjusted† OR 
(95% CI) 
Study Population (ref: 
BDES) 
BMES 1.42 (1.03-1.97) 1.71 (1.16-2.54) 5.45 (1.86-15.90) 7.30 (2.05-25.96) 
RS 1.06 (0.79-1.42) 1.10 (0.79-1.53) 3.54 (1.16-10.80) 3.43 (0.82-14.31) 
Age (per year) 1.08 (1.06-1.09) 1.07 (1.05-1.09) 1.08 (1.01-1.15) 1.13 (1.05-1.23) 
Sex (male) 1.06 (0.82-1.37) 0.89 (0.65-1.22) 0.86 (0.33-2.23) 0.81 (0.28-2.34) 
Smoking Status Never 1.00 1.00 1.00 1.00 
Past 1.51 (1.13-2.01) 1.64 (1.16-2.33) 1.32 (0.46-3.77) 1.97 (0.59-6.55) 
Current 1.65 (1.14-2.38) 1.67 (1.10-2.55) 2.14 (0.47-9.76) 2.01 (0.38-10.57) 
CFH (rs1061170) TT 1.00  -  1.00  -  
CT 1.64 (1.22-2.21)  -  1.24 (0.38-4.07)  -  
CC 2.92 (2.00-4.25)  -  2.06 (0.50-8.39)  -  
ARMS2 (rs10490924) GG 1.00 - 1.00 -
GT 1.77 (1.34-2.33)  -  2.79 (0.97-8.03)  -  
TT 4.64 (2.62-8.21)  -  1.18 (0.25-5.51)  -  
Combined Genetic Risk 
Score‡ 
0 risk alleles 1.00 1.00 1.00 1.00 
1 risk allele 1.72 (1.17-2.54) 1.76 (1.17-2.64) 3.61 (0.52-25.34) 4.91 (0.60-40.03) 
2-4 risk alleles 3.56 (2.42-5.25) 3.34 (2.21-5.04) 6.39 (1.04-39.09) 12.46 (1.52-101.97) 
Blood Pressure (per 
10mmHg) 
Systolic 0.99 (0.93-1.05)  -  1.05 (0.81-1.36)  -  
Diastolic 0.84 (0.74-0.95) 0.82 (0.71-0.95) 1.07 (0.67-1.70)  -  
WBCC (per SD increase) 1.01 (0.87-1.17)  -  1.04 (0.65-1.64)  -  
Total Cholesterol (per SD increase) 0.98 (0.86-1.12)  -  0.62 (0.36-1.04) 0.47 (0.26-0.84) 
HDL Cholesterol (per SD increase) 1.02 (0.88-1.17)  -  1.19 (0.77-1.83)  -  
Drusen Area§ Low  1.00 1.00  -   -  
Intermediate 2.04 (1.34-3.10) 2.32 (1.50-3.59)  -   -  
High 8.57 (5.42-13.56) 10.67 (6.45-17.67)  -   -  
RPE Abnormality Presence 0.99 (0.76-1.29) 1.68 (1.23-2.29)  -   -  
OR=odds ratio, CI=confidence interval, CFH=complement factor H, ARMS2=age-related maculopathy susceptibility gene 2, WBCC=white blood cell count, HDL=high density 
lipoprotein, SD=standard deviation, RPE=retinal pigment epithelium 
*Adjusted for study population, age, sex, smoking, combined genetic risk, diastolic blood pressure, drusen area and RPE abnormalities. 
†Adjusted for study population, age, sex, smoking, combined genetic risk and total cholesterol.  
‡Total number of risk alleles from CFH and ARMS2 combined (reference: 0 risk alleles). 
§Total drusen area categorised as low, intermediate and high representing the lowest 20% of drusen area, the central 60%, and highest 20%, respectively. 
Bold values indicate significant odds ratios. 
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Figure 6-1 Receiver operating characteristic (ROC) curve indicating the prognostic 
performance of the model in predicting probabilities of 5-year progression from 
unilateral to bilateral involvement by any AMD. 
 
 
  
242 
 
A supplementary analysis using a recently developed comprehensive gene-environment 
risk score105 found no additional improvement to the adjusted model for predicting 
progression to bilateral any AMD (data not shown). There was no meaningful 
difference in the association between these risk factors and progression to bilateral any 
AMD after inclusion of secular trend terms in the model (data not shown).   
 
Factors associated with progression to bilateral late AMD 
Compared to participants who stayed in the unilateral late AMD category over 5 years, 
those who progressed to bilateral late AMD were on average older (Table 6-1).  
However, there was no significant trend for age, smoking or genetic associations with 
this progression in either separate or pooled cohorts (Table 6-2).  
 
Progression to bilateral late AMD was more commonly observed in the BMES 
compared to the BDES (Table 6-4). The presence of ≥2 risk alleles from the CFH and 
ARMS2 genes combined presented a 12-fold risk of progression after multivariable 
adjustment. Increased serum total cholesterol was independently associated with 
decreased risk of progression. After inclusion of secular trend terms, progression to 
bilateral late AMD was also more common in the RS compared to the BDES. However, 
the association between AMD risk factors and the progression remained essentially the 
same as in the model without secular trends (data not shown).      
 
DISCUSSION 
This is one of few studies to assess progression to bilateral any or late AMD over a 
clinically relevant time (5-year) interval. On average, the progression rate to bilateral 
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any AMD was 19% to 28%, and to bilateral late AMD it was 27% to 68% in persons 
with unilateral involvement 5 years prior. 
 
More severe levels of AMD in one eye were previously reported to be associated with 
increased incidence and progression of AMD in the fellow eye271. Using data from the 
3CC we additionally examined risk factors associated with progression to bilateral 
involvement, and documented that three well known AMD risk factors (older age, 
genetic risk and smoking), as well as early AMD lesion characteristics, are associated 
with an increased risk of  progression to bilateral involvement in pooled data of three 
cohorts.  
 
The BDES population includes a younger age spectrum (age 43+ years) compared to the 
BMES (aged 51+ years) and the RS (aged 55+ years), which may, in part, explain why 
higher proportions of progression were present in the BMES and RS relative to the 
BDES (Tables 6-1 and 6-4).  
 
One clinic-based study reported a 5-year incidence of late AMD in the fellow eye of 
26% of unilateral late AMD patients enrolled in a randomized clinical trial270. Similarly 
in the BMES 29% and in the BDES 22% were progressed to late AMD in the fellow 
(second) eye in 5 years among participants with unilateral late AMD29,44, while in the 
RS the 5-year cumulative incidence of late AMD in the fellow eye was greater at 39%38. 
These previous findings are comparatively lower than the 68% progression to bilateral 
late AMD found in the BMES, 28% in the BDES and 55% in the RS in this report. As 
we examined AMD progression within any 5-year period over the 10-20 year follow-up 
periods, rather than in a single 5-year interval, the mean age of participants included in 
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this report is considerably older than the mean ages of 64.5 years in the BMES, 61.7 
years in the BDES and 68.9 years in the RS baseline samples only. 
 
Factors associated with progression to bilateral any AMD 
There are limited data available in the literature for comparison with our findings. In 
pooled data analyses of the 3CC, either past or current smoking was significantly 
associated with a 50% greater risk of progression to bilateral any AMD. The risk 
magnitude and 95% confidence intervals of the associations of past and current smoking 
with the progression were similar compared to never smoking. This finding could be 
due to the fact that some past smokers had only recently stopped smoking. The RS and 
BDES used definitions slightly different from those used in the BMES for current and 
past smoking. Despite heterogeneity in the smoking questions asked and in definitions 
of current and past smokers across three studies, the contribution of smoking to 
progression to bilateral AMD is evident in the increased sample size of pooled-data.  
 
Consistent with a previous BMES finding265, we also documented increased risk of 
progression among those with ≥1 risk allele of the CFH or ARMS2 gene individually or 
in combination, in our pooled data. The inverse association between increased diastolic 
blood pressure and reduced risk of progression to bilateral any AMD is not readily 
explained.  
 
As in previous studies, drusen area was found to be the strongest predictor of 
progression to bilateral any AMD272. An AUC of 0.79 for the final model suggests that 
the model has considerable value in distinguishing persons who progress to bilaterality 
from those who do not.  
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Factors associated with progression to bilateral late AMD 
The relatively small numbers of participants with unilateral late AMD in each 
individual population and in pooled data is likely the reason for the lack of associations 
with smoking found in our analyses. Risk alleles of the CFH and ARMS2 genes were 
not significantly associated individually with progression to bilateral late AMD in each 
study sample or in pooled data. However, the presence of ≥2 risk alleles of the CFH and 
ARMS2 genes combined was associated with a significantly high risk of progression to 
bilateral involvement by late AMD, a blinding condition with significant impact on the 
affected individuals. Note that due to small numbers resulting in substantially wide 
confidence intervals (95% CI 1.5-102), this bilateral late AMD risk estimate (OR 12.5) 
is likely unstable.   
 
The inverse association between increased cholesterol and risk of progression to 
bilateral late AMD is not readily explained. In a previous report on the pooled data 
analysis from the same 3CC, an increase in serum total cholesterol levels was also 
found to be associated with a reduced incidence of neovascular AMD117. Findings 
concerning the relationship between serum total cholesterol levels and AMD risk are 
largely inconsistent169,266,273,274. While HDL cholesterol is protective for cardiovascular 
disease risk166-168, the association between HDL cholesterol and AMD risk has similarly 
been inconsistent154,156,274. In this study we found that HDL cholesterol levels were not 
associated with progression to bilateral any or late AMD.   
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Study strengths and limitations  
Strengths of this study include the relatively large sample size for unilateral any AMD 
cases from the 3CC Caucasian cohorts. Care has been taken to harmonize AMD grading 
and to confirm all late AMD cases across three cohorts57. Additionally, the 5-step 
severity scale developed after harmonization of AMD phenotypes32 in the 3CC was 
used to uniformly define any and late AMD. We were also able to document that 
secular trends had no impact on the association between risk factors and the progression 
to bilateral AMD. 
 
Limitations of this study include the relatively small sample size within each cohort and 
in the pooled samples for unilateral late AMD cases, resulting in low study power to 
assess some risk factors. The cohort samples included in this study are almost 
Caucasians of Northern and Western European descent, and therefore the results 
presented may not be applicable to other ethnic populations. 
 
SUMMARY 
Our findings from this report show that in 5 years, one in five to one in four older 
persons with unilateral any AMD progressed to bilateral any AMD, and nearly one in 
two with unilateral late AMD progressed to bilateral late AMD. Findings from pooled 
data of three cohorts suggest that three known AMD risk factors (age, smoking and 
AMD genetic variants) and early AMD lesion characteristics are significantly 
associated with progression to bilateral involvement among unilateral AMD cases. Of 
these risk factors, only smoking is modifiable.  
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Chapter 7 
 
Implications of the Findings from this 
Thesis 
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My work in this thesis documented the long-term incidence, progression and associated 
risk factors of age-related macular degeneration (AMD) and its component lesions in an 
older Australian population-based cohort, the Blue Mountains Eye Study.  
 
The 15-year incidence rates of Early and Late AMD were 15.1% and 4.1%, 
respectively, in the BMES. The 15-year incidence of pure geographic atrophy (GA) was 
2.2 %, and progression of GA measured as enlargement of the GA lesion was 
1.95mm2/year. The 15-year incidence of reticular drusen was 4.0%, and 34% of eyes 
with this lesion progressed to late AMD within 5 years. The 15-year incidence of 
medium drusen was 13.9%, and the progression to late AMD from this lesion was 5.0%, 
over 15 years. Progression to late AMD from medium drusen with co-presented 
pigmentary abnormalities was 4-fold (23.0%) of that for eyes with medium drusen 
alone. The prevalence of distinct soft drusen was 23.9% in Singaporean Asians 
compared to 6.2% in white Australians, and the prevalence of indistinct soft and 
reticular drusen was 6.5% in Singaporean Asians compared to 8.3% in white 
Australians. One in five to one in four persons with unilateral any AMD progressed to 
bilateral, and nearly one in two with unilateral late AMD progressed to bilateral in 5 
years.  
 
Age and known genetic risk from the CFH and ARMS2 were significantly associated 
with the 15-year incidence of early AMD, late AMD, GA, reticular drusen, medium 
drusen and the progression from unilateral any AMD to bilateral. Current smoking was 
associated with the long-term incidence of late AMD, GA, reticular drusen and the 
progression from unilateral any AMD to bilateral. There was no longitudinal association 
between smoking and the incidence of early AMD or medium drusen. Weekly fish 
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consumption was associated with a reduced risk of 15-year incident late AMD, and the 
progression from reticular drusen to late AMD in 5 years was reduced in those with 
high dietary intake of lutein-zeaxanthin.  
 
While genetic screening is not conventional practice in ophthalmology clinics, being 
genetically susceptible to AMD is an important risk stratifier of AMD. Smoking may 
have a promoting role in progression from early to late AMD. Weekly fish consumption 
and dietary intake of food rich in lutein-zeaxanthin may help to prevent or slow the 
development of late AMD.  
 
Importantly, early AMD characteristics including large macular areas involved by, and 
central location of early AMD lesions, the co-presence of different types of early AMD 
lesions and the presence of reticular drusen, are indicative of high risk of progressing to 
late AMD. The choice of AMD severity scales used in assessing risk of late AMD 
should be considered carefully as it may have different risk estimates depending on the 
type of study sample, i.e. population-based or clinic-based, and may have implication in 
study power calculations for intervention trials.  
 
It is also important to understand the differences in the risk and severity of AMD lesions 
in different racial populations given the current demographic of Australia being 
ethnically diverse. In 2014 it was estimated that 28% of Australia’s population was born 
overseas, and nearly half this number originated from Asia275. The relatively milder 
spectrum of early AMD lesions in Asian population implies that the risk of progression 
to late AMD in Asians likely differs from that of Caucasians. Further studies are needed 
to explore the interrelationship of environmental and genetic risk factors relating to 
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AMD risk, which may provide insight into mechanisms explaining ethnic differences in 
risk of AMD between Caucasians and other ethnic populations. 
 
The findings presented in this thesis were all derived from population-based studies that 
used retinal fundus photography todocument and assess AMD and its component 
lesions. While this method of assessment has provided much knowledge on current 
understanding of the characteristics, development and progression of AMD, the advent 
of new technologies in retinal imaging in recent years have furthered this knowledge 
and will continue to do so in the future. Novel features of OCT are currently used to 
examine structural alternations associated with early and late stages of AMD including 
drusen thickness and volume, RPE and choroidal thickness, examining vitreoretinal 
interface abnormalities, the hyperfluorescent edge of GA during progression and the 
presence of fluid and other features of neovascular AMD210,276-285. However, while use 
of these technologies in clinical settings may be straightforward, their implementation 
in large scale population-based studies would be very challenging, particularly the 
logistics of time demanded for having multiple imaging examination methods and the 
willingness of participants to undergo such rigorous testing of their eyes during 
examinations. The use of multimodal imaging should nevertheless be employed, if 
possible, in new population-based studies as it allows better classification of certain 
AMD lesions and quantification of some AMD characteristics such as GA progression. 
 
Given Australia’s ageing population and that AMD is strongly age-related, estimates of  
the long-term incidence and progression, and examination of associated risk factors of 
AMD are essential to understanding the aetiology of AMD, developing strategies to 
prevent adverse consequence of AMD, and improving management and services for the 
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affected individuals. Knowledge about modifiable lifestyle behaviours that can either 
increase or reduce risk of late AMD should be advocated and included in education 
provided to patients with early AMD. Contribution from my work in this thesis should 
ultimately help maintain good quality of life for an ageing population and minimise the 
economic burden of AMD. 
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The Incidence and Progression of Age-Related
Macular Degeneration over 15 Years
The Blue Mountains Eye Study
Nichole Joachim, BSc (Hons), Paul Mitchell, MD, PhD, George Burlutsky, MApplStat,
Annette Kiﬂey, MApplStat, PhD, Jie Jin Wang, MMed, PhD
Purpose: To assess the 15-year incidence and progression of age-related macular degeneration (AMD) in an
older Australian population.
Design: Population-based cohort study.
Participants: Blue Mountains Eye Study (BMES) participants (n ¼ 3654) aged 49þ years were examined
during 1992e1994. Of these, 2334 (75.8% of survivors) were reexamined after 5 years (1997e1999), 1952 (76.7%
of survivors) after 10 years (2002e2004), and 1149 (56.1% of survivors) after 15 years (2007e2010).
Methods: Color retinal photographs were taken, and comprehensive questionnaires were administered at each
visit and DNA was genotyped. Retinal photographic grading was performed by the same graders following the
Wisconsin AMD grading protocol. Side-by-side comparisons were used to conﬁrm newly developed AMD lesions.
Incidence was estimated using KaplaneMeier estimates. Associations of AMD incidence with age, sex, smoking
status, presence of the complement factor H (CFH)-rs1061170 and age-related maculopathy susceptibility 2
(ARMS2)-rs10490924 polymorphisms, and ﬁsh consumption were analyzed using discrete logistic regression
models. Generalized estimation equation models were used to assess the risk of incident late AMD associated with
baseline AMD lesion characteristics.
Main Outcome Measures: The 15-year incidence and progression of AMD, and associated factors.
Results: The 15-year incidence was 22.7% for early AMD and 6.8% for late AMD. After adjusting for
competing risks, early and late AMD incidence were 15.1% and 4.1%, respectively. Age was strongly associated
with early and late AMD incidence (bothP< 0.0001). After age standardization to the Beaver DamEye Study (BDES)
population, early and late AMD incidence in the BMES were 13.1% and 3.3%, respectively. Female sex and the
presence of both risk alleles of CFH-rs1061170 or ARMS2-rs10490924 were independently associated with early
AMD incidence, whereas current smoking and presence of1 risk allele ofCFH-rs1061170 or ARMS2-rs10490924
were associated with late AMD incidence. Fish consumption was inversely associated with late but not early AMD
incidence. Severity of early AMD lesion characteristics was a strong predictor of progression to late AMD.
Conclusions: We documented the 15-year incidence of early and late AMD in an older Australian population
that were comparable to BDES observations. Risk of progression to late AMD was strongly associated with
severity of early AMD lesions. Ophthalmology 2015;122:2482-2489 ª 2015 by the American Academy of
Ophthalmology.Age-related macular degeneration (AMD) continues to be
one of the leading causes of blindness and visual impair-
ment in older populations despite recent advances in
treatments.1e4 The incidence and progression of early and
late-stage AMD over 5 and 10 years have been reported in a
number of large population-based studies in the United
States, Europe, Asia, and Australia over the past 2 deca-
des.2,5e10 Greater severity of early AMD lesions, including
increased drusen area, presence of pigmentary abnormal-
ities, and location of lesions close to the fovea, was shown
to be associated with greater risk of progression to late
AMD.6,7,10,11 The relationship between demographic and
lifestyle risk factors, including older age, sex, and smoking2482  2015 by the American Academy of Ophthalmology
Published by Elsevier Inc.status, with the incidence and progression of AMD was also
shown in some of these populations.12
However, data on the incidence ofAMDover the long-term
(>10 years) are limited. The Copenhagen City Eye Study and
the Beaver Dam Eye Study (BDES) are the only population-
based studies thus far to report 14- and 15-year AMD
incidence, respectively.11,13 In this report, we aimed to build
on the previous 5- and 10-year AMD incidence ﬁndings to
describe the 15-year incidence of early and late AMD and its
component lesions in an older Australian population (the Blue
Mountains Eye Study [BMES]) and to assess risk factors and
baseline early AMD lesions characteristics associated with the
risk of progression to late AMD over the longer term.http://dx.doi.org/10.1016/j.ophtha.2015.08.002
ISSN 0161-6420/15
Joachim et al  15-Year Incidence and Progression of AMDMethods
Study Population
The BMES is a population-based study of vision and eye disease in
persons aged 49 years and older residing in the Blue Mountains
region, west of Sydney Australia. The study recruited 3654 par-
ticipants (82.4% of those eligible) during baseline examinations
(1992e1994, BMES I). Of these, 2334 participants (75.8% of
survivors; 575 deceased) attended 5-year follow-up examinations
(1997e1999, BMES II); 10-year examinations were attended by
1952 participants (76.7% of survivors; a further 535 died;
2002e2004, BMES III). The ﬁnal 15-year follow up examinations
were attended by 1149 participants (56.1% of survivors; a further
496 died; 2007e2009, BMES IV). The mean (median, minimum,
and maximum) follow-up period was 5.1 years (4.9, 3.4, and 7.8,
respectively) for the 2334 BMES II participants; 10.5 years (10.4,
8.9, and 12.9, respectively) for the 1952 BMES III participants;
and 15.6 years (15.5, 13.6, and 17.7, respectively) for the 1149
BMES IV participants. All 4 examinations were approved by the
University of Sydney and Western Sydney Area Health Service
Human Research Ethics Committees and adhered to the tenets of
the Declaration of Helsinki. Written informed consent was ob-
tained from all participants at each visit.
Procedures
A comprehensive questionnaire was administered, and eye exam-
inations were performed at each visit, as previously described.10,14
Brieﬂy, 30 stereoscopic retinal fundus photographs of the macula
and other retinal ﬁelds of both eyes were obtained using a Zeiss
FF3 fundus camera (Carl Zeiss, Oberkochen, Germany) and
Kodachrome 25 slide ﬁlm (Kodak) at BMES I, II, and III exami-
nations. At the BMES IV examination, because of the unavail-
ability of Kodachrome, 40 digital photographs were obtained with
a Canon CF-60 DSi fundus camera with a DS Mark II body (Canon
Inc., Tokyo, Japan). Photographs were obtained for both eyes in
98%, 98%, 85%, and 92% at the baseline, 5-, 10-, and 15-year
examinations, respectively, and for at least 1 eye in 99%, 99%,
87%, and 92% at the baseline, 5-, 10-, and 15-year examinations,
respectively. Diet was assessed from a self-administered food
frequency questionnaire completed by participants at each exami-
nation. Blood samples were collected from participants at the
BMES II and III examinations, and DNA extraction and geno-
typing were performed in >80% of these BMES participants.
Photographic Grading
Retinal photographic grading was performed by 2 senior graders and
closely followed the Wisconsin Age-Related Maculopathy Grading
System protocol.15 As previously described, ﬁlm fundus
photographs were initially graded in a masked manner, and side-
by-side grading between BMES I and II, and BMES I and III was
performed subsequently for participants with AMD lesions identi-
ﬁed after each follow-up examination.9,14 Inter- and intra-grader
reliability showed good agreement for AMD grading, with
quadratic weighted kappa values ranging from 0.64e0.93 and
0.54e0.94, respectively.14 Adjudication was provided by a senior
retinal specialist (P.M.) if needed. The BMES IV digital retinal
photographs were graded in the same masked manner using the
grading software DH Client (Digital Healthcare: Image
Management Systems, www.digital-healthcare.com, Cambridge,
UK). Consensus on BMES incident late AMD cases was provided
by lead investigators of the Three Continent AMD Consortium.16
Late AMD was deﬁned as the presence of neovascular AMD,
indicated by retinal pigment epithelial or neurosensory subretinaldetachment, retinal or subretinal hemorrhage, subretinal ﬁbrosis or
old atrophic disciform scars, or photocoagulation scars with a
history of neovascular AMD, or the presence of pure geographic
atrophy (GA) within the macula, as described in the International
Age-Related Maculopathy Classiﬁcation.17 Early AMD was
deﬁned as the presence of large (125 mm in diameter) indistinct
soft drusen, reticular drusen, or the copresence of large distinct
soft drusen and retinal pigmentary abnormalities (hyperpigmenta-
tion or depigmentation of retinal pigment epithelial cells), within
the macula, in the absence of any late AMD lesions. The maximal
diameter of individual drusen and collective macular areas
involved by drusen and pigmentary abnormalities within the eye
was estimated as speciﬁed in the Wisconsin Age-Related Macul-
opathy Grading System, using circles with diameters of 63 mm, 125
mm, 250 mm, 350 mm, and 644 mm, 0.5 or 1 disc area.15
Deﬁnition of Age-Related Macular Degeneration
Incidence in the First Eye
Incident late AMD in the ﬁrst eye was deﬁned as the appearance of
neovascular AMD or GA in either eye at any follow-up exami-
nation when the lesion was not present in either eye at baseline. For
participants at risk of incident neovascular AMD, cases with this
lesion at baseline were excluded but cases with GA at baseline
were not excluded. Participants with GA or neovascular AMD at
baseline and with neovascular AMD at follow-up were excluded
from those at risk of incident GA. If GA was secondary to neo-
vascular AMD or laser treatment of neovascular AMD, it was not
considered as incident GA.
The BMES participants who developed late AMD during the
follow-up period were all seen by the principal investigator of the
BMES (PM) for conﬁrmation and were treated and followed at the
Eye Clinic, Westmead Hospital. These participants also were
labeled using BMES identiﬁcation numbers in their patient records
and were included as incident late AMD cases.
Incident early AMD was deﬁned as the appearance of indistinct
soft or reticular drusen, or the co-presence of distinct soft drusen
and retinal pigmentary abnormalities in either eye, at any follow-up
examination where no late or early AMD was present in either eye
at baseline. Participants with distinct soft drusen or retinal
pigmentary abnormalities alone at baseline who later developed
complementary lesions that comprised a diagnosis of early AMD
were included as incident early AMD cases. Incidence of indistinct
soft or reticular drusen was deﬁned as the appearance of these le-
sions in either eye at follow-up visits, where none were present at
baseline, and excluding late AMD, regardless of the presence of
retinal pigmentary abnormalities. Incidence of retinal pigmentary
abnormalities was deﬁned as the appearance of these abnormalities
in either eye at follow-up visits in participants with no pigment
abnormalities at baseline and no late AMD at any follow-up visits.
Other Study Outcomes
The incidence of early and late AMD in the second eye of par-
ticipants with unilateral early or late AMD at baseline and the
progression from early AMD to late AMD in at least 1 eye over 15
years were assessed among persons with AMD in 1 or both eyes at
baseline.
Genotyping
Genotyping was performed on the BMES cohort and the BMES
Extension Survey (1999e2000) samples using an Illumina Human
670-Quad custom array version 1 (Illumina Inc., San Diego, CA) with
stringent quality-control testing using PLINK (Purcell S. PLINK
version 1.07. Available at: http://pngu.mgh.harvard.edu/purcell/plink/,2483
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ciation scan data were imputed with the 1000 Genomes panel
(Version 1), using IMPUTE 2.0 (Department of Statistics, University
of Oxford, Oxford, UK).18 The imputation r2 was 0.968 for
complement factor H (CFH)-rs1061170 and 0.996 for age-related
maculopathy susceptibility 2 (ARMS2)-rs104900924.
The CFH single nucleotide polymorphism (SNP) rs1061170
was also genotyped in 1928 participants using TaqMan assays
(Applied Biosystems, Foster City, CA)19 and the ARMS2 SNP
rs10490924 was genotyped in 638 participants using restriction
fragment length polymorphism analysis.20 In this report of the
BMES cohort sample, we used typed SNPs when this information
was available and imputed SNPs for the remaining participants.
Other Risk Factors
Participants were classiﬁed as nonsmokers if they answered “no” to
the question whether they smoke regularly. Past smoking was
deﬁned if participants had smoked regularly but quit smoking more
than 1 year before the examination. Current smoking was deﬁned if
participants were current smokers or had stopped smoking <1 year
before the examination. Regular ﬁsh consumption was deﬁned as
consuming 1 serving of ﬁsh per week.
Statistical Analyses
SAS software version 9.3 (SAS Inc, Cary NC) was used for ana-
lyses. The 15-year person-speciﬁc incidence of early and late AMD
and their component lesions were estimated using KaplaneMeier
product limit survival estimates and, alternatively, competing risk
analyses to control for the risk of death. The BMES population was
also directly age-standardized to the BDES population11 to
compare 15-year AMD incident rates between the 2 populations.
Further, the probabilities of late AMD development from different
severity levels of AMD over 15 years were reported according to
steps on the AREDS simpliﬁed severity scale.21
The associations between known AMD risk factors (age, sex,
smoking, ﬁsh consumption, the CFH-rs1061170 and ARMS2-
rs10490924 risk alleles) and the 15-year incidence of early and
late AMD were assessed using age-, sex-, and multivariate-
adjusted discrete logistic regression models. Generalized esti-
mating equation models, using the GENMOD procedure in SAS,22
were applied to eye-speciﬁc data to assess the associations between
incidence of late AMD and early AMD lesion characteristics (area
and location of drusen and retinal pigmentary abnormality). For
comparison, the association between 15-year incident late AMD
and steps on the AREDS simpliﬁed severity scale21 was also
assessed using the GENMOD procedure applied to person-
speciﬁc data, with time intervals included in the model. Associa-
tion estimates are presented as age-, sex-, and smoking-adjusted or
multivariable-adjusted (age, sex, smoking, ﬁsh consumption, the
CFH-rs1061170 and ARMS2-rs10490924 risk alleles) odds ratios
(ORs) and 95% conﬁdence intervals (CIs).
Results
We included participants who were censored up to the 5-, 10-, or
15-year follow-up examination to estimate incidence. Of 3654
baseline participants, 854 (23.4%) died with no follow-up infor-
mation available and 326 (8.9%) were lost to follow-up and had no
retinal photographs available at all 3 time points, leaving 2474
(67.7%) with gradable retinal photographs who were examined at
the 5-, 10-, or 15-year examination, or 2 or all 3 examinations. Of
these 2474 participants, 574 (23.2%), 75 (3.0%), and 7 (0.3%)
were seen only at 5-, 10-, or 15-year examination, respectively; 7892484(31.9%) were seen at 2 of the examinations (5- and 10-year, 5- and
15-year, or 10- and 15-year examinations); and 1029 (41.6%) were
seen at all 3 examinations.
Table 1 compares the baseline characteristics between
participants examined at either or all of the 5-, 10-, or 15-year
examinations (n ¼ 2474) and those who were alive but not
examined at any follow-up examination (n ¼ 326) or those who
died (n¼854) without reexamination in the BMES cohort.
Compared with those who were followed, those who were lost to
follow-up were more likely to have been younger at baseline (mean
age, 60.6 vs. 64.3 years), to have a lower socioeconomic status
(deﬁned by homeownership and trade or higher qualiﬁcation), and
to be current smokers (22.5% vs. 13.1%), but less likely to have a
history of heart disease (7.7% vs. 14.4%). Histories of stroke,
cancer, diabetes, hypertension, and self-ranked health were not
signiﬁcantly different among those examined versus those not
examined. Participants who died without attending any follow-up
were on average 10 years older and more likely to be living
alone, to have walking disabilities and systemic diseases, and to
use community services at baseline (Table 1).
The 15-year incidence of early- and late-stage AMD lesions
by age and sex is presented in Table 2. There was an increased
15-year incidence of late AMD associated with older age.
Although a similar increase was observed for early AMD
including up to 80 years of age, the 15-year incidence of early
AMD, particularly incidence of indistinct or reticular drusen,
decreased in those aged 80 years at baseline. The 15-year
incidence of both early AMD and neovascular AMD was
higher in women compared with men. After adjusting for gender,
age was strongly associated with incidence of early and late
AMD lesions (both P < 0.0001).
The 15-year incidence of early and late AMD in the BMES
population, after adjusting for the competing risk of death, was
15.1% and 4.1%, respectively. By using the competing risk
method, the BMES early and late AMD incidence rates were age
standardized to that of the BDES population. We found similar
age-standardized incident rates of early AMD (13.1%; 95% CI,
11.7e14.6, vs. 14.3%, estimated 95% CI, 13.1e15.5) and late
AMD (3.3%, 95% CI, 2.6e4.0, vs. 3.1%, estimated 95% CI,
2.6e3.6) over 15 years in the BMES when compared with the
corresponding incidence rates in the BDES population.11
The AREDS simpliﬁed severity scale was applied to the
BMES baseline AMD status, and the probabilities of developing
late AMD over 15 years from various levels in the scale are
shown in Table 3. The 15-year incidence of late AMD among
persons at Step 0 at baseline ranged from 1.2% to 4.5%; at Steps
1, 2, and 3, the 15-year incidence of late AMD ranged from 4.5%
to 12.0%, 21.1% to 41.7%, and 0.0% to 33.3%, respectively.
Corresponding incidence among persons at Step 4 (baseline) was
76.5% (Table 3).
After controlling for the competing risk of death, the cumulative
incidence of early AMD in the second eye of persons with early
AMD in the ﬁrst eye was 67.0% over the follow-up period. The
corresponding incidence of late AMD in the second eye of persons
with late AMD in the ﬁrst eye was 35.4% and of those with early
AMD in the ﬁrst eye was 24.6%.
Known AMD risk factors associated with 15-year incident early
and late AMD are listed in Table 4. In the age-sex adjusted model,
2 risk alleles of CFH-rs1061170 (OR, 2.8) and either 1 or 2 risk
alleles of ARMS2-rs10490924 (ORs, 1.6e2.6) were associated
Table 2. Fifteen-Year Incidence* of Late and Early Age-Related Macular Degeneration Lesions by Age and Sex
Incident AMD Lesions
Age at Baseline (Yrs)
Women Men<60 60e69 70e79 80 All Ages
No. at
Risk
Incidence
(%)
No. at
Risk
Incidence
(%)
No. at
Risk
Incidence
(%)
No. at
Risk
Incidence
(%)
No. at
Risk
Incidence
(%)
Incidence
(%)
Incidence
(%)
GA 774 0.4 960 2.1 519 9.5 102 19.3 2355 2.6 2.5 2.8
Neovascular AMD 778 0.7 988 4.8 547 12.9 108 13.8 2421 4.4 5.2 3.3
Any late AMD 778 1.1 988 6.8 547 20.2 108 27.3 2421 6.8 7.5 6.0
Early AMD 737 8.7 855 26.9 388 51.4 56 29.3 2036 22.7 25.7 18.4
Indistinct/reticular drusen 755 7.1 918 21.0 440 40.3 72 19.2 2185 18.1 21.5 13.5
Pigmentary abnormality 729 21.4 871 32.4 440 48.7 83 42.6 2124 31.1 32.1 29.6
AMD ¼ age-related macular degeneration; GA ¼ geographic atrophy.
*Using KaplaneMeier estimates incorporating persons censored up to the 5-, 10-, and 15-year examinations.
Table 1. Comparison of Baseline Characteristics between Participants Examined and Not Examined at 15 Years in the Blue Mountains
Eye Study Cohort
Baseline Characteristics Examined (n [ 2474) Not Examined or No Photographs (n [ 326) P Value* Died (n [ 854)
Mean age (yrs) (95% CI) 64.3 (64.0e64.7) 60.6 (59.8e61.5) <0.0001 73.7 (73.1e74.4)
Age group % % %
<60 yrs 31.6 50.3 <0.0001 8.7
60e69 yrs 40.7 35.0 0.05 22.1
70e79 yrs 22.9 13.5 0.0001 41.0
80 yrs 4.8 1.2 0.003 28.2
Women 57.6 63.5 0.04 51.5
Currently married 66.1 62.0 0.1 53.0
Home owner 91.1 82.4 <0.0001 83.8
Low job prestige 36.3 37.4 0.7 42.5
Trade or higher qualiﬁcation 60.6 55.3 0.08 51.2
Living alone 25.5 24.2 0.6 34.6
Walking disability 3.3 3.4 1.0 20.4
Regular use of community services 3.7 4.6 0.4 15.8
Self-ranked health
Excellent 21.8 20.9 0.7 13.8
Good 57.1 56.7 0.9 47.4
Fair 18.9 18.4 0.8 29.8
Poor 2.2 4.1 0.04 9.0
History of stroke 3.3 3.1 0.8 12.1
History of heart disease 14.4 7.7 0.0009 24.3
History of cancer 7.4 6.1 0.4 12.5
History of diabetes 6.3 8.6 0.1 11.6
Presence of hypertension 70.0 66.6 0.2 78.2
Smoking status
Never 85.6 75.9 <0.0001 80.6
Past 1.3 1.6 0.6 1.3
Current 13.1 22.5 <0.0001 18.1
Fish consumption (1 serving/wk) 59.4 62.0 0.4 60.2
CFH-rs1061170
TT 39.3 25.0 0.5y 20.0
CT 46.7 75.0 60.0
CC 14.0 0.0 20.0
ARMS2-rs10490924
GG 61.8 25.0 0.2y 50.0
GT 34.0 75.0 50.0
TT 4.3 0.0 0.0
ARMS2 ¼ age-related maculopathy susceptibility gene 2 (T risk allele); CFH ¼ complement factor H (C risk allele); CI ¼ conﬁdence interval.
*P value for difference between participants examined and not examined (or had no photographs), excluding those who had died.
yUnadjusted tests for heterogeneity used to calculate P values.
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Table 3. Number and Proportion of Participants Who Developed Late Age-Related Macular Degeneration over 15 Years by Levels of the
Age-Related Eye Disease Study Simpliﬁed Severity Scale for Age-Related Macular Degeneration at Baseline
Drusen Size and No. of Eyes
Pigment Abnormality
None (C1) 1 Eye (C2) 2 Eyes (C3)
No. of Events/
No. of Subjects %*
No. of Events/
No. of Subjects %* No. of Events/No. of Subjects %*
None or small, only 1 or both eyes (R1) 19/1573 1.2 (0.6) 3/67 4.5 (1.5) 4/19 21.1 (21.1)
Intermediate, 1 eye (no large) (R2) 10/224 4.5 (2.7) 3/25 12.0 (4.0) 5/12 41.7 (36.4)
Intermediate, both eyes (no large) (R3) 6/55 10.9 (7.4) 3/10 30.0 (20.0) 0/4 0.0 (0.0)
Large, 1 eye (R4) 7/61 11.5 (8.1) 4/14 28.6 (28.6) 5/26 19.2 (11.5)
Large, both eyes (R5) 5/18 27.8 (27.8) 3/9 33.3 (33.3) 13/17 76.5 (70.6)
AREDS Step 0 ¼ R1C1 and R2C1; no retinal pigment changes with no or small hard drusen in 1 or both eyes or intermediate (but not large) drusen in 1 eye
only.
AREDS Step 1¼ R1C2, R2C2, R3C1, and R4C1; pigment changes in 1 eye with small hard drusen in 1 or both eyes or intermediate drusen in 1 eye only/no
pigment changes in either eye but intermediate drusen in both eyes or large drusen in 1 eye.
AREDS Step 2 ¼ R1C3, R2C3, R3C2, R4C2, and R5C1; pigment changes in both eyes with small hard drusen in 1 or both eyes or intermediate drusen in 1
eye only/pigment changes in 1 eye with intermediate drusen in both eyes or large drusen in 1 eye/no pigment changes in either eye but large drusen in both
eyes.
AREDS Step 3 ¼ R3C3, R4C3, R5C2; pigment changes in both eyes with intermediate drusen in both eyes or large drusen in 1 eye/pigment changes in 1
eye with large drusen in both eyes.
AREDS Step 4 ¼ R5C3; pigment changes in both eyes with large drusen in both eyes.
*The BMES 10-year incidence rates are in parentheses.
Ophthalmology Volume 122, Number 12, December 2015with a greater risk of 15-year incident early AMD. There was no
signiﬁcant association between smoking or ﬁsh consumption and
15-year early AMD incidence. Current smoking at baseline and the
presence of at least 1 risk allele of CFH-rs1061170 (ORs, 1.9e3.8)
or ARMS2-rs10490924 (ORs, 1.8e4.9) were signiﬁcantly associ-
ated with an increased risk of 15-year incident late AMD.
Conversely, the incidence of late AMD was signiﬁcantly reduced
among persons who consumed 1 serving of ﬁsh per week
(OR, 0.5) compared with those who consumed ﬁsh less than
weekly. These associations remained signiﬁcant after multivariable
adjustment as shown in Table 4.Table 4. Common Age-Related Macular Degeneration Risk Facto
Age-Related Macula
Risk Factor
15-Year I
Early AMD
Age- and Sex-Adjusted
OR (95% CI)
Multiv
OR
Age, per 10 yrs 1.12 (1.10e1.14) 1.11
Sex (male) 0.70 (0.55e0.90) 0.66
Smoking (current) 1.14 (0.74e1.73) 1.45
CFH-rs1061170
TT 1.00
CT 1.18 (0.88e1.59) 1.08
CC 2.81 (1.97e4.00) 2.56
ARMS2-rs10490924
GG 1.00
GT 1.63 (1.24e2.14) 1.53
TT 2.58 (1.38e4.81) 2.16
Fish consumption (1 servings/wk) 0.90 (0.69e1.17) 0.92
ARMS2 ¼ age-related maculopathy susceptibility gene 2 (T risk allele); CFH ¼ com
*Multivariable-adjusted logistic regression model including age, sex, smoking, C
2486Table 5 presents the eye-speciﬁc associations between the
baseline early AMD lesion characteristics and the 15-year
incidence of late AMD. After adjusting for age, sex, and
smoking, the presence of large drusen (OR, 7.0), indistinct soft
drusen (OR, 19.3), drusen location closer to the foveal center
(OR, 7.3e21.0), and larger drusen area (OR, 7.2e30.9) were
highly predictive of the late AMD development. Likewise, the
presence of retinal pigmentary abnormalities (OR, 6.6) was
associated with an increased risk of late AMD, as was each
step increment in the AREDS 5-Step scale (ORs, 4.8e169.4).
These associations remained after further adjustment for ﬁshrs Associated with 15-Year Incidence of Early and Late Stage
r Degeneration
ncidence of Age-Related Macular Degeneration
Late AMD
ariable-Adjusted
(95% CI)*
Age- and Sex-Adjusted
OR (95% CI)
Multivariable-Adjusted
OR (95% CI)*
(1.09e1.14) 1.17 (1.13e1.20) 1.20 (1.16e1.25)
(0.48e0.90) 0.77 (0.50e1.16) 0.80 (0.48e1.32)
(0.90e2.36) 3.96 (2.31e6.80) 3.63 (1.86e7.06)
1.00 1.00 1.00
(0.78e1.51) 1.91 (1.12e3.29) 2.25 (1.22e4.15)
(1.71e3.84) 3.77 (2.03e6.99) 4.45 (2.19e9.03)
1.00 1.00 1.00
(1.12e2.08) 1.79 (1.14e2.80) 2.59 (1.56e4.31)
(1.07e4.37) 4.88 (2.06e11.55) 5.81 (2.09e16.12)
(0.68e1.24) 0.45 (0.29e0.71) 0.48 (0.29e0.79)
plement factor H (C risk allele); CI ¼ conﬁdence interval; OR ¼ odds ratio.
FH, ARMS2 polymorphisms, and ﬁsh consumption.
Table 5. The 15-Year Risk of Late Age-Related Macular Degeneration by Baseline Early Age-Related Macular Degeneration
Characteristics
Baseline Early AMD Lesion Characteristics*
Crude Late AMD Incidence (%) Age-, Sex-, and
Smoking-Adjusted
OR (95% CI)
Multivariable-Adjusted
OR (95% CI)y5 Years 10 Years 15 Years
Eye-Speciﬁc
Maximum drusen size
None or <125 mm 0.5 3.1 3.0 1.0 1.0
125 mm 13.0 39.7 14.3 7.0 (4.0e12.2) 7.4 (4.0e14.0)
Drusen type
None or small drusen <125 mm 0.5 2.9 3.0 1.0 1.0
Distinct soft drusen 1.3 11.5 3.7 1.3 (0.5e3.9) 1.6 (0.5e5.1)
Indistinct soft drusen 22.6 62.5 50.0 19.3 (9.7e38.6) 21.4 (9.4e48.5)
Drusen location
None or <63 mm with an area <250 mm in diameter 0.3 2.0 2.5 1.0 1.0
1500e3000 mm from foveal center 1.0 2.6 5.9 1.0 (0.3e2.8) 1.4 (0.5e4.3)
500e1500 mm from foveal center 9.3 39.3 21.4 7.3 (3.7e14.5) 8.2 (3.7e18.2)
Within 500 mm radius of foveal center 17.8 51.2 50.0 21.0 (10.7e41.0) 18.5 (8.7e39.2)
Drusen area
None or <375 mm in diameter 0.5 2.9 3.0 1.0 1.0
375 mm in diameter to <0.5 disc area 7.0 34.8 16.7 7.2 (3.2e16.3) 7.9 (3.2e19.7)
0.5 disc area 30.0 79.0 66.7 30.9 (13.8e69.2) 33.0 (12.3e88.4)
Retinal pigmentary abnormality
Absent 0.4 3.4 2.8 1.0 1.0
Present 10.9 34.6 13.1 6.6 (3.9e11.1) 7.2 (4.1e12.8)
Person-Speciﬁc
AREDS simpliﬁed AMD severity scale
Step 0z 0.2 1.8 1.9 1.0 1.0
Step 1x 2.4 9.0 13.3 4.8 (2.5e9.3) 7.8 (3.6e17.0)
Step 2k 11.0 50.0 10.5 12.6 (6.2e25.6) 15.2 (6.8e34.0)
Step 3{ 12.8 9.1 22.2 10.1 (3.5e28.8) 13.1 (3.3e52.1)
Step 4# 47.1 80.0 100.0 169.4 (55.2e519.9) 119.4 (24.6e580.5)
AMD ¼ age-related macular degeneration; AREDS ¼ Age-Related Eye Disease Study; CI ¼ conﬁdence interval; OR ¼ odds ratio.
*Assessed within the anatomic macular area (within 3000 mm radius of the foveal center).
yMultivariable ORs adjusted for age, sex, smoking status, CFH-rs1061170, ARMS2-rs10490924, and ﬁsh consumption.
zNo retinal pigment changes with no or small hard drusen in 1 or both eyes or intermediate (but not large) drusen in 1 eye only.
xPigment changes in 1 eye with small hard drusen in 1 or both eyes or intermediate drusen in 1 eye only/no pigment changes in either eye but intermediate
drusen in both eyes or large drusen in 1 eye.
kPigment changes in both eyes with small hard drusen in 1 or both eyes or intermediate drusen in 1 eye only/pigment changes in 1 eye with intermediate
drusen in both eyes or large drusen in 1 eye/no pigment changes in either eye but large drusen in both eyes.
{Pigment changes in both eyes with intermediate drusen in both eyes or large drusen in 1 eye/pigment changes in 1 eye with large drusen in both eyes.
#Pigment changes in both eyes with large drusen in both eyes.
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polymorphisms.Discussion
We found an overall 15-year incidence of 22.7% for early
AMD and 6.8% for late AMD in persons aged 49 years or
more in this older Australian cohort. After adjusting for the
competing risk of death, the incidence of early and late
AMD was 15.1% and 4.1%, respectively. The 15-year
incidence of late AMD or late AMD lesions increased
with increasing age, but the incidence of early AMD
decreased in persons 80 years of age or older at baseline.
Women had a higher 15-year incidence of any AMD
compared with men.
Our study is one of very few studies to report the long-
term (>10 years) incidence of AMD from an olderpopulation-based cohort. The Copenhagen City Eye Study13
reported the 14-year incidence of early and late AMD as
31.5% and 14.8%, respectively, considerably higher than
our incidence estimates observed in the BMES. The older
age range (60e80 years) of the Copenhagen study sample
and the low 14-year follow-up rate of 38%13 could explain
the relatively high incidence found in this study. In the
BDES, the 15-year early AMD incidence was 14.3%,
whereas the late AMD incidence was 3.1%,11 comparable to
our 15-year incidence estimates in the BMES after age
standardization to the BDES population.
We found that the overall 15-year incidence of both
early and late AMD was substantially higher compared
with the 10-year incident rates in the BMES cohort.
However, the 15-year incidence of early AMD was rela-
tively lower among participants aged 80 years or older,
dissimilar to previous ﬁndings of 10-year early AMD
incidence in the same cohort.10 The lower incidence in this2487
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low number of subjects who were at risk of early AMD at
this age.
The AREDS simpliﬁed severity scale was previously
validated using the 10-year incidence of late AMD data
from the BMES.10 We found that the probabilities of
developing late AMD by baseline AREDS scale Steps
0 and 1 over 15 years were twice as high as the 10-year
late AMD incidence from the same steps, whereas the
probabilities of developing late AMD by baseline AREDS
scale Steps 2, 3, or 4 (when both eyes had large soft drusen
or retinal pigmentary changes) over 15 years were some-
what similar to the 10-year late AMD incident rates.10 This
observation could suggest that the time needed for
progression from severe early AMD to late AMD likely
may be within 10 years or less, whereas the duration of
15 years is more applicable to those with less severe
stages of early AMD at baseline.
Second-eye incidence of late AMD has been reported in a
number of clinic-based studies.23e26 In the BMES, we
found a substantially higher incidence of early or late AMD
in the second eye of persons with early or late AMD in the
ﬁrst eye at baseline. This is comparable to previous obser-
vations in the BDES, which reported a 39% second-eye
incidence of late AMD in those with unilateral late AMD at
baseline.11
We previously demonstrated that the incidence of spe-
ciﬁc early AMD lesions and late AMD was greater in
women compared with men.9,10 Although we found a
similar pattern in this report, the association between female
sex and 15-year incident AMD was only signiﬁcant for early
but not for late AMD. We also found that current smoking at
baseline was signiﬁcantly associated with incident late but
not incident early AMD over 15 years. This is in keeping
with previous ﬁndings from the BMES and other studies of
white populations, including the Rotterdam study.12,27e29
Weekly ﬁsh consumption of at least 1 or more servings
was associated with a reduced risk of late but not early
AMD over the 15-year follow-up period. Similar ﬁndings
were reported in a meta-analysis of pooled data from 9
studies, in that ﬁsh intake at least twice a week was asso-
ciated with reduced risks of early and late AMD.30
Consistent with genetic knowledge of AMD, 2 risk alleles
of CFH and 1 or 2 risk alleles of ARMS2 were
signiﬁcantly associated with increased risk of early and
late AMD over the longer term, with a greater risk
magnitude for late AMD.31
Increasing severity of baseline early AMD lesions,
including larger drusen size (125 mm), drusen location
closer to the fovea, larger area involved by drusen, and the
presence of retinal pigment epithelial abnormalities, has
been well recognized to predict the incidence of late
AMD.6,7,10,11 We also previously reported a high risk of
developing GA from eyes with indistinct soft and reticular
drusen, central location, and larger area involved by drusen
over 15 years.32 These associations were generally
consistent across the 10- and 15-year AMD incidence,
although with different risk magnitude: Magnitude of the
risk of late AMD associated with baseline early AMD lesion
characteristics was higher for the 10-year than for the248815-year incidence, particularly so for central location of soft
drusen. This observation may suggest that early AMD
characteristics are indicative of a more severe stage likely
leading to late AMD within 10 years rather than 15 years.
Study Limitations
We were able to follow approximately 75% of survivors of
this older cohort at the 5- and 10-year visits. However,
follow-up rate reduced to only 56% by the time the 15-year
examinations were performed. This could have introduced
selection bias due to selective follow-up and survival. Per-
sons who died were older and more likely to have chronic
systemic conditions and disabilities. Participants who were
lost to follow-up were likely to have been younger (mean
age, 61 vs. 64 years) and more likely to smoke (23% vs.
13%) at baseline. It is thus likely that our estimates of the
15-year incidence of AMD could have been underestimated,
although the “true incidence” would not be more useful than
the current estimate, because only those who survived
demand eye health and aged care services.
Strengths of this study include the relatively long-term
follow-up of a population-based cohort, the use of retinal
photographs to document macular conditions, and a vali-
dated AMD grading system to assess the size and location of
AMD lesions. A major limitation of our study is the sub-
stantial number of participants lost to follow-up at the
15-year visit, as mentioned previously. A further limitation
includes the lack of high-resolution imaging (e.g., spectral-
domain optical coherence tomography), unavailable at the
time of the BMES examinations, which might have
increased the ability to detect some AMD lesions, such as
early-stage GA.
In summary, we documented the 15-year incidence of
early and late AMD in an older Australian cohort, particu-
larly among persons with no lesions or only early-stage
lesions at baseline. Our incidence rates for early and late
AMD were comparable to those reported in the BDES
population over the same follow-up period. Current smok-
ing at baseline was a stronger risk factor for 15-year inci-
dence of late AMD than early AMD.
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Incidence and Progression of Geographic
Atrophy
Observations from a Population-based Cohort
Nichole Joachim, BSc (Hons),1 Paul Mitchell, MD, PhD,1 Annette Kiﬂey, MBBS, MAppStat,1
Elena Rochtchina, MAppStat,1 Thomas Hong, BAppSci, MScMed,1 Jie Jin Wang, MMed, PhD1,2
Purpose: To examine early age-related macular degeneration (AMD) lesion characteristics and risk factors
associated with the long-term development and progression of geographic atrophy (GA).
Design: Population-based cohort.
Participants: Of 3654 participants aged 49 years in the Blue Mountains Eye Study, 75.8%, 76.7%, and
56.1% of survivors attended the 5-, 10-, and 15-year follow-up examinations, respectively.
Methods: Retinal photographs were taken at each visit. Incident GA was conﬁrmed using a side-by-side
grading method. Computer planimetry was used to measure the area involved by GA. Fast and slow/normal
progression rates were deﬁned as GA area enlargement by 2 and <2 mm2/year, respectively. Incident GA was
estimated using the KaplaneMeier product-limit method. Early AMD lesion characteristics were assessed for
association with GA incidence using eye-speciﬁc data and generalized estimating equation models adjusting for
age, current smoking, and presence of risk alleles of the complement factor H (CFH) or age-related maculopathy
susceptibility 2 (ARMS2) genes, genotyped or imputed using genome-wide scan data.
Main Outcome Measures: Incidence and progression of GA.
Results: By excluding 41 subjects with GA at baseline, of 2503 participants at risk of GA, incident pure GA
(without coexisting neovascular AMD lesions) was conﬁrmed in 57 participants, with a 15-year incidence of 3.6%.
Baseline early AMD lesion characteristics associated with GA incidence included drusen type (soft indistinct:
odds ratio [OR], 59.0; 95% conﬁdence interval [CI], 20.4e171.0; reticular drusen: OR, 13.9; 95% CI, 4.0e47.6);
drusen location within a 500-mm radius of the fovea (OR, 15.1; 95% CI, 7.4e30.8); drusen area greater than 375
mm in diameter (OR, 10.1; 95% CI, 4.0e25.6); presence of retinal pigment epithelial depigmentation (OR, 9.0; 95%
CI, 4.1e19.8); or hyperpigmentation (OR, 12.0; 95% CI, 6.1e23.5), referenced to subjects with no or hard drusen
only. Fast progression was more frequent among current smokers at baseline, subjects with the CFH or ARMS2
risk genotypes, and pseudophakic eyes.
Conclusions: Early AMD lesion characteristics (type, location, area involved) were strongly associated with
higher long-term risk of developing GA independent of age, smoking, and AMD genetic susceptibility from the
CFH or ARMS2 genes. Known AMD risk factors also were more frequently present among quickly progressing GA
cases.
Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references.
Ophthalmology 2013;120:2042-2050 ª 2013 by the American Academy of Ophthalmology.Geographic atrophy (GA) is 1 of 2 types of age-related
macular degeneration (AMD) and is characterized by
a sharply deﬁned area of retinal pigment epithelium (RPE)
degeneration in which choroidal blood vessels are visible.1
It accounts for approximately 35% to 40% of late-stage
AMD cases.2 There is currently no effective treatment
for GA, and once the foveal center is involved, affected
patients are deprived of central vision and may develop
legal blindness.3e5
Although the short-term (e.g., 2e5 years) incidence of
GA is available from population-based studies,6e9 there are
limited data available on long-term incidence (over 10 to
15 years). Two large population-based studies with long-
term follow-up, the Beaver Dam Eye Study (BDES) and
the Blue Mountains Eye Study (BMES), reported that the
10-year incidence of pure GA was 0.8%10 and 1.7%,112042  2013 by the American Academy of Ophthalmology
Published by Elsevier Inc.respectively. The 15-year incidence of pure GA in the
BDES was 1.3%.12 In both studies, the presence of large
drusen and retinal pigmentary abnormalities was found to
be associated with increased long-term incidence of late
AMD, including GA and neovascular AMD.10,11,13,14
However, population-based data for the associations of
early AMD lesions with long-term incidence of pure GA are
limited.
The natural history and progression of GA have been
assessed in both the BDES and BMES populations4,15 and
clinic-based cohort studies.16,17 Larger atrophic areas at
baseline were found to be associated with fast progression of
GA lesions,3,16 and the shape of the atrophic area, termed
“GA conﬁguration” (classic, multifocal, and merged), also
appears to have different progression rates.4 In a previous
BMES report, 5-year progression of GA occurred in 43%ISSN 0161-6420/13/$ - see front matter
http://dx.doi.org/10.1016/j.ophtha.2013.03.029
Joachim et al  Incidence and Progression of GAof eyes with GA at baseline, where GA progression was
deﬁned as an increase in the atrophic area by 2 subﬁelds of
the Wisconsin grading grid or by extension of atrophy into
the foveal center without quantitative measures.15
This report examines the 15-year incidence of pure GA
and associations of early AMD lesion characteristics with
GA incidence in the BMES cohort. We also assess the 5-year
GA progression rate, indicated by quantitative measures of
the size of atrophic areas and GA involvement with respect
to the fovea, and explore factors associated with fast versus
slow progression of prevalent and incident cases of pure GA.Methods
Study Population
The BMES is a population-based cohort study of vision and eye
disease in persons aged 49 years or older residing in the Blue
Mountains region west of Sydney, Australia.18,19 The baseline
study recruited and examined 3654 participants (82.4% of those
eligible) between 1992 and 1994 (BMES I). Of these, 2334
participants (75.8% of survivors) attended the 5-year follow-up
examinations (1997e1999; BMES II). The 10-year (2002e2004;
BMES III) and 15-year (2007e2009; BMES IV) follow-up
examinations were attended by 1952 participants (76.7% of
survivors) and 1149 participants (56.1% of survivors), respectively.
All examinations were approved by the Western Sydney Area
Health Service and University of Sydney Human Research Ethics
Committees and adhered to the tenets of the Declaration of Hel-
sinki. Written informed consent was obtained from all participants.
At each visit, a comprehensive questionnaire was administered
and eye examinations were performed, as previously described.18
This included 30 stereoscopic retinal fundus photographs of the
macula and other retinal ﬁelds of both eyes using a Zeiss FF3
fundus camera (Carl Zeiss, Oberkochen, Germany) at the BMES
I, II, and III examinations and 40 degree digital photographs
with a Canon CF-60 DSi (Canon Inc., Tokyo, Japan) at the
BMES IV examination. Visual acuity was assessed following the
Early Treatment Diabetic Retinopathy Study protocol.19 Blood
samples were collected at the BMES II examination. DNA
extraction and genotyping were performed in more than 80% of
the BMES participants.
Photographic Grading
The details of photographic grading have been reported else-
where18 and closely followed the Wisconsin Age-Related Macul-
opathy Grading System (WARMGS) protocol.1 For this report,
side-by-side grading of retinal photographs of each subject taken
at the BMES I, II, III, and IV was performed to conﬁrm incident
pure GA cases. Incident pure GA was deﬁned as the ﬁrst appear-
ance of GA in either eye of subjects who had no sign of GA at the
previous visit and no neovascular AMD (including pigment
epithelial or sensory subretinal detachment, retinal or subretinal
hemorrhage, subretinal ﬁbrosis or old atrophic disciform scars, or
photocoagulation scars) at all previous and current examinations.
All incident late AMD cases including incident GA cases also were
conﬁrmed by BMES, BDES, and Rotterdam Eye Study principal
investigators.
Circles of deﬁned diameters (63, 125, 250, 350, and 644 mm and
0.5 disc area, and 1 disc area) were used to estimate the size of
drusen, RPE depigmentation and hyperpigmentation, and the areas
involved by each lesion.1 The locations of lesions were deﬁned as
within 500 mm, between 500 and 1500 mm, and between 1500 and3000 mm radius of the foveal center, as deﬁned by the WARMGS
grid.1 The presence and absence of drusen and pigmentary
abnormalities were graded ﬁrst, followed by detailed grading of
size, location, and area of lesions. Early AMD was deﬁned as the
presence of large (>125-mm diameter), indistinct soft or reticular
drusen or both large distinct soft drusen and retinal pigmentary
abnormalities within the macular area.
Computer Planimetry
Geographic atrophy progression was assessed in both prevalent
(from baseline examination, BMES I) and incident pure GA cases
(detected at follow-up visits, BMES II or III) that had retinal
photographs available at subsequent visits. Progression was
measured as increasing size of the atrophic areas over 5 years from
one BMES examination to the next and converted to progression
rate in millimeters squared per year. The retinal photographs from
the BMES I, II, and III, on 35-mm ﬁlm, were scanned using
a CanoScan 5600F scanner (Canon Inc.) at 2400 dots per inch. The
digital format of the WARMGS grid was enlarged according to the
resolution of the scanned photographs using Adobe Photoshop
CS4 (Adobe Systems Inc., San Jose, CA) so that the measurements
could be performed digitally. The resolution of the grid was
amended according to the resolution of the BMES IV digital
photographs when used for images taken at the BMES IV.
A random sample of retinal photographs without pathology from
each BMES examination was used to obtain the scaling factor
(microns per pixel) using Photoshop. This was calculated by
dividing 4500 mm, taken as the constant distance between the
center of the optic disc to the center of the fovea, by the same
distance measured in pixels to obtain the number of microns per
pixel. This scale factor was then set into ImageJ software (Rasband
WS. ImageJ software [1997e2012]. Bethesda, MD: US National
Institutes of Health; available at: http://imagej.nih.gov/ij/; accessed
August 10, 2011) to allow measurements to be read in microns.
Tracings were made along the margin of GA and area measure-
ments were obtained using the “region of interest” manager.
Deﬁnition of Geographic Atrophy Progression
The average progression of GA was calculated using data from the
BMES, BDES,4 and Age-Related Eye Disease Study (AREDS)20
and was found to be an area between 1 and 2 mm2 per year. We
deﬁned this as the normal progression rate. If the GA progression
rate was greater than 2 mm2/year, this was deﬁned as fast
progression. If the GA progression rate was less than 1 mm2/year,
this was deﬁned as slow progression. Figure 1 shows examples of
cases with different progression rates.
The conﬁguration of GA has been used and described by
previous studies.4,21 The “classic” conﬁguration is deﬁned as a single
round atrophic area, the “multifocal” conﬁguration is deﬁned as 2 or
more areas of atrophy within the macula region, and the “merged”
conﬁguration is deﬁned as 2 or more initially separate areas
(multifocal) that subsequently amalgamated into a large irregular
atrophic area. We added a “mixed” conﬁguration in our report to
include eyes with 2 or more conﬁguration types described earlier.
Geographic atrophy progression was assessed using 2 indica-
tors: enlargement of the atrophic area and progression to involve
the fovea associated with worsened best-corrected visual acuity
(BCVA) in eyes that had not yet developed GA at the fovea when it
was ﬁrst detected.
Genotyping
The complement factor H (CFH) single nucleotide polymorphism
(SNP) rs1061170 and the age-related maculopathy susceptibility
2 (ARMS2) SNP rs10490924 were genotyped in 1874 and 5932043
Figure 1. Examples of the fast (A), normal (B), and slow (C) progression of geographic atrophy (GA) by enlargement of atrophic areas. Tracings around the
GA perimeter show the increase in area from the ﬁrst detection of GA (i) to 5 years (ii) and 10 years after the ﬁrst detection of GA (iii).
Ophthalmology Volume 120, Number 10, October 2013participants, respectively, usingTaqMan assays (AppliedBiosystems,
Foster City, CA)22 and restriction fragment length polymorphism
analysis.23 In the remaining subjects, imputed SNPs of these 2
genes were obtained from BMES genome-wide association scan
data with imputation. For the latter, genotyping was performed using
the Illumina Human 670-Quad custom array (version 1), and stringent
quality control was performedusing PLINK (PLINKv1.07.Available
at: http://pngu.mgh.harvard.edu/purcell/plink/. Accessed June 7,
2012).24 Imputation from the 1000 Genomes was performed using
IMPUTE 2.0.25 The imputation r2 was 0.968 for CFH-rs1061170
and 0.996 for ARMS2-rs10490924. In our study sample, 1501 and
509 participants had both typed and imputed rs1061170 and
rs10490924, respectively, and the concordance rates between typed
and imputed SNPs were 99.6% for rs1061170 and 99.2% for
rs10490924. Of 2503 participants used in our analyses, 151 had
rs1061170 imputed and 1287 had rs10490924 imputed.
Deﬁnition of Baseline Variables Associated with
Geographic Atrophy
Smoking history was obtained from an interviewer-administered
questionnaire. If participants answered “no” to smoking regu-
larly, they were classiﬁed as nonsmokers. If participants answered
“yes” and had given up smoking 1 year before the baseline
examination, they were classiﬁed as past smokers. Current smokers
were deﬁned as participants who currently smoked or stopped
smoking <1 year before baseline examinations. Regular ﬁsh
consumption was assessed from a food frequency questionnaire2044completed by participants and deﬁned as 1 or more servings per
week, compared with infrequent consumption (<1 serving per
week).
Statistical Methods
Analyses were performed using SAS version 9.1 (SAS Inc., Cary,
NC). Fifteen-year person-speciﬁc GA incidence was assessed using
KaplaneMeier product limit survival estimates, including overall
and incident rates by the AREDS simpliﬁed severity scale
(5 steps)26 according to baseline AMD levels. Estimates were then
recalculated after adjusting for the competing risk of death. The
traditional KaplaneMeier procedure assumes that participants
censored during the study, because of death or loss to follow-up,
remain at similar risk of developing GA as those who completed
the study (does not differentiate risk of GA between those who
died and those who survived). A competing risk approach takes
into account the probability of survival of participants between the
2 time points and the associated reduced risk of developing GA
among those who died; because they died before developing GA,
they are no longer at risk.
Associations between 15-year incidence of GA and common
AMD risk factors (age, current smoking status, sex, presence of
risk alleles of CFH-rs1061170 or ARMS2-rs10490924, and regular
ﬁsh consumption) were assessed using age-adjusted and
multivariable-adjusted discrete logistic regression models,
and expressed as odds ratios (ORs). CFH-rs1061170 and
ARMS2-rs10490924 were assessed categorically, in a general
Table 1. Comparison of Baseline Characteristics between Partic-
ipants with and without Incident Geographic Atrophy, Examined
up to 15 years in the Blue Mountains Eye Study Cohort
Characteristic
Participants*
No Late AMD
(n¼2446)
Incident GA
(n¼57) P Valuey
Mean age, yrs (SD) 63.9 (8.5) 72.3 (6.7) <0.0001
Mean BCVA, no.
of letters read (SD)
Better eye 56.2 (4.8) 52.8 (5.5) <0.0001
Worse eye 51.5 (10.9) 46.5 (10.6) 0.0006
Sex (male) 42.6 36.8 0.4
Smoking
Current 12.9 19.6 0.1
Past 35.7 30.4 0.4
Joachim et al  Incidence and Progression of GAmodel, using homozygous wild genotype (no risk alleles) as the
referent and heterozygous (1 risk allele) and homozygous risk
genotypes (2 risk alleles) as separate categories. These SNPs also
were assessed in an additive model where genotype was treated as
a continuous variable. Eye-speciﬁc data were used to assess the
association between early AMD lesion characteristics (type, area,
and location of early lesions) and the 15-year incidence of GA. To
handle the correlation between the 2 eyes of the same individual
and multiple measures of the same eyes (observations from the
same individual are in a cluster), the GENMOD procedure in SAS
was used to perform generalized estimation equation modeling
with an exchangeable working correlation matrix, using subject
identiﬁcation as a cluster indicator (The GENMOD Procedure.
SAS/STAT 9.1 User’s Guide. Cary, NC: SAS Inc.). Because of the
small number of cases available for assessment of GA progression,
only descriptive data are provided.Fish consumption
(1 serving/wk)
60.4 43.5 0.02
CFH-rs1061170
TT 40.3 24.0 0.0
CT 46.5 46.0 0.9
CC 13.3 30.0 0.0007
ARMS2-rs10490924
GG 62.5 54.0 0.2
GT 33.6 40.0 0.3
TT 4.0 6.0 0.5
AMD ¼ age-related macular degeneration; ARMS2 ¼ age-related macul-
opathy susceptibility gene 2 (T risk allele); BCVA ¼ best-corrected visual
acuity; CFH ¼ complement factor H (C risk allele); GA ¼ geographic
atrophy; SD ¼ standard deviation.
*Data shown as percentages unless otherwise indicated.
yManteleHaenszel chi-square.Results
Of 3654 baseline participants, 2572 had been followed-up at least
once since the baseline examination. Of these, 68 participants had
late AMD at baseline or developed neovascular AMD by ﬁrst
follow-up after baseline (and were thus not at risk of developing
GA), and 1 participant had ungradable photographs at all visits.
This left 2503 participants included in the assessment of GA
incidence. Table 1 presents baseline characteristics of the BMES
participants with incident GA and without any late AMD.
Subjects with incident GA were signiﬁcantly older and had
signiﬁcantly worse BCVA in both their better and worse eyes
compared with those without late AMD. Participants with
incident GA also were more likely to have 2 risk alleles of the
CFH gene compared with those without any late AMD. The
frequency of 1 or 2 ARMS2 gene risk alleles was slightly higher
in subjects with incident GA, but the differences were not
statistically signiﬁcant (Table 1).
Incidence of Pure Geographic Atrophy
Incident pure GA was identiﬁed in 57 participants (82 eyes) of
2503 subjects at risk, with an overall 15-year incidence of 3.6%
(95% conﬁdence interval [CI], 2.7e4.7). After accounting for the
competing risk of death, the 15-year incidence of GA decreased to
2.2% (95% CI, 1.6e2.8). After age standardization to the
Australian census 2011 population aged 50 years, the estimated
15-year incidence became 1.8% (95% CI, 1.2e2.4). Bilateral
involvement occurred in 27 of the 57 participants (47.4%). Of the
participants with bilateral involvement, 21 had bilateral involve-
ment at the same follow-up visit, 4 had bilateral involvement at the
subsequent follow-up visit, and 2 who had unilateral GA at base-
line developed incident GA in the fellow eye during the follow-up
period.
Table 2 presents the incidence of pure GA at the 5-, 10-, and
15-year follow-up examinations by different stages of AMD at
baseline according to the AREDS 5-step severity scale.26 Age was
signiﬁcantly associated with advancing severity level (P for trend
<0.0001). At each of the follow-up visits, incidence of pure GA
increased with increasing baseline AREDS severity step from 0 to
4, except for cases with AREDS scale step 3 (Table 2).
Age-related macular degeneration risk factors assessed for
association with the 15-year incidence of GA are shown in Table 3.
Increasing age was signiﬁcantly associated with the development
of GA within 15 years (P< 0.0001). In an age-adjusted model,
current smoking (P¼0.0001) and homozygous risk genotypes of
CFH-rs1061170 (P¼0.002) and ARMS2-rs10490924 (P¼0.04)
were associated with an increased risk of incident GA. There wasno signiﬁcant sex difference found in the long-term risk of GA.
Regular ﬁsh consumption had a signiﬁcant protective effect against
the development of GA (P¼0.02). In a model simultaneously
adjusting for the above-mentioned risk factors, the signiﬁcant
associations of age, current smoking, and genetic risks from the
CFH and ARMS2 genes with GA incidence remained, and the
association of weekly ﬁsh consumption with incident GA became
nonsigniﬁcant (Table 3).
Table 4 demonstrates the relationship between early AMD
lesion characteristics and 15-year incidence of GA using eye-
speciﬁc data. Drusen characteristics that were strongly associated
with increased risk of developing GA over the 15-year period
included soft indistinct (OR, 28.58) and reticular drusen (OR,
14.39), drusen within a 500-mm radius of the foveal center
(OR, 9.97), and a collective drusen area >375 mm in diameter (OR,
7.62e33.36). The baseline presence of RPE depigmentation
(OR, 6.99) and hyperpigmentation (OR, 11.27) was signiﬁcantly
associated with a higher risk of developing pure GA over the same
period, as was location of pigmentary abnormalities within
a 1500-mm radius of the foveal center. These associations remained
signiﬁcant after adjusting for age, sex, smoking, regular ﬁsh
consumption, and presence of the CFH and ARMS2 risk alleles
(Table 4).
Progression of Pure Geographic Atrophy
To investigate the progression of pure GA, both prevalent (n¼7)
and incident GA cases (n¼12) with gradable follow-up retinal
photographs were included. There were 41 baseline participants
with GA, but only 7 were pure GA cases (10 eyes) and had follow-
up retinal photographs available for this analysis. There were2045
Table 2. Incidence of Pure Geographic Atrophy at the 5-, 10-, and 15-Year Follow-up Visits of the Blue Mountains Eye Study Population
by the Age-Related Eye Disease Study (AREDS) 5-Step Severity Scale26
AREDS Category at Baseline
No. of Participants
(n[2503) Mean Age, Yrs ± SD
Mean BCVA in Worse Eye,
No. of Letters Read ± SD
Incidence GA (%)
5 Yrs 10 Yrs 15 Yrs
Step 0* 1873 62.67.9 53.46.8 0.0 0.2 1.0
Step 1y 207 67.48.4 50.010.8 0.5 4.7 9.6
Step 2z 72 71.39.0 50.67.4 6.9 23.9 38.4
Step 3x 36 71.18.5 49.57.8 8.3 8.3 19.8
Step 4k 13 70.57.0 48.19.7 30.8 60.4 100.0
BCVA ¼ best-corrected visual acuity; GA ¼ geographic atrophy; SD ¼ standard deviation.
*No retinal pigment changes with none or small hard drusen in 1 or both eyes or intermediate (but not large) drusen in 1 eye only.
yPigment changes in 1 eye with small hard drusen in 1 or both eyes or intermediate drusen in 1 eye only/no pigment changes in either eye but intermediate
drusen in both eyes or large drusen in 1 eye.
zPigment changes in both eyes with small hard drusen in 1 or both eyes or intermediate drusen in 1 eye only/pigment changes in 1 eye with intermediate
drusen in both eyes or large drusen in 1 eye/no pigment changes in either eye but large drusen in both eyes.
xPigment changes in both eyes with intermediate drusen in both eyes or large drusen in 1 eye/pigment changes in 1 eye with large drusen in both eyes.
kPigment changes in both eyes with large drusen in both eyes.
Ophthalmology Volume 120, Number 10, October 201316 participants (23 eyes) with incident GA and follow-up retinal
photographs, and 4 persons (5 eyes) were excluded because of
subsequent development of neovascular AMD, leaving a total
of 19 participants (28 eyes) who met the criteria for analysis of
progression rate.
The average size of the GA lesions at ﬁrst observation among
eyes with baseline pure GA and incident pure GA was 5.0 (standard
deviation [SD], 7.0) and 4.6 mm2 (SD, 4.5 mm2), respectively. Five
years after the ﬁrst detection of GA, the average size of baseline
pure GA lesions had increased to 13.0 mm2 (SD, 8.8 mm2) and
incident GA lesions had increased to 15.9 mm2 (SD, 8.1 mm2).
The average GA progression rate for baseline and incident eyes
combined (n¼28) was 1.95 mm2/year. Table 5 presents the 3
indicators of GA progression (enlargement of atrophic area,Table 3. Common Age-Related Macular Degeneration Risk
Factors Associated with 15-Year Incidence of Geographic Atrophy
Risk Factor
15-Year Incidence of GA
Age-Adjusted (Where
Appropriate) Multivariate Adjusted*
OR 95% CI OR 95% CI
Age, per year 1.18 1.14e1.22 1.22 1.16e1.27
Sex (male) 0.84 0.49e1.47 0.77 0.39e1.49
Smoking (current) 4.11 2.01e8.38 4.20 1.76e10.02
CFH-rs1061170y 1.92 1.28e2.88 1.99 1.26e3.15
TT 1.00 d d
CT 1.66 0.82e3.38 d d
CC 3.65 1.66e8.03 d d
ARMS2-rs10490924y 1.66 1.02e2.70 2.38 1.41e4.02
GG 1.00 d d
GT 1.54 0.85e2.79 d d
TT 3.32 0.96e11.53 d d
Fish consumption
(1 servings/wk)
0.48 0.27e0.88 0.54 0.28e1.03
ARMS2 ¼ age-related maculopathy susceptibility gene 2 (T risk allele);
CFH ¼ complement factor H (C risk allele); CI ¼ conﬁdence interval;
GA ¼ geographic atrophy; OR ¼ odds ratio.
*Multivariate model adjusted for age, sex, smoking, CFH, ARMS2, and
regular ﬁsh consumption.
yComputed using additive model.
2046progression of atrophy into the fovea, and worsening in BCVA).
Of participants with baseline GA, none survived to the 15-year
follow-up. These participants were signiﬁcantly older than partic-
ipants without GA at baseline (mean age, 82.6 vs. 65.9 years,
respectively). The multifocal conﬁguration of GA had the fastest
progression rate from the ﬁrst detection to the next examination 5
years later, whereas the slowest progression rate was observed in
eyes presenting with the classic conﬁguration. Central GA
(involving the fovea) was present in 57% (n¼16) of 28 eyes with
GA at the ﬁrst detection. Of the remainder, 92% of 12 eyes with GA
had progression into the fovea within the next 5 years. The mean
BCVA deteriorated by an average 18 letters over the same period.
Table 6 presents the frequencies of risk factors in fast or slow/
normal progression groups. Fast, slow, and normal progression
were observed in 10, 7, and 2 participants, respectively,
according to the worse eye if the cases were bilateral (n¼2). A
larger proportion of participants with fast progressing GA were
current smokers (30% vs. 0% in the slow/normal progression
group), had 1 or both eyes pseudophakic before or at the ﬁrst
detection of GA in the same eye (30% vs. 11%), and had the
homozygous risk genotype of the CFH (50% vs. 22%) or the
ARMS2 (10% vs. 0%) alleles compared with subjects who had
slow/normal progress. Participants who regularly consumed
ﬁsh were more frequently represented in the slow/normal
progress groups compared with the fast progress group (57%
vs. 38%).Discussion
In this older Australian cohort, we found an overall 3.6%
incidence of pure GA over 15 years. Common AMD risk
factors, including increasing age, history of smoking,
genetic risk from the CFH and ARMS2 alleles, and regular
ﬁsh consumption, were associated with long-term incidence
of pure GA. In addition, early AMD lesion characteristics
strongly predicted risk of GA independent of the known risk
factors discussed earlier. We also found that fast progression
of GA was more likely to occur in affected individuals who
were current smokers or possessed at least 1 risk allele of the
CFH gene or both risk alleles of the ARMS2 gene, and in
pseudophakic eyes, whereas slow progression of GA was
Table 4. Relationship between Baseline Drusen and Retinal Pigmentary Abnormalities and the 15-Year Incidence of Geographic
Atrophy, Analyzed by Eye
Early AMD Characteristics No. Who Developed GA No. at Risk
15-Year Incidence of GA
Age-Adjusted Multivariate Adjusted*
OR 95% CI OR 95% CI
Drusen type
None or hard drusen only 27 4094 1.00 d 1.00 d
Intermediate 24 488 3.92 2.36e6.52 5.30 2.67e10.49
Soft distinct 2 100 1.61 0.41e6.26 3.02 0.70e13.08
Soft indistinct 24 100 28.58 12.66e64.53 59.02 20.38e170.95
Reticular 15 44 14.39 5.56e37.22 13.85 4.03e47.64
Drusen location
None or 3000 mm from foveal center 27 4094 1.00 d 1.00 d
1500e3000 mm from foveal center 1 42 1.93 0.38e9.92 3.40 0.49e23.73
500e1500 mm from foveal center 4 188 1.83 0.61e5.50 3.65 1.21e10.99
Within a 500-mm radius of foveal center 48 451 9.97 5.88e16.90 15.08 7.38e30.82
Drusen area
None or <375 mm in diameter 39 4535 1.00 d 1.00 d
375 to <0.5 disc area 16 156 7.62 3.76e15.4 10.11 4.00e25.57
0.5 disc area 25 87 33.36 13.65e81.56 61.12 18.37e203.34
RPE depigmentation
Present vs. absent 20 144 6.99 3.87e12.32 9.02 4.10e19.80
Location
None or 1500 mm from foveal center 62 4881 1.00 d 1.00 d
500e1500 mm from foveal center 8 72 5.24 2.31e11.90 8.04 2.84e22.80
Within a 500-mm radius of foveal center 12 67 10.35 4.74e22.67 11.20 3.61e34.75
Area
None to <375 mm in diameter 70 4932 1.00 d 1.00 d
375 mm to <2 disc areasy 12 88 8.40 4.04e17.46 5.62 2.07e15.28
Hyperpigmentation
Present vs. absent 41 317 11.27 6.70e18.96 12.02 6.14e23.53
Location
None or 1500 mm from foveal center 41 4723 1.00 d 1.00 d
500e1500 mm from foveal center 16 98 13.17 6.33e27.38 14.91 6.47e34.37
Within a 500-mm radius of foveal center 25 146 16.37 8.55e31.33 14.97 5.95e37.63
Area
None or <64 mm in diameter 45 4727 1.00 d 1.00 d
64 mm in diameter 37 240 12.21 7.08e21.05 11.18 5.65e22.10
AMD ¼ age-related macular degeneration; CI ¼ conﬁdence interval; GA ¼ geographic atrophy; OR ¼ odds ratio; RPE ¼ retinal pigment epithelium.
*Multivariate model adjusted for age, sex, smoking, regular ﬁsh consumption, and the CFH and ARMS2 risk alleles.
yThere were no cases 2 disc areas.
Joachim et al  Incidence and Progression of GAmore likely to occur in those who consumed 1 or more
servings of ﬁsh weekly.
The BMES and BDES12 are the only 2 studies to have
reported GA incidence over a 15-year follow-up period in
population-based older samples. Both study protocols and
methods used, including examination procedures and retinal
photographic grading of AMD signs, were similar, whereas
the BDES population had a slightly younger age limit (43
years) than the BMES population (49 years). The BMES
found an incidence of 3.6% that was more than double the
1.3% rate observed in the BDES12 over the 15-year period.
The 10-year cumulative incidence of GA was also double in
the BMES (1.7%)11 compared with the BDES (0.8%).10 After
accounting for the competing risk of death and age
standardization of the BMES population to the general
Australian population, the 15-year incidence of pure GA
was 1.8%; however, the 95%CI of 1.2 to 2.4 is consistent with
the ﬁnding of a 1.3% 15-year incidence reported from the
BDES. Apart from the different age ranges of the 2 studysamples, there are likely different environmental exposures
(smoking, sunlight exposure) that could explain the difference
in GA incidence between the 2 studies. The association
between smoking and incidence of late AMD was somewhat
dissimilar in the BMES compared with the BDES, as previ-
ously reported.27e29 There was a higher frequency of baseline
current smokers in the BDES (men 21%, women 18%)
comparedwith theBMES (men 15%,women 11%).However,
current smokers had a 4-fold greater risk of incident late AMD
compared with nonsmokers in the BMES,28 whereas no
similar association was found between past or current
smoking and incident late AMD (or GA) in the BDES.29,30
A Danish study of 946 subjects aged 60 years, which
used a similar grading system to detect AMD from color
fundus photographs, reported a 14-year incidence of GA of
4.9%,31 substantially higher than the 15-year incidence
found in the BDES and BMES. The difference could be due
to an older baseline age (60 years) of the Danish study
sample compared with the baseline ages of those in the2047
Table 5. Progression in Atrophic Area, Foveal Involvement, and Best-Corrected Visual Acuity Over 5 and 10 Years in Eyes with Pure
Geographic Atrophy
Characteristics of Progression
GA Progression
First Observation to 5 Yrs Between 5 and 10 Yrs First Observation to 10 Yrs
n Mean mm2 (SD) n Mean mm2 (SD) n Mean mm2 (SD)
Change in mean GA area
Prevalent (baseline) GA eyes (n¼10) 9 7.7 (5.2) 3 4.5 (2.9) 4 7.5 (4.4)
Incident GA eyes (n¼18) 18 11.2 (6.0) 3 8.6 (6.3) 3 20.3 (16.2)
All GA eyes (n¼28) 27 10.1 (5.9) 6 6.6 (4.9) 7 13.0 (12.0)
Change in mean GA area
(by GA conﬁguration)*
Classic 7 5.5 (5.3) 4 4.7 (4.6) 5 9.3 (10.3)
Merged 7 10.3 (6.0) 0 d 0 d
Multifocal 6 13.8 (6.2) 3 13.7 (1.0) 3 31.1 (1.9)
Mixed 7 11.2 (3.8) 1 d 1 d
n % n % n %
Change in foveal involvement* 11 92 0 0 2 67
n Difference in the mean
no. of letters
read correctly (SD)
n Difference in the mean
no. of letters read
correctly (SD)
n Difference in the
mean no. of letters
read correctly (SD)
Change in BCVA (later visit minus
previous visit)*
27 18.6 (17.9) 8 1.25 (6.6) 8 9.5 (21.6)
BCVA ¼ best-corrected visual acuity; GA ¼ geographic atrophy; SD ¼ standard deviation.
For foveal involvement, n ¼ number of eyes with GA that progressed and number of eyes with GA that were at risk of progression into the fovea (eyes that
had already developed GA in the fovea were not included).
*Prevalent and incident GA eyes were combined.
Ophthalmology Volume 120, Number 10, October 2013BDES or BMES. Participants aged <60 years at baseline
comprised 32.5% of the BMES population compared with
none in the same age group in the Danish Study, which
could have accounted for the differences in the incidence
rates between the 2 studies. We do not have directly
comparable data from the Danish study, so direct age
standardization between the 2 study samples is not possible.
Because of relatively high proportions of study participants
who had died or were lost to follow-up (37.9%) in theTable 6. Proportion of Participants Presenting with the Selected Risk
Risk Characteristics Fast (2 mm2/yr) (n¼10)
Mean baseline age (yrs) 71.9
Sex (male) 30.0
Smoking
Past 40.0
Current 30.0
Fish consumption (1 serving/wk) 37.5
Pseudophakic* 30.0
CFH-rs1061170
TT 10.0
CT 40.0
CC 50.0
ARMS2-rs10490924
GG 50.0
GT 40.0
TT 10.0
ARMS2 ¼ age-related maculopathy susceptibility gene 2; CFH ¼ complement
*Pseudophakia detected before or at the same examination as GA detected.
2048Danish study31 and in the 15-year follow-up examinations
of our study cohort, survival bias also could have affected
the incidence estimates of the 2 studies.
Previous studies have documented that eyes with early
AMD lesions had a substantially higher risk of progression to
late AMD, including GA and neovascular AMD.13,15,32
Therefore, the strong association between early AMD
lesion characteristics and risk of developing GA found in our
study is expected.Factors by Fast and Slow Progression of Pure Geographic Atrophy
Participants with GA Progression (%)
Slow (<1 mm2/yr) (n¼7) Slow/Normal (<2 mm2/yr) (n¼9)
72.4 75.2
28.6 33.3
28.6 33.3
0.0 0.0
50.0 57.1
14.3 11.1
71.4 55.6
14.3 22.2
14.3 22.2
57.1 55.6
42.9 44.4
0.0 0.0
factor H; GA ¼ geographic atrophy.
Joachim et al  Incidence and Progression of GAWe found that average progression of GA, measured as
enlargement in GA area, was 1.95 mm2/year, which is
similar to the average progression found in other
population-based studies (1.2e1.8 mm2/year)4,20 but lower
than the progression rate found in a clinic-based sample
(2.6 mm2/year).16 In deﬁning the progression rate in terms
of enlargement in area, we have assumed a steady, similar
enlargement rate in GA area across all stages of GA
progression. Whether such an assumption holds is unclear,
as indicated by Klein et al.4 We also found a faster
progression rate among cases with multifocal compared
with classic GA conﬁguration, consistent with the BDES
ﬁnding in pure GA cases.4 However, multifocal GA
conﬁguration usually indicates a more advanced stage of
GA, and therefore the different progression rates observed
may be due to differing stages of GA rather than the
morphologic differences of GA conﬁgurations per se.
Nevertheless, these ﬁndings were based on a small
number of GA cases and should be interpreted with caution.
Older age and history of smoking have been consistently
identiﬁed as risk factors for late AMD in population-based
studies.9,33e35 The association between smoking and 15-
year incident GA documented in this study is in keeping
with previous observations.27,28 Past smokers in the BMES
were shown to have a 3-fold higher risk of incident GA after
adjusting for age, sex, and other factors as previously re-
ported.28 We found that similar risk factors associated with
a high risk of developing GA also were associated with fast
progression of GA, including genetic inﬂuence from the
CFH and ARMS2 genes, current smoking, and less
frequent consumption of ﬁsh. The higher proportion of
participants who consumed ﬁsh at least weekly in the
slow/normal progression group compared with the fast
progression group is consistent with evidence suggesting
a beneﬁcial effect of omega 3 fatty acids on the
development and progression to either form of late
AMD.36e38 The higher proportion of pseudophakic partic-
ipants in the fast progression group than in the slow/normal
progression group lends support to the hypothesis that
sunlight exposure also could be a risk factor for GA.39,40
Study Strengths and Limitations
Strengths of our study include its long-term follow-up of an
older predominantly Caucasian cohort that is comparable
to the BDES cohort. However, the low follow-up rate at the
15-year examinations may have led to an over- or underes-
timation of GA incidence. Our ﬁndings from all GA cases,
including both clinical and subclinical cases, without
apparent visual symptoms reﬂect the natural history of the
condition. We were able to assess GA progression and risk
characteristics associated with the progression by comparing
fast with slow/normal progression groups. However, we
cannot exclude the possibility that GA progresses differently
at different stages of the disease and that fast progress cases
may occur in a more advanced stage. Limitations of this
study include the lack of optical coherence tomography
measures because of timing (early 1990s, when optical
coherence tomography was not available). We also could not
statistically validate the association between certain riskfactors and progression of GA lesions because of the small
number of cases available to analyze progression. Concor-
dance studies have shown differences in progression between
bilateral GA cases and unilateral GA cases with early AMD
in the fellow eye41; however, we were unable to assess this
because of the small number of GA cases in these subgroups.
In conclusion, we report the 15-year incidence of GA to
be 3.6% (2.2% after adjustment for competing risk of death)
in this older Australian cohort and conﬁrm strong associa-
tions between baseline early AMD lesion characteristics and
higher risk of developing GA over the long term, indepen-
dent of age, smoking, and genetic susceptibility from the 2
major AMD genes (CFH and ARMS2). Similar AMD risk
factors were also found to be associated with fast progres-
sion of GA over 5 to 10 years.References
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Incidence, Progression, and Associated Risk Factors
ofMediumDrusen in Age-RelatedMacular Degeneration
Findings From the 15-Year Follow-up of an Australian Cohort
Nichole D. L. Joachim, BSc(Hons); Paul Mitchell, MD, PhD; Annette Kifley, MAppStats, PhD;
Jie JinWang, MMed, PhD
IMPORTANCE The natural course and prognosis of medium drusen and risk factors associated
with the incidence and progression of this lesion type in age-relatedmacular degeneration
(AMD) are not well understood.
OBJECTIVE To assess the 15-year incidence and progression of medium drusen and associated
risk factors.
DESIGN, SETTING, AND PARTICIPANTS Population-based cohort in the BlueMountains region,
west of Sydney, Australia. Included in the study were 3654 participants 49 years or older who
attended baseline examinations of the Blue Mountains Eye Study (1992-1994), and 75.8%,
76.7%, and 56.1% of survivors who attended the 5-year, 10-year, and 15-year follow-up
examinations, respectively.
MAIN OUTCOMES ANDMEASURES Color retinal fundus photographs were obtained at each
examination. The incidence and progression of medium drusen (maximum diameter, 63 to
<125 μm) were assessed using Kaplan-Meier product-limit survival methods, controlling for
competing risk of death. Factors associated with a 15-year incidence of medium drusen were
assessed using discrete logistic regressionmodels after adjusting for age, sex, smoking status,
serum lipid levels, systemic and dietary factors, and CFH rs1061170 and ARMS2 rs10490924
polymorphisms. Associations between lesion characteristics and the progression to late AMD
were assessed using generalized estimating equationmodels and eye-specific data.
RESULTS Among 1317 participants at risk, the 15-year cumulative incidence of medium drusen
was 13.9% (n = 281). Increasing age (per decade older) (odds ratio [OR], 1.4; 95% CI, 1.2-1.8)
and the presence of at least 3 risk alleles of the CFH rs1061170 or ARMS2 rs10490924 genes
(OR, 2.1; 95% CI, 1.1-4.1) were associated with a higher incidence. There was no association
between past smoking (OR, 0.8; 95% CI, 0.6-1.1) or current smoking (OR, 0.6; 95% CI, 0.4-1.1)
and the development of medium drusen. The progression rate to late AMD in eyes with both
medium drusen and retinal pigmentary abnormalities was 4-fold higher than that in eyes with
medium drusen alone. Larger total area and central location of medium drusen were
associated with a greater likelihood of the progression to worse stages of AMD.
CONCLUSIONS AND RELEVANCE Older age and the presence of CFH and ARMS2 risk alleles are
2main risk factors associated with the development of medium drusen. The copresence of
medium drusen plus retinal pigment epithelium abnormalities signals a greater risk of the
progression to late AMD than the presence of medium drusen alone.
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E arly age-related macular degeneration (AMD) is char-acterizedby thepresenceofdrusenand retinalpigmen-tary abnormalities.1,2 Drusen vary in size (diameter
range, ≤63 to ≥250 μm) and type (hard, soft, distinct, and in-
distinct). Pigmentary abnormalities include clusters of pig-
ment granules within the sensory retina (increased pigmen-
tation) and sharply demarcated areas of retinal pigment
epithelium (RPE) depigmentation.
The international classification and grading system for
AMD categorizes medium drusen as intermediate soft dru-
sen, defined as drusen with a maximum diameter of 63 to
less than 125 μm, larger than the maximum diameter of hard
drusen (<63 μm) but smaller than the minimum diameter of
large soft drusen (≥ 125 μm).1 A similar definition of this dru-
sen type was used by the Age-Related Eye Disease Study2 and
clinical classification system,3 categorized as medium dru-
sen. Furthermore, the Wisconsin Age-Related Maculopathy
Grading System4 defines medium drusen by the maximum
diameter, although the categorization of medium drusen is
not used. In this study, we describe this type of drusen as
medium drusen.
Despite recent interest in medium drusen and their inclu-
sion in AMD incidence studies,5,6 knowledge of the associated
risk factors and the progression of medium drusen is limited.
Medium drusen have been underrepresented in studies3,7-9
compared with large drusen, soft drusen, and pigmentary
lesions. In this study, we aimed to assess the 15-year inci-
dence and progression of medium drusen in an older Austra-
lian cohort, as well as associations between common AMD
risk factors and the development and progression of medium
drusen.
Methods
Population
The Blue Mountains Eye Study (BMES) is a population-based
cohort study of vision and eye disease in Australians 49 years
or older residing in the Blue Mountains region, west of Syd-
ney. The survey methods and the BMES baseline population
have been previously described.10,11 Briefly, 3654 residents
(82.4% of those eligible) participated in baseline examina-
tions from1992 to 1994 (BMES I). Of these, 2334 (75.8%of sur-
vivors) were reexamined from 1997 to 1999 (BMES II), 1952
(76.7%ofsurvivors)werereexaminedfrom2002to2004(BMES
III), and 1149 (56.1%of survivors)were reexamined from2007
to 2009 (BMES IV). Baseline and all follow-up examinations
were approved by human research ethics committees of the
WesternSydneyAreaHealthServiceand theUniversityof Syd-
ney and adhered to the tenets of the Declaration of Helsinki.
Written informed consent was obtained from all participants
at each visit.
Procedures
At each visit, a comprehensive interviewwith questionnaires
ondemographicand lifestyle factors andmedicalhistorieswas
conducted. A validated Food Frequency Questionnaire was
self-administered by participants before each visit. Compre-
hensive eye examinations were performed as described
previously.10 Briefly, 30° stereoscopic retinal photographs of
the macula and other retinal fields of both eyes were ob-
tained using a fundus camera (FF3; Carl Zeiss) at the BMES I,
II, and III examinations, and 40° photographs were obtained
usingadigital camera (CF-60DSiwithDsMark III body;Canon)
at the BMES IV examination.
Photographic Grading
Retinal photographic grading of both eyes of each participant
was conducted by 2 senior graders using a modified Wiscon-
sinAge-RelatedMaculopathyGrading Systemprotocol.10 The
WisconsinAge-RelatedMaculopathyGradingSystemgridcon-
sists of 3 concentric circles that subdivide themacula fromthe
foveal center, with radii of 500, 1500, and 3000 μm that de-
marcate the central, inner, and outer subfields of themacula,
respectively. The grid was superimposed on the macula dur-
ing the grading. The grading procedures and intergrader and
intragraderagreementshavebeenpreviouslydescribed,10with
quadraticweightedκvalues ranging from0.64 to0.93and0.54
to 0.94, respectively. Adjudication was provided by a senior
retinal specialist (P.M.) if needed.
Late AMD was defined per an international age-related
maculopathy classification1 as the presence of neovascular
AMD (indicated by RPE or neurosensory subretinal detach-
ment, retinal or subretinal hemorrhage, subretinal fibrosis or
old atrophic disciformscars, or photocoagulation scars) or the
presenceof geographic atrophy. EarlyAMDwasdefinedas the
presenceof large (diameter, ≥125μm) indistinct soft drusenor
reticular drusen or the presence of large distinct soft drusen
andretinalpigmentaryabnormalities (hyperpigmentationand
depigmentation of RPE cells) within the macula, in the ab-
sence of any lateAMD lesions. Themaximumdiameters of in-
dividual drusen and collectivemacular areas involvedbydru-
sen and pigmentary abnormalities within the eye were
estimated as specified in the Wisconsin Age-Related Macu-
lopathy Grading System4 using circles with diameters of 63,
125, 250, 350, and 644 μm, 0.5 disc area, and 1 disc area.
Definition ofMediumDrusen Incidence and Progression
The incidence of medium drusen was defined as its presence
at the 5-year, 10-year, or 15-year follow-up visit in personswho
had no drusen or hard drusen only in any eye at baseline vis-
its. The progression of medium drusen was defined as a pro-
gression to worse AMD lesions, including large soft drusen,
retinal pigmentary abnormalities, or late AMD at follow-up
visits, in eyes with medium drusen as the most severe lesion
at baseline visits.
Genotyping
Genotypingdatawereavailable in2761participantsof theBMES
cross-section II examinations,which included theoriginal co-
hort andBMES extension survey (1999-2000) samples. A cus-
tomarray (Human670-Quad,version1; Illumina Inc)wasused,
with stringent quality control testing using a whole-genome
association analysis tool set (PLINK, version 1.07; http://pngu
.mgh.harvard.edu/purcell/plink/).Afterquality control check-
ing,2534participantswithgenome-wideassociationstudydata
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were imputedwithagenetic variationcatalog (1000Genomes,
version1;http://www.1000genomes.org/)usingasoftwarepro-
gram (IMPUTE, version 2.0; https://mathgen.stats.ox.ac.uk
/impute/impute_v2.html).12The imputation r2coefficientswere
0.968 forCFH (OMIM 134370) rs1061170 and 0.996 forARMS2
(OMIM 611313) rs10490924.
The CFH single-nucleotide polymorphism rs1061170 was
also genotyped in 1928 participants using an assay (TaqMan;
AppliedBiosystems),13 and theARMS2 single-nucleotidepoly-
morphismrs10490924wasgenotyped in638participantsusing
restriction fragment length polymorphism analysis.14 Im-
puted single-nucleotidepolymorphismsof these 2 geneswere
used for the remaining participants. Of the 1544 and 547 par-
ticipants who had both typed and imputed rs1061170 and
rs10490924, respectively, theconcordanceratesbetweentyped
and imputedsingle-nucleotidepolymorphismswere99.6%for
rs1061170 and 99.2% for rs10490924.
Other Risk Factors
Participants were classified as nonsmokers if they answered
no to thequestionofwhether theysmoke regularly.Past smok-
ingwas recorded if participantshad smoked regularly but quit
smoking at least 1 year before the examination. Current smok-
ing was recorded if participants were current smokers or had
stopped smoking less than 1 year before the examination. Al-
cohol consumption (including beer, wine, or spirits) was cat-
egorizedasnone, 1 to2, ormore than2 standarddrinksperday.
ThesecategorieswerebasedonAustralianNationalHealthand
MedicalResearchCouncil15 recommendationsofnomore than
2 standard drinks per day.
Systolic anddiastolic bloodpressuremeasurementswere
recorded fromthe first and fifthKorotkoff soundsusingamer-
cury sphygmomanometer after participants had been seated
for at least 5 minutes.16 Dietary consumption and supple-
mentusewereextracted fromthe self-administeredFoodFre-
quency Questionnaire.17 The Australian tables of food
composition18,19 and theUSDepartment of Agriculture carot-
enoid food composition database20were used to estimate the
intake of nutrients, including lutein and zeaxanthin intake in
micrograms. Regular fish consumption was defined as con-
suming at least 1 serving of fish per week.
Fasting blood samples were collected from 3222 baseline
participants to assess white blood cell count and cholesterol
levels as previously described.21-23 Briefly, white blood cell
count was determined using cell counting methods (Coulter
Counter; Beckman Coulter, Inc).21 Total cholesterol, high-
density lipoprotein cholesterol, and triglycerides concentra-
tions were measured on a reflectance photometric analyzer
(Reflotron; Roche Diagnostics).22
Statistical Analysis
A software package (SAS, version 9.3; SAS Institute Inc) was
used for statistical analyses. The 15-year incidence of
medium drusen was estimated using Kaplan-Meier product-
limit survival estimates and competing risk analyses that
control for competing risk of death among persons at risk of
medium drusen, after excluding participants with any worse
stage of early or late AMD lesions at baseline. Associations
between common AMD risk factors (age, sex, smoking status,
blood pressure, white blood cell count, fish consumption,
alcohol consumption, antioxidant and zinc supplementation
intake, CFH rs1061170 and ARMS2 rs10490924 risk alleles,
and total cholesterol, high-density lipoprotein cholesterol,
and triglycerides concentrations) and the 15-year incidence of
medium drusen were assessed using age– and sex–adjusted
discrete logistic regression models. If these risk factors
reached P ≤ .09 in the age– and sex–adjusted regression mod-
els, they were included in the multivariable-adjusted logistic
regression model. The final multivariable-adjusted logistic
regression model included age, sex, past and current smok-
ing, zinc supplementation, and the combined CFH rs1061170
and ARMS2 rs10490924 risk alleles as covariables. The com-
bined CFH rs1061170 and ARMS2 rs10490924 risk alleles were
categorized as none, 1, 2, or 3 or more.
Frequencies of the progression from medium drusen
alone, as well as from medium drusen plus RPE abnormali-
ties, to worsening stages of AMD were reported. Generalized
estimating equation models using the GENMOD procedure
Table 1. Fifteen-Year Incidence ofMediumDrusen by Age and Sexa
Age, y
Women Men Both
No. of Cases/No. at Risk % (95% CI) No. of Cases/No. at Risk % (95% CI) No. of Cases/No. at Risk % (95% CI)
15-Year Kaplan-Meier Incidence of Medium Drusen
49-54 32/145 28.5 (20.8-38.3) 17/110 19.9 (12.7-30.3) 49/255 24.7 (19.1-31.6)
55-64 68/319 28.9 (23.3-35.4) 49/257 27.0 (20.8-34.6) 117/576 28.1 (23.8-32.9)
65-74 59/219 41.1 (31.3-52.7) 43/167 43.9 (32.8-57.0) 102/386 42.7 (35.1-51.3)
≥75 8/51 15.7 (8.2-28.9) 5/49 15.8 (5.5-40.5) 13/100 16.2 (8.6-29.4)
Total 167/734 32.2 (28.0-36.9) 114/583 29.0 (24.5-34.3) 281/1317 30.8 (27.7-34.3)
15-Year Cumulative Incidence of Medium Drusen After Controlling for Competing Risk of Death
49-54 13/145 24.1 (17.0-31.2) 8/110 16.8 (9.7-23.9) 21/255 20.9 (15.8-25.9)
55-64 37/319 22.2 (17.6-26.7) 48/257 17.6 (13.3-21.9) 85/576 20.0 (16.9-23.2)
65-74 63/219 17.8 (13.9-21.8) 79/167 13.0 (9.7-16.4) 142/386 15.5 (13.0-18.1)
≥75 40/51 2.5 (0.8-4.1) 39/49 1.8 (0.3-3.3) 79/100 2.2 (1.0-3.3)
Total 153/734 15.8 (13.7-17.9) 174/583 11.8 (9.9-13.7) 327/1317 13.9 (12.5-15.3)
a The definition of medium drusen herein excludes larger soft drusen, retinal pigmentary abnormalities, and late age-relatedmacular degeneration.
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(SAS, version 9.3; SAS Institute Inc)24 were applied to eye-
specific data to assess associations between medium drusen
area and location characteristics and the progression to early
or late AMD. Association estimates are presented as age– and
sex–adjusted or multivariable-adjusted odds ratios (ORs) and
95% CIs.
Results
Prevalence ofMediumDrusen
Of 3654 baseline participants, we excluded persons with late
AMD (n = 75), early AMD (n = 185), or large soft distinct dru-
sen (n = 113), andwe included 3281 for the assessment ofme-
dium drusen. The status of medium drusen could be clearly
defined in2959participants, amongwhom534(18.0%)hadme-
diumdrusen, including445 (83.3%)withmediumdrusenalone
and 89 (16.7%) with medium drusen plus RPE abnormalities.
Medium drusen was bilateral in 16.6% (74 of 445).
Incidence ofMediumDrusen
Among 1317 persons without any AMD lesions at baseline
who had been followed up, the 5-year, 10-year, and 15-year
cumulative incidences of medium drusen were 10.1% (95%
CI, 8.6%-11.9%), 17.7% (95% CI, 15.6%-20.1%), and 30.8% (95%
CI, 27.7%-34.3%), respectively. After controlling for compet-
ing risk of death, the 5-year, 10-year, and 15-year cumulative
incidences of medium drusen were 5.7% (95% CI, 4.8%-
6.6%), 9.2% (95% CI, 9.1%-9.3%), and 13.9% (95% CI, 12.5%-
15.3%). The 15-year incidences of medium drusen by age and
sex are listed in Table 1. The incidence rates across all age
groups were comparable, except for those 75 years or older.
The incidence of medium drusen was slightly lower in men
compared with women.
Table 2. Comparison of Baseline Characteristics of ParticipantsWith vsWithout IncidentMediumDrusen
Baseline Characteristic
Without Incident
Medium Drusen
With Incident
Medium Drusen P Value
Age, mean (SD), y 62.1 (8.1) 62.3 (7.5) .65
Female sex, % 54.7 59.4 .16
Smoking status, % <.001a
Never smoker 47.8 61.8
Past smoker 37.3 28.7
Current smoker 14.8 9.5
CFH rs1061170, % .40a
TT 42.3 38.2
CT 47.0 49.0
CC 10.6 12.9
ARMS2 rs10490924, % .09a
GG 65.6 57.9
GT 30.4 37.8
TT 4.0 4.3
CFH and ARMS2 combined risk, % .15a
No risk alleles 28.7 21.3
1 Risk allele 40.6 44.0
2 Risk alleles 25.5 27.6
≥3 Risk alleles 5.2 7.1
Blood pressure, mean (SD), mm Hg
Systolic 143.4 (19.9) 144.6 (21.1) .39
Diastolic 83.2 (10.0) 83.8 (9.1) .38
White blood cell count, mean (SD), /μL 6371.8 (1760.9) 6175.4 (1409.6) .06
Total cholesterol concentration, mean (SD), mg/dL 232.4 (40.7) 233.9 (42.2) .60
High-density lipoprotein cholesterol concentration,
mean (SD), mg/dL
55.3 (17.4) 56.4 (14.7) .29
Triglycerides concentration, mean (SD), mg/dL 155.3 (90.8) 147.7 (97.9) .23
Fish consumption of ≥1 serving per wk, % 60.3 60.2 .98
Alcohol consumption, standard drinks per d, % .65a
None 29.6 31.6
1-2 58.6 55.5
>2 11.8 12.9
Any antioxidant supplementation, % 36.1 35.2 .79
Any zinc supplementation, % 16.9 11.6 .04
Dietary lutein and zeaxanthin intake, mean (SD), μg 0.8 (0.5) 0.8 (0.4) .55
SI conversion factors: To convert
white blood cell count to ×109/L,
multiply by 0.001; to convert total
and high-density lipoprotein
cholesterol concentrations to
millimoles per liter, multiply by
0.0259; to convert triglycerides level
to millimoles per liter, multiply by
0.0113.
a Unadjusted tests for heterogeneity
were used to calculate these
P values.
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Baseline characteristics of participants with and without
incident medium drusen are listed in Table 2. There were no
significant differences in the mean age or the frequency of
female sex between participants with and without incident
medium drusen. However, participants with incident
medium drusen were marginally more likely to have at least 1
risk allele of ARMS2 rs10490924 and have a lower mean
white blood cell count and were less likely to be past or cur-
rent smokers or to take zinc supplementation.
Table 3 lists associations between known AMD risk fac-
tors and the incidence of medium drusen. Each decade in-
crease in age was significantly associated with a 15-year inci-
denceofmediumdrusen after adjusting for sex. Thepresence
ofat least3 riskallelesofCFH rs1061170andARMS2 rs10490924
combinedwas significantly associatedwith an increased risk
of developing medium drusen (OR, 2.1; 95% CI, 1.1-3.9) after
adjusting for age and sex. These associations remained simi-
lar after additional adjustment for past and current smoking
and for zinc supplementation. The 15-year incidence of me-
dium drusenwas inversely associatedwith a higher intake of
zinc; however, this association was marginally nonsignifi-
cant in both age– and sex–adjusted and multivariable-adjus-
tedmodels.Risk factors, including smokingstatus, bloodpres-
sure,whitebloodcell count, serumlipid levels, fishandalcohol
consumption, antioxidant supplementation, and lutein and
zeaxanthin intake, were not significantly associatedwith the
15-year incidence of medium drusen in the age– and sex–
adjusted models.
Progression ofMediumDrusen
The frequency of the progression to large soft drusen in eyes
withmediumdrusenalonewas similar to that ineyeswithme-
dium drusen plus RPE abnormalities (41.8% and 50.0%, re-
spectively;P = .20).However, theprogressionto late-stageAMD
or lateAMD lesions (geographic atrophyor neovascularAMD)
was 4-fold higher in eyes with medium drusen plus RPE ab-
normalities compared with eyes with medium drusen alone
(23.0% vs 5.0%). An example of medium drusen progression
is shown in the Figure.
Table 4 summarizes the 15-year progression of medium
drusen to early and late AMD in relation to total area and lo-
cationofmediumdrusen. EyeswithmediumdrusenplusRPE
abnormalitieswere excluded. After adjusting for age and sex,
a large total area (≥375 μm) compared with a small total area
(<375μm)ofmediumdrusenwas significantly associatedwith
high riskofdevelopingearlyAMD(OR, 2.9; 95%CI, 1.5-5.4) and
any (early or late) AMD (OR, 3.0; 95% CI, 1.6-5.5). However, it
wasnot significantly associatedwith riskof lateAMD(OR, 2.3;
95%CI,0.8-6.8).After furtheradjusting for smokingstatus, fish
consumption, and the presence of the CFH and ARMS2 risk
alleles, these associations remained. Similarly, the associa-
tionbetween a central locationofmediumdrusen and thede-
velopmentofearlyAMD(OR,2.6;95%CI, 1.4-4.8)andanyAMD
(OR,2.4;95%CI, 1.3-4.5)wassignificantafteradjustingfor these
covariables.
Discussion
We found that 13.9% of at-risk persons 49 years or older de-
veloped medium drusen over 15 years. The incidence of me-
dium drusen did not appear to differ across the 3 age groups
from 49 to 74 years, but it was slightly higher in women com-
pared with men. The lower incidence of medium drusen ob-
served in participants 75 years or older at baseline is likely be-
cause most persons in this age group had died or passed this
early stageofAMD,and fewparticipants in this agegroupwere
considered at risk of developing medium drusen.
A per decade increase in age and the presence of at least 3
risk alleles of CFH rs1061170 and ARMS2 rs10490924 com-
bined were independently associated with an increased risk
of developingmediumdrusen.Noother knownAMDrisk fac-
tors were found to be associated with the incidence.
Few population-based reports on the incidence of me-
dium drusen are available in the literature. The 5-year, 10-
year,and15-year incidenceratesofmediumdrusen intheBMES
were 5.7%,9.2%, and 13.9%, respectively. In theReykjavikEye
Study,25 a population-based study of residents in Iceland, the
5-year incidence ofmediumdrusen increasedwith older age,
ranging from 5.0% in individuals 50 to 59 years old to 22.7%
in individuals 70 to 79 years old. In comparison, the overall
5-year incidence of medium drusen was 10.1% in the BMES
(using theKaplan-Meiermethod), or 5.7%after accounting for
competing risk of death. TheCopenhagenCityEye Study26 re-
porteda27.4%14-year incidenceofmediumdrusenamongper-
sons 60 to 80 years old at baseline. The Beaver Dam Eye
Study27,28 found 14.0% and 23.9%, respectively, 10-year and
15-year cumulative incidencesofmediumdrusenafter adjust-
ing for competing riskofdeath,higher than the9.2%and13.9%
incidences at 10 years and 15 years, respectively, in our co-
hort study. Sources of disparity between our findings and the
results of theReykjavikEye Study25 andCopenhagenCityEye
Study26 likely include variations in defining medium drusen
Table 3. Associations Between KnownAge-RelatedMacular
Degeneration Risk Factors and the 15-Year Incidence ofMediumDrusen
Risk Factor
15-Year Incidence of Medium Drusen,
Odds Ratio (95% CI)
Age and Sex Adjusted,
Where Appropriate
Multivariable
Adjusteda
Age, per decade older, y 1.4 (1.2-1.7) 1.4 (1.2-1.8)
Male sex 0.8 (0.6-1.0) 0.9 (0.6-1.2)
Smoking status
Never smoker 1 [Reference] 1 [Reference]
Past smoker 0.7 (0.5-0.9) 0.8 (0.6-1.1)
Current smoker 0.6 (0.4-1.0) 0.6 (0.4-1.1)
CFH and ARMS2 combined riskb
No risk alleles 1 [Reference] 1 [Reference]
1 Risk allele 1.4 (1.0-2.0) 1.6 (1.1-2.4)
2 Risk alleles 1.4 (0.9-2.1) 1.5 (0.9-2.2)
≥3 Risk alleles 2.1 (1.1-3.9) 2.1 (1.1-4.1)
Zinc supplementation 0.7 (0.5-1.1) 0.7 (0.4-1.0)
a Adjusted for age, sex, past and current smoking, any zinc supplementation,
and the combined CFH and ARMS2 risk alleles.
b Single-nucleotide polymorphisms CFH rs1061170 and ARMS2 rs10490924.
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and different methods used to calculate the incidence esti-
mates (eg, the competing risk approach was not used in the
ReykjavikEyeStudyor theCopenhagenCityEyeStudy).While
the Beaver Dam Eye Study had a lower age limit (43 years at
baseline) for their study sample, variations in other environ-
mental exposures, aswell as gradingvariations indefiningme-
diumdrusen, couldalsoexplain thedifference in incidencebe-
tween our study and the BDES.27,28
The age-related increase in medium drusen incidence
before adjusting for competing risk of death found herein is
consistent with other AMD stages and lesions.7,29,30 Past or
current smoking was not associated herein with the 15-year
Figure. An Example of the Progression ofMediumDrusen
At BaselineA
At 10 YearsC
At 5 YearsB
At 15 YearsD
A, Left eye with medium drusen plus
retinal pigment epithelium
abnormalities at baseline. B, Large
soft drusen at 5 years. C, More
apparent retinal pigmentary
abnormality at 10 years.
D, Geographic atrophy at 15 years.
Table 4. Fifteen-Year Progression ofMediumDrusen toWorse Age-RelatedMacular Degeneration (AMD) Stages byMediumDrusen Area
and Location at Baselinea
Medium Drusen
Characteristic
15-Year Progression to Worse AMD Stage
Early AMD Any Late AMD Any Early or Late AMD
No. of
Cases/
No. at Risk
aOR (95% CI) No. of
Cases/
No. at Risk
aOR (95% CI) No. of
Cases/
No. at Risk
aOR (95% CI)
Age and Sex
Adjusted
Multivariable
Adjusted
Age and Sex
Adjusted
Multivariable
Adjusted
Age and Sex
Adjusted
Multivariable
Adjusted
Area
Diameter <375 μm 73/308 1.0 1.0 13/327 1.0 1.0 76/311 1.0 1.0
Diameter ≥375 μm 41/68 2.9
(1.5-5.4)
3.2
(1.4-7.2)
9/71 2.3
(0.8-6.8)
1.6
(0.4-6.6)
44/71 3.0
(1.6-5.5)
3.3
(1.5-7.4)
P value <.001 NA NA .03 NA NA <.001 NA NA
Location
Radius of the foveal center
≥500 μm
30/150 1.0 1.0 5/160 1.0 1.0 32/152 1.0 1.0
Radius of the foveal center
<500 μm
82/222 2.6
(1.5-4.3)
2.6
(1.4-4.8)
17/235 3.1
(0.8-11.4)
3.5
(0.6-20.4)
86/226 2.5
(1.5-4.2)
2.4
(1.3-4.5)
P value <.001 NA NA .06 NA NA <.001 NA NA
Abbreviations: aOR, adjusted odds ratio; NA, not applicable.
a As defined in the BlueMountains Eye Study, early AMD includes large
indistinct soft or reticular drusen or large distinct soft drusen with retinal
pigmentary abnormalities. Odds ratios are adjusted for age, sex, past and
current smoking, fish consumption, and increasing numbers of CFH and
ARMS2 gene risk alleles (0, 1, or 2). P values are for differences in the number
of cases between small vs large areas or between farther vs closer locations of
intermediate drusen by AMD stage.
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incidence of medium drusen as in previous BMES observa-
tions.31,32 Although current smoking was previously strongly
associated with the prevalence and incidence of late AMD,
the association between smoking and early AMD was much
weaker than that between smoking and late AMD.31,32 Smok-
ing may likely be a promoter, having a greater role in the
progression from early to late AMD than in the initiation of
early AMD.
We demonstrated that risk of the progression of medium
drusen to late AMDwas substantially higher formediumdru-
sen plus RPE abnormalities. This parallels previous findings
of faster progression fromearly to lateAMD in eyeswith large
drusenplusRPEabnormalities comparedwith eyeswith large
drusen alone.27,30,33 This observation supports the use of se-
verity scales that incorporate multiple lesion types to better
classify risk of the progression to late AMD.2,3,34
Wealso foundthateyeswithmediumdrusen locatedcloser
to the fovea or eyeswith large totalmacular areas involved by
mediumdrusenweremore likely toprogress toearlyAMD.The
nonsignificantassociationof thesecharacteristicswith thepro-
gression to late AMD was likely due to the few incident late
AMD cases in this cohort. These findings are consistent with
the Beaver Dam Eye Study28 in that the 15-year incidences of
both early and late AMDwere higher in eyeswith a large total
areaofmediumdrusenatbaseline comparedwitha small total
area of medium drusen at baseline.
The strengths of this study include its long-term fol-
low-up of an older Australian cohort, the use of retinal photo-
graphs, and the availability of a validated AMD grading sys-
tem to assess the size and location of AMD lesions. Its
limitations include the low follow-up rate at the 15-year
examination, which could have led to an overestimation or
underestimation of the incidence. Because only color fundus
photographs rather than high-resolution imaging (eg,
spectral-domain optical coherence tomography) were avail-
able during baseline and follow-up examinations, this may
have led to an underestimation of the prevalence and inci-
dence. However, we used only color photographs among the
entire BMES cohort to ensure that the comparisons were
valid. Although the medium drusen category has been
included in retinal photographic grading since the 5-year
follow-up examinations, side-by-side grading of baseline and
follow-up retinal images provided precise classification of this
drusen type.
Conclusions
In summary, the 15-year cumulative incidence of medium
drusen was 13.9% in this at-risk older Australian cohort. The
proportion of eyes that progressed to late AMD was signifi-
cantly higher in eyes with medium drusen plus RPE abnor-
malities compared with eyes with medium drusen alone.
Larger total area and central location of medium drusen
were associated with a greater likelihood of the progression
to worse stages of AMD. These findings are informative for
the monitoring and management of patients at risk of early
and late AMD.
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